# Disease ID,Disorder name,Gene symbols,OMIM ID,Chromosome,Class,2005 Entrez_ID,in largest Comp.,i,mu
1428,"Spinocerebellar ataxia 14, 605361 (3)","PRKCG, PKCC, PKCG, SCA14",176980,19q13.4,Neurological,5582,1,0,0
1428,"Spinocerebellar ataxia 4, pure Japanese type, 117210 (3)",PLEKHG4,609526,16q22.1,Neurological,25894,1,0,542
1428,"Spinocerebellar ataxia-27, 609307 (3)","FGF14, FHF4, SCA27",601515,13q34,Neurological,2259,1,0,548
1428,"Spinocerebellar ataxia-6, 183086 (3)","CACNA1A, CACNL1A4, SCA6",601011,19p13,Neurological,773,1,0,583
1428,"Spinocerebellar ataxia 12, 604326 (3)",PPP2R2B,604325,5q31-q33,Neurological,5521,1,0,799
1428,"Spinocerebellar ataxia 8, 608768 (3)",SCA8,603680,13q21,Neurological,6315,1,0,827
1428,"Spinocerebellar ataxia-7, 164500 (3)","ATXN7, SCA7, OPCA3",607640,3p21.1-p12,Neurological,6314,1,0,828
1428,"Spinocerebellar ataxia-2, 183090 (3)","ATXN2, ATX2, SCA2",601517,12q24,Neurological,6311,1,0,829
1428,"Spinocerebellar ataxia-1, 164400 (3)","ATXN1, ATX1, SCA1",601556,6p23,Neurological,6310,1,0,830
1428,"Spinocerebellar ataxia 17, 607136 (3)","TBP, SCA17",600075,6q27,Neurological,6908,1,0,850
1428,Spinocerebellar ataxia 25 (3),SCA25,608703,2p21-p13,Neurological,338435,1,0,852
1428,"Spinocerebellar ataxia, autosomal recessive with axonal neuropathy, 607250 (3)",TDP1,607198,14q31-q32,Neurological,55775,1,0,853
1428,Spinocerebellar ataxia-10 (3),"ATXN10, SCA10",603516,22q13,Neurological,25814,1,0,854
154,"Ataxia, cerebellar, Cayman type, 601238 (3)","ATCAY, CLAC, KIAA1872",608179,19p13.3,Neurological,85300,1,1,1
154,"Ataxia-ocular apraxia-2, 606002 (3)","SETX, SCAR1, AOA2",608465,9q34,Neurological,23064,1,1,223
154,"Ataxia, episodic (3)","CACNB4, EJM",601949,2q22-q23,Neurological,785,1,1,381
154,"Ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia, 208920 (3)","APTX, AOA, AOA1",606350,9p13.3,Neurological,54840,1,1,680
154,"Ataxia with isolated vitamin E deficiency, 277460 (3)","TTPA, TTP1, AVED",600415,8q13.1-q13.3,Neurological,7274,1,1,795
886,"Leukemia, acute myelomonocytic (3)",AF1Q,604684,1q21,Cancer,10962,1,2,2
886,"Leukemia, acute myelogenous (3)","KRAS2, RASK2",190070,12p12.1,Cancer,3845,1,2,23
886,"Leukemia, acute lymphocytic (3)","BCR, CML, PHL, ALL",151410,22q11.21,Cancer,613,1,2,34
886,"Leukemia, chronic myeloid, 608232 (3)","BCR, CML, PHL, ALL",151410,22q11.21,Cancer,613,1,2,34
886,"Leukemia, Philadelphia chromosome-positive, resistant to imatinib (3)",ABL1,189980,9q34.1,Cancer,25,1,2,42
886,"Leukemia, post-chemotherapy, susceptibility to (3)","NQO1, DIA4, NMOR1",125860,16q22.1,Cancer,1728,1,2,145
886,"Leukemia, acute myeloid, 601626 (3)","CALM, CLTH",603025,11q14,Cancer,8301,1,2,146
886,"Leukemia, acute T-cell lymphoblastic (3)","CALM, CLTH",603025,11q14,Cancer,8301,1,2,146
886,"Leukemia/lymphoma, chronic B-cell, 151400 (3)","CCND1, PRAD1, BCL1",168461,11q13,Cancer,595,1,2,187
886,"Leukemia/lymphoma, B-cell, 2 (3)",BCL2,151430,18q21.3,Cancer,596,1,2,188
886,"Leukemia, acute lymphoblastic (3)","NBS1, NBS",602667,8q21,Cancer,4683,1,2,326
886,"Leukemia, juvenile myelomonocytic, 607785 (3)","PTPN11, PTP2C, SHP2, NS1",176876,12q24.1,Cancer,5781,1,2,334
886,"Leukemia/lymphoma, T-cell (3)",TCRA,186880,14q11.2,Cancer,6955,1,2,401
886,"Leukemia, juvenile myelomonocytic, 607785 (3)","NF1, VRNF, WSS, NFNS",162200,17q11.2,Cancer,4763,1,2,420
886,"Leukemia, acute myeloblastic (3)",ARNT,126110,1q21,Cancer,405,1,2,495
886,"Leukemia, megakaryoblastic, of Down syndrome, 190685 (3)","GATA1, GF1, ERYF1, NFE1",305371,Xp11.23,Cancer,2623,1,2,496
886,"Leukemia, megakaryoblastic, with or without Down syndrome, 190685 (3)","GATA1, GF1, ERYF1, NFE1",305371,Xp11.23,Cancer,2623,1,2,496
886,"Leukemia, acute myeloid, 601626 (3)","ARHGEF12, LARG, KIAA0382",604763,11q23.3,Cancer,23365,1,2,497
886,"Leukemia, acute promyelocytic, PL2F/RARA type (3)","ZNF145, PLZF",176797,11q23.1,Cancer,7704,1,2,498
886,"Leukemia, acute myelogenous, 601626 (3)",GMPS,600358,3q24,Cancer,8833,1,2,499
886,"Leukemia, acute promyelocytic, PML/RARA type (3)","PML, MYL",102578,15q22,Cancer,5371,1,2,500
886,"Leukemia-2, T-cell acute lymphoblastic (3)",TAL2,186855,9q31,Cancer,6887,1,2,501
886,"Leukemia-1, T-cell acute lymphocytic (3)","TAL1, TCL5, SCL",187040,1p32,Cancer,6886,1,2,502
886,"Leukemia, acute lymphoblastic (3)","ZNFN1A1, IK1, LYF1",603023,7p12,Cancer,10320,1,2,503
886,"Leukemia, acute myeloid, 601626 (3)","KIT, PBT",164920,4q12,Cancer,3815,1,2,504
886,"Leukemia, acute myeloid, 601626 (3)","CHIC2, BTL",604332,4q11-q12,Cancer,26511,1,2,505
886,"Leukemia, acute myeloid, 601626 (3)",NPM1,164040,5q35,Cancer,4869,1,2,506
886,"Leukemia, acute promyelocytic, NPM/RARA type (3)",NPM1,164040,5q35,Cancer,4869,1,2,506
886,"Leukemia, acute lymphoblastic (3)",FLT3,136351,13q12,Cancer,2322,1,2,507
886,"Leukemia, acute myeloid, 601626 (3)",FLT3,136351,13q12,Cancer,2322,1,2,507
886,"Leukemia, acute myeloid, reduced survival in (3)",FLT3,136351,13q12,Cancer,2322,1,2,507
886,"Leukemia, acute promyelocytic, NUMA/RARA type (3)",NUMA1,164009,11q13,Cancer,4926,1,2,508
886,"Leukemia, acute myeloid, 601626 (3)","RUNX1, CBFA2, AML1",151385,21q22.3,Cancer,861,1,2,509
886,"Leukemia, acute myeloid, 601626 (3)",LPP,600700,3q28,Cancer,4026,1,2,510
886,"Leukemia, juvenile myelomonocytic, 607785 (3)",GRAF,605370,5q31,Cancer,23092,1,2,511
886,"Leukemia, chronic lymphatic, susceptibility to, 151400 (3)","ARL11, ARLTS1",609351,13q14.3,Cancer,115761,1,2,512
886,"Leukemia, chronic lymphatic, susceptibility to, 151400 (3)","P2RX7, P2X7",602566,12q24,Cancer,5027,1,2,513
886,"Leukemia, acute myeloid, 601626 (3)","CEBPA, CEBP",116897,19q13.1,Cancer,1050,1,2,514
886,"Leukemia, acute myeloid, 601626 (3)","WHSC1L1, NSD3",607083,8p12,Cancer,54904,1,2,515
886,"Leukemia, acute myeloid, 601626 (3)","NUP214, D9S46E, CAN, CAIN",114350,9q34.1,Cancer,8021,1,2,516
886,"Leukemia, T-cell acute lymphoblastic (3)","NUP214, D9S46E, CAN, CAIN",114350,9q34.1,Cancer,8021,1,2,516
886,"Leukemia, acute promyeloyctic, STAT5B/RARA type (3)",STAT5B,604260,17q11.2,Cancer,6777,1,2,517
886,"Leukemia, acute myeloid, 601626 (3)",AF10,602409,10p12,Cancer,8028,1,2,518
886,"Leukemia, acute T-cell lymphoblastic (3)",AF10,602409,10p12,Cancer,8028,1,2,518
886,"Leukemia, acute lymphoblastic, susceptibility to (3)","HOXD4, HOX4B",142981,2q31-q32,Cancer,3233,1,2,519
1316,"Retinitis pigmentosa-17, 600852 (3)","CA4, RP17",114760,17q23,Ophthamological,762,1,3,3
1316,"Retinitis pigmentosa-12, autosomal recessive, 600105 (3)","CRB1, RP12",604210,1q31-q32.1,Ophthamological,23418,1,3,8
1316,"Retinitis pigmentosa, AR, 268000 (3)",RLBP1,180090,15q26,Ophthamological,6017,1,3,28
1316,"Retinitis punctata albescens, 136880 (3)",RLBP1,180090,15q26,Ophthamological,6017,1,3,28
1316,"Retinitis pigmentosa-4, autosomal dominant (3)","RHO, RP4, OPN2",180380,3q21-q24,Ophthamological,6010,1,3,30
1316,"Retinitis pigmentosa, autosomal recessive (3)","RHO, RP4, OPN2",180380,3q21-q24,Ophthamological,6010,1,3,30
1316,"Retinitis pigmentosa-19, 601718 (3)","ABCA4, ABCR, STGD1, FFM, RP19",601691,1p21-p13,Ophthamological,24,1,3,43
1316,Retinitis pigmentosa-20 (3),"RPE65, RP20",180069,1p31,Ophthamological,6121,1,3,94
1316,"Retinitis pigmentosa, late-onset dominant, 268000 (3)","CRX, CORD2, CRD",602225,19q13.3,Ophthamological,1406,1,3,96
1316,"Retinitis pigmentosa, juvenile (3)","AIPL1, LCA4",604392,17p13.1,Ophthamological,23746,1,3,97
1316,"Retinitis pigmentosa-14, 600132 (3)","TULP1, RP14",602280,6p21.3,Ophthamological,7287,1,3,167
1316,"Retinitis pigmentosa, autosomal recessive (3)","PDE6B, PDEB, CSNB3",180072,4p16.3,Ophthamological,5158,1,3,328
1316,"Retinitis pigmentosa-11, 600138 (3)","PRPF31, PRP31",606419,19q13.4,Ophthamological,26121,1,3,422
1316,"Retinitis pigmentosa, AR, without hearing loss, 268000 (3)",USH2A,608400,1q41,Ophthamological,7399,1,3,423
1316,"Retinitis pigmentosa, autosomal recessive (3)","CNGA1, CNCG1",123825,4p12-cen,Ophthamological,1259,1,3,520
1316,"Retinitis pigmentosa, autosomal recessive, 268000 (3)","CNGB1, CNCG3L, CNCG2",600724,16q13,Ophthamological,1258,1,3,521
1316,"Retinitis pigmentosa, autosomal recessive (3)","PDE6A, PDEA",180071,5q31.2-q34,Ophthamological,5145,1,3,535
1316,"Retinitis pigmentosa-7, 608133 (3)","RDS, RP7, PRPH2, PRPH, AVMD, AOFMD",179605,6p21.1-cen,Ophthamological,5961,1,3,562
1316,"Retinitis pigmentosa, digenic, 608133 (3)","RDS, RP7, PRPH2, PRPH, AVMD, AOFMD",179605,6p21.1-cen,Ophthamological,5961,1,3,562
1316,"Retinitis punctata albescens, 136880 (3)","RDS, RP7, PRPH2, PRPH, AVMD, AOFMD",179605,6p21.1-cen,Ophthamological,5961,1,3,562
1316,"Retinitis pigmentosa-30, 607921 (3)","FSCN2, RFSN",607643,17q25,Ophthamological,25794,1,3,596
1316,"Retinitis pigmentosa-13, 600059 (3)","PRPF8, PRPC8, RP13",607300,17p13.3,Ophthamological,10594,1,3,620
1316,"Retinitis pigmentosa-3, 300389 (3)","RPGR, RP3, CRD, RP15, COD1",312610,Xp21.1,Ophthamological,6103,1,3,678
1316,"Retinitis pigmentosa, X-linked with deafness and sinorespiratory infections, 300455 (3)","RPGR, RP3, CRD, RP15, COD1",312610,Xp21.1,Ophthamological,6103,1,3,678
1316,"Retinitis pigmentosa, X-linked, with recurrent respiratory infections, 300455 (3)","RPGR, RP3, CRD, RP15, COD1",312610,Xp21.1,Ophthamological,6103,1,3,678
1316,"Retinitis pigmentosa, autosomal dominant (3)",RGR,600342,10q23,Ophthamological,5995,1,3,736
1316,"Retinitis pigmentosa, autosomal recessive (3)",RGR,600342,10q23,Ophthamological,5995,1,3,736
1316,"Retinitis pigmentosa-10, 180105 (3)",IMPDH1,146690,7q31.3-q32,Ophthamological,3614,1,3,758
1316,"Retinitis pigmentosa-1, 180100 (3)","RP1, ORP1",603937,8q11-q13,Ophthamological,6101,1,3,761
1316,"Retinitis pigmentosa-9, 180104 (3)",RP9,607331,7p14.2,Ophthamological,6100,1,3,786
1316,Retinitis pigmentosa-2 (3),RP2,312600,Xp11.3,Ophthamological,6102,1,3,787
1316,"Retinitis pigmentosa, MERTK-related, 268000 (3)",MERTK,604705,2q14.1,Ophthamological,10461,1,3,788
1316,Retinitis pigmentosa-27 (3),"NRL, D14S46E, RP27",162080,14q11.1-q11.2,Ophthamological,4901,1,3,789
1316,"Retinitis pigmentosa, late onset, 268000 (3)","NR2E3, PNR, ESCS",604485,15q23,Ophthamological,10002,1,3,790
1316,"Retinitis pigmentosa, digenic (3)","ROM1, ROSP1",180721,11q13,Ophthamological,6094,1,3,791
1316,"Retinitis pigmentosa-26, 608380 (3)",CERKL,608381,2q31.2-q32.3,Ophthamological,375298,1,3,792
1316,"Retinitis pigmentosa-18, 601414 (3)","HPRP3, RP18",607301,1q21.2,Ophthamological,9129,1,3,793
7308,Renal tubular acidosis-osteopetrosis syndrome (3),CA2,259730,8q22,Renal,760,1,4,4
7308,"Renal tubular acidosis, distal, 179800, 602722 (3)","SLC4A1, AE1, EPB3",109270,17q21-q22,Renal,6521,1,4,63
7308,"Renal tubular acidosis, distal, autosomal recessive, 602722 (3)","ATP6V0A4, ATP6N1B, VPP2, RTA1C, RTADR",605239,7q33-q34,Renal,50617,1,4,297
7308,"Renal tubular acidosis, proximal, with ocular abnormalities, 604278 (3)","SLC4A4, NBC1, KNBC, SLC4A5",603345,4q21,Renal,8671,1,4,552
7308,"Renal tubular acidosis with deafness, 267300 (3)","ATP6B1, VPP3",192132,2cen-q13,Renal,525,1,4,817
2969,"Medullary thyroid carcinoma, familial, 155240 (3)","NTRK1, TRKA, MTC",191315,1q21-q22,Cancer,4914,1,5,5
2969,"Medullary thyroid carcinoma, 155240 (3)","RET, MEN2A",164761,10q11.2,Cancer,5979,1,5,229
811,"Insensitivity to pain, congenital, with anhidrosis, 256800 (3)","NTRK1, TRKA, MTC",191315,1q21-q22,Neurological,4914,1,6,5
724,"Hypercholesterolemia, familial, autosomal recessive, 603813 (3)","ARH, FHCB2, FHCB1",605747,1p36-p35,Metabolic,26119,1,7,6
724,"Hypercholesterolemia, familial, 3, 603776 (3)","PCSK9, NARC1, HCHOLA3, FH3",607786,1p34.1-p32,Metabolic,255738,1,7,431
724,"Hypercholesterolemia, susceptibility to, 143890 (3)","ITIH4, PK120, ITIHL1",600564,3p21.2-p14.1,Metabolic,3700,1,7,462
724,"Hypercholesterolemia, familial, modification of, 143890 (3)",APOA2,107670,1q21-q23,Metabolic,336,1,7,631
724,"Hypercholesterolemia, due to ligand-defective apo B, 144010 (3)","APOB, FLDB",107730,2p24,Metabolic,338,1,7,632
724,"Hypercholesterolemia, susceptibility to, 143890 (3)",GSBS,604088,7p15,Metabolic,10842,1,7,757
724,"Hypercholesterolemia, familial, 143890 (3)","LDLR, FHC, FH",606945,19p13.2,Metabolic,3949,1,7,836
724,"Hypercholesterolemia, familial, due to LDLR defect, modifier of, 143890 (3)",EPHX2,132811,8p21-p12,Metabolic,2053,1,7,892
268,"Cardiomyopathy, dilated, 1J, 605362 (3)","EYA4, DFNA10, CMD1J",603550,6q23,Cardiovascular,2070,1,8,7
268,"Cardiomyopathy, hypertrophic, with WPW, 600858 (3)","PRKAG2, WPWS",602743,7q36,Cardiovascular,51422,1,8,29
268,"Cardiomyopathy, dilated, 1A, 115200 (3)","LMNA, LMN1, EMD2, FPLD, CMD1A, HGPS, LGMD1B",150330,1q21.2,Cardiovascular,4000,1,8,46
268,"Cardiomyopathy, hypertrophic, early-onset fatal (3)",COX15,603646,10q24,Cardiovascular,1355,1,8,88
268,"Cardiomyopathy, familial hypertrophic, 4, 115197 (3)","MYBPC3, CMH4",600958,11p11.2,Cardiovascular,4607,1,8,259
268,"Cardiomyopathy, dilated, 1D, 601494 (3)","TNNT2, CMH2, CMD1D",191045,1q32,Cardiovascular,7139,1,8,260
268,"Cardiomyopathy, familial hypertrophic, 2, 115195 (3)","TNNT2, CMH2, CMD1D",191045,1q32,Cardiovascular,7139,1,8,260
268,"Cardiomyopathy, dilated, 115200 (3)","MYH7, CMH1, MPD1",160760,14q12,Cardiovascular,4625,1,8,261
268,"Cardiomyopathy, familial hypertrophic, 1, 192600 (3)","MYH7, CMH1, MPD1",160760,14q12,Cardiovascular,4625,1,8,261
268,"Cardiomyopathy, familial hypertrophic, 192600 (3)","MYH6, ASD3, MYHCA",160710,14q12,Cardiovascular,4624,1,8,262
268,"Cardiomyopathy, dilated, 1G, 604145 (3), Tibial muscular dystrophy, tardive, 600334 (3)","TTN, CMD1G, TMD, LGMD2J",188840,2q24.3,Cardiovascular,7273,1,8,263
268,"Cardiomyopathy, familial hypertrophic, 9 (3)","TTN, CMD1G, TMD, LGMD2J",188840,2q24.3,Cardiovascular,7273,1,8,263
268,"Cardiomyopathy, familial hypertrophic (3)",TNNI3,191044,19q13.4,Cardiovascular,7137,1,8,264
268,"Cardiomyopathy, familial restrictive, 115210 (3)",TNNI3,191044,19q13.4,Cardiovascular,7137,1,8,264
268,"Cardiomyopathy, familial hypertrophic, 192600 (3) ()",TNNC1,191040,3p21.3-p14.3,Cardiovascular,7134,1,8,265
268,"Cardiomyopathy, familial hypertrophic, 192600 (3)","CAV3, LGMD1C",601253,3p25,Cardiovascular,859,1,8,266
268,"Cardiomyopathy, dilated, 1M, 607482 (3)","CSRP3, CRP3, CLP, CMD1M",600824,11p15.1,Cardiovascular,8048,1,8,267
268,"Cardiomyopathy, idiopathic dilated, 115200 (3)","PLN, PLB",172405,6q22.1,Cardiovascular,5350,1,8,268
268,"Cardiomyopathy, dilated, 115200 (3)",ACTC,102540,15q14,Cardiovascular,70,1,8,269
268,"Cardiomyopathy, familial hypertrophic, 192600 (3)",ACTC,102540,15q14,Cardiovascular,70,1,8,269
268,"Cardiomyopathy, dilated, with ventricular tachycardia, 608569 (3)","ABCC9, SUR2",601439,12p12.1,Cardiovascular,10060,1,8,270
268,"Cardiomyopathy, Familial hypertrophic, 8, 608751 (3)","MYL3, CMH8",160790,3p,Cardiovascular,4634,1,8,271
268,"Cardiomyopathy, familial hypertrophic, 3, 115196 (3)","TPM1, CMH3",191010,15q22.1,Cardiovascular,7168,1,8,272
268,"Cardiomyopathy, familial hypertrophic, 10, 608758 (3)","MYL2, CMH10",160781,12q23-q24.3,Cardiovascular,4633,1,8,273
268,"Cardiomyopathy, hypertrophic, mid-left ventricular chamber type, 608758 (3)","MYL2, CMH10",160781,12q23-q24.3,Cardiovascular,4633,1,8,273
268,"Cardiomyopathy, dilated, 1I, 604765 (3)","DES, CMD1I",125660,2q35,Cardiovascular,1674,1,8,274
268,"Cardiomyopathy, dilated, X-linked, 302045 (3)","DMD, BMD",300377,Xp21.2,Cardiovascular,1756,1,8,275
268,"Cardiomyopathy, hypertrophic, midventricular, digenic, 192600 (3)","MYLK2, MLCK",606566,20q13.3,Cardiovascular,85366,1,8,276
268,"Cardiomyopathy, dilated, 1L, 606685 (3)","SGCD, SGD, LGMD2F, CMD1L",601411,5q33,Cardiovascular,6444,1,8,277
268,"Cardiomyopathy, dilated, 1N, 607487 (3)","TCAP, LGMD2G, CMD1N",604488,17q12,Cardiovascular,8557,1,8,278
268,"Cardiomyopathy, X-linked dilated, 300069 (3)","TAZ, EFE2, BTHS, CMD3A, LVNCX",300394,Xq28,Cardiovascular,6901,1,8,279
406,"Deafness, autosomal dominant 10, 601316 (3)","EYA4, DFNA10, CMD1J",603550,6q23,"Ear,Nose,Throat",2070,1,9,7
406,"Deafness, X-linked 3, conductive, with stapes fixation, 304400 (3)","POU3F4, DFN3",300039,Xq21.1,"Ear,Nose,Throat",5456,1,9,37
406,"Deafness, autosomal dominant 4, 600652 (3)","MYH14, KIAA2034, DFNA4",608568,19q13.33,"Ear,Nose,Throat",79784,1,9,105
406,"Deafness, autosomal dominant 1, 124900 (3)","DIAPH1, DFNA1, LFHL1",602121,5q31,"Ear,Nose,Throat",1729,1,9,144
406,"Deafness, autosomal dominant 3, 601544 (3)","GJB6, CX30, DFNA3, HED, ED2",604418,13q12,"Ear,Nose,Throat",10804,1,9,253
406,"Deafness, nonsyndromic neurosensory, digenic (3)","GJB6, CX30, DFNA3, HED, ED2",604418,13q12,"Ear,Nose,Throat",10804,1,9,253
406,"Deafness, autosomal dominant 40 (3)","CRYM, DFNA40",123740,16p13.11-p12.3,"Ear,Nose,Throat",1428,1,9,299
406,"Deafness, autosomal dominant 3, 601544 (3)","GJB2, CX26, DFNB1, PPK, DFNA3, KID, HID",121011,13q11-q12,"Ear,Nose,Throat",2706,1,9,312
406,"Deafness, autosomal recessive 1, 220290 (3)","GJB2, CX26, DFNB1, PPK, DFNA3, KID, HID",121011,13q11-q12,"Ear,Nose,Throat",2706,1,9,312
406,"Deafness, autosomal dominant 2, 600101 (3)","GJB3, CX31, DFNA2",603324,1p35.1,"Ear,Nose,Throat",2707,1,9,338
406,"Deafness, autosomal dominant, with peripheral neuropathy (3)","GJB3, CX31, DFNA2",603324,1p35.1,"Ear,Nose,Throat",2707,1,9,338
406,"Deafness, autosomal recessive (3)","GJB3, CX31, DFNA2",603324,1p35.1,"Ear,Nose,Throat",2707,1,9,338
406,"Deafness, X-linked 1, progressive (3)","TIMM8A, DFN1, DDP, MTS, DDP1",300356,Xq22,"Ear,Nose,Throat",1678,1,9,343
406,"Deafness, autosomal dominant 36, with dentinogenesis, 605594 (3)","DSPP, DPP, DGI1, DFNA39, DTDP2",125485,4q21.3,"Ear,Nose,Throat",1834,1,9,348
406,"Deafness, autosomal dominant 2, 600101 (3)","KCNQ4, DFNA2",603537,1p34,"Ear,Nose,Throat",9132,1,9,390
406,"Deafness, nonsyndromic (3) ()",KIAA1199,608366,15q24,"Ear,Nose,Throat",57214,1,9,391
406,"Deafness, autosomal dominant 17, 603622 (3)","MYH9, MHA, FTNS, DFNA17",160775,22q11.2,"Ear,Nose,Throat",4627,1,9,414
406,"Deafness, autosomal dominant 13, 601868 (3)","COL11A2, STL3, DFNA13",120290,6p21.3,"Ear,Nose,Throat",1302,1,9,417
406,"Deafness, autosomal recessive 9, 601071 (3)","OTOF, DFNB9, NSRD9",603681,2p23-p22,"Ear,Nose,Throat",9381,1,9,464
406,"Deafness, autosomal recessive 23, 609533 (3)","PCDH15, DFNB23",605514,10q21-q22,"Ear,Nose,Throat",65217,1,9,465
406,"Deafness, autosomal recessive 16, 603720 (3)","STRC, DFNB16",606440,15q15,"Ear,Nose,Throat",161497,1,9,466
406,"Deafness, autosomal dominant nonsyndromic sensorineural, 607841 (3)",MYO1A,601478,12q13-q15,"Ear,Nose,Throat",4640,1,9,467
406,"Deafness, autosomal dominant 11, neurosensory, 601317 (3)","MYO7A, USH1B, DFNB2, DFNA11",276903,11q13.5,"Ear,Nose,Throat",4647,1,9,468
406,"Deafness, autosomal recessive 2, neurosensory, 600060 (3)","MYO7A, USH1B, DFNB2, DFNA11",276903,11q13.5,"Ear,Nose,Throat",4647,1,9,468
406,"Deafness, autosomal dominant 22, 606346 (3)","MYO6, DFNA22, DFNB37",600970,6q13,"Ear,Nose,Throat",4646,1,9,469
406,"Deafness, autosomal recessive 37, 607821 (3)","MYO6, DFNA22, DFNB37",600970,6q13,"Ear,Nose,Throat",4646,1,9,469
406,"Deafness, sensorineural, with hypertrophic cardiomyopathy, 606346 (3)","MYO6, DFNA22, DFNB37",600970,6q13,"Ear,Nose,Throat",4646,1,9,469
406,"Deafness, autosomal recessive 29 (3)","CLDN14, DFNB29",605608,21q22.3,"Ear,Nose,Throat",23562,1,9,470
406,"Deafness, autosomal recessive 4, 600791 (3)","SLC26A4, PDS, DFNB4",605646,7q31,"Ear,Nose,Throat",5172,1,9,471
406,"Deafness, autosomal recessive 30, 607101 (3)","MYO3A, DFNB30",606808,10p11.1,"Ear,Nose,Throat",53904,1,9,472
406,"Deafness, congenital heart defects, and posterior embryotoxon (3)","JAG1, AGS, AHD",601920,20p12,"Ear,Nose,Throat",182,1,9,473
406,"Deafness, autosomal dominant 36, 606705 (3)","TMC1, DFNB7, DFNB11, DFNA36",606706,9q13-q21,"Ear,Nose,Throat",117531,1,9,474
406,"Deafness, autosomal recessive 7, 600974 (3)","TMC1, DFNB7, DFNB11, DFNA36",606706,9q13-q21,"Ear,Nose,Throat",117531,1,9,474
406,"Deafness, autosomal recessive 22, 607039 (3)","OTOA, DFNB22",607038,16p12.2,"Ear,Nose,Throat",146183,1,9,475
406,"Deafness, autosomal dominant 5 (3)",DFNA5,600994,7p15,"Ear,Nose,Throat",1687,1,9,476
406,"Deafness, autosomal recessive 12, modifier of, 601386 (3)","ATP2B2, PMCA2",108733,3p26-p25,"Ear,Nose,Throat",491,1,9,477
406,"Deafness, autosomal dominant 12, 601842 (3)","TECTA, DFNA8, DFNA12, DFNB21",602574,11q22-q24,"Ear,Nose,Throat",7007,1,9,478
406,"Deafness, autosomal dominant 8, 601543 (3)","TECTA, DFNA8, DFNA12, DFNB21",602574,11q22-q24,"Ear,Nose,Throat",7007,1,9,478
406,"Deafness, autosomal recessive 21, 603629 (3)","TECTA, DFNA8, DFNA12, DFNB21",602574,11q22-q24,"Ear,Nose,Throat",7007,1,9,478
406,"Deafness, autosomal recessive 6, 600971 (3)","TMIE, DFNB6",607237,3p21,"Ear,Nose,Throat",259236,1,9,479
406,"Deafness, autosomal recessive 18, 602092 (3)","USH1C, DFNB18",605242,11p15.1,"Ear,Nose,Throat",10083,1,9,480
406,"Deafness, autosomal dominant 20/26, 604717 (3)","ACTG1, DFNA20, DFNA26",102560,17q25.3,"Ear,Nose,Throat",71,1,9,481
406,"Deafness, autosomal recessive 31, 607084 (3)","WHRN, CIP98, KIAA1526, DFNB31",607928,9q32-q34,"Ear,Nose,Throat",25861,1,9,482
406,"Deafness, autosomal dominant 28, 608641 (3)","TFCP2L3, DFNA28",608576,8q22,"Ear,Nose,Throat",79977,1,9,483
406,"Deafness, autosomal recessive 12, 601386 (3)","CDH23, USH1D",605516,10q21-q22,"Ear,Nose,Throat",64072,1,9,484
406,"Deafness, autosomal dominant 15, 602459 (3)","POU4F3, BRN3C",602460,5q31,"Ear,Nose,Throat",5459,1,9,485
406,"Deafness, autosomal recessive 36, 609006 (3)",ESPN,606351,1p36.3-p36.1,"Ear,Nose,Throat",83715,1,9,486
406,"Deafness, autosomal recessive 10, congenital, 605316 (3)","TMPRSS3, ECHOS1, DFNB8, DFNB10",605511,21q22.3,"Ear,Nose,Throat",64699,1,9,487
406,"Deafness, autosomal recessive 8, childhood onset, 601072 (3)","TMPRSS3, ECHOS1, DFNB8, DFNB10",605511,21q22.3,"Ear,Nose,Throat",64699,1,9,487
406,"Deafness, autosomal recessive 61 (3)","PRES, DFNB61, SLC26A5",604943,7q22.1,"Ear,Nose,Throat",375611,1,9,488
406,"Deafness, autosomal dominant 9, 601369 (3)","COCH, DFNA9",603196,14q12-q13,"Ear,Nose,Throat",1690,1,9,489
406,"Deafness, autosomal recessive 3, 600316 (3)","MYO15A, DFNB3",602666,17p11.2,"Ear,Nose,Throat",51168,1,9,490
873,"Leber congenital amaurosis, 204000 (3)","CRB1, RP12",604210,1q31-q32.1,Ophthamological,23418,1,10,8
873,"Leber congenital amaurosis, type I, 204000 (3)","GUCY2D, GUC2D, LCA1, CORD6",600179,17p13.1,Ophthamological,3000,1,10,92
873,"Leber congenital amaurosis, type III, 604232 (3)","RDH12, LCA3",608830,14q23.3,Ophthamological,145226,1,10,93
873,"Leber congenital amaurosis-2, 204100 (3)","RPE65, RP20",180069,1p31,Ophthamological,6121,1,10,94
873,"Leber congenital amaurosis, 204000 (3)","RPGRIP1, LCA6, CORD9",605446,14q11,Ophthamological,57096,1,10,95
873,"Leber congenital amaurosis, 204000 (3)","CRX, CORD2, CRD",602225,19q13.3,Ophthamological,1406,1,10,96
873,"Leber congenital amaurosis, 604393 (3)","AIPL1, LCA4",604392,17p13.1,Ophthamological,23746,1,10,97
1229,"Pigmented paravenous chorioretinal atrophy, 172870 (3)","CRB1, RP12",604210,1q31-q32.1,Ophthamological,23418,1,11,8
1170,"Ovarian carcinoma, endometrioid type (3)",CTNNB1,116806,3p22-p21.3,Cancer,1499,1,12,9
1170,Ovarian cancer (3),"BRCA1, PSCP",113705,17q21,Cancer,672,1,12,10
1170,Ovarian carcinoma (3),"RRAS2, TC21",600098,11pter-p15.5,Cancer,22800,1,12,11
1170,"Ovarian cancer, somatic, (3)","ERBB2, NGL, NEU, HER2",164870,17q21.1,Cancer,2064,1,12,12
1170,Ovarian cancer (3),"MSH2, COCA1, FCC1, HNPCC1",609309,2p22-p21,Cancer,4436,1,12,13
1170,"Ovarian cancer, endometrial type (3)","MSH6, GTBP, HNPCC5",600678,2p16,Cancer,2956,1,12,14
1170,Ovarian carcinoma (3),"CDH1, UVO",192090,16q22.1,Cancer,999,1,12,15
1170,"Ovarian cancer, 604370 (3)",PIK3CA,171834,3q26.3,Cancer,5290,1,12,16
1174,"Pallidopontonigral degeneration, 168610 (3)","MAPT, MTBT1, DDPAC, MSTD",157140,17q21.1,Neurological,4137,1,13,17
1178,Pancreatic cancer (3),"MADH4, DPC4, SMAD4, JIP",600993,18q21.1,Cancer,4089,1,14,18
1178,"Pancreatic cancer, 260350 (3)","BRCA2, FANCD1",600185,13q12.3,Cancer,675,1,14,19
1178,"Pancreatic cancer, 260350 (3)","TP53, P53, LFS1",191170,17p13.1,Cancer,7157,1,14,20
1178,"Pancreatic carcinoma, somatic (3)","RBBP8, RIM",604124,18q11.2,Cancer,5932,1,14,21
1178,"Pancreatic cancer, somatic (3)","ACVR1B, ACVRLK4, ALK4",601300,12q13,Cancer,91,1,14,22
1178,"Pancreatic carcinoma, somatic, 260350 (3)","KRAS2, RASK2",190070,12p12.1,Cancer,3845,1,14,23
1178,"Pancreatic cancer, 260350 (3)","ARMET, ARP",601916,3p21.1,Cancer,7873,1,14,24
1178,"Pancreatic cancer, sporadic (3)","STK11, PJS, LKB1",602216,19p13.3,Cancer,6794,1,14,25
1178,"Pancreatic cancer/melanoma syndrome, 606719 (3)","CDKN2A, MTS1, P16, MLM, CMM2",600160,9p21,Cancer,1029,1,14,26
1483,"Tetralogy of Fallot, 187500 (3)","ZFPM2, FOG2",603693,8q23,Cardiovascular,23414,1,15,27
1483,"Tetralogy of Fallot, 187500 (3)","JAG1, AGS, AHD",601920,20p12,Cardiovascular,182,1,15,473
1483,"Tetrology of Fallot, 187500 (3)","NKX2E, CSX",600584,5q34,Cardiovascular,1482,1,15,690
562,"Fundus albipunctatus, 136880 (3)",RLBP1,180090,15q26,Ophthamological,6017,1,16,28
562,"Fundus flavimaculatus, 248200 (3)","ABCA4, ABCR, STGD1, FFM, RP19",601691,1p21-p13,Ophthamological,24,1,16,43
562,"Fundus albipunctatus, 136880 (3)",RDH5,601617,12q13-q14,Ophthamological,5959,1,16,388
221,"Bothnia retinal dystrophy, 607475 (3)",RLBP1,180090,15q26,Ophthamological,6017,1,17,28
1105,"Newfoundland rod-cone dystrophy, 607476 (3)",RLBP1,180090,15q26,Ophthamological,6017,1,18,28
1601,"Wolff-Parkinson-White syndrome, 194200 (3)","PRKAG2, WPWS",602743,7q36,Cardiovascular,51422,1,19,29
1110,"Night blindness, congenital stationery, rhodopsin-related (3)","RHO, RP4, OPN2",180380,3q21-q24,Ophthamological,6010,1,20,30
1110,"Night blindness, congenital stationary, X-linked, type 2, 300071 (3)","CACNA1F, CSNB2",300110,Xp11.23,Ophthamological,778,1,20,327
1110,"Night blindness, congenital stationary, type 3, 163500 (3)","PDE6B, PDEB, CSNB3",180072,4p16.3,Ophthamological,5158,1,20,328
1110,"Night blindness, congenital stationary (3)",GNAT1,139330,3p21,Ophthamological,2779,1,20,329
1110,"Night blindness, congenital stationary, type 1, 310500 (3)","CSNB1, NYX",300278,Xp11.4,Ophthamological,60506,1,20,330
1277,"Proud syndrome, 300004 (3)","ARX, ISSX, PRTS, MRXS1, MRX36, MRX54",300382,Xp22.13,multiple,170302,1,21,31
1055,"Myoclonic epilepsy with mental retardation and spasticity, 300432 (3)","ARX, ISSX, PRTS, MRXS1, MRX36, MRX54",300382,Xp22.13,Neurological,170302,1,22,31
1055,"Myoclonic epilepsy, juvenile, 1, 254770 (3)","EFHC1, FLJ10466, EJM1",608815,6p12-p11,Neurological,114327,1,22,822
1055,"Myoclonic epilepsy, severe, of infancy, 607208 (3)","GABRG2, GEFSP3, CAE2, ECA2",137164,5q31.1-q33.1,Neurological,2566,1,22,823
908,"Lissencephaly, X-linked with ambiguous genitalia, 300215 (3)","ARX, ISSX, PRTS, MRXS1, MRX36, MRX54",300382,Xp22.13,Neurological,170302,1,23,31
908,"Lissencephaly-1, 607432 (3)","PAFAH1B1, LIS1",601545,17p13.3,Neurological,5048,1,23,38
908,"Lissencephaly, X-linked, 300067 (3)","DCX, DBCN, LISX",300121,Xq22.3-q23,Neurological,1641,1,23,39
908,"Lissencephaly syndrome, Norman-Roberts type, 257320 (3)","RELN, RL",600514,7q22,Neurological,5649,1,23,40
807,"Infantile spasm syndrome, 308350 (3)","ARX, ISSX, PRTS, MRXS1, MRX36, MRX54",300382,Xp22.13,Neurological,170302,1,24,31
990,"Mental retardation, X-linked 36, 300430 (3)","ARX, ISSX, PRTS, MRXS1, MRX36, MRX54",300382,Xp22.13,Neurological,170302,1,25,31
990,"Mental retardation, X-linked 54, 300419 (3)","ARX, ISSX, PRTS, MRXS1, MRX36, MRX54",300382,Xp22.13,Neurological,170302,1,25,31
990,"Mental retardation, X-linked, 60, 300486 (3)",OPHN1,300127,Xq12,Neurological,4983,1,25,41
990,"Mental retardation, X-linked nonspecific, 309541 (3)","GDI1, RABGD1A, MRX41, MRX48",300104,Xq28,Neurological,2664,1,25,58
990,"Mental retardation, X-linked 30, 300558 (3)","PAK3, MRX30, MRX47",300142,Xq21.3-q24,Neurological,5063,1,25,79
990,"Mental retardation, X-linked, 34, 300426 (3)","IL1RAPL, MRX34",300206,Xp22.1-p21.3,Neurological,11141,1,25,321
990,"Mental retardation, X-linked nonsyndromic (3)","FGD1, FGDY, AAS",305400,Xp11.21,Neurological,2245,1,25,397
990,"Mental retardation, X-linked, JARID1C-related, 300534 (3)","SMCX, MRXJ, DXS1272E, XE169, JARID1C",314690,Xp11.22-p11.21,Neurological,8242,1,25,413
990,"Mental retardation, X-linked, Snyder-Robinson type, 309583 (3)","SMS, SRS, MRSR",300105,Xp22.1,Neurological,6611,1,25,582
990,"Mental retardation, X-linked, 300425 (3)","NLGN4, KIAA1260, AUTSX2",300427,Xp22.33,Neurological,57502,1,25,601
990,"Mental retardation, X-linked nonspecific, type 19 (3)","RPS6KA3, RSK2, MRX19",300075,Xp22.2-p22.1,Neurological,6197,1,25,607
990,"Mental retardation, X-linked (3)","SLC6A8, CRTR",300036,Xq28,Neurological,6535,1,25,630
990,"Mental retardation, X-linked, with seizures and carrier manifestations, 300397 (3)","SLC6A8, CRTR",300036,Xq28,Neurological,6535,1,25,630
990,"Mental retardation, X-linked 58, 300218 (3)","TM4SF2, MXS1, A15",300096,Xq11,Neurological,7102,1,25,692
990,"Mental retardation, X-linked nonsyndromic (3)",ZNF41,314995,Xp22.1-cen,Neurological,7592,1,25,737
990,"Mental retardation, X-linked, 300458 (3)","MECP2, RTT, PPMX, MRX16, MRX79",300005,Xq28,Neurological,4204,1,25,740
990,"Mental retardation, X-linked, with progressive spasticity, 300279 (3)","MECP2, RTT, PPMX, MRX16, MRX79",300005,Xq28,Neurological,4204,1,25,740
990,"Mental retardation, X-linked, FRAXE type (3)","FMR2, FRAXE, MRX2",309548,Xq28,Neurological,2334,1,25,768
990,"Mental retardation, nonsyndromic, autosomal recessive, 2A, 607417 (3)","CRBN, MRT2A",609262,3p26.2,Neurological,51185,1,25,769
990,"Mental retardation, X-linked nonsyndromic (3)",AGTR2,300034,Xq22-q23,Neurological,186,1,25,770
990,"Mental retardation, X-linked nonsyndromic, DLG3-related (3)","DLG3, NEDLG, SAP102, MRX",300189,Xq13.1,Neurological,1741,1,25,771
990,"Mental retardation, X-linked-44, 300501 (3)","FTSJ1, JM23, SPB1, MRX44, MRX9",300499,Xp11.23,Neurological,24140,1,25,772
990,"Mental retardation, X-linked-9, 309549 (3)","FTSJ1, JM23, SPB1, MRX44, MRX9",300499,Xp11.23,Neurological,24140,1,25,772
990,"Mental retardation, X-linked nonspecific, 63, 300387 (3)","FACL4, ACS4, MRX63",300157,Xq22.3,Neurological,2182,1,25,773
990,"Mental retardation, nonsyndromic, autosomal recessive, 249500 (3)","PRSS12, BSSP3",606709,4q25-q26,Neurological,8492,1,25,774
990,"Mental retardation, X-linked 45, 300498 (3)","ZNF81, MRX45",314998,Xp22.1-p11,Neurological,347344,1,25,775
990,"Mental retardation, X-linked, with isolated growth hormone deficiency, 300123 (3)","SOX3, MRGH",313430,Xq26.3,Neurological,6658,1,25,776
990,"Mental retardation, X-linked nonspecific, type 46, 300436 (3)","ARHGEF6, MRX46, COOL2",300267,Xq26,Neurological,9459,1,25,777
1196,"Partington syndrome, 309510 (3)","ARX, ISSX, PRTS, MRXS1, MRX36, MRX54",300382,Xp22.13,Neurological,170302,1,26,31
1257,Preeclampsia/eclampsia 4 (3),"STOX1, PEE4",609397,10q22.1,Cardiovascular,219736,1,27,32
1257,"Preeclampsia, susceptibility to (3)","AGT, SERPINA8",106150,1q42-q43,Cardiovascular,183,1,27,753
1257,"Preeclampsia, susceptibility to, 189800 (3)",EPHX1,132810,1q42.1,Cardiovascular,2052,1,27,754
622,"GRACILE syndrome, 603358 (3)","BCS1L, FLNMS, GRACILE",603647,2q33,Metabolic,617,1,28,33
1016,"Mitochondrial complex III deficiency, 124000 (3)","BCS1L, FLNMS, GRACILE",603647,2q33,multiple,617,1,29,33
1016,"Mitochondrial complex I deficiency, 252010 (3)","NDUFS4, AQDQ",602694,5q11.1,multiple,4724,1,29,81
1016,"Mitochondrial complex I deficiency, 252010 (3)","NDUFV1, UQOR1",161015,11q13,multiple,4723,1,29,83
1016,"Mitochondrial respiratory chain complex II deficiency, 252011 (3)","SDHA, SDH2, SDHF",600857,5p15,multiple,6389,1,29,86
1016,"Mitochondrial complex I deficiency, 252010 (3)",NDUFS1,157655,2q33-q34,multiple,4719,1,29,153
1016,"Mitochondrial complex I deficiency, 252010 (3)",NDUFS2,602985,1q23,multiple,4720,1,29,658
1016,"Mitochondrial complex III deficiency, 124000 (3)","UQCRB, UQBP, QPC",191330,8q22,multiple,7381,1,29,659
877,"Leigh syndrome, 256000 (3)","BCS1L, FLNMS, GRACILE",603647,2q33,Neurological,617,1,30,33
877,"Leigh syndrome, due to COX deficiency, 256000 (3)",SURF1,185620,9q34,Neurological,6834,1,30,80
877,"Leigh syndrome, 256000 (3)","NDUFS4, AQDQ",602694,5q11.1,Neurological,4724,1,30,81
877,"Leigh syndrome, 256000 (3)",NDUFS3,603846,11p11.11,Neurological,4722,1,30,82
877,"Leigh syndrome, 256000 (3)","NDUFV1, UQOR1",161015,11q13,Neurological,4723,1,30,83
877,"Leigh syndrome, 256000 (3)","NDUFS7, PSST",601825,19p13,Neurological,374291,1,30,84
877,"Leigh syndrome, 256000 (3)",NDUFS8,602141,11q13,Neurological,4728,1,30,85
877,"Leigh syndrome, 256000 (3)","SDHA, SDH2, SDHF",600857,5p15,Neurological,6389,1,30,86
877,"Leigh syndrome, 256000 (3)","DLD, LAD, PHE3",238331,7q31-q32,Neurological,2654,1,30,87
877,"Leigh syndrome due to cytochrome c oxidase deficiency, 256000 (3)",COX15,603646,10q24,Neurological,1355,1,30,88
877,"Leigh syndrome, French-Canadian type, 220111 (3)","LRPPRC, LRP130, LSFC",607544,2p21-p16,Neurological,10128,1,30,89
877,"Leigh syndrome, X-linked, 308930 (3)","PDHA1, PHE1A",312170,Xp22.2-p22.1,Neurological,5160,1,30,90
212,"Blood group, OK, 111380 (3)",BSG,109480,19p13.3,Hematological,682,1,31,35
212,"Blood group, Ii, 110800 (3)",GCNT2,600429,6p24-p23,Hematological,2651,1,31,56
212,"Blood group, Diego, 110500 (3)","SLC4A1, AE1, EPB3",109270,17q21-q22,Hematological,6521,1,31,63
212,"Blood group, Waldner, 112010 (3)","SLC4A1, AE1, EPB3",109270,17q21-q22,Hematological,6521,1,31,63
212,"Blood group, Wright, 112050 (3)","SLC4A1, AE1, EPB3",109270,17q21-q22,Hematological,6521,1,31,63
212,"Blood group, ABO system (3)",ABO,110300,9q34,Hematological,28,1,31,193
212,Blood group Cromer (3),DAF,125240,1q32,Hematological,1604,1,31,282
212,"Blood group, Indian system (3)","CD44, MDU2, MDU3, MIC4",107269,11pter-p13,Hematological,960,1,31,285
212,"Blood group, Kidd (3)","SLC14A1, JK, UTE, UT1",111000,18q11-q12,Hematological,6563,1,31,316
212,"Blood group, Colton, 110450 (3)","AQP1, CHIP28, CO",107776,7p14,Hematological,358,1,31,392
212,"Blood group, Landsteiner-Wiener (3)",LW,111250,19p13.3,Hematological,3386,1,31,550
212,"Blood group, P system, 111400 (3)","A4GALT, PK",607922,22q13.2,Hematological,53947,1,31,553
212,"Blood group, XG system (3)",XG,314700,Xpter-p22.32,Hematological,7499,1,31,554
212,"Blood group, P system, 111400 (3)","B3GALT3, GLCT3, P",603094,3q25,Hematological,8706,1,31,555
212,"Blood group, Lewis (3)","FUT3, LE",111100,19p13.3,Hematological,2525,1,31,571
212,"Blood group, Gerbich (3)","GYPC, GE, GPC",110750,2q14-q21,Hematological,2995,1,31,714
212,"Blood group, Ss (3)","GYPB, SS, MNS",111740,4q28-q31,Hematological,2994,1,31,715
212,"Blood group, Rhesus (3)",RHCE,111700,1p36.2-p34,Hematological,6006,1,31,743
212,"Blood group, Dombrock (3)","ART4, DO",110600,12p13-p12,Hematological,420,1,31,818
212,"Blood group, Kell (3)",KEL,110900,7q33,Hematological,3792,1,31,869
212,"Blood group, MN (3)","GYPA, MN, GPA",111300,4q28.2-q31.1,Hematological,2993,1,31,874
212,"Blood group GIL, 607457 (3)",AQP3,600170,9p13,Hematological,360,1,31,876
212,"Blood group, Auberger system (3)","LU, AU, BCAM",111200,19q13.2,Hematological,4059,1,31,890
212,"Blood group, Lutheran system (3)","LU, AU, BCAM",111200,19q13.2,Hematological,4059,1,31,890
212,"Blood group, Yt system, 112100 (3)","ACHE, YT",100740,7q22,Hematological,43,1,31,894
212,"Blood group, Knops system, 607486 (3)","CR1, C3BR",120620,1q32,Hematological,1378,1,31,896
15,"ABCD syndrome, 600501 (3)","EDNRB, HSCR2, ABCDS",131244,13q22,multiple,1910,1,32,36
681,"Hirschsprung disease-2, 600155 (3)","EDNRB, HSCR2, ABCDS",131244,13q22,Gastrointestinal,1910,1,33,36
681,"Hirschsprung disease, 142623 (3)",GDNF,600837,5p13.1-p12,Gastrointestinal,2668,1,33,57
681,"Hirschsprung disease, 142623 (3)",EDN3,131242,20q13.2-q13.3,Gastrointestinal,1908,1,33,177
681,"Hirschsprung disease, 142623 (3)","NRTN, NTN",602018,19p13.3,Gastrointestinal,4902,1,33,226
681,"Hirschsprung disease, cardiac defects, and autonomic dysfunction (3)",ECE1,600423,1p36.1,Gastrointestinal,1889,1,33,227
681,"Hirschsprung disease, short-segment, 142623 (3)","PMX2B, NBPHOX, PHOX2B",603851,4p12,Gastrointestinal,8929,1,33,228
681,"Hirschsprung disease, 142623 (3)","RET, MEN2A",164761,10q11.2,Gastrointestinal,5979,1,33,229
1573,"Waardenburg-Shah syndrome, 277580 (3)","EDNRB, HSCR2, ABCDS",131244,13q22,multiple,1910,1,34,36
1573,"Waardenburg-Shah syndrome, 277580 (3)","SOX10, WS4",602229,22q13,multiple,6663,1,34,202
346,Colorectal cancer (3),CTNNB1,116806,3p22-p21.3,Cancer,1499,1,35,9
346,"Colorectal cancer, hereditary nonpolyposis, type 1, 120435 (3)","MSH2, COCA1, FCC1, HNPCC1",609309,2p22-p21,Cancer,4436,1,35,13
346,"Colorectal cancer, hereditary nonpolyposis, type 5 (3)","MSH6, GTBP, HNPCC5",600678,2p16,Cancer,2956,1,35,14
346,"Colorectal cancer, 114500 (3)",PIK3CA,171834,3q26.3,Cancer,5290,1,35,16
346,"Colorectal cancer, 114500 (3)","TP53, P53, LFS1",191170,17p13.1,Cancer,7157,1,35,20
346,"Colorectal cancer, hereditary nonpolyposis, type 2, 609310 (3)","MLH1, COCA2, HNPCC2",120436,3p21.3,Cancer,4292,1,35,104
346,"Colorectal cancer, somatic, 109800 (3)","FGFR3, ACH",134934,4p16.3,Cancer,2261,1,35,147
346,Colon cancer (3),BCL10,603517,1p22,Cancer,8915,1,35,176
346,"Colorectal cancer, susceptibility to (3)","CCND1, PRAD1, BCL1",168461,11q13,Cancer,595,1,35,187
346,"Colon cancer, advanced (3)","SRC, ASV, SRC1",190090,20q12-q13,Cancer,6714,1,35,197
346,Colon cancer (3),"TGFBR2, HNPCC6",190182,3p22,Cancer,7048,1,35,213
346,"Colorectal cancer, hereditary nonpolyposis, type 6 (3)","TGFBR2, HNPCC6",190182,3p22,Cancer,7048,1,35,213
346,Colorectal cancer (3),"APC, GS, FPC",175100,5q21-q22,Cancer,324,1,35,239
346,"Colorectal adenomatous polyposis, autosomal recessive, with pilomatricomas, 132600 (3)",MUTYH,604933,1p34.3-p32.1,Cancer,4595,1,35,240
346,"Colorectal cancer, somatic (3)",BRAF,164757,7q34,Cancer,673,1,35,244
346,Colon adenocarcinoma (3),"RAD54L, HR54, HRAD54",603615,1p32,Cancer,8438,1,35,288
346,Colorectal cancer (3),BAX,600040,19q13.3-q13.4,Cancer,581,1,35,323
346,Colorectal cancer (3),NRAS,164790,1p13.2,Cancer,4893,1,35,347
346,Colorectal cancer (3),DCC,120470,18q21.3,Cancer,1630,1,35,386
346,"Colon cancer, hereditary nonpolypopsis, type 7 (3)","MLH3, HNPCC7",604395,14q24.3,Cancer,27030,1,35,407
346,"Colorectal cancer, somatic, 114500 (3)","MLH3, HNPCC7",604395,14q24.3,Cancer,27030,1,35,407
346,"Colonic adenoma recurrence, reduced risk of, 114500 (3)",ODC1,165640,2p25,Cancer,4953,1,35,434
346,Colon adenocarcinoma (3),RAD54B,604289,8q21.3-q22,Cancer,25788,1,35,454
346,"Colorectal cancer, somatic, 114500 (3)","FLCN, BHD",607273,17p11.2,Cancer,201163,1,35,538
346,Colorectal cancer (3),MCC,159350,5q21,Cancer,4163,1,35,557
346,"Colorectal cancer, 114500 (3)",EP300,602700,22q13,Cancer,2033,1,35,572
346,"Colorectal cancer, 114500 (3)","PDGFRL, PDGRL, PRLTS",604584,8p22-p21.3,Cancer,5157,1,35,603
346,"Colorectal cancer, hereditary nonpolyposis, type 4 (3)","PMS2, PMSL2, HNPCC4",600259,7p22,Cancer,5395,1,35,605
346,"Colorectal cancer, 114500 (3)","BUB1B, BUBR1",602860,15q15,Cancer,701,1,35,608
346,Colon cancer (3),"PTPN12, PTPG1",600079,7q11.23,Cancer,5782,1,35,609
346,"Colorectal cancer, hereditary nonpolyposis, type 3 (3)","PMS1, PMSL1, HNPCC3",600258,2q31-q33,Cancer,5378,1,35,610
346,Colorectal cancer with chromosomal instability (3),BUB1,602452,2q14,Cancer,699,1,35,611
346,"Colorectal cancer, 114500 (3)",AXIN2,604025,17q24,Cancer,8313,1,35,612
346,"Colorectal cancer, sporadic, 114500 (3)","PLA2G2A, PLA2B, PLA2L, MOM1",172411,1p35,Cancer,5320,1,35,613
346,"Colorectal cancer, somatic (3)",DLC1,604258,8p22-p21.3,Cancer,10395,1,35,614
346,"Colon cancer, somatic, 114500 (3)","PTPRJ, DEP1",600925,11p11.2,Cancer,5795,1,35,615
228,Breast cancer-1 (3),"BRCA1, PSCP",113705,17q21,Cancer,672,1,36,10
228,Breast-ovarian cancer (3),"BRCA1, PSCP",113705,17q21,Cancer,672,1,36,10
228,"Breast cancer, lobular (3)","CDH1, UVO",192090,16q22.1,Cancer,999,1,36,15
228,"Breast cancer, 114480 (3)",PIK3CA,171834,3q26.3,Cancer,5290,1,36,16
228,"Breast cancer 2, early onset (3)","BRCA2, FANCD1",600185,13q12.3,Cancer,675,1,36,19
228,"Breast cancer, male, susceptibility to, 114480 (3)","BRCA2, FANCD1",600185,13q12.3,Cancer,675,1,36,19
228,"Breast cancer, 114480 (3)","TP53, P53, LFS1",191170,17p13.1,Cancer,7157,1,36,20
228,"Breast cancer, somatic, 114480 (3)","KRAS2, RASK2",190070,12p12.1,Cancer,3845,1,36,23
228,"Breast and colorectal cancer, susceptibility to (3)","CHEK2, RAD53, CHK2, CDS1, LFS2",604373,22q12.1,Cancer,11200,1,36,196
228,"Breast cancer, susceptibility to, 114480 (3)","CHEK2, RAD53, CHK2, CDS1, LFS2",604373,22q12.1,Cancer,11200,1,36,196
228,"Breast cancer, 114480 (3)","SLC22A1L, BWSCR1A, IMPT1",602631,11p15.5,Cancer,5002,1,36,211
228,"Breast cancer, invasive intraductal (3)","RAD54L, HR54, HRAD54",603615,1p32,Cancer,8438,1,36,288
228,"Breast cancer, male, with Reifenstein syndrome (3)","AR, DHTR, TFM, SBMA, KD, SMAX1",313700,Xq11-q12,Cancer,367,1,36,293
228,"Breast cancer, susceptibility to, 114480 (3)",BARD1,601593,2q34-q35,Cancer,580,1,36,324
228,"Breast cancer, early-onset, 114480 (3)","BRIP1, BACH1, FANCJ",605882,17q22,Cancer,83990,1,36,375
228,"Breast cancer, susceptibility to, 114480 (3)","ATM, ATA, AT1",607585,11q22.3,Cancer,472,1,36,457
228,"Breast cancer, susceptibility to, 114480 (3)","RAD51A, RECA",179617,15q15.1,Cancer,5888,1,36,621
228,"Breast cancer, susceptibility to (3)",XRCC3,600675,14q32.3,Cancer,7517,1,36,831
228,"Breast cancer, 114480 (3)","PPM1D, WIP1",605100,17q22-q23,Cancer,8493,1,36,844
228,Breast cancer (3),TSG101,601387,11p15.2-p15.1,Cancer,7251,1,36,855
228,"Breast cancer, sporadic (3)",PHB,176705,17q21,Cancer,5245,1,36,887
228,"Breast cancer, somatic, 114480 (3)","RB1CC1, CC1, KIAA0203",606837,8q11,Cancer,9821,1,36,889
909,"Listeria monocytogenes, susceptibility to (3)","CDH1, UVO",192090,16q22.1,Immunological,999,1,37,15
352,Cone-rod dystrophy 3 (3),"ABCA4, ABCR, STGD1, FFM, RP19",601691,1p21-p13,Ophthamological,24,1,38,43
352,"Cone-rod dystrophy 6, 601777(3)","GUCY2D, GUC2D, LCA1, CORD6",600179,17p13.1,Ophthamological,3000,1,38,92
352,"Cone-rod dystrophy 9, 608194 (3)","RPGRIP1, LCA6, CORD9",605446,14q11,Ophthamological,57096,1,38,95
352,"Cone-rod retinal dystrophy-2, 120970 (3)","CRX, CORD2, CRD",602225,19q13.3,Ophthamological,1406,1,38,96
352,Cone-rod dystrophy (3),"AIPL1, LCA4",604392,17p13.1,Ophthamological,23746,1,38,97
352,"Cone dystrophy-1, 304020 (3)","RPGR, RP3, CRD, RP15, COD1",312610,Xp21.1,Ophthamological,6103,1,38,678
352,"Cone-rod dystrophy, 300029 (3)","RPGR, RP3, CRD, RP15, COD1",312610,Xp21.1,Ophthamological,6103,1,38,678
352,"Cone dystrophy-3, 602093 (3)","GUCA1A, GCAP",600364,6p21.1,Ophthamological,2978,1,38,679
1439,"Stargardt disease-1, 248200 (3)","ABCA4, ABCR, STGD1, FFM, RP19",601691,1p21-p13,Ophthamological,24,1,39,43
1439,"Stargardt disease 3, 600110 (3)","ELOVL4, ADMD, STGD2, STGD3",605512,6q14,Ophthamological,6785,1,39,463
2937,"Macular dystrophy, age-related, 2, 153800 (3)","ABCA4, ABCR, STGD1, FFM, RP19",601691,1p21-p13,Ophthamological,24,1,40,43
2937,"Macular dystrophy, vitelliform type, 153700 (3)",VMD2,607854,11q13,Ophthamological,7439,1,40,412
2937,"Macular dystrophy, autosomal dominant, chromosome 6-linked, 600110 (3)","ELOVL4, ADMD, STGD2, STGD3",605512,6q14,Ophthamological,6785,1,40,463
2937,"Macular corneal dystrophy, 217800 (3)","CHST6, MCDC1",605294,16q22,Ophthamological,4166,1,40,561
2937,Macular dystrophy (3),"RDS, RP7, PRPH2, PRPH, AVMD, AOFMD",179605,6p21.1-cen,Ophthamological,5961,1,40,562
2937,"Macular dystrophy, vitelliform, 608161 (3)","RDS, RP7, PRPH2, PRPH, AVMD, AOFMD",179605,6p21.1-cen,Ophthamological,5961,1,40,562
902,"Lipodystrophy, congenital generalized, type 1, 608594 (3)","AGPAT2, LPAAB, BSCL, BSCL1",603100,9q34.3,Metabolic,10555,1,41,44
902,"Lipodystrophy, familial partial, with decreased subcutaneous fat of face and neck (3)","PPARGC1A, PPARGC1",604517,4p15.1,Metabolic,10891,1,41,45
902,"Lipodystrophy, familial partial, 151660 (3)","LMNA, LMN1, EMD2, FPLD, CMD1A, HGPS, LGMD1B",150330,1q21.2,Metabolic,4000,1,41,46
902,"Lipodystrophy, familial partial, 151660 (3)","PPARG, PPARG1, PPARG2",601487,3p25,Metabolic,5468,1,41,47
902,"Lipodystrophy, congenital generalized, type 2, 269700 (3)","BSCL2, SPG17",606158,11q13,Metabolic,26580,1,41,48
110,"Anemia, sideroblastic, with ataxia, 301310 (3)","ABCB7, ABC7, ASAT",300135,Xq13.1-q13.3,Hematological,22,1,42,49
110,"Anemia, neonatal hemolytic, fatal and near-fatal (3)",SPTB,182870,14q22-q23.2,Hematological,6710,1,42,61
110,"Anemia, congenital dyserythropoietic, type I, 224120 (3)","CDAN1, CDA1",607465,15q15,Hematological,146059,1,42,158
110,"Anemia, hemolytic, due to UMPH1 deficiency, 266120 (3)","NT5C3, UMPH1, PSN1",606224,7p15-p14,Hematological,51251,1,42,257
110,"Anemia, Diamond-Blackfan, 105650 (3)","RPS19, DBA",603474,19q13.2,Hematological,6223,1,42,337
110,"Anemia, hypochromic microcytic, 206100 (3)",NRAMP2,600523,12q13,Hematological,4891,1,42,346
110,"Anemia, hemolytic, Rh-null, regulator type, 268150 (3)","RHAG, RH50A",180297,6p21.1-p11,Hematological,6005,1,42,741
110,"Anemia, sideroblastic/hypochromic (3)","ALAS2, ANH1, ASB",301300,Xp11.21,Hematological,212,1,42,851
110,"Anemia, hemolytic, due to PK deficiency (3)","PKLR, PK1",266200,1q21,Hematological,5313,1,42,895
1437,"Squamous cell carcinoma, head and neck, 601400 (3)",ING1,601566,13q34,Cancer,3621,1,43,50
1437,"Squamous cell carcinoma, burn scar-related, somatic (3)","TNFRSF6, APT1, FAS, CD95, ALPS1A",134637,10q24.1,Cancer,355,1,43,400
1437,"Squamous cell carcinoma, head and neck, 601400 (3)","TNFRSF10B, DR5, TRAILR2",603612,8p22-p21,Cancer,8795,1,43,877
3558,"Ventricular fibrillation, idiopathic, 603829 (3)","SCN5A, LQT3, IVF, HB1, SSS1",600163,3p21,Cardiovascular,6331,1,44,51
698,"Homocystinuria due to MTHFR deficiency, 236250 (3)",MTHFR,607093,1p36.3,Metabolic,4524,1,45,52
698,"Homocystinuria, B6-responsive and nonresponsive types (3)",CBS,236200,21q22.3,Metabolic,875,1,45,53
54,"Adrenocortical tumor, somatic (3)","PRKAR1A, TSE1, CNC1, CAR",188830,17q23-q24,Cancer,5573,1,46,54
289,"Cerebellar ataxia, 604290 (3)",CP,117700,3q23-q24,Neurological,1356,1,47,55
289,"Cerebellar ataxia, pure (3)","CACNA1A, CACNL1A4, SCA6",601011,19p13,Neurological,773,1,47,583
665,"Hemosiderosis, systemic, due to aceruloplasminemia, 604290 (3)",CP,117700,3q23-q24,Hematological,1356,1,48,55
766,"Hypoceruloplasminemia, hereditary, 604290 (3)",CP,117700,3q23-q24,Metabolic,1356,1,49,55
58,"Adult i phenotype with congenital cataract, 110800 (3)",GCNT2,600429,6p24-p23,Hematological,2651,1,50,56
58,"Adult i phenotype without cataract, 110800 (3)",GCNT2,600429,6p24-p23,Hematological,2651,1,50,56
287,"Central hypoventilation syndrome, 209880 (3)",GDNF,600837,5p13.1-p12,Respiratory,2668,1,51,57
287,"Central hypoventilation syndrome, congenital, 209880 (3)",EDN3,131242,20q13.2-q13.3,Respiratory,1908,1,51,177
287,"Central hypoventilation syndrome, congenital, 209880 (3)",BDNF,113505,11p13,Respiratory,627,1,51,208
287,"Central hypoventilation syndrome, congenital, 209880 (3)","PMX2B, NBPHOX, PHOX2B",603851,4p12,Respiratory,8929,1,51,228
287,"Central hypoventilation syndrome, congenital, 209880 (3)","RET, MEN2A",164761,10q11.2,Respiratory,5979,1,51,229
1359,"Schizophrenia 5, 603175 (3)",TRAR4,608923,6q23.2,Psychiatric,319100,1,52,59
1359,"Schizoaffective disorder, susceptibility to, 181500 (3)",DISC1,605210,1q42.1,Psychiatric,27185,1,52,154
1359,"Schizophrenia, susceptibility to, 181500 (3)",DISC1,605210,1q42.1,Psychiatric,27185,1,52,154
1359,"Schizophrenia, susceptibility to, 181500 (3)","RTN4R, NOGOR",605566,22q11,Psychiatric,65078,1,52,292
1359,"Schizophrenia, chronic (3)","APP, AAA, CVAP, AD1",104760,21q21,Psychiatric,351,1,52,384
1359,"Schizophrenia, susceptibility to, 181500 (3)",HTR2A,182135,13q14-q21,Psychiatric,3356,1,52,416
1359,"Schizophrenia, susceptibility to, 4 600850 (3)","PRODH, PRODH2, SCZD4",606810,22q11.2,Psychiatric,5625,1,52,566
1359,"Schizophrenia, susceptibility to, 181500 (3)",COMT,116790,22q11.2,Psychiatric,1312,1,52,567
1359,"Schizophrenia, susceptibility to, 181500 (3)",SYN2,600755,3p25,Psychiatric,6854,1,52,568
1359,"Schizophrenia, susceptibility to, 181510 (3)","EPN4, EPNR, KIAA0171, SCZD1",607265,5q33.3,Psychiatric,9685,1,52,569
495,"Epilepsy, benign neonatal, type 2, 121201 (3)","KCNQ3, EBN2, BFNC2",602232,8q24,Neurological,3786,1,53,60
495,"Epilepsy, generalized idiopathic, 600669 (3)","CACNB4, EJM",601949,2q22-q23,Neurological,785,1,53,381
495,"Epilepsy, juvenile myoclonic, 606904 (3)","CACNB4, EJM",601949,2q22-q23,Neurological,785,1,53,381
495,"Epilepsy, nocturnal frontal lobe, 1, 600513 (3)","CHRNA4, ENFL1",118504,20q13.2-q13.3,Neurological,1137,1,53,426
495,"Epilepsy, myoclonic, Lafora type, 254780 (3)","EPM2A, MELF, EPM2",607566,6q24,Neurological,7957,1,53,619
495,"Epilepsy, progressive myoclonic 1, 254800 (3)","CSTB, STFB, EPM1",601145,21q22.3,Neurological,1476,1,53,624
495,"Epilepsy, X-linked, with variable learning disabilities and behavior disorders, 300491 (3)",SYN1,313440,Xp11.4-p11.2,Neurological,6853,1,53,683
495,"Epilepsy, childhood absence, evolving to juvenile myoclonic epilepsy (3)","JRK, JH8",603210,8q24,Neurological,8629,1,53,747
495,"Epilepsy, childhood absence, 607681 (3)","GABRG2, GEFSP3, CAE2, ECA2",137164,5q31.1-q33.1,Neurological,2566,1,53,823
495,"Epilepsy, generalized, with febrile seizures plus, 604233 (3)","GABRG2, GEFSP3, CAE2, ECA2",137164,5q31.1-q33.1,Neurological,2566,1,53,823
495,"Epilepsy, benign, neonatal, type 1, 121200 (3)","KCNQ2, EBN1",602235,20q13.3,Neurological,3785,1,53,824
495,"Epilepsy, partial, with auditory features, 600512 (3)","LGI1, EPT, ETL1",604619,10q24,Neurological,9211,1,53,842
495,"Epilepsy, juvenile myoclonic, 606904 (3)","GABRA1, EJM",137160,5q34-q35,Neurological,2554,1,53,857
495,"Epilepsy, idopathic generalized, susceptibility to, 600669 (3)",ME2,154270,18q21,Neurological,4200,1,53,863
495,"Epilepsy, myoclonic, Lafora type, 254780 (3)","NHLRC1, EPM2A, EPM2B",608072,6p22.3,Neurological,378884,1,53,864
495,"Epilepsy, progressive myoclonic 2B, 254780 (3)","NHLRC1, EPM2A, EPM2B",608072,6p22.3,Neurological,378884,1,53,864
495,"Epilepsy, generalized, with febrile seizures plus, type 2, 604233 (3)","SCN1A, GEFSP2, SMEI",182389,2q24,Neurological,6323,1,53,865
495,"Epilepsy, severe myoclonic, of infancy, 607208 (3)","SCN1A, GEFSP2, SMEI",182389,2q24,Neurological,6323,1,53,865
495,"Epilepsy, nocturnal frontal lobe, 3, 605375 (3)","CHRNB2, EFNL3",118507,1q21,Neurological,1141,1,53,866
495,"Epilepsy, childhood absence, 607682 (3)","CLCN2, EGMA, ECA3, EGI3",600570,3q26-qter,Neurological,1181,1,53,867
495,"Epilepsy, juvenile absence, 607631 (3)","CLCN2, EGMA, ECA3, EGI3",600570,3q26-qter,Neurological,1181,1,53,867
495,"Epilepsy, juvenile myoclonic, 606904 (3)","CLCN2, EGMA, ECA3, EGI3",600570,3q26-qter,Neurological,1181,1,53,867
495,"Epilepsy with grand mal seizures on awakening, 607628 (3)","CLCN2, EGMA, ECA3, EGI3",600570,3q26-qter,Neurological,1181,1,53,867
495,"Epilepsy, neonatal myoclonic, with suppression-burst pattern, 609304 (3)","SLC25A22, GC1",609302,11p15.5,Neurological,79751,1,53,868
472,Elliptocytosis-3 (3),SPTB,182870,14q22-q23.2,Hematological,6710,1,54,61
472,Elliptocytosis-2 (3),SPTA1,182860,1q21,Hematological,6708,1,54,62
472,"Elliptocytosis, Malaysian-Melanesian type (3)","SLC4A1, AE1, EPB3",109270,17q21-q22,Hematological,6521,1,54,63
472,Elliptocytosis-1 (3),"EPB41, EL1",130500,1p36.2-p34,Hematological,2035,1,54,64
104,"Amyotrophic lateral sclerosis, due to SOD1 deficiency, 105400 (3)","SOD1, ALS1",147450,21q22.1,Neurological,6647,1,55,65
104,"Amyotrophic lateral sclerosis, susceptibility to, 105400 (3)",DCTN1,601143,2p13,Neurological,1639,1,55,215
104,"Amyotrophic lateral sclerosis, susceptibility to, 105400 (3)",PRPH,170710,12q12-q13,Neurological,5630,1,55,560
104,"Amyotrophic lateral sclerosis, susceptibility to, 105400 (3)",NEFH,162230,22q12.2,Neurological,4744,1,55,686
104,"Amyotrophic lateral sclerosis, juvenile, 205100 (3)","ALS2, ALSJ, PLSJ, IAHSP",606352,2q33,Neurological,57679,1,55,735
104,"Amyotrophic lateral sclerosis 8, 608627 (3)","VAPB, VAPC, ALS8",605704,20q13.3,Neurological,9217,1,55,843
470,"Ehlers-Danlos syndrome, type I, 130000 (3)",COL5A2,120190,2q31,Connective tissue disorder,1290,1,56,66
470,"Ehlers-Danlos syndrome, type VIIA2, 130060 (3)",COL1A2,120160,7q22.1,Connective tissue disorder,1278,1,56,67
470,"Ehlers-Danlos syndrome, type I, 130000 (3)",COL1A1,120150,17q21.31-q22,Connective tissue disorder,1277,1,56,68
470,"Ehlers-Danlos syndrome, type VII, 130060 (3)",COL1A1,120150,17q21.31-q22,Connective tissue disorder,1277,1,56,68
470,"Ehlers-Danlos syndrome, progeroid form, 130070 (3)","B4GALT7, XGALT1, XGPT1",604327,5q35.2-q35.3,Connective tissue disorder,11285,1,56,69
470,"Ehlers-Danlos due to tenascin X deficiency, 606408 (3)","TNXB, TNX, TNXB1, TNXBS, TNXB2",600985,6p21.3,Connective tissue disorder,7148,1,56,70
470,"Ehlers-Danlos syndrome, hypermobility type, 130020 (3)","TNXB, TNX, TNXB1, TNXBS, TNXB2",600985,6p21.3,Connective tissue disorder,7148,1,56,70
470,"Ehlers-Danlos syndrome, type III, 130020 (3)",COL3A1,120180,2q31,Connective tissue disorder,1281,1,56,71
470,"Ehlers-Danlos syndrome, type IV, 130050 (3)",COL3A1,120180,2q31,Connective tissue disorder,1281,1,56,71
470,"Ehlers-Danlos syndrome, type VI, 225400 (3)","PLOD, PLOD1",153454,1p36.3-p36.2,Connective tissue disorder,5351,1,56,72
470,"Ehlers-Danlos syndrome, type I, 130000 (3)",COL5A1,120215,9q34.2-q34.3,Connective tissue disorder,1289,1,56,73
470,"Ehlers-Danlos syndrome, type II, 130010 (3)",COL5A1,120215,9q34.2-q34.3,Connective tissue disorder,1289,1,56,73
470,"Ehlers-Danlos syndrome, type VIIC, 225410 (3)","ADAMTS2, NPI",604539,5q23,Connective tissue disorder,9509,1,56,74
474,"Emery-Dreifuss muscular dystrophy, AD, 181350 (3)","LMNA, LMN1, EMD2, FPLD, CMD1A, HGPS, LGMD1B",150330,1q21.2,Muscular,4000,1,57,46
474,"Emery-Dreifuss muscular dystrophy, AR, 604929 (3)","LMNA, LMN1, EMD2, FPLD, CMD1A, HGPS, LGMD1B",150330,1q21.2,Muscular,4000,1,57,46
474,"Emery-Dreifuss muscular dystrophy, 310300 (3)","EMD, EDMD, STA",300384,Xq28,Muscular,2010,1,57,75
475,Emphysema (3),"PI, AAT",107400,14q32.1,Respiratory,5265,1,58,76
475,Emphysema-cirrhosis (3),"PI, AAT",107400,14q32.1,Respiratory,5265,1,58,76
479,Endometrial carcinoma (3),"MSH6, GTBP, HNPCC5",600678,2p16,Cancer,2956,1,59,14
479,Endometrial carcinoma (3),"CDH1, UVO",192090,16q22.1,Cancer,999,1,59,15
479,Endometrial carcinoma (3),"PTEN, MMAC1",601728,10q23.31,Cancer,5728,1,59,77
479,Endometrial carcinoma (3),MSH3,600887,5q11-q12,Cancer,4437,1,59,78
872,"Leanness, inherited (3)","AGRP, ART, AGRT",602311,16q22,Nutritional,181,1,60,91
9,"3-methylglutaconicaciduria, type III, 258501 (3)","OPA3, MGA3",606580,19q13.2-q13.3,Metabolic,80207,1,61,98
1144,"Optic atrophy and cataract, 165300 (3)","OPA3, MGA3",606580,19q13.2-q13.3,Ophthamological,80207,1,62,98
1144,"Optic atrophy 1, 165500 (3)","OPA1, NTG, NPG",605290,3q28-q29,Ophthamological,4976,1,62,655
757,"Hypertriglyceridemia, susceptibility to, 145750 (3)",APOA5,606368,11q23,Metabolic,116519,1,63,99
757,"Hypertriglyceridemia, one form (3)",APOA1,107680,11q23,Metabolic,335,1,63,594
757,"Hypertriglyceridemia, susceptibility to, 145750 (3)","LIPI, LPDL, PRED5",609252,21q11.2,Metabolic,149998,1,63,760
757,"Hypertriglyceridemia, susceptibility to, 145750 (3)","RP1, ORP1",603937,8q11-q13,Metabolic,6101,1,63,761
918,"Lung cancer, 211980 (3)","KRAS2, RASK2",190070,12p12.1,Cancer,3845,1,64,23
918,"Lung cancer, somatic, 211980 (3)","MAP3K8, COT, EST, TPL2",191195,10p11.2,Cancer,1326,1,64,209
918,"Lung cancer, 211980 (3)",PPP2R1B,603113,11q22-q24,Cancer,5519,1,64,210
918,"Lung cancer, 211980 (3)","SLC22A1L, BWSCR1A, IMPT1",602631,11p15.5,Cancer,5002,1,64,211
1449,"Stomach cancer, 137215 (3)","KRAS2, RASK2",190070,12p12.1,Cancer,3845,1,65,23
207,"Bladder cancer, 109800 (3)","KRAS2, RASK2",190070,12p12.1,Cancer,3845,1,66,23
207,"Bladder cancer, 109800 (3)","FGFR3, ACH",134934,4p16.3,Cancer,2261,1,66,147
207,"Bladder cancer, somatic, 109800 (3)",HRAS,190020,11p15.5,Cancer,3265,1,66,408
207,"Bladder cancer, 109800 (3)",RB1,180200,13q14.1-q14.2,Cancer,5925,1,66,785
396,"Cyclic ichthyosis with epidermolytic hyperkeratosis, 607602 (3)",KRT1,139350,12q13,Dermatological,3848,1,67,100
494,"Epidermolytic hyperkeratosis, 113800 (3)",KRT1,139350,12q13,Dermatological,3848,1,68,100
494,"Epidermolytic hyperkeratosis, 113800 (3)",KRT10,148080,17q21-q22,Dermatological,3858,1,68,428
494,"Epidermolytic palmoplantar keratoderma, 144200 (3)","KRT9, EPPK",607606,17q12-q21,Dermatological,3857,1,68,862
847,"Keratosis palmoplantaria striata, 148700 (3)",KRT1,139350,12q13,Dermatological,3848,1,69,100
847,"Keratosis palmoplantaris striata III, 607654 (3)",KRT1,139350,12q13,Dermatological,3848,1,69,100
847,Keratosis palmoplantaris striata II (3),"DSP, KPPS2, PPKS2",125647,6p24,Dermatological,1832,1,69,394
847,"Keratosis follicularis spinulosa decalvans, 308800 (3)","SAT, SSAT, KFSD",313020,Xp22.1,Dermatological,6303,1,69,459
847,"Keratosis palmoplantaris striata I, 148700 (3)",DSG1,125670,18q12.1-q12.2,Dermatological,1828,1,69,856
794,"Ichthyosis histrix, Curth-Macklin type, 146590 (3)",KRT1,139350,12q13,Dermatological,3848,1,70,100
794,"Ichthyosis bullosa of Siemens, 146800 (3)","KRT2A, KRT2E",600194,12q11-q13,Dermatological,3849,1,70,101
794,"Ichthyosis, lamellar, autosomal recessive, 242300 (3)","TGM1, ICR2, LI1",190195,14q11.2,Dermatological,7051,1,70,317
794,"Ichthyosis, cyclic, with epidermolytic hyperkeratosis, 607602 (3)",KRT10,148080,17q21-q22,Dermatological,3858,1,70,428
794,"Ichthyosis, X-linked (3)","STS, ARSC1, ARSC, SSDD",308100,Xp22.32,Dermatological,412,1,70,492
794,"Ichthyosis, congenital, autosomal recessive (3)",ICHYN,609383,5q33,Dermatological,348938,1,70,493
794,"Ichthyosis, harlequin, 242500 (3)","ABCA12, ICR2B, LI2",607800,2q34,Dermatological,26154,1,70,494
794,"Ichthyosis, lamellar 2, 601277 (3)","ABCA12, ICR2B, LI2",607800,2q34,Dermatological,26154,1,70,494
1545,"Unna-Thost disease, nonepidermolytic, 600962 (3)",KRT1,139350,12q13,Dermatological,3848,1,71,100
1042,"Myasthenic syndrome, congenital, associated with episodic apnea, 254210 (3)","CHAT, CMS1A2",118490,10q11.2,Muscular,1103,1,72,102
1042,"Myasthenic syndrome, fast-channel congenital, 608930 (3)","CHRNA1, ACHRD, CMS2A, SCCMS, FCCMS",100690,2q24-q32,Muscular,1134,1,72,537
1042,"Myasthenic syndrome, slow-channel congenital, 601462 (3)","CHRNA1, ACHRD, CMS2A, SCCMS, FCCMS",100690,2q24-q32,Muscular,1134,1,72,537
1042,Myasthenic syndrome (3),"SCN4A, HYPP, NAC1A",603967,17q23.1-q25.3,Muscular,6329,1,72,699
1042,"Myasthenic syndrome, congenital, associated with acetylcholine receptor deficiency, 608931 (3)","RAPSN, CMS1D, CMS1E",601592,11p11.2-p11.1,Muscular,5913,1,72,705
1042,"Myasthenic syndrome, congenital, associated with facial dysmorphism and acetylcholine receptor deficiency, 608931 (3)","RAPSN, CMS1D, CMS1E",601592,11p11.2-p11.1,Muscular,5913,1,72,705
1042,"Myasthenic syndrome, congenital, associated with acetylcholine receptor deficiency, 608931 (3)","CHRNE, SCCMS, CMS2A, FCCMS, CMS1E, CMS1D",100725,17p13-p12,Muscular,1145,1,72,706
1042,"Myasthenic syndrome, fast-channel congenital, 608930 (3)","CHRNE, SCCMS, CMS2A, FCCMS, CMS1E, CMS1D",100725,17p13-p12,Muscular,1145,1,72,706
1042,"Myasthenic syndrome, slow-channel congenital, 601462 (3)","CHRNE, SCCMS, CMS2A, FCCMS, CMS1E, CMS1D",100725,17p13-p12,Muscular,1145,1,72,706
1042,"Myasthenic syndrome, fast-channel congenital, 608930 (3)","CHRND, ACHRD, SCCMS, CMS2A, FCCMS",100720,2q33-q34,Muscular,1144,1,72,707
1042,"Myasthenic syndrome, slow-channel congenital, 601462 (3)","CHRND, ACHRD, SCCMS, CMS2A, FCCMS",100720,2q33-q34,Muscular,1144,1,72,707
1042,"Myasthenic syndrome, congenital, associated with acetylcholine receptor deficiency, 608931 (3)","CHRNB1, ACHRB, SCCMS, CMS2A, CMS1D",100710,17p12-p11,Muscular,1140,1,72,708
1042,"Myasthenic syndrome, slow-channel congenital, 601462 (3)","CHRNB1, ACHRB, SCCMS, CMS2A, CMS1D",100710,17p12-p11,Muscular,1140,1,72,708
1237,Platelet ADP receptor defect (3),"P2RY12, P2Y12",600515,3q24-q25,Hematological,64805,1,73,103
1237,"Platelet disorder, familial, with associated myeloid malignancy, 601399 (3)","RUNX1, CBFA2, AML1",151385,21q22.3,Hematological,861,1,73,509
1237,Platelet-activating factor acetylhydrolase deficiency (3),"PLA2G7, PAFAH",601690,6p21.2-p12,Hematological,7941,1,73,547
1237,"Platelet glycoprotein IV deficiency, 608404 (3)",CD36,173510,7q11.2,Hematological,948,1,73,859
252,"Cafe-au-lait spots, multiple, with leukemia, 114030 (3)","MSH2, COCA1, FCC1, HNPCC1",609309,2p22-p21,Cancer,4436,1,74,13
252,"Cafe-au-lait spots with glioma or leukemia, 114030 (3)","MLH1, COCA2, HNPCC2",120436,3p21.3,Cancer,4292,1,74,104
275,"Carpal tunnel syndrome, familial (3)","TTR, PALB",176300,18q11.2-q12.1,Unclassified,7276,1,75,106
277,"Cataract, cerulean, type 2, 601547 (3)","CRYBB2, CRYB2",123620,22q11.2-q12.2,Ophthamological,1415,1,76,107
277,"Cataract, sutural, with punctate and cerulean opacities, 607133 (3)","CRYBB2, CRYB2",123620,22q11.2-q12.2,Ophthamological,1415,1,76,107
277,"Cataract, zonular pulverulent-3, 601885 (3)","GJA3, CX46, CZP3, CAE3",121015,13q11,Ophthamological,2700,1,76,108
277,"Cataract, cortical pulverulent, late-onset (3)","LIM2, MP19",154045,19q13.4,Ophthamological,3982,1,76,109
277,"Cataract, pulverulent (3)",CRYBB1,600929,22q11.2-q12.1,Ophthamological,1414,1,76,110
277,"Cataract, polymorphic and lamellar, 604219 (3)","MIP, AQP0",154050,12q13,Ophthamological,4284,1,76,111
277,"Cataract, congenital, 604219 (3)","BFSP2, CP49, CP47",603212,3q21-q25,Ophthamological,8419,1,76,112
277,"Cataract, juvenile-onset, 604219 (3)","BFSP2, CP49, CP47",603212,3q21-q25,Ophthamological,8419,1,76,112
277,"Cataract, congenital zonular, with sutural opacities, 600881 (3)","CRYBA1, CRYB1",123610,17q11.1-q12,Ophthamological,1411,1,76,113
277,"Cataract, posterior polar 2 (3)","CRYAB, CRYA2, CTPP2",123590,11q22.3-q23.1,Ophthamological,1410,1,76,114
277,"Cataract, autosomal dominant nuclear (3)","CRYAA, CRYA1",123580,21q22.3,Ophthamological,1409,1,76,115
277,"Cataract, congenital progressive, autosomal recessive (3)","CRYAA, CRYA1",123580,21q22.3,Ophthamological,1409,1,76,115
277,"Cataract, zonular central nuclear, autosomal dominant (3)","CRYAA, CRYA1",123580,21q22.3,Ophthamological,1409,1,76,115
277,"Cataract, congenital (3)",PITX3,602669,10q25,Ophthamological,5309,1,76,116
277,"Cataract, crystalline aculeiform, 115700 (3)","CRYGD, CRYG4",123690,2q33-q35,Ophthamological,1421,1,76,117
277,"Cataracts, punctate, progressive juvenile-onset (3)","CRYGD, CRYG4",123690,2q33-q35,Ophthamological,1421,1,76,117
277,"Cataract, lamellar, 116800 (3)","HSF4, CTM",602438,16q21-q22.1,Ophthamological,3299,1,76,118
277,"Cataract, Marner type, 116800 (3)","HSF4, CTM",602438,16q21-q22.1,Ophthamological,3299,1,76,118
277,"Cataract, Coppock-like, 604307 (3)","CRYGC, CRYG3, CCL",123680,2q33-q35,Ophthamological,1420,1,76,119
277,"Cataract, variable zonular pulverulent (3)","CRYGC, CRYG3, CCL",123680,2q33-q35,Ophthamological,1420,1,76,119
277,"Cataract, congenital, with late-onset corneal dystrophy (3)","PAX6, AN2, MGDA",607108,11p13,Ophthamological,5080,1,76,120
277,"Cataract, zonular pulverulent-1, 116200 (3)","GJA8, CX50, CAE1",600897,1q21.1,Ophthamological,2703,1,76,121
1154,"Osteoarthritis of hip, female-specific, susceptibility to, 165720 (3)","FRZB, FRZB1, SRFP3",605083,2q31-q33,Connective tissue disorder,2487,1,77,122
1154,"Osteoarthrosis, 165720 (3)",COL2A1,120140,12q13.11-q13.2,Connective tissue disorder,1280,1,77,306
1154,"Osteoarthritis, hand, susceptibility to, 607850 (3)","MATN3, EDM5, HOA",602109,2p24-p23,Connective tissue disorder,4148,1,77,847
1154,"Osteoarthritis, susceptibility to, 165720 (3)","ASPN, PLAP1",608135,9q21.3-q22,Connective tissue disorder,54829,1,77,888
301,"Charcot-Marie-Tooth disease, type 4B1, 601382 (3)","MTMR2, CMT4B1",603557,11q22,Neurological,8898,1,78,123
301,"Charcot-Marie-Tooth disease, type 4C, 601596 (3)",KIAA1985,608206,5q32,Neurological,79628,1,78,124
301,"Charcot-Marie-Tooth neuropathy, X-linked dominant, 1, 302800 (3)","GJB1, CX32, CMTX1",304040,Xq13.1,Neurological,2705,1,78,125
301,"Charcot-Marie-Tooth disease, type 4D, 601455 (3)","NDRG1, HMSNL, CMT4D",605262,8q24.3,Neurological,10397,1,78,126
301,"Charcot-Marie-Tooth disease, type 2D, 601472 (3)","GARS, SMAD1, CMT2D",600287,7p15,Neurological,2617,1,78,127
301,"Charcot-Marie-Tooth disease, type 1A, 118220 (3)","PMP22, CMT1A, CMT1E, DSS",601097,17p11.2,Neurological,5376,1,78,128
301,"Charcot-Marie-Tooth disease, type 1E, 118300 (3)","PMP22, CMT1A, CMT1E, DSS",601097,17p11.2,Neurological,5376,1,78,128
301,"Charcot-Marie-Tooth disease, type 2A1, 118210 (3)","KIF1B, CMT2A, CMT2A1",605995,1p36.2,Neurological,23095,1,78,129
301,"Charcot-Marie-Tooth disease, type 4B2, 604563 (3)","SBF2, MTMR13, CMT4B2",607697,11p15,Neurological,81846,1,78,130
301,"Charcot-Marie-Tooth disease, type 4B2, with early-onset glaucoma, 607739 (3)","SBF2, MTMR13, CMT4B2",607697,11p15,Neurological,81846,1,78,130
301,"Charcot-Marie-Tooth disease, axonal, type 2F, 606595 (3)","HSPB1, HSP27, CMT2F",602195,7q11.23,Neurological,3315,1,78,131
301,"Charcot-Marie-Tooth disease, type 1C, 601098 (3)","LITAF, CMT1C",603795,16p13.3-p12,Neurological,9516,1,78,132
301,"Charcot-Marie-Tooth disease, dominant intermediate 3, 607791 (3)","MPZ, CMT1B, CMTDI3, CHM, DSS",159440,1q22,Neurological,4359,1,78,133
301,"Charcot-Marie-Tooth disease, type 1B, 118200 (3)","MPZ, CMT1B, CMTDI3, CHM, DSS",159440,1q22,Neurological,4359,1,78,133
301,"Charcot-Marie-Tooth disease, type 2I, 607677 (3)","MPZ, CMT1B, CMTDI3, CHM, DSS",159440,1q22,Neurological,4359,1,78,133
301,"Charcot-Marie-Tooth disease, type 2J, 607736 (3)","MPZ, CMT1B, CMTDI3, CHM, DSS",159440,1q22,Neurological,4359,1,78,133
301,"Charcot-Marie-Tooth disease, type 2A2, 609260 (3)","MFN2, KIAA0214, CMT2A2",608507,1p36.2,Neurological,9927,1,78,134
301,"Charcot-Marie-Tooth disease, type 1F, 607734 (3)","NEFL, CMT2E, CMT1F",162280,8p21,Neurological,4747,1,78,135
301,"Charcot-Marie-Tooth disease, type 2E, 607684 (3)","NEFL, CMT2E, CMT1F",162280,8p21,Neurological,4747,1,78,135
301,"Charcot-Marie-Tooth disease, mixed axonal and demyelinating type, 214400 (3)","GDAP1, CMT4A, CMT2K, CMT2G",606598,8q13-q21.1,Neurological,54332,1,78,136
301,"Charcot-Marie-Tooth disease, type 2G, 607706 (3)","GDAP1, CMT4A, CMT2K, CMT2G",606598,8q13-q21.1,Neurological,54332,1,78,136
301,"Charcot-Marie-Tooth disease, type 2K, 607831 (3)","GDAP1, CMT4A, CMT2K, CMT2G",606598,8q13-q21.1,Neurological,54332,1,78,136
301,"Charcot-Marie-Tooth disease, type 4A, 214400 (3)","GDAP1, CMT4A, CMT2K, CMT2G",606598,8q13-q21.1,Neurological,54332,1,78,136
301,"Charcot-Marie-Tooth disease, dominant intermediate B, 606482 (3)",DNM2,602378,19p13.2,Neurological,1785,1,78,137
301,"Charcot-Marie-Tooth disease, foot deformity of (3)","HOXD10, HOX4D",142984,2q31-q32,Neurological,3236,1,78,138
301,"Charcot-Marie-Tooth disease, type 2B, 600882 (3)","RAB7, CMT2B, PSN",602298,3q21,Neurological,7879,1,78,139
301,"Charcot-Marie-Tooth disease, type 1D, 607678 (3)","EGR2, KROX20",129010,10q21.1-q22.1,Neurological,1959,1,78,140
806,"Incontinentia pigmenti, type II, 308300 (3)","IKBKG, NEMO, FIP3, IP2",300248,Xq28,Dermatological,8517,1,79,141
466,"Ectodermal dysplasia, anhidrotic, lymphedema and immunodeficiency, 300301 (3)","IKBKG, NEMO, FIP3, IP2",300248,Xq28,Dermatological,8517,1,80,141
466,"Ectodermal dysplasia, hypohidrotic, with immune deficiency, 300291 (3)","IKBKG, NEMO, FIP3, IP2",300248,Xq28,Dermatological,8517,1,80,141
466,"Ectodermal dysplasia, Margarita Island type, 225060 (3)","HVEC, PVRL1, PVRR1, PRR1",600644,11q23-q24,Dermatological,5818,1,80,201
466,"Ectodermal dysplasia, anhidrotic, 224900 (3)",EDARADD,606603,1q42.2-q43,Dermatological,128178,1,80,249
466,"Ectodermal dysplasia-1, anhidrotic, 305100 (3)","ED1, EDA, HED",300451,Xq12-q13.1,Dermatological,1896,1,80,250
466,"Ectodermal dysplasia, anhidrotic, with T-cell immunodeficiency (3)","NFKBIA, IKBA",164008,14q13,Dermatological,4792,1,80,251
466,"Ectodermal dysplasia, hypohidrotic, autosomal dominant, 129490 (3)","EDAR, DL, ED3, EDA3",604095,2q11-q13,Dermatological,10913,1,80,252
466,"Ectodermal dysplasia, hypohidrotic, autosomal recessive, 224900 (3)","EDAR, DL, ED3, EDA3",604095,2q11-q13,Dermatological,10913,1,80,252
466,"Ectodermal dysplasia 2, hidrotic, 129500 (3)","GJB6, CX30, DFNA3, HED, ED2",604418,13q12,Dermatological,10804,1,80,253
466,"Ectodermal dysplasia/skin fragility syndrome, 604536 (3)",PKP1,601975,1q32,Dermatological,5317,1,80,254
2053,"Adrenal adenoma, sporadic (3)",MEN1,131100,11q13,Cancer,4221,1,81,142
1189,"Parathyroid adenoma, sporadic (3)",MEN1,131100,11q13,Cancer,4221,1,82,142
1189,"Parathyroid adenoma with cystic changes, 145001 (3)","HRPT2, C1orf28",607393,1q25-q31,Cancer,79577,1,82,704
1189,"Parathyroid carcinoma, 608266 (3)","HRPT2, C1orf28",607393,1q25-q31,Cancer,79577,1,82,704
115,"Angiofibroma, sporadic (3)",MEN1,131100,11q13,Endocrine,4221,1,83,142
904,"Lipoma, sporadic (3)",MEN1,131100,11q13,Cancer,4221,1,84,142
904,Lipoma (3),LPP,600700,3q28,Cancer,4026,1,84,510
904,Lipoma (3),"HMGA2, HMGIC, BABL, LIPO",600698,12q14.3,Cancer,8091,1,84,543
904,"Lipomatosis, mutiple, 151900 (3)","HMGA2, HMGIC, BABL, LIPO",600698,12q14.3,Cancer,8091,1,84,543
2265,Carcinoid tumor of lung (3),MEN1,131100,11q13,Cancer,4221,1,85,142
1037,Multiple endocrine neoplasia I (3),MEN1,131100,11q13,Cancer,4221,1,86,142
1037,"Multiple endocrine neoplasia IIA, 171400 (3)","RET, MEN2A",164761,10q11.2,Cancer,5979,1,86,229
1037,"Multiple endocrine neoplasia IIB, 162300 (3)","RET, MEN2A",164761,10q11.2,Cancer,5979,1,86,229
743,"Hyperparathyroidism, AD, 145000 (3)",MEN1,131100,11q13,Endocrine,4221,1,87,142
743,"Hyperparathyroidism, neonatal, 239200 (3)","CASR, HHC1, PCAR1, FIH",601199,3q13.3-q21,Endocrine,846,1,87,703
743,"Hyperparathyroidism, familial primary, 145000 (3)","HRPT2, C1orf28",607393,1q25-q31,Endocrine,79577,1,87,704
743,"Hyperparathyroidism-jaw tumor syndrome, 145001 (3)","HRPT2, C1orf28",607393,1q25-q31,Endocrine,79577,1,87,704
1267,"Prolactinoma, hyperparathyroidism, carcinoid syndrome (3)",MEN1,131100,11q13,Endocrine,4221,1,88,142
1126,"Obesity, resistance to (3)","PPARG, PPARG1, PPARG2",601487,3p25,Nutritional,5468,1,89,47
1126,"Obesity, severe, 601665 (3)","PPARG, PPARG1, PPARG2",601487,3p25,Nutritional,5468,1,89,47
1126,"Obesity, late-onset, 601665 (3)","AGRP, ART, AGRT",602311,16q22,Nutritional,181,1,89,91
1126,"Obesity, susceptibility to, 601665 (3)",CART,602606,5q13.2,Nutritional,9607,1,89,143
1126,"Obesity, severe, susceptibility to, 601665 (3)",MC3R,155540,20q13.2,Nutritional,4159,1,89,161
1126,"Obesity, adrenal insufficiency, and red hair (3)",POMC,176830,2p23.3,Nutritional,5443,1,89,222
1126,"Obestiy with impaired prohormone processing, 600955 (3)","PCSK1, NEC1, PC1, PC3",162150,5q15-q21,Nutritional,5122,1,89,281
1126,"Obesity, mild, early-onset, 601665 (3)","NR0B2, SHP",604630,1p36.1,Nutritional,8431,1,89,291
1126,"Obesity, severe, 601665 (3)",SIM1,603128,6q16.3-q21,Nutritional,6492,1,89,300
1126,"Obesity, autosomal dominant, 601665 (3)",MC4R,155541,18q22,Nutritional,4160,1,89,556
1126,"Obesity, susceptibility to, 601665 (3)",ADRB2,109690,5q32-q34,Nutritional,154,1,89,635
1126,"Obesity, susceptibility to, 601665 (3)",ADRB3,109691,8p12-p11.2,Nutritional,155,1,89,636
1126,"Obesity, morbid, with hypogonadism (3)","LEPR, OBR",601007,1p31,Nutritional,3953,1,89,637
1126,"Obesity, hyperphagia, and developmental delay (3)","NTRK2, TRKB",600456,9q22.1,Nutritional,4915,1,89,638
1126,"Obesity, susceptibility to, 601665 (3)",UCP1,113730,4q31,Nutritional,7350,1,89,639
1126,"Obesity, susceptibility to, 601665 (3)",UCP2,601693,11q13,Nutritional,7351,1,89,640
1126,"Obesity, morbid, with hypogonadism (3)","LEP, OB",164160,7q31.3,Nutritional,3952,1,89,641
1126,"Obesity, severe, due to leptin deficiency (3)","LEP, OB",164160,7q31.3,Nutritional,3952,1,89,641
1126,"Obesity, severe, and type II diabetes, 601665 (3)",UCP3,602044,11q13,Nutritional,7352,1,89,642
1126,"Obesity, hyperphagia, and developmental delay (3)","AKR1C2, DDH2, DD2, HAKRD",600450,10p15-p14,Nutritional,1646,1,89,643
1126,"Obesity, susceptibility to, 601665 (3)","ENPP1, PDNP1, NPPS, M6S1, PCA1",173335,6q22-q23,Nutritional,5167,1,89,644
1126,"Obesity, susceptibility to, 601665 (3)",GHRL,605353,3p26-p25,Nutritional,51738,1,89,645
1126,"Obesity, susceptibility to, 300306 (3)","SLC6A14, OBX",300444,Xq23-q24,Nutritional,11254,1,89,646
1245,"Polyposis, juvenile intestinal, 174900 (3)","MADH4, DPC4, SMAD4, JIP",600993,18q21.1,Cancer,4089,1,90,18
1245,"Polyposis, juvenile intestinal, 174900 (3)","BMPR1A, ACVRLK3, ALK3",601299,10q22.3,Cancer,657,1,90,581
833,"Juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome, 175050 (3)","MADH4, DPC4, SMAD4, JIP",600993,18q21.1,Cancer,4089,1,91,18
195,"Benzene toxicity, susceptibility to (3)","NQO1, DIA4, NMOR1",125860,16q22.1,Unclassified,1728,1,92,145
298,"Cervical cancer, somatic, 603956 (3)","FGFR3, ACH",134934,4p16.3,Cancer,2261,1,93,147
28,"Achondroplasia, 100800 (3)","FGFR3, ACH",134934,4p16.3,Skeletal,2261,1,94,147
767,"Hypochondroplasia, 146000 (3)","FGFR3, ACH",134934,4p16.3,Skeletal,2261,1,95,147
391,Crouzon syndrome with acanthosis nigricans (3),"FGFR3, ACH",134934,4p16.3,Skeletal,2261,1,96,147
391,"Crouzon syndrome, 123500 (3)","FGFR2, BEK, CFD1, JWS",176943,10q26,Skeletal,2263,1,96,149
1490,"Thanatophoric dysplasia, types I and II, 187600 (3)","FGFR3, ACH",134934,4p16.3,Skeletal,2261,1,97,147
1034,"Muenke syndrome, 602849 (3)","FGFR3, ACH",134934,4p16.3,Skeletal,2261,1,98,147
827,"Jackson-Weiss syndrome, 123150 (3)","FGFR1, FLT2, KAL2",136350,8p11.2-p11.1,Skeletal,2260,1,99,148
827,"Jackson-Weiss syndrome, 123150 (3)","FGFR2, BEK, CFD1, JWS",176943,10q26,Skeletal,2263,1,99,149
836,"Kallmann syndrome 2, 147950 (3)","FGFR1, FLT2, KAL2",136350,8p11.2-p11.1,multiple,2260,1,100,148
836,Kallmann syndrome (3),"KAL1, KMS, ADMLX",308700,Xp22.3,multiple,3730,1,100,701
1215,"Pfeiffer syndrome, 101600 (3)","FGFR1, FLT2, KAL2",136350,8p11.2-p11.1,Skeletal,2260,1,101,148
1215,"Pfeiffer syndrome, 101600 (3)","FGFR2, BEK, CFD1, JWS",176943,10q26,Skeletal,2263,1,101,149
1344,"Saethre-Chotzen syndrome, 101400 (3)","FGFR2, BEK, CFD1, JWS",176943,10q26,Developmental,2263,1,102,149
1344,"Saethre-Chotzen syndrome, 101400 (3)","TWIST, ACS3, SCS",601622,7p21,Developmental,7291,1,102,628
1344,"Saethre-Chotzen syndrome with eyelid anomalies, 101400 (3)","TWIST, ACS3, SCS",601622,7p21,Developmental,7291,1,102,628
379,Craniofacial-skeletal-dermatologic dysplasia (3),"FGFR2, BEK, CFD1, JWS",176943,10q26,multiple,2263,1,103,149
572,"Gastric cancer, somatic, 137215 (3)","ERBB2, NGL, NEU, HER2",164870,17q21.1,Cancer,2064,1,104,12
572,"Gastric cancer, familial diffuse, 137215 (3)","CDH1, UVO",192090,16q22.1,Cancer,999,1,104,15
572,"Gastric cancer, somatic, 137215 (3)","FGFR2, BEK, CFD1, JWS",176943,10q26,Cancer,2263,1,104,149
572,"Gastric cancer, 137215 (3)","APC, GS, FPC",175100,5q21-q22,Cancer,324,1,104,239
572,"Gastric cancer, somatic, 137215 (3)",MUTYH,604933,1p34.3-p32.1,Cancer,4595,1,104,240
572,"Gastric cancer, 137215 (3)","IRF1, MAR",147575,5q31.1,Cancer,3659,1,104,331
572,"Gastric cancer, somatic, 137215 (3)","CASP10, MCH4, ALPS2",601762,2q33-q34,Cancer,843,1,104,332
572,"Gastric cancer, somatic, 137215 (3)","KLF6, COPEB, BCD1, ZF9",602053,10p15,Cancer,1316,1,104,779
572,"Gastric cancer risk after H. pylori infection, 137215 (3)",IL1RN,147679,2q14.2,Cancer,3557,1,104,780
572,"Gastric cancer risk after H. pylori infection, 137215 (3)",IL1B,147720,2q14,Cancer,3553,1,104,781
383,"Craniosynostosis, nonspecific (3)","FGFR2, BEK, CFD1, JWS",176943,10q26,Skeletal,2263,1,105,149
383,"Craniosynostosis, type 2, 604757 (3)","MSX2, CRS2, HOX8",123101,5q34-q35,Skeletal,4488,1,105,461
131,"Apert syndrome, 101200 (3)","FGFR2, BEK, CFD1, JWS",176943,10q26,Connective tissue disorder,2263,1,106,149
192,"Beare-Stevenson cutis gyrata syndrome, 123790 (3)","FGFR2, BEK, CFD1, JWS",176943,10q26,multiple,2263,1,107,149
259,Cancer susceptibility (3),"MSH6, GTBP, HNPCC5",600678,2p16,Cancer,2956,1,108,14
259,Cancer progression/metastasis (3),FGFR4,134935,5q35.1-qter,Cancer,2264,1,108,150
188,"Basal cell carcinoma, somatic, 605462 (3)",PTCH2,603673,1p32,Cancer,8643,1,109,151
188,"Basal cell carcinoma, somatic, 605462 (3)","PTCH, NBCCS, BCNS, HPE7",601309,9q22.3,Cancer,5727,1,109,235
188,Basal cell carcinoma (3),"RASA1, GAP, CMAVM, PKWS",139150,5q13.3,Cancer,5921,1,109,280
188,"Basal cell carcinoma, sporadic (3)","SMOH, SMO",601500,7q31-q32,Cancer,6608,1,109,439
970,"Medulloblastoma, 155255 (3)",PTCH2,603673,1p32,Cancer,8643,1,110,151
970,"Medulloblastoma, desmoplastic, 155255 (3)","SUFU, SUFUXL, SUFUH",607035,10q24-q25,Cancer,51684,1,110,833
457,"Dysfibrinogenemia, gamma type (3)",FGG,134850,4q28,Hematological,2266,1,111,152
457,"Dysfibrinogenemia, beta type (3)",FGB,134830,4q28,Hematological,2244,1,111,398
457,"Dysfibrinogenemia, alpha type, causing bleeding diathesis (3)",FGA,134820,4q28,Hematological,2243,1,111,399
457,"Dysfibrinogenemia, alpha type, causing recurrent thrombosis (3)",FGA,134820,4q28,Hematological,2243,1,111,399
770,"Hypofibrinogenemia, gamma type (3)",FGG,134850,4q28,Hematological,2266,1,112,152
1497,"Thrombosis, hyperhomocysteinemic (3)",CBS,236200,21q22.3,Hematological,875,1,113,53
1497,"Thrombophilia, dysfibrinogenemic (3)",FGG,134850,4q28,Hematological,2266,1,113,152
1497,Thrombophilia due to heparin cofactor II deficiency (3),"HCF2, HC2, SERPIND1",142360,22q11,Hematological,3053,1,113,286
1497,Thrombophilia due to HRG deficiency (3),HRG,142640,3q27,Hematological,3273,1,113,301
1497,"Thrombotic thrombocytopenic purpura, familial, 274150 (3)","ADAMTS13, VWFCP, TTP",604134,9q34,Hematological,11093,1,113,325
1497,"Thrombophilia, dysfibrinogenemic (3)",FGB,134830,4q28,Hematological,2244,1,113,398
1497,Thrombophilia due to factor V Liverpool (3),F5,227400,1q23,Hematological,2153,1,113,442
1497,Thrombophilia due to protein C deficiency (3),PROC,176860,2q13-q14,Hematological,5624,1,113,626
1497,Thrombophilia due to thrombomodulin defect (3),"THBD, THRM",188040,20p11.2,Hematological,7056,1,113,752
151,"Asperger syndrome, 300494 (3)",NLGN3,300336,Xq13,Psychiatric,54413,1,114,155
151,"Asperger syndrome, 300497 (3)","NLGN4, KIAA1260, AUTSX2",300427,Xp22.33,Psychiatric,57502,1,114,601
173,"Autism, X-linked, 300425 (3)",NLGN3,300336,Xq13,Psychiatric,54413,1,115,155
173,"Autism, susceptibility to, 209850 (3)",GLO1,138750,6p21.3-p21.2,Psychiatric,2739,1,115,437
173,"Autism, X-linked, 300495 (3)","NLGN4, KIAA1260, AUTSX2",300427,Xp22.33,Psychiatric,57502,1,115,601
173,"Autism, X-linked, 300425 (3)","MECP2, RTT, PPMX, MRX16, MRX79",300005,Xq28,Psychiatric,4204,1,115,740
793,"Ichthyosiform erythroderma, congenital, nonbullous, 1, 242100 (3)",ALOXE3,607206,17p13.1,Dermatological,59344,1,116,156
793,"Ichthyosiform erythroderma, congenital, nonbullous, 1, 242100 (3)",ALOX12B,603741,17pter-p13.1,Dermatological,242,1,116,190
793,"Ichthyosiform erythroderma, congenital, 242100 (3)","TGM1, ICR2, LI1",190195,14q11.2,Dermatological,7051,1,116,317
1551,"Usher syndrome, type 1G, 606943 (3)","SANS, USH1G",607696,17q24-q25,multiple,124590,1,117,157
1551,"Usher syndrome, type 2A, 276901 (3)",USH2A,608400,1q41,multiple,7399,1,117,423
1551,"Usher syndrome, type 1F, 602083 (3)","PCDH15, DFNB23",605514,10q21-q22,multiple,65217,1,117,465
1551,"Usher syndrome, type 1B (3)","MYO7A, USH1B, DFNB2, DFNA11",276903,11q13.5,multiple,4647,1,117,468
1551,"Usher syndrome, type 1C, 276904 (3)","USH1C, DFNB18",605242,11p15.1,multiple,10083,1,117,480
1551,"Usher syndrome, type 1D, 601067 (3)","CDH23, USH1D",605516,10q21-q22,multiple,64072,1,117,484
1551,"Usher syndrome, type IIC, 605472 (3)","MASS1, VLGR1, KIAA0686, FEB4, USH2C",602851,5q14,multiple,84059,1,117,677
1551,"Usher syndrome, type 3, 276902 (3)","USH3A, USH3",606397,3q21-q25,multiple,7401,1,117,879
1503,Thyroid carcinoma (3),"TP53, P53, LFS1",191170,17p13.1,Cancer,7157,1,118,20
1503,"Thyroid carcinoma, papillary, 188550 (3)","PRKAR1A, TSE1, CNC1, CAR",188830,17q23-q24,Cancer,5573,1,118,54
1503,"Thyroid carcinoma, follicular, 188470 (3)","PTEN, MMAC1",601728,10q23.31,Cancer,5728,1,118,77
1503,"Thyroid carcinoma, papillary, 188550 (3)","TIF1G, RFG7, PTC7",605769,1p13,Cancer,51592,1,118,159
1503,"Thyroid adenoma, hyperfunctioning (3)",TSHR,603372,14q31,Cancer,7253,1,118,356
1503,"Thyroid carcinoma, follicular, somatic, 188470 (3)",HRAS,190020,11p15.5,Cancer,3265,1,118,408
1503,"Thyroid carcinoma, papillary, 188550 (3)","TRIM24, TIF1, TIF1A, PTC6",603406,7q32-q34,Cancer,8805,1,118,813
1503,"Thyroid carcinoma, papillary, 188550 (3)","NCOA4, ELE1, PTC3",601984,10q11.2,Cancer,8031,1,118,845
1503,"Thyroid carcinoma, papillary, 188550 (3)","PCM1, PTC4",600299,8p22-p21.3,Cancer,5108,1,118,884
1503,"Thyroid carcinoma, follicular, 188470 (3)","MINPP1, HIPER1",605391,10q23,Cancer,9562,1,118,885
1503,"Thyroid carcinoma, papillary, 188550 (3)","GOLGA5, RFG5, PTC5",606918,14q,Cancer,9950,1,118,886
1047,"Myeloid malignancy, predisposition to (3)","CSF1R, FMS",164770,5q33.2-q33.3,Cancer,1436,1,119,160
1047,"Myelogenous leukemia, acute (3)","IRF1, MAR",147575,5q31.1,Cancer,3659,1,119,331
1047,"Myelogenous leukemia, acute (3)","FACL6, ACS2",604443,5q31,Cancer,23305,1,119,691
1047,"Myeloid leukemia, acute, M4Eo subtype (3)",CBFB,121360,16q22,Cancer,865,1,119,733
98,"Alzheimer disease-4, 606889 (3)","PSEN2, AD4, STM2",600759,1q31-q42,Neurological,5664,1,120,162
98,"Alzheimer disease, type 3, 607822 (3)","PSEN1, AD3",104311,14q24.3,Neurological,5663,1,120,164
98,"Alzheimer disease, type 3, with spastic paraparesis and apraxia, 607822 (3)","PSEN1, AD3",104311,14q24.3,Neurological,5663,1,120,164
98,"Alzheimer disease, type 3, with spastic paraparesis and unusual plaques, 607822 (3)","PSEN1, AD3",104311,14q24.3,Neurological,5663,1,120,164
98,"Alzheimer disease-1, APP-related (3)","APP, AAA, CVAP, AD1",104760,21q21,Neurological,351,1,120,384
98,"Alzheimer disease, susceptibility to, 104300 (3)","ACE, DCP1, ACE1",106180,17q23,Neurological,1636,1,120,387
98,"Alzheimer disease-2, 104310 (3)","APOE, AD2",107741,19q13.2,Neurological,348,1,120,415
98,"Alzheimer disease, susceptibility to (3)","BLMH, BMH",602403,17q11.2,Neurological,642,1,120,433
98,"Alzheimer disease, late-onset, susceptibility to, 104300 (3)",NOS3,163729,7q36,Neurological,4846,1,120,584
98,"Alzheimer disease, late-onset, 104300 (3)","APBB2, FE65L1",602710,4p14,Neurological,323,1,120,585
98,"Alzheimer disease, susceptibility to (3)",A2M,103950,12p13.3-p12.3,Neurological,2,1,120,586
98,"Alzheimer disease, susceptibility to, 104300 (3)",MPO,606989,17q23.1,Neurological,4353,1,120,587
98,"Alzheimer disease, late-onset, susceptibility to, 104300 (3)","PLAU, URK",191840,10q24,Neurological,5328,1,120,588
98,"Alzheimer disease, susceptibility to, 104300 (3)","PACIP1, PAXIP1L, PTIP",608254,7q36,Neurological,22976,1,120,589
617,"Goiter, congenital (3)","TPO, TPX",606765,2p25,Endocrine,7173,1,121,163
617,"Goiter, nonendemic, simple (3)","TG, AITD3",188450,8q24.2-q24.3,Endocrine,7038,1,121,355
755,"Hyperthyroidism, congenital (3)","TPO, TPX",606765,2p25,Endocrine,7173,1,122,163
3503,"Thyroid hormone organification defect IIA, 274500 (3)","TPO, TPX",606765,2p25,Endocrine,7173,1,123,163
3503,"Thyroid hormone resistance, 188570 (3)","THRB, ERBA2, THR1",190160,3p24.3,Endocrine,7068,1,123,656
3503,"Thyroid hormone resistance, autosomal recessive, 274300 (3)","THRB, ERBA2, THR1",190160,3p24.3,Endocrine,7068,1,123,656
3512,"Total iodide organification defect, 274500 (3)","TPO, TPX",606765,2p25,Endocrine,7173,1,124,163
412,"Dementia, frontotemporal, with parkinsonism, 600274 (3)","MAPT, MTBT1, DDPAC, MSTD",157140,17q21.1,Neurological,4137,1,125,17
412,"Dementia, Pick disease-like, 172700 (3)","MAPT, MTBT1, DDPAC, MSTD",157140,17q21.1,Neurological,4137,1,125,17
412,"Dementia, frontotemporal, 600274 (3)","PSEN1, AD3",104311,14q24.3,Neurological,5663,1,125,164
412,"Dementia, Lewy body, 127750 (3)",SNCB,602569,5q35,Neurological,6620,1,125,224
412,"Dementia, Lewy body, 127750 (3)","SNCA, NACP, PARK1, PARK4",163890,4q21,Neurological,6622,1,125,225
412,"Dementia, vascular, susceptibility to (3)","TNF, TNFA",191160,6p21.3,Neurological,7124,1,125,315
412,"Dementia, familial British, 176500 (3)","ITM2B, BRI, ABRI, FBD",603904,13q14,Neurological,9445,1,125,350
412,"Dementia, familial Danish, 117300 (3)","ITM2B, BRI, ABRI, FBD",603904,13q14,Neurological,9445,1,125,350
1225,"Pick disease, 172700 (3)","PSEN1, AD3",104311,14q24.3,Neurological,5663,1,126,164
1423,Spherocytosis-1 (3),SPTB,182870,14q22-q23.2,Hematological,6710,1,127,61
1423,"Spherocytosis, recessive (3)",SPTA1,182860,1q21,Hematological,6708,1,127,62
1423,"Spherocytosis, hereditary (3)","SLC4A1, AE1, EPB3",109270,17q21-q22,Hematological,6521,1,127,63
1423,Spherocytosis-2 (3),"ANK1, SPH2",182900,8p11.2,Hematological,286,1,127,165
1423,"Spherocytosis, hereditary, Japanese type (3)",EPB42,177070,15q15,Hematological,2038,1,127,573
912,"Long QT syndrome-3, 603830 (3)","SCN5A, LQT3, IVF, HB1, SSS1",600163,3p21,Cardiovascular,6331,1,128,51
912,"Long QT syndrome 4, 600919 (3)","ANK2, LQT4",106410,4q25-q27,Cardiovascular,287,1,128,166
912,Long QT syndrome-5 (3),"KCNE1, JLNS, LQT5",176261,21q22.1-q22.2,Cardiovascular,3753,1,128,216
912,Long QT syndrome-6 (3),"KCNE2, MIRP1, LQT6",603796,21q22.1,Cardiovascular,9992,1,128,217
912,"Long QT syndrome-1, 192500 (3)","KCNQ1, KCNA9, LQT1, KVLQT1, ATFB1",607542,11p15.5,Cardiovascular,3784,1,128,218
912,Long QT syndrome-2 (3),"KCNH2, LQT2, HERG",152427,7q35-q36,Cardiovascular,3757,1,128,219
912,"Long QT syndrome-7, 170390 (3)","KCNJ2, HHIRK1, KIR2.1, IRK1, LQT7",600681,17q23.1-q24.2,Cardiovascular,3759,1,128,220
1383,"Severe combined immunodeficiency due to ADA deficiency, 102700 (3)",ADA,608958,20q13.11,Immunological,100,1,129,168
1383,"Severe combined immunodeficiency, T-cell negative, B-cell/natural killer cell-positive type, 600802 (3)",IL7R,146661,5p13,Immunological,3575,1,129,169
1383,Severe combined immunodeficiency due to PTPRC deficiency (3),"PTPRC, CD45, LCA",151460,1q31-q32,Immunological,5788,1,129,170
1383,"Severe combined immunodeficiency, X-linked, 300400 (3)","IL2RG, SCIDX1, SCIDX, IMD4",308380,Xq13,Immunological,3561,1,129,171
1383,"Severe combined immunodeficiency, T-negative/B-positive type, 600802 (3)","CD3D, T3D",186790,11q23,Immunological,915,1,129,172
1383,"Severe combined immunodeficiency, Athabascan type, 602450 (3)","DCLRE1C, ARTEMIS, SCIDA",605988,10p,Immunological,64421,1,129,173
1383,"Severe combined immunodeficiency, B cell-negative, 601457 (3)",RAG2,179616,11p13,Immunological,5897,1,129,174
1383,"Severe combined immunodeficiency, B cell-negative, 601457 (3)",RAG1,179615,11p13,Immunological,5896,1,129,175
1385,Sezary syndrome (3),BCL10,603517,1p22,Cancer,8915,1,130,176
1386,"Shah-Waardenburg syndrome, 277580 (3)",EDN3,131242,20q13.2-q13.3,multiple,1908,1,131,177
1388,"Shprintzen-Goldberg syndrome, 182212 (3)","FBN1, MFS1, WMS",134797,15q21.1,multiple,2200,1,132,178
723,"Hypercholanemia, familial, 607748 (3)",BAAT,602938,9q22.3,Gastrointestinal,570,1,133,179
723,"Hypercholanemia, familial, 607748 (3)","TJP2, ZO2",607709,9q12-q13,Gastrointestinal,9414,1,133,676
723,"Hypercholanemia, familial, 607748 (3)",EPHX1,132810,1q42.1,Gastrointestinal,2052,1,133,754
1186,"Paragangliomas, familial nonchromaffin, 3, 605373 (3)","SDHC, PGL3",602413,1q21,Cancer,6391,1,134,180
1186,"Paraganglioma, familial malignant, 168000 (3)","SDHB, SDH1, SDHIP",185470,1p36.1-p35,Cancer,6390,1,134,181
1186,"Paragangliomas, familial central nervous system, 168000 (3)","SDHD, PGL1",602690,11q23,Cancer,6392,1,134,182
1186,"Paragangliomas, familial nonchromaffin, 1, with and without deafness, 168000 (3)","SDHD, PGL1",602690,11q23,Cancer,6392,1,134,182
1186,"Paraganglioma, sporadic corotid body, 168000 (3)","SDHD, PGL1",602690,11q23,Cancer,6392,1,134,182
1218,"Pheochromocytoma, extraadrenal, and cervical paraganglioma, 115310 (3)","SDHB, SDH1, SDHIP",185470,1p36.1-p35,Cancer,6390,1,135,181
1218,"Pheochromocytoma, 171300 (3)","SDHD, PGL1",602690,11q23,Cancer,6392,1,135,182
1218,"Pheochromocytoma, 171300 (3)",VHL,608537,3p26-p25,Cancer,7428,1,135,311
992,"Merkel cell carcinoma, somatic (3)","SDHD, PGL1",602690,11q23,Cancer,6392,1,136,182
265,"Carcinoid tumors, intestinal, 114900 (3)","SDHD, PGL1",602690,11q23,Cancer,6392,1,137,182
153,"Asthma, dimished response to antileukotriene treatment in, 600807 (3)",ALOX5,152390,10q11.2,Respiratory,240,1,138,183
153,"Asthma, susceptibility to, 600807 (3)","TNF, TNFA",191160,6p21.3,Respiratory,7124,1,138,315
153,"Asthma, susceptibility to, 1, 607277 (3)","PTGDR, AS1",604687,14q22.1,Respiratory,5729,1,138,322
153,"Asthma, 600807 (3)","PHF11, NYREN34",607796,13q14.1,Respiratory,51131,1,138,491
153,"Asthma, susceptibility to, 600807 (3)","PLA2G7, PAFAH",601690,6p21.2-p12,Respiratory,7941,1,138,547
153,"Asthma, nocturnal, susceptibility to (3)",ADRB2,109690,5q32-q34,Respiratory,154,1,138,635
153,"Asthma, susceptibility to, 600807 (3)","IL13, ALRH",147683,5q31,Respiratory,3596,1,138,661
153,"Asthma, susceptibility to, 600807 (3)","SCGB3A2, UGRP1",606531,5q31-q34,Respiratory,117156,1,138,666
153,"Asthma, susceptibility to, 600807 (3)","IL12B, NKSF2",161561,5q31.1-q33.1,Respiratory,3593,1,138,801
153,"Asthma, susceptibility to, 2, 608584 (3)","GPR154, GPRA, VRR1, PGR14",608595,7p15-p14,Respiratory,387129,1,138,810
153,"Asthma, susceptibility to (3)",HNMT,605238,1p32,Respiratory,3176,1,138,839
153,"Asthma, susceptibility to, 600807 (3)","UGB, CC10, CCSP, SCGB1A1",192020,11q12.3-q13.1,Respiratory,7356,1,138,840
153,"Asthma, atopic, susceptibility to (3)","MS4A2, FCER1B",147138,11q13,Respiratory,2206,1,138,841
163,"Atherosclerosis, susceptibility to (3)",ALOX5,152390,10q11.2,Cardiovascular,240,1,139,183
1315,"Retinal degeneration, late-onset, autosomal dominant, 605670 (3)","C1QTNF5, CTRP5, LORD",608752,11q23.3,Ophthamological,114902,1,140,184
1315,"Retinal degeneration, autosomal recessive, prominin-related (3)","PROM1, PROML1, AC133",604365,4p16.2-p12,Ophthamological,8842,1,140,634
1315,"Retinal degeneration, autosomal recessive, clumped pigment type (3)","NRL, D14S46E, RP27",162080,14q11.1-q11.2,Ophthamological,4901,1,140,789
1315,"Retinal dystrophy, early-onset severe (3)",LRAT,604863,4q31,Ophthamological,9227,1,140,794
1454,"Stroke, susceptibility to, 601367 (3)","ALOX5AP, FLAP",603700,13q12,Cardiovascular,241,1,141,185
1454,"Stroke, susceptibility to, 1, 606799 (3)","PDE4D, DPDE3, STRK1",600129,5q12,Cardiovascular,5144,1,141,536
1054,"Myocardial infarction, susceptibility to (3)","ALOX5AP, FLAP",603700,13q12,Cardiovascular,241,1,142,185
1054,"Myocardial infarction, decreased susceptibility to (3)",F7,227500,13q34,Cardiovascular,2155,1,142,364
1054,"Myocardial infarction, susceptibility to (3)","ACE, DCP1, ACE1",106180,17q23,Cardiovascular,1636,1,142,387
1054,Myocardial infarction susceptibility (3),"APOE, AD2",107741,19q13.2,Cardiovascular,348,1,142,415
1054,"Myocardial infarction, susceptibility to, 608446 (3)","GCLM, GLCLR",601176,1p22.1,Cardiovascular,2730,1,142,436
1054,"Myocardial infarction, susceptibility to (3)","OLR1, LOX1",602601,12p13-p12,Cardiovascular,4973,1,142,653
1054,"Myocardial infarction, susceptibility to (3)","THBD, THRM",188040,20p11.2,Cardiovascular,7056,1,142,752
1054,"Myocardial infarction, susceptibility to (3)",LGALS2,150571,22q13.1,Cardiovascular,3957,1,142,819
1054,"Myocardial infarction, susceptibility to (3)","LTA, TNFB",153440,6p21.3,Cardiovascular,4049,1,142,820
1054,"Myocardial infarction, susceptibility to, 608446 (3)","TNFSF4, GP34, OX4OL",603594,1q25,Cardiovascular,7292,1,142,821
948,"Maple syrup urine disease, type III, 248600 (3)","DLD, LAD, PHE3",238331,7q31-q32,Metabolic,2654,1,143,87
948,"Maple syrup urine disease, type Ib (3)","BCKDHB, E1B",248611,6p22-p21,Metabolic,594,1,143,186
948,"Maple syrup urine disease, type Ia, 248600 (3)","BCKDHA, MSUD1",608348,19q13.1-q13.2,Metabolic,593,1,143,191
948,"Maple syrup urine disease, type II (3)","DBT, BCATE2",248610,1p31,Metabolic,1629,1,143,541
1572,"von Hippel-Lindau disease, modification of, 193300 (3)","CCND1, PRAD1, BCL1",168461,11q13,Cancer,595,1,144,187
1572,"von Hippel-Lindau syndrome, 193300 (3)",VHL,608537,3p26-p25,Cancer,7428,1,144,311
1281,Pseudohypoaldosteronism type II (3),"WNK4, PRKWNK4, PHA2B",601844,17q21-q22,Endocrine,65266,1,145,189
1281,"Pseudohypoaldosteronism, type I, 264350 (3)","SCNN1G, PHA1",600761,16p13-p12,Endocrine,6340,1,145,358
1281,"Pseudohypoaldosteronism, type I, 264350 (3)",SCNN1B,600760,16p13-p12,Endocrine,6338,1,145,359
1281,"Pseudohypoaldosteronism, type IIC, 145260 (3)","WNK1, PRKWNK1, KDP, PHA2C",605232,12p13,Endocrine,65125,1,145,558
1281,"Pseudohypoaldosteronism type I, autosomal dominant, 177735 (3)","NR3C2, MLR, MCR",600983,4q31.1,Endocrine,4306,1,145,765
1281,"Pseudohypoaldosteronism, type I, 264350 (3)",SCNN1A,600228,12p13,Endocrine,6337,1,145,883
362,"Cornea plana congenita, recessive, 217300 (3)","KERA, CNA2",603288,12q22,Ophthamological,11081,1,146,192
362,"Corneal dystrophy, hereditary polymorphous posterior, 2, 122000 (3)","COL8A2, FECD, PPCD2",120252,1p34.3-p32.3,Ophthamological,1296,1,146,205
362,"Corneal fleck dystrophy, 121850 (3)","PIP5K3, CFD",609414,2q35,Ophthamological,200576,1,146,336
362,"Corneal clouding, autosomal recessive (3)",APOA1,107680,11q23,Ophthamological,335,1,146,594
362,"Corneal dystrophy, Avellino type, 607541 (3)","TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2",601692,5q31,Ophthamological,7045,1,146,724
362,"Corneal dystrophy, Groenouw type I, 121900 (3)","TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2",601692,5q31,Ophthamological,7045,1,146,724
362,"Corneal dystrophy, lattice type I, 122200 (3)","TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2",601692,5q31,Ophthamological,7045,1,146,724
362,"Corneal dystrophy, lattice type IIIA, 608471 (3)","TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2",601692,5q31,Ophthamological,7045,1,146,724
362,"Corneal dystrophy, Reis-Bucklers type, 608470 (3)","TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2",601692,5q31,Ophthamological,7045,1,146,724
362,"Corneal dystrophy, Thiel-Behnke type, 602082 (3)","TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2",601692,5q31,Ophthamological,7045,1,146,724
362,"Corneal dystrophy, gelatinous drop-like, 204870 (3)","TACSTD2, TROP2, M1S1",137290,1p32,Ophthamological,4070,1,146,725
362,"Corneal dystrophy, hereditary polymorphous posterior, 122000 (3)","VSX1, RINX, PPCD, PPD, KTCN",605020,20p11.2,Ophthamological,30813,1,146,726
1594,"Williams-Beuren syndrome, 194050 (3)",ELN,130160,7q11.2,multiple,2006,1,147,194
395,"Cutis laxa, AD, 123700 (3)",ELN,130160,7q11.2,Connective tissue disorder,2006,1,148,194
395,"Cutis laxa, neonatal (3)","ATP7A, MNK, MK, OHS",300011,Xq12-q13,Connective tissue disorder,538,1,148,647
395,"Cutis laxa, autosomal dominant, 123700 (3)","FBLN5, ARMD3",604580,14q32.1,Connective tissue disorder,10516,1,148,812
395,"Cutis laxa, autosomal recessive, 219100 (3)","FBLN5, ARMD3",604580,14q32.1,Connective tissue disorder,10516,1,148,812
1463,"Supravalvar aortic stenosis, 185500 (3)",ELN,130160,7q11.2,Cardiovascular,2006,1,149,194
1164,"Osteoporosis-pseudoglioma syndrome, 259770 (3)","LRP5, BMND1, LRP7, LR3, OPPG, VBCH2",603506,11q13.4,Bone,4041,1,150,195
1166,Osteosarcoma (3),"TP53, P53, LFS1",191170,17p13.1,Cancer,7157,1,151,20
1166,"Osteosarcoma, somatic, 259500 (3)","CHEK2, RAD53, CHK2, CDS1, LFS2",604373,22q12.1,Cancer,11200,1,151,196
1163,"Osteoporosis, idiopathic, 166710 (3)",COL1A2,120160,7q22.1,Bone,1278,1,152,67
1163,"Osteoporosis, 166710 (3)",COL1A1,120150,17q21.31-q22,Bone,1277,1,152,68
1163,"Osteoporosis, 166710 (3)","LRP5, BMND1, LRP7, LR3, OPPG, VBCH2",603506,11q13.4,Bone,4041,1,152,195
1163,"Osteoporosis, postmenopausal, susceptibility, 166710 (3)","CALCR, CRT",114131,7q21.3,Bone,799,1,152,198
1163,Osteoporosis (3),"CALCA, CALC1",114130,11p15.2-p15.1,Bone,796,1,152,199
1163,"Osteoporosis, hypophosphatemic, (3)","SLC17A2, NPT2",182309,5q35,Bone,6569,1,152,200
1617,"Zlotogora-Ogur syndrome, 225000 (3)","HVEC, PVRL1, PVRR1, PRR1",600644,11q23-q24,multiple,5818,1,153,201
1614,"Yemenite deaf-blind hypopigmentation syndrome, 601706 (3)","SOX10, WS4",602229,22q13,multiple,6663,1,154,202
465,"EBD, Bart type, 132000 (3)",COL7A1,120120,3p21.3,Dermatological,1294,1,155,203
465,"EBD, localisata variant (3)",COL7A1,120120,3p21.3,Dermatological,1294,1,155,203
493,"Epidermolysis bullosa dystrophica, AD, 131750 (3)",COL7A1,120120,3p21.3,Dermatological,1294,1,156,203
493,"Epidermolysis bullosa dystrophica, AR, 226600 (3)",COL7A1,120120,3p21.3,Dermatological,1294,1,156,203
493,"Epidermolysis bullosa, pretibial, 131850 (3)",COL7A1,120120,3p21.3,Dermatological,1294,1,156,203
493,"Epidermolysis bullosa pruriginosa, 604129 (3)",COL7A1,120120,3p21.3,Dermatological,1294,1,156,203
493,"Epidermolysis bullosa, generalized atrophic benign, 226650 (3)","LAMA3, LOCS",600805,18q11.2,Dermatological,3909,1,156,256
493,"Epidermolysis bullosa, junctional, Herlitz type, 226700 (3)","LAMA3, LOCS",600805,18q11.2,Dermatological,3909,1,156,256
493,"Epidermolysis bullosa, generalized atrophic benign, 226650 (3)",ITGB4,147557,17q11-qter,Dermatological,3691,1,156,295
493,"Epidermolysis bullosa, junctional, with pyloric atresia, 226730 (3)",ITGB4,147557,17q11-qter,Dermatological,3691,1,156,295
493,"Epidermolysis bullosa of hands and feet, 131800 (3)",ITGB4,147557,17q11-qter,Dermatological,3691,1,156,295
493,"Epidermolysis bullosa simplex, Koebner, Dowling-Meara, and Weber-Cockayne types, 131900, 131760, 131800 (3)",KRT14,148066,17q12-q21,Dermatological,3861,1,156,360
493,"Epidermolysis bullosa simplex, recessive, 601001 (3)",KRT14,148066,17q12-q21,Dermatological,3861,1,156,360
493,"Epidermolysis bullosa, lethal acantholytic, 609638 (3)","DSP, KPPS2, PPKS2",125647,6p24,Dermatological,1832,1,156,394
493,"Epidermolysis bullosa, junctional, with pyloric stenosis, 226730 (3)",ITGA6,147556,Chr.2,Dermatological,3655,1,156,654
493,"Epidermolysis bullosa simplex, Ogna type, 131950 (3)","PLEC1, PLTN, EBS1",601282,8q24,Dermatological,5339,1,156,709
493,"Epidermolysis bullosa, generalized atrophic benign, 226650 (3)","LAMC2, LAMNB2, LAMB2T",150292,1q25-q31,Dermatological,3918,1,156,716
493,"Epidermolysis bullosa, Herlitz junctional type, 226700 (3)","LAMC2, LAMNB2, LAMB2T",150292,1q25-q31,Dermatological,3918,1,156,716
493,"Epidermolysis bullosa, generalized atrophic benign, 226650 (3)","COL17A1, BPAG2",113811,10q24.3,Dermatological,1308,1,156,835
493,"Epidermolysis bullosa simplex, Koebner, Dowling-Meara, and Weber-Cockayne types, 131900, 131760, 131800 (3)",KRT5,148040,12q13,Dermatological,3852,1,156,860
493,"Epidermolysis bullosa simplex with mottled pigmentation, 131960 (3)",KRT5,148040,12q13,Dermatological,3852,1,156,860
493,"Epidermolysis bullosa, generalized atrophic benign, 226650 (3)",LAMB3,150310,1q32,Dermatological,3914,1,156,861
493,"Epidermolysis bullosa, Herlitz junctional type, 226700 (3)",LAMB3,150310,1q32,Dermatological,3914,1,156,861
1510,"Toenail dystrophy, isolated, 607523 (3)",COL7A1,120120,3p21.3,Dermatological,1294,1,157,203
1518,"Transient bullous of the newborn, 131705 (3)",COL7A1,120120,3p21.3,Dermatological,1294,1,158,203
496,"Epiphyseal dysplasia, multiple, COL9A1-related (3)","COL9A1, MED",120210,6q13,Bone,1297,1,159,204
496,"Epiphyseal dysplasia, multiple, 3, 600969 (3)","COL9A3, EDM3, IDD",120270,20q13.3,Bone,1299,1,159,206
496,"Epiphyseal dysplasia, multiple, with myopathy (3)","COL9A3, EDM3, IDD",120270,20q13.3,Bone,1299,1,159,206
496,"Epiphyseal dysplasia, multiple, type 2, 600204 (3)","COL9A2, EDM2",120260,1p33-p32.2,Bone,1298,1,159,207
496,"Epiphyseal dysplasia, multiple, 226900 (3)","SLC26A2, DTD, DTDST, D5S1708, EDM4",606718,5q32-q33.1,Bone,1836,1,159,606
496,"Epiphyseal dysplasia, multiple 1, 132400 (3)","COMP, EDM1, MED, PSACH",600310,19p13.1,Bone,1311,1,159,815
496,"Epiphyseal dysplasia, multiple, 5, 607078 (3)","MATN3, EDM5, HOA",602109,2p24-p23,Bone,4148,1,159,847
558,"Fuchs endothelial corneal dystrophy, 136800 (3)","COL8A2, FECD, PPCD2",120252,1p34.3-p32.3,Ophthamological,1296,1,160,205
817,"Intervertebral disc disease, susceptibility to, 603932 (3)","COL9A3, EDM3, IDD",120270,20q13.3,Neurological,1299,1,161,206
817,"Intervertebral disc disease, susceptibility to, 603932 (3)","COL9A2, EDM2",120260,1p33-p32.2,Neurological,1298,1,161,207
1128,"Obsessive-compulsive disorder, protection against, 164230 (3)",BDNF,113505,11p13,Psychiatric,627,1,162,208
1128,"Obsessive-compulsive disorder, susceptibility to, 164230 (3)",HTR2A,182135,13q14-q21,Psychiatric,3356,1,162,416
1128,"Obsessive-compulsive disorder 1, 164230 (3)","SLC6A4, HTT, OCD1",182138,17q11.1-q12,Psychiatric,6532,1,162,629
984,"Memory impairment, susceptibility to (3)",BDNF,113505,11p13,Neurological,627,1,163,208
365,"Coronary artery disease, susceptibility to (3)","PON1, PON, ESA",168820,7q21.3,Cardiovascular,5444,1,164,212
365,"Coronary artery spasm, susceptibility to (3)","PON1, PON, ESA",168820,7q21.3,Cardiovascular,5444,1,164,212
365,"Coronary artery disease in familial hypercholesterolemia, protection against, 143890 (3)","ABCA1, ABC1, HDLDT1, TGD",600046,9q22-q31,Cardiovascular,19,1,164,435
365,"Coronary artery disease, autosomal dominant, 1, 608320 (3)","MEF2A, ADCAD1",600660,15q26,Cardiovascular,4205,1,164,720
365,"Coronary artery disease, susceptibility to (3)",PON2,602447,7q21.3,Cardiovascular,5445,1,164,721
365,"Coronary heart disease, susceptibility to (3)","MMP3, STMY1",185250,11q23,Cardiovascular,4314,1,164,722
365,"Coronary artery disease, susceptibility to (3)",KL,604824,13q12,Cardiovascular,9365,1,164,723
910,"Loeys-Dietz syndrome, 609192 (3)","TGFBR2, HNPCC6",190182,3p22,Connective tissue disorder,7048,1,165,213
910,"Loeys-Dietz syndrome, 609192 (3)",TGFBR1,190181,9q33-q34,Connective tissue disorder,7046,1,165,214
913,"Lower motor neuron disease, progressive, without sensory symptoms, 607641 (3)",DCTN1,601143,2p13,Neurological,1639,1,166,215
1397,"Simpson-Golabi-Behmel syndrome, type 1, 312870 (3)","GPC3, SDYS, SGBS1",300037,Xq26,multiple,2719,1,167,221
1595,"Wilms tumor, 194070 (3)","BRCA2, FANCD1",600185,13q12.3,Cancer,675,1,168,19
1595,"Wilms tumor, somatic, 194070 (3)","GPC3, SDYS, SGBS1",300037,Xq26,Cancer,2719,1,168,221
1595,"Wilms tumor, type 1, 194070 (3)",WT1,607102,11p13,Cancer,7490,1,168,305
1595,"Wilms tumor susceptibility-5, 601583 (3)","POU6F2, WTSL, WT5",609062,7p14-p13,Cancer,11281,1,168,318
1192,"Parkinson disease 4, autosomal dominant Lewy body, 605543 (3)","SNCA, NACP, PARK1, PARK4",163890,4q21,Neurological,6622,1,169,225
1192,"Parkinson disease, familial, 168601 (3)","SNCA, NACP, PARK1, PARK4",163890,4q21,Neurological,6622,1,169,225
1192,"Parkinson disease, juvenile, type 2, 600116 (3)","PRKN, PARK2, PDJ",602544,6q25.2-q27,Neurological,5071,1,169,243
1192,"Parkinson disease, 168600 (3)",SNCAIP,603779,5q23.1-q23.3,Neurological,9627,1,169,389
1192,"Parkinson disease 7, autosomal recessive early-onset, 606324 (3)","DJ1, PARK7",602533,1p36,Neurological,11315,1,169,409
1192,"Parkinson disease, resistance to, 168600 (3)",DBH,609312,9q34,Neurological,1621,1,169,539
1192,"Parkinson disease, early onset, 605909 (3)","PINK1, PARK6",608309,1p36,Neurological,65018,1,169,570
1192,"Parkinson disease-8, 607060 (3)","LRRK2, PARK8",609007,12q12,Neurological,120892,1,169,662
1192,"Parkinson disease, 168600 (3)","NR4A2, NURR1, NOT, TINUR",601828,2q22-q23,Neurological,4929,1,169,734
1192,"Parkinson disease, familial, 168600 (3)","UCHL1, PARK5",191342,4p14,Neurological,7345,1,169,848
1192,"Parkinson disease, susceptibility to, 168600 (3)",NDUFV2,600532,18p11.31-p11.2,Neurological,4729,1,169,849
1192,"Parkinson disease, 168600 (3)","TBP, SCA17",600075,6q27,Neurological,6908,1,169,850
683,Histiocytoma (3),"TP53, P53, LFS1",191170,17p13.1,Cancer,7157,1,170,20
684,"HIV-1, susceptibility to (3)","IL10, CSIF",124092,1q31-q32,Immunological,3586,1,171,230
684,"HIV infection, susceptibility/resistance to (3)","CMKBR5, CCCKR5",601373,3p21,Immunological,1234,1,171,231
684,"HIV-1 disease, delayed progression of (3)","CCL5, SCYA5, D17S136E, TCP228",187011,17q11.2-q12,Immunological,6352,1,171,232
684,"HIV-1 disease, rapid progression of (3)","CCL5, SCYA5, D17S136E, TCP228",187011,17q11.2-q12,Immunological,6352,1,171,232
684,"HIV infection, susceptibility/resistance to (3)","CMKBR2, CCR2",601267,3p21,Immunological,1231,1,171,233
689,"Holoprosencephaly-4, 142946 (3)","TGIF, HPE4",602630,18p11.3,Developmental,7050,1,172,234
689,Holoprosencephaly-7 (3),"PTCH, NBCCS, BCNS, HPE7",601309,9q22.3,Developmental,5727,1,172,235
689,"Holoprosencephaly-2, 157170 (3)","SIX3, HPE2",603714,2p21,Developmental,6496,1,172,236
689,"Holoprosencephaly-3, 142945 (3)","SHH, HPE3, HLP3, SMMCI",600725,7q36,Developmental,6469,1,172,237
689,"Holoprosencephaly-5, 609637 (3)","ZIC2, HPE5",603073,13q32,Developmental,7546,1,172,238
46,"Adenoma, periampullary (3)","APC, GS, FPC",175100,5q21-q22,Cancer,324,1,173,239
47,Adenomatous polyposis coli (3),"APC, GS, FPC",175100,5q21-q22,Cancer,324,1,174,239
47,"Adenomatous polyposis coli, attenuated (3)","APC, GS, FPC",175100,5q21-q22,Cancer,324,1,174,239
47,"Adenomas, multiple colorectal, 608456 (3)",MUTYH,604933,1p34.3-p32.1,Cancer,4595,1,174,240
47,"Adenomas, salivary gland pleomorphic, 181030 (3)","PLAG1, SGPA, PSA",603026,8q12,Cancer,5324,1,174,241
45,"Adenocarcinoma of lung, somatic, 211980 (3)","ERBB2, NGL, NEU, HER2",164870,17q21.1,Cancer,2064,1,175,12
45,"Adenocarcinoma of lung, response to tyrosine kinase inhibitor in, 211980 (3)",EGFR,131550,7p12.3-p12.1,Cancer,1956,1,175,242
45,"Adenocarcinoma of lung, somatic, 211980 (3)","PRKN, PARK2, PDJ",602544,6q25.2-q27,Cancer,5071,1,175,243
45,"Adenocarcinoma, ovarian, somatic (3)","PRKN, PARK2, PDJ",602544,6q25.2-q27,Cancer,5071,1,175,243
45,"Adenocarcinoma of lung, somatic, 211980 (3)",BRAF,164757,7q34,Cancer,673,1,175,244
49,"Adenosine deaminase deficiency, partial, 102700 (3)",ADA,608958,20q13.11,Immunological,100,1,176,168
594,"Glomerulocystic kidney disease, hypoplastic, 137920 (3)","TCF2, HNF2",189907,17cen-q21.3,Renal,6928,1,177,245
1020,MODY5 with nephron agenesis (3),"TCF2, HNF2",189907,17cen-q21.3,Endocrine,6928,1,178,245
1020,MODY5 with non-diabetic renal disease and Mullerian aplasia (3),"TCF2, HNF2",189907,17cen-q21.3,Endocrine,6928,1,178,245
1020,"MODY, type V, 604284 (3)","TCF2, HNF2",189907,17cen-q21.3,Endocrine,6928,1,178,245
1020,"MODY, type III, 600496 (3)","TCF1, HNF1A, MODY3",142410,12q24.2,Endocrine,6927,1,178,248
1020,"MODY, type I, 125850 (3)","HNF4A, TCF14, MODY1",600281,20q12-q13.1,Endocrine,3172,1,178,339
1020,"MODY, one form, 125850 (3)",INS,176730,11p15.5,Endocrine,3630,1,178,340
1020,"MODY, type II, 125851 (3)",GCK,138079,7p15-p13,Endocrine,2645,1,178,341
1020,"MODY, type IV (3)",IPF1,600733,13q12.1,Endocrine,3651,1,178,342
427,"Diabetes mellitus, insulin-resistant, with acanthosis nigricans and hypertension, 604367 (3)","PPARG, PPARG1, PPARG2",601487,3p25,Endocrine,5468,1,179,47
427,"Diabetes mellitus, noninsulin-dependent, 125853 (3)","TCF2, HNF2",189907,17cen-q21.3,Endocrine,6928,1,179,245
427,"Diabetes mellitus, insulin-dependent, 222100 (3)","TCF1, HNF1A, MODY3",142410,12q24.2,Endocrine,6927,1,179,248
427,"Diabetes mellitus, noninsulin-dependent, 2, 125853 (3)","TCF1, HNF1A, MODY3",142410,12q24.2,Endocrine,6927,1,179,248
427,"Diabetes mellitus, insulin-dependent, 5, 600320 (3)","SUMO4, IDDM5",608829,6q25,Endocrine,387082,1,179,289
427,"Diabetes mellitus, noninsulin-dependent, 125853 (3)","HNF4A, TCF14, MODY1",600281,20q12-q13.1,Endocrine,3172,1,179,339
427,"Diabetes mellitus, neonatal-onset, 606176 (3)",GCK,138079,7p15-p13,Endocrine,2645,1,179,341
427,"Diabetes mellitus, type II, susceptibility to, 125853 (3)",IPF1,600733,13q12.1,Endocrine,3651,1,179,342
427,"Diabetes mellitus, noninsulin-dependent, 125853 (3)",GCGR,138033,17q25,Endocrine,2642,1,179,345
427,"Diabetes mellitus, noninsulin-dependent (3)","SLC2A2, GLUT2",138160,3q26.1-q26.3,Endocrine,6514,1,179,361
427,"Diabetic nephropathy, susceptibility to, 603933 (3)","ACE, DCP1, ACE1",106180,17q23,Endocrine,1636,1,179,387
427,"Diabetes mellitus, noninsulin-dependent, 125853 (3)",IRS2,600797,13q34,Endocrine,8660,1,179,393
427,"Diabetes mellitus, insulin-resistant, with acanthosis nigricans (3)",INSR,147670,19p13.2,Endocrine,3643,1,179,403
427,"Diabetes mellitus, noninsulin-dependent, 601283 (3)",CAPN10,605286,2q37.3,Endocrine,11132,1,179,421
427,"Diabetes mellitus, permanent neonatal, with cerebellar agenesis, 609069 (3)",PTF1A,607194,10p12.3,Endocrine,256297,1,179,545
427,"Diabetes mellitus, noninsulin-dependent, 125853 (3)","NEUROD1, NIDDM",601724,2q32,Endocrine,4760,1,179,551
427,"Diabetes mellitus, 125853 (3)","ABCC8, SUR, PHHI, SUR1",600509,11p15.1,Endocrine,6833,1,179,563
427,"Diabetes mellitus, type I, susceptibility to, 222100 (3)","FOXP3, IPEX, AIID, XPID, PIDX",300292,Xp11.23-q13.3,Endocrine,50943,1,179,575
427,"Diabetes mellitus, noninsulin-dependent (3)",IRS1,147545,2q36,Endocrine,3667,1,179,579
427,"Diabetes mellitus, noninsulin-dependent, 125853 (3)",GPD2,138430,2q24.1,Endocrine,2820,1,179,597
427,"Diabetes mellitus, non-insulin-dependent, susceptibility to, 125853 (3)","ENPP1, PDNP1, NPPS, M6S1, PCA1",173335,6q22-q23,Endocrine,5167,1,179,644
427,"Diabetes mellitus, permanent neonatal, with neurologic features, 606176 (3)","KCNJ11, BIR, PHHI",600937,11p15.1,Endocrine,3767,1,179,668
427,"Diabetes, permanent neonatal, 606176 (3)","KCNJ11, BIR, PHHI",600937,11p15.1,Endocrine,3767,1,179,668
427,"Diabetes mellitus, noninsulin-dependent (3)","SLC2A4, GLUT4",138190,17p13,Endocrine,6517,1,179,669
427,"Diabetes mellitus, noninsulin-dependent, susceptibility to, 125853 (3)","RETN, RSTN, FIZZ3",605565,19p13.2,Endocrine,56729,1,179,670
427,"Diabetes mellitus, insulin-dependent, susceptibility to, 222100 (3)","PTPN8, PEP, PTPN22, LYP",600716,1p13,Endocrine,26191,1,179,671
427,"Diabetic retinopathy, NIDDM-related, susceptibility to, 125853 (3)",VEGF,192240,6p12,Endocrine,7422,1,179,672
427,"Diabetes mellitus, noninsulin-dependent, 125853 (3)","MAPK8IP1, IB1",604641,11p12-p11.2,Endocrine,9479,1,179,673
427,"Diabetes mellitus, type II, 125853 (3)",AKT2,164731,19q13.1-q13.2,Endocrine,208,1,179,674
1101,"Neutropenia, severe congenital, 202700 (3)","GFI1, ZNF163",600871,1p22,Hematological,2672,1,180,246
1101,"Neutropenia, severe congenital, X-linked, 300299 (3)","WAS, IMD2, THC",300392,Xp11.23-p11.22,Hematological,7454,1,180,320
1101,"Neutropenia, alloimmune neonatal (3)","FCGR3A, CD16, IGFR3",146740,1q23,Hematological,2214,1,180,410
1101,"Neutropenia, congenital, 202700 (3)",ELA2,130130,19p13.3,Hematological,1991,1,180,424
79,"Alexander disease, 203450 (3)","NDUFV1, UQOR1",161015,11q13,multiple,4723,1,181,83
79,"Alexander disease, 203450 (3)",GFAP,137780,17q21,multiple,2670,1,181,247
668,Hepatoblastoma (3),CTNNB1,116806,3p22-p21.3,Cancer,1499,1,182,9
668,"Hepatocellular carcinoma, 114550 (3)",CTNNB1,116806,3p22-p21.3,Cancer,1499,1,182,9
668,"Hepatocellular carcinoma, 114550 (3)","TP53, P53, LFS1",191170,17p13.1,Cancer,7157,1,182,20
668,"Hepatic adenoma, 142330 (3)","TCF1, HNF1A, MODY3",142410,12q24.2,Cancer,6927,1,182,248
668,"Hepatocellular carcinoma, childhood type, 114550 (3)",MET,164860,7q31,Cancer,4233,1,182,283
668,"Hepatocellular cancer, 114550 (3)","PDGFRL, PDGRL, PRLTS",604584,8p22-p21.3,Cancer,5157,1,182,603
668,Hepatocellular carcinoma (3),"IGF2R, MPRI",147280,6q26,Cancer,3482,1,182,627
668,"Hepatocellular carcinoma, somatic, 114550 (3)","CASP8, MCH5",601763,2q33-q34,Cancer,841,1,182,783
668,"Hepatocellular carcinoma, 114550 (3)","AXIN1, AXIN",603816,16p13.3,Cancer,8312,1,182,875
467,"Ectopia pupillae, 129750 (3)","PAX6, AN2, MGDA",607108,11p13,Ophthamological,5080,1,183,120
467,"Ectopia lentis, familial, 129600 (3)","FBN1, MFS1, WMS",134797,15q21.1,Ophthamological,2200,1,183,178
463,Dystransthyretinemic hyperthyroxinemia(3),"TTR, PALB",176300,18q11.2-q12.1,Hematological,7276,1,184,106
865,"Larson syndrome, 150250 (3)","FLNB, SCT, AOI",603381,3p14.3,Skeletal,2317,1,185,255
868,"Laryngoonychocutaneous syndrome, 245660 (3)","LAMA3, LOCS",600805,18q11.2,multiple,3909,1,186,256
269,"Carney complex, type 1, 160980 (3)","PRKAR1A, TSE1, CNC1, CAR",188830,17q23-q24,multiple,5573,1,187,54
269,"Carney complex variant, 608837 (3)",MYH8,160741,17p13.1,multiple,4626,1,187,258
261,"Capillary malformation-arteriovenous malformation, 608354 (3)","RASA1, GAP, CMAVM, PKWS",139150,5q13.3,Cardiovascular,5921,1,188,280
1308,"Renal cell carcinoma, papillary, familial and sporadic, 605074 (3)",MET,164860,7q31,Cancer,4233,1,189,283
1308,"Renal cell carcinoma, somatic (3)",VHL,608537,3p26-p25,Cancer,7428,1,189,311
1308,"Renal cell carcinoma, papillary, 1, 605074 (3)","PRCC, RCCP1",179755,1q21,Cancer,5546,1,189,344
1308,"Renal carcinoma, chromophobe, somatic, 144700 (3)","FLCN, BHD",607273,17p11.2,Cancer,201163,1,189,538
1308,"Renal cell carcinoma, 144700 (3)","TRC8, RCA1, HRCA1",603046,8q24.1,Cancer,11236,1,189,578
1308,"Renal cell carcinoma, papillary, 1, 605074 (3)",TFE3,314310,Xp11.22,Cancer,7030,1,189,688
1308,"Renal cell carcinoma, clear cell, somatic, 144700 (3)",OGG1,601982,3p26.2,Cancer,4968,1,189,694
137,"Apparent mineralocorticoid excess, hypertension due to (3)","HSD11B2, HSD11K",218030,16q22,Bone,3291,1,190,284
752,"Hypertension, essential, susceptibility to, 145500 (3)",ECE1,600423,1p36.1,Cardiovascular,1889,1,191,227
752,"Hypertension, mild low-renin (3)","HSD11B2, HSD11K",218030,16q22,Cardiovascular,3291,1,191,284
752,"Hypertension, pregnancy-induced, 189800 (3)",NOS3,163729,7q36,Cardiovascular,4846,1,191,584
752,"Hypertension, susceptibility to, 145500 (3)",NOS3,163729,7q36,Cardiovascular,4846,1,191,584
752,"Hypertension, essential, salt-sensitive, 145500 (3)",ADD1,102680,4p16.3,Cardiovascular,118,1,191,664
752,"Hypertension, insulin resistance-related, susceptibility to, 125853 (3)","RETN, RSTN, FIZZ3",605565,19p13.2,Cardiovascular,56729,1,191,670
752,"Hypertension, essential, susceptibility to, 145500 (3)","AGT, SERPINA8",106150,1q42-q43,Cardiovascular,183,1,191,753
752,"Hypertension, essential, 145500 (3)","AGTR1, AGTR1A, AT2R1",106165,3q21-q25,Cardiovascular,185,1,191,762
752,"Hypertension, salt-sensitive essential, susceptibility to, 145500 (3)","CYP3A5, P450PCN3",605325,7q22.1,Cardiovascular,1577,1,191,763
752,"Hypertension, essential, 145500 (3)","PTGIS, CYP8A1, PGIS, CYP8",601699,20q13.11-q13.13,Cardiovascular,5740,1,191,764
752,"Hypertension, early-onset, autosomal dominant, with exacerbation in pregnancy, 605115 (3)","NR3C2, MLR, MCR",600983,4q31.1,Cardiovascular,4306,1,191,765
752,"Hypertension, essential, susceptibility to, 145500 (3)",GNB3,139130,12p13,Cardiovascular,2784,1,191,766
752,"Hypertension, diastolic, resistance to, 608622 (3)",KCNMB1,603951,5q34,Cardiovascular,3779,1,191,767
1040,"Muscular dystrophy, limb-girdle, type 2J, 608807 (3)","TTN, CMD1G, TMD, LGMD2J",188840,2q24.3,Muscular,7273,1,192,263
1040,"Muscular dystrophy, limb-girdle, type IC, 607801 (3)","CAV3, LGMD1C",601253,3p25,Muscular,859,1,192,266
1040,"Muscular dystrophy, limb-girdle, type 2F, 601287 (3)","SGCD, SGD, LGMD2F, CMD1L",601411,5q33,Muscular,6444,1,192,277
1040,"Muscular dystrophy, limb-girdle, type 2G, 601954 (3)","TCAP, LGMD2G, CMD1N",604488,17q12,Muscular,8557,1,192,278
1040,"Muscular dystrophy, rigid spine, 1, 602771 (3)","SEPN1, SELN, RSMD1",606210,1p36-p35,Muscular,57190,1,192,287
1040,"Muscular dystrophy, limb-girdle, type 2K, 609308 (3)",POMT1,607423,9q34.1,Muscular,10585,1,192,303
1040,"Muscular dystrophy, Fukuyama congenital, 253800 (3)",FCMD,607440,9q31,Muscular,2218,1,192,304
1040,"Muscular dystrophy, limb-girdle, type 2C, 253700 (3)","SGCG, LGMD2C, DMDA1, SCG3",608896,13q12,Muscular,6445,1,192,335
1040,"Muscular dystrophy, limb-girdle, type 2A, 253600 (3)","CAPN3, CANP3",114240,15q15.1-q21.1,Muscular,825,1,192,402
1040,"Muscular dystrophy, limb-girdle, type 2E, 604286 (3)","SGCB, LGMD2E",600900,4q12,Muscular,6443,1,192,648
1040,"Muscular dystrophy, limb-girdle, type 2D, 608099 (3)","SGCA, ADL, DAG2, LGMD2D, DMDA2",600119,17q12-q21.33,Muscular,6442,1,192,649
1040,"Muscular dystrophy, limb-girdle, type 2B, 253601 (3)","DYSF, LGMD2B",603009,2p13.3-p13.1,Muscular,8291,1,192,657
1040,"Muscular dystrophy, limb-girdle, type 2H, 254110 (3)","TRIM32, HT2A, LGMD2H",602290,9q31-q34.1,Muscular,22954,1,192,665
1040,"Muscular dystrophy, congenital, due to partial LAMA2 deficiency, 607855 (3)","LAMA2, LAMM",156225,6q22-q23,Muscular,3908,1,192,675
1040,"Muscular dystrophy, congenital merosin-deficient, 607855 (3)","LAMA2, LAMM",156225,6q22-q23,Muscular,3908,1,192,675
1040,"Muscular dystrophy, limb-girdle, type 1A, 159000 (3)","TTID, MYOT",604103,5q31,Muscular,9499,1,192,697
1040,"Muscular dystrophy with epidermolysis bullosa simplex, 226670 (3)","PLEC1, PLTN, EBS1",601282,8q24,Muscular,5339,1,192,709
1040,"Muscular dystrophy, congenital, type 1D, 608840 (3)","LARGE, KIAA0609, MDC1D",603590,22q12.3-q13.1,Muscular,9215,1,192,710
1040,"Muscular dystrophy, congenital, 1C (3)","FKRP, MDC1C, LGMD2I",606596,19q13.3,Muscular,79147,1,192,711
1040,"Muscular dystrophy, limb-girdle, type 2I, 607155 (3)","FKRP, MDC1C, LGMD2I",606596,19q13.3,Muscular,79147,1,192,711
925,"Lymphoma, T-cell (3)","MSH2, COCA1, FCC1, HNPCC1",609309,2p22-p21,Cancer,4436,1,193,13
925,"Lymphoma, follicular (3)",BCL10,603517,1p22,Cancer,8915,1,193,176
925,"Lymphoma, MALT (3)",BCL10,603517,1p22,Cancer,8915,1,193,176
925,"Lymphoma, non-Hodgkin (3)","RAD54L, HR54, HRAD54",603615,1p32,Cancer,8438,1,193,288
925,"Lymphocytic leukemia, acute T-cell (3)",RAP1GDS1,179502,4q21-q25,Cancer,5910,1,193,452
925,"Lymphoma, progression of (3)","FCGR2B, CD32",604590,1q22,Cancer,2213,1,193,453
925,"Lymphoma, non-Hodgkin (3)",RAD54B,604289,8q21.3-q22,Cancer,25788,1,193,454
925,"Lymphoproliferative syndrome, X-linked, 308240 (3)","SH2D1A, LYP, IMD5, XLP, XLPD",300490,Xq25,Cancer,4068,1,193,455
925,"Lymphoma, diffuse large cell (3)",BCL8,601889,15q11-q13,Cancer,606,1,193,456
925,"Lymphoma, B-cell non-Hodgkin, somatic (3)","ATM, ATA, AT1",607585,11q22.3,Cancer,472,1,193,457
925,"Lymphoma, mantle cell (3)","ATM, ATA, AT1",607585,11q22.3,Cancer,472,1,193,457
925,"Lymphoma, somatic (3)","MAD1L1, TXBP181",602686,7p22,Cancer,8379,1,193,458
787,"Hypothyroidism, congenital, due to DUOX2 deficiency, 607200 (3)","DUOX2, THOX2",606759,15q15.3,Endocrine,50506,1,194,290
787,"Hypothyroidism, congenital, due to thyroid dysgenesis or hypoplasia, 218700 (3)",PAX8,167415,2q12-q14,Endocrine,7849,1,194,352
787,"Hypothyroidism, autoimmune, 140300 (3)",CTLA4,123890,2q33,Endocrine,1493,1,194,353
787,"Hypothyroidism, congenital, 274400 (3)","SLC5A5, NIS",601843,19p13.2-p12,Endocrine,6528,1,194,354
787,"Hypothyroidism, hereditary congenital (3)","TG, AITD3",188450,8q24.2-q24.3,Endocrine,7038,1,194,355
787,"Hypothyroidism, congenital, due to TSH resistance, 275200 (3)",TSHR,603372,14q31,Endocrine,7253,1,194,356
787,"Hypothyroidism, subclinical (3)",TSHR,603372,14q31,Endocrine,7253,1,194,356
787,"Hypothyroidism, nongoitrous (3)",TSHB,188540,1p13,Endocrine,7252,1,194,357
109,"Androgen insensitivity, 300068 (3)","AR, DHTR, TFM, SBMA, KD, SMAX1",313700,Xq11-q12,Endocrine,367,1,195,293
1205,Perineal hypospadias (3),"AR, DHTR, TFM, SBMA, KD, SMAX1",313700,Xq11-q12,Endocrine,367,1,196,293
1272,"Prostate cancer, 176807 (3)","BRCA2, FANCD1",600185,13q12.3,Cancer,675,1,197,19
1272,"Prostate cancer, 176807 (3)","PTEN, MMAC1",601728,10q23.31,Cancer,5728,1,197,77
1272,"Prostate cancer, familial, 176807 (3)","CHEK2, RAD53, CHK2, CDS1, LFS2",604373,22q12.1,Cancer,11200,1,197,196
1272,Prostate cancer (3),"AR, DHTR, TFM, SBMA, KD, SMAX1",313700,Xq11-q12,Cancer,367,1,197,293
1272,"Prostate cancer, susceptibility to, 176807 (3)","AR, DHTR, TFM, SBMA, KD, SMAX1",313700,Xq11-q12,Cancer,367,1,197,293
1272,"Prostate cancer, susceptibility to, 176807 (3)",MXI1,600020,10q25,Cancer,4601,1,197,404
1272,"Prostate cancer 1, 176807, 601518 (3)","RNASEL, RNS4, PRCA1, HPC1",180435,1q25,Cancer,6041,1,197,430
1272,"Prostate cancer, somatic, 176807 (3)","MAD1L1, TXBP181",602686,7p22,Cancer,8379,1,197,458
1272,"Prostate cancer, susceptibility to, 176807 (3)","ELAC2, HPC2",605367,17p11,Cancer,60528,1,197,574
1272,"Prostate cancer, susceptibility to, 176807 (3)",ATBF1,104155,16q22.3-q23.1,Cancer,463,1,197,652
1272,"Prostate cancer, somatic, 176807 (3)","KLF6, COPEB, BCD1, ZF9",602053,10p15,Cancer,1316,1,197,779
1272,"Prostate cancer, hereditary, 176807 (3)",MSR1,153622,8p22,Cancer,4481,1,197,809
1272,"Prostate cancer, progression and metastasis of, 176807 (3)","EPHB2, EPHT3, DRT, ERK",600997,1p36.1-p35,Cancer,2048,1,197,814
1426,"Spinal muscular atrophy, distal, type V, 600794 (3)","BSCL2, SPG17",606158,11q13,Muscular,26580,1,198,48
1426,"Spinal muscular atrophy, distal, type V, 600794 (3)","GARS, SMAD1, CMT2D",600287,7p15,Muscular,2617,1,198,127
1426,"Spinal and bulbar muscular atrophy of Kennedy, 313200 (3)","AR, DHTR, TFM, SBMA, KD, SMAX1",313700,Xq11-q12,Muscular,367,1,198,293
1426,"Spinal muscular atrophy-1, 253300 (3)","SMN1, SMA1, SMA2, SMA3, SMA4",600354,5q12.2-q13.3,Muscular,6606,1,198,438
1426,"Spinal muscular atrophy-2, 253550 (3)","SMN1, SMA1, SMA2, SMA3, SMA4",600354,5q12.2-q13.3,Muscular,6606,1,198,438
1426,"Spinal muscular atrophy-3, 253400 (3)","SMN1, SMA1, SMA2, SMA3, SMA4",600354,5q12.2-q13.3,Muscular,6606,1,198,438
1426,"Spinal muscular atrophy-4, 271150 (3)","SMN1, SMA1, SMA2, SMA3, SMA4",600354,5q12.2-q13.3,Muscular,6606,1,198,438
1426,"Spinal muscular atrophy, juvenile (3)",HEXB,606873,5q13,Muscular,3074,1,198,544
1426,"Spinal muscular atrophy with respiratory distress, 604320 (3)","IGHMBP2, SMUBP2, CATF1, SMARD1",600502,11q13.2-q13.4,Muscular,3508,1,198,700
1426,"Spinal muscrular atrophy, late-onset, Finkel type, 182980 (3)","VAPB, VAPC, ALS8",605704,20q13.3,Muscular,9217,1,198,843
749,"Hyperprolinemia, type II, 239510 (3)","ALDH4A1, ALDH4, P5CDH",606811,1p36,Metabolic,8659,1,199,294
749,"Hyperprolinemia, type I, 239500 (3)","PRODH, PRODH2, SCZD4",606810,22q11.2,Metabolic,5625,1,199,566
1161,"Osteopetrosis, autosomal dominant, type I, 607634 (3)","LRP5, BMND1, LRP7, LR3, OPPG, VBCH2",603506,11q13.4,Bone,4041,1,200,195
1161,"Osteopetrosis, autosomal recessive, 259700 (3)","OSTM1, GL",607649,6q21,Bone,28962,1,200,296
1161,"Osteopetrosis, recessive, 259700 (3)","TCIRG1, TIRC7, OC116, OPTB1",604592,11q13.4-q13.5,Bone,10312,1,200,440
1161,"Osteopetrosis, autosomal dominant, type II, 166600 (3)","CLCN7, CLC7, OPTA2",602727,16p13,Bone,1186,1,200,732
1161,"Osteopetrosis, recessive, 259700 (3)","CLCN7, CLC7, OPTA2",602727,16p13,Bone,1186,1,200,732
508,"Esophageal cancer, 133239 (3)","TGFBR2, HNPCC6",190182,3p22,Cancer,7048,1,201,213
508,"Esophageal squamous cell carcinoma, 133239 (3)","WWOX, FOR",605131,16q23.3-q24.1,Cancer,51741,1,201,298
508,"Esophageal carcinoma, somatic, 133239 (3)",RNF6,604242,13q12.11,Cancer,6049,1,201,429
508,"Esophageal squamous cell carcinoma, 133239 (3)","LZTS1, F37, FEZ1",606551,8p22,Cancer,11178,1,201,599
1578,"Warburg micro syndrome 1, 600118 (3)","RAB3GAP, WARBM1, P130",602536,2q21.3,multiple,22930,1,202,302
1578,"Walker-Warburg syndrome, 236670 (3)",POMT1,607423,9q34.1,multiple,10585,1,202,303
1578,"Walker-Warburg syndrome, 236670 (3)",FCMD,607440,9q31,multiple,2218,1,202,304
1576,"WAGR syndrome, 194072 (3)",WT1,607102,11p13,multiple,7490,1,203,305
1575,"Wagner syndrome, 143200 (3)",COL2A1,120140,12q13.11-q13.2,Ophthamological,1280,1,204,306
1574,"Waardenburg syndrome/albinism, digenic, 103470 (3)",TYR,606933,11q14-q21,multiple,7299,1,205,307
1574,"Waardenburg syndrome, type I, 193500 (3)","PAX3, WS1, HUP2, CDHS",606597,2q35,multiple,5077,1,205,308
1574,"Waardenburg syndrome, type III, 148820 (3)","PAX3, WS1, HUP2, CDHS",606597,2q35,multiple,5077,1,205,308
1574,"Waardenburg syndrome, typ IID, 608890 (3)","SNAI2, SLUG, WS2D",602150,8q11,multiple,6591,1,205,309
1574,"Waardenburg syndrome/ocular albinism, digenic, 103470 (3)","MITF, WS2A",156845,3p14.1-p12.3,multiple,4286,1,205,310
1574,"Waardenburg syndrome, type IIA, 193510 (3)","MITF, WS2A",156845,3p14.1-p12.3,multiple,4286,1,205,310
1571,"Vohwinkel syndrome, 124500 (3)","GJB2, CX26, DFNB1, PPK, DFNA3, KID, HID",121011,13q11-q12,multiple,2706,1,206,312
1571,"Vohwinkel syndrome with ichthyosis, 604117 (3)",LOR,152445,1q21,multiple,4014,1,206,313
1378,"Sepsis, susceptibility to (3)","CASP12, CASP12P1",608633,11q22.3,Immunological,120329,1,207,314
1378,"Septic shock, susceptibility to (3)","TNF, TNFA",191160,6p21.3,Immunological,7124,1,207,315
1550,"Urolithiasis, hypophosphatemic (3)","SLC17A2, NPT2",182309,5q35,Metabolic,6569,1,208,200
1550,"Urolithiasis, 2,8-dihydroxyadenine (3)",APRT,102600,16q24.3,Metabolic,353,1,208,396
1373,"Self-healing collodion baby, 242300 (3)","TGM1, ICR2, LI1",190195,14q11.2,Dermatological,7051,1,209,317
1599,"Witkop syndrome, 189500 (3)","MSX1, HOX7, HYD1, OFC5",142983,4p16.1,Developmental,4487,1,210,319
1598,"Wiskott-Aldrich syndrome, 301000 (3)","WAS, IMD2, THC",300392,Xp11.23-p11.22,Immunological,7454,1,211,320
372,"Cowden disease, 158350 (3)","PTEN, MMAC1",601728,10q23.31,Cancer,5728,1,212,77
372,"Cowden-like syndrome, 158350 (3)","BMPR1A, ACVRLK3, ALK3",601299,10q22.3,Cancer,657,1,212,581
1555,"VATER association with hydrocephalus, 276950 (3)","PTEN, MMAC1",601728,10q23.31,multiple,5728,1,213,77
895,Lhermitte-Duclos syndrome (3),"PTEN, MMAC1",601728,10q23.31,Cancer,5728,1,214,77
1138,"Oligodendroglioma, 137800 (3)","PTEN, MMAC1",601728,10q23.31,Cancer,5728,1,215,77
986,"Meningioma, 607174 (3)","PTEN, MMAC1",601728,10q23.31,Cancer,5728,1,216,77
986,"Meningioma, NF2-related, somatic, 607174 (3)",NF2,607379,22q12.2,Cancer,4771,1,216,395
986,"Meningioma, SIS-related (3)","PDGFB, SIS",190040,22q12.3-q13.1,Cancer,5155,1,216,604
986,"Meningioma, 607174 (3)","MN1, MGCR",156100,22q12.3-qter,Cancer,4330,1,216,713
182,"Bannayan-Riley-Ruvalcaba syndrome, 153480 (3)","PTEN, MMAC1",601728,10q23.31,Unclassified,5728,1,217,77
182,"Bannayan-Zonana syndrome, 153480 (3)","PTEN, MMAC1",601728,10q23.31,Unclassified,5728,1,217,77
1478,T-cell acute lymphoblastic leukemia (3),BAX,600040,19q13.3-q13.4,Cancer,581,1,218,323
1478,"T-cell prolymphocytic leukemia, sporadic (3)","ATM, ATA, AT1",607585,11q22.3,Cancer,472,1,218,457
2188,"Basal cell nevus syndrome, 109400 (3)","PTCH, NBCCS, BCNS, HPE7",601309,9q22.3,multiple,5727,1,219,235
1296,Pyropoikilocytosis (3),SPTA1,182860,1q21,Hematological,6708,1,220,62
1111,"Nijmegen breakage syndrome, 251260 (3)","NBS1, NBS",602667,8q21,multiple,4683,1,221,326
1113,"Noncompaction of left ventricular myocardium, isolated, 300183 (3)","TAZ, EFE2, BTHS, CMD3A, LVNCX",300394,Xq28,Cardiovascular,6901,1,222,279
1115,"Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, 211980 (3)",EGFR,131550,7p12.3-p12.1,Cancer,1956,1,223,242
1115,"Nonsmall cell lung cancer, somatic (3)",BRAF,164757,7q34,Cancer,673,1,223,244
1115,Nonsmall cell lung cancer (3),"IRF1, MAR",147575,5q31.1,Cancer,3659,1,223,331
1114,"Non-Hodgkin lymphoma, somatic, 605027 (3)","CASP10, MCH4, ALPS2",601762,2q33-q34,Cancer,843,1,224,332
1117,Norrie disease (3),"NDP, ND",310600,Xp11.4,Neurological,4693,1,225,333
1116,"Noonan syndrome 1, 163950 (3)","PTPN11, PTP2C, SHP2, NS1",176876,12q24.1,Developmental,5781,1,226,334
1447,"Stickler syndrome, type I, 108300 (3)",COL2A1,120140,12q13.11-q13.2,multiple,1280,1,227,306
1447,"Stickler syndrome, type III, 184840 (3)","COL11A2, STL3, DFNA13",120290,6p21.3,multiple,1302,1,227,417
1447,"Stickler syndrome, type II, 604841 (3)","COL11A1, STL2",120280,1p21,multiple,1301,1,227,797
26,"Achondrogenesis-hypochondrogenesis, type II, 200610 (3)",COL2A1,120140,12q13.11-q13.2,Bone,1280,1,228,306
854,"Kniest dysplasia, 156550 (3)",COL2A1,120140,12q13.11-q13.2,Skeletal,1280,1,229,306
1408,"SMED Strudwick type, 184250 (3)",COL2A1,120140,12q13.11-q13.2,Skeletal,1280,1,230,306
2112,"Aneurysm, familial arterial (3)",COL3A1,120180,2q31,Unclassified,1281,1,231,71
186,"Bart-Pumphrey syndrome, 149200 (3)","GJB2, CX26, DFNB1, PPK, DFNA3, KID, HID",121011,13q11-q12,multiple,2706,1,232,312
843,"Keratitis-ichthyosis-deafness syndrome, 148210 (3)","GJB2, CX26, DFNB1, PPK, DFNA3, KID, HID",121011,13q11-q12,multiple,2706,1,233,312
792,"Hystrix-like ichthyosis with deafness, 602540 (3)","GJB2, CX26, DFNB1, PPK, DFNA3, KID, HID",121011,13q11-q12,multiple,2706,1,234,312
845,"Keratoderma, palmoplantar, with deafness, 148350 (3)","GJB2, CX26, DFNB1, PPK, DFNA3, KID, HID",121011,13q11-q12,Dermatological,2706,1,235,312
507,"Erythrokeratoderma, progressive symmetric, 602036 (3)",LOR,152445,1q21,Dermatological,4014,1,236,313
507,"Erythrokeratodermia variabilis, 133200 (3)","GJB3, CX31, DFNA2",603324,1p35.1,Dermatological,2707,1,236,338
507,"Erythrokeratodermia variabilis with erythema gyratum repens, 133200 (3)","GJB4, CX30.3",605425,1p35.1,Dermatological,127534,1,236,598
1026,Morning glory disc anomaly (3),"PAX6, AN2, MGDA",607108,11p13,Skeletal,5080,1,237,120
1022,"Mohr-Tranebjaerg syndrome, 304700 (3)","TIMM8A, DFN1, DDP, MTS, DDP1",300356,Xq22,Neurological,1678,1,238,343
731,"Hyperinsulinism, familial, 602485 (3)",GCK,138079,7p15-p13,Metabolic,2645,1,239,341
418,"Dentinogenesis imperfecta, Shields type II, 125490 (3)","DSPP, DPP, DGI1, DFNA39, DTDP2",125485,4q21.3,Bone,1834,1,240,348
418,"Dentinogenesis imperfecta, Shields type III, 125500 (3)","DSPP, DPP, DGI1, DFNA39, DTDP2",125485,4q21.3,Bone,1834,1,240,348
410,"Dejerine-Sottas disease, 145900 (3)","PMP22, CMT1A, CMT1E, DSS",601097,17p11.2,multiple,5376,1,241,128
410,"Dejerine-Sottas syndrome, 145900 (3)","MPZ, CMT1B, CMTDI3, CHM, DSS",159440,1q22,multiple,4359,1,241,133
410,"Dejerine-Sottas neuropathy, 145900 (3)","EGR2, KROX20",129010,10q21.1-q22.1,multiple,1959,1,241,140
410,"Dejerine-Sottas neuropathy, autosomal recessive, 145900 (3)","PRX, CMT4F",605725,19q13.1-q13.2,multiple,57716,1,241,349
374,"CPT deficiency, hepatic, type IA, 255120 (3)",CPT1A,600528,11q13,Metabolic,1374,1,242,351
374,"CPT deficiency, hepatic, type II, 600649 (3)",CPT2,600650,1p32,Metabolic,1376,1,242,782
374,"CPT II deficiency, lethal neonatal, 608836 (3)",CPT2,600650,1p32,Metabolic,1376,1,242,782
417,"Dentin dysplasia, type II, 125420 (3)","DSPP, DPP, DGI1, DFNA39, DTDP2",125485,4q21.3,Bone,1834,1,243,348
1456,Subcortical laminar heterotopia (3),"PAFAH1B1, LIS1",601545,17p13.3,Neurological,5048,1,244,38
1456,"Subcortical laminal heteropia, X-linked, 300067 (3)","DCX, DBCN, LISX",300121,Xq22.3-q23,Neurological,1641,1,244,39
898,"Li-Fraumeni syndrome, 151623 (3)","TP53, P53, LFS1",191170,17p13.1,Cancer,7157,1,245,20
898,"Li-Fraumeni syndrome, 609265 (3)","CHEK2, RAD53, CHK2, CDS1, LFS2",604373,22q12.1,Cancer,11200,1,245,196
896,"Liddle syndrome, 177200 (3)","SCNN1G, PHA1",600761,16p13-p12,Renal,6340,1,246,358
896,"Liddle syndrome, 177200 (3)",SCNN1B,600760,16p13-p12,Renal,6338,1,246,359
897,"Li Fraumeni syndrome, 151623 (3)","CDKN2A, MTS1, P16, MLM, CMM2",600160,9p21,Cancer,1029,1,247,26
524,"Fanconi-Bickel syndrome, 227810 (3)","SLC2A2, GLUT2",138160,3q26.1-q26.3,Metabolic,6514,1,248,361
520,Factor XIIIB deficiency (3),F13B,134580,1q31-q32.1,Hematological,2165,1,249,362
520,Factor XIIIA deficiency (3),"F13A1, F13A",134570,6p25-p24,Hematological,2162,1,249,363
520,Factor VII deficiency (3),F7,227500,13q34,Hematological,2155,1,249,364
520,"Factor XI deficiency, autosomal dominant (3)",F11,264900,4q35,Hematological,2160,1,249,365
520,"Factor XI deficiency, autosomal recessive (3)",F11,264900,4q35,Hematological,2160,1,249,365
520,Factor XII deficiency (3),"F12, HAF",234000,5q33-qter,Hematological,2161,1,249,366
520,Factor X deficiency (3),F10,227600,13q34,Hematological,2159,1,249,367
520,"Factor V and factor VIII, combined deficiency of, 227300 (3)",MCFD2,607788,2p21-p16.3,Hematological,90411,1,249,368
520,Factor H and factor H-like 1 (3),"HF1, CFH, HUS",134370,1q32,Hematological,3075,1,249,369
253,"Caffey disease, 114000 (3)",COL1A1,120150,17q21.31-q22,Connective tissue disorder,1277,1,250,68
523,"Fanconi anemia, complementation group D1, 605724 (3)","BRCA2, FANCD1",600185,13q12.3,multiple,675,1,251,19
523,"Fanconi anemia, complementation group A, 227650 (3)","FANCA, FACA, FA1, FA, FAA",607139,16q24.3,multiple,2175,1,251,370
523,"Fanconi anemia, complementation group F (3)",FANCF,603467,11p15,multiple,2188,1,251,371
523,"Fanconi anemia, complementation group D2 (3)","FANCD2, FANCD, FACD, FAD",227646,3p25.3,multiple,2177,1,251,372
523,"Fanconi anemia, complementation group C (3)","FANCC, FACC",227645,9q22.3,multiple,2176,1,251,373
523,"Fanconi anemia, complementation group G (3)","XRCC9, FANCG",602956,9p13,multiple,2189,1,251,374
523,"Fanconi anemia, complementation group J, 609054 (3)","BRIP1, BACH1, FANCJ",605882,17q22,multiple,83990,1,251,375
523,"Fanconi anemia, complementation group E (3)","FANCE, FACE",600901,6p22-p21,multiple,2178,1,251,376
523,"Fanconi anemia, complementation group B, 300514 (3)","FAAP95, FAAP90, FLJ34064, FANCB",300515,Xp22.31,multiple,2187,1,251,377
523,"Fanconi anemia, complementation group L (3)","PHF9, FANCL",608111,2p16.1,multiple,55120,1,251,378
523,"Fanconi anemia, complementation group M (3)","FANCM, KIAA1596",609644,14q21.3,multiple,57697,1,251,379
528,Favism (3),"G6PD, G6PD1",305900,Xq28,Metabolic,2539,1,252,380
1471,"Systemic lupus erythematosus, susceptibility to, 2, 605218, 152700 (3)","PDCD1, SLEB2",600244,2q37.3,Immunological,5133,1,253,382
1471,"Systemic lupus erythematosus, susceptibility, 152700 (3)","TNFSF6, APT1LG1, FASL",134638,1q23,Immunological,356,1,253,385
1471,"Systemic lupus erythematosus, susceptibility to, 152700 (3)","PTPN8, PEP, PTPN22, LYP",600716,1p13,Immunological,26191,1,253,671
1471,"Systemic lupus erythematosus, susceptibility to, 152700 (3)","DNASE1, DNL1",125505,16p13.3,Immunological,1773,1,253,755
136,Apolipoprotein H deficiency (3),APOH,138700,17q23-qter,Metabolic,350,1,254,383
136,Apolipoprotein C3 deficiency (3),APOC3,107720,11q23,Metabolic,345,1,254,564
136,"ApoA-I and apoC-III deficiency, combined (3)",APOA1,107680,11q23,Metabolic,335,1,254,594
136,Apolipoprotein A-II deficiency (3),APOA2,107670,1q21-q23,Metabolic,336,1,254,631
103,"Amyloidosis, senile systemic (3)","TTR, PALB",176300,18q11.2-q12.1,Neurological,7276,1,255,106
103,"Amyloidosis, cerebroarterial, Dutch type (3)","APP, AAA, CVAP, AD1",104760,21q21,Neurological,351,1,255,384
103,"Amyloidosis, hereditary renal, 105200 (3)",FGA,134820,4q28,Neurological,2243,1,255,399
103,"Amyloidosis, Finnish type, 105120 (3)",GSN,137350,9q34,Neurological,2934,1,255,592
103,"Amyloidosis, renal, 105200 (3)",LYZ,153450,Chr.12,Neurological,4069,1,255,593
103,"Amyloidosis, 3 or more types (3)",APOA1,107680,11q23,Neurological,335,1,255,594
117,"Angiotensin I-converting enzyme, benign serum increase (3)","ACE, DCP1, ACE1",106180,17q23,Endocrine,1636,1,256,387
9308,"Renal tubular dysgenesis, 267430 (3)","ACE, DCP1, ACE1",106180,17q23,Renal,1636,1,257,387
9308,"Renal tubular dysgenesis, 267430 (3)",REN,179820,1q32,Renal,5972,1,257,622
9308,"Renal tubular dysgenesis, 267430 (3)","AGT, SERPINA8",106150,1q42-q43,Renal,183,1,257,753
9308,"Renal tubular dysgenesis, 267430 (3)","AGTR1, AGTR1A, AT2R1",106165,3q21-q25,Renal,185,1,257,762
1352,"SARS, progression of (3)","ACE, DCP1, ACE1",106180,17q23,Immunological,1636,1,258,387
138,Aquaporin-1 deficiency (3),"AQP1, CHIP28, CO",107776,7p14,Unclassified,358,1,259,392
1401,"Skin fragility-woolly hair syndrome, 607655 (3)","DSP, KPPS2, PPKS2",125647,6p24,Dermatological,1832,1,260,394
1097,"Neurofibromatosis, type 1 (3)","NF1, VRNF, WSS, NFNS",162200,17q11.2,Cancer,4436,1,261,13
1097,"Neurofibromatosis, type I, with leukemia, 162200 (3)","MSH2, COCA1, FCC1, HNPCC1",609309,2p22-p21,Cancer,4436,1,261,13
1097,"Neurofibromatosis, type 2, 101000 (3)",NF2,607379,22q12.2,Cancer,4771,1,261,395
1360,"Schwannomatosis, 162091 (3)",NF2,607379,22q12.2,Cancer,4771,1,262,395
13,Aarskog-Scott syndrome (3),"FGD1, FGDY, AAS",305400,Xp11.21,multiple,2245,1,263,397
61,"Afibrinogenemia, congenital, 202400 (3)",FGB,134830,4q28,Hematological,2244,1,264,398
61,"Afibrinogenemia, 202400 (3)",FGA,134820,4q28,Hematological,2243,1,264,399
174,"Autoimmune lymphoproliferative syndrome, type II, 603909 (3)","CASP10, MCH4, ALPS2",601762,2q33-q34,Immunological,843,1,265,332
174,"Autoimmune lymphoproliferative syndrome, 601859 (3)","TNFRSF6, APT1, FAS, CD95, ALPS1A",134637,10q24.1,Immunological,355,1,265,400
174,"Autoimmune lymphoproliferative syndrome, type IA, 601859 (3)","TNFRSF6, APT1, FAS, CD95, ALPS1A",134637,10q24.1,Immunological,355,1,265,400
174,"Autoimmune polyglandular disease, type I, 240300 (3)","AIRE, APECED",607358,21q22.3,Immunological,326,1,265,687
174,"Autoimmune lymphoproliferative syndrome, type IIB, 607271 (3)","CASP8, MCH5",601763,2q33-q34,Immunological,841,1,265,783
1198,"PCWH, 609136 (3)","SOX10, WS4",602229,22q13,Neurological,6663,1,266,202
1059,"Myopathy, cardioskeletal, desmin-related, with cataract, 608810 (3)","CRYAB, CRYA2, CTPP2",123590,11q22.3-q23.1,Muscular,1410,1,267,114
1059,"Myopathy, Laing distal, 160500 (3)","MYH7, CMH1, MPD1",160760,14q12,Muscular,4625,1,267,261
1059,"Myopathy, myosin storage, 608358 (3)","MYH7, CMH1, MPD1",160760,14q12,Muscular,4625,1,267,261
1059,"Myopathy, distal, with decreased caveolin 3 (3)","CAV3, LGMD1C",601253,3p25,Muscular,859,1,267,266
1059,"Myopathy, desmin-related, cardioskeletal, 601419 (3)","DES, CMD1I",125660,2q35,Muscular,1674,1,267,274
1059,"Myopathy, congenital (3)",ITGA7,600536,12q13,Muscular,3679,1,267,432
1059,"Myopathy, centronuclear, 160150 (3)",MYF6,159991,12q21,Muscular,4618,1,267,559
1059,"Myopathy, distal, with anterior tibial onset, 606768 (3)","DYSF, LGMD2B",603009,2p13.3-p13.1,Muscular,8291,1,267,657
1059,"Myopathy due to CPT II deficiency, 255110 (3)",CPT2,600650,1p32,Muscular,1376,1,267,782
1059,"Myopathy, actin, congenital, with cores (3)","ACTA1, ASMA, NEM3, NEM1",102610,1q42.1,Muscular,58,1,267,825
1059,"Myopathy, actin, congenital, with excess of thin myofilaments, 161800 (3)","ACTA1, ASMA, NEM3, NEM1",102610,1q42.1,Muscular,58,1,267,825
1059,"Myopathy, nemaline, 3, 161800 (3)","ACTA1, ASMA, NEM3, NEM1",102610,1q42.1,Muscular,58,1,267,825
1059,Myopathy due to phosphoglycerate mutase deficiency (3),"PGAM2, PGAMM",261670,7p13-p12.3,Muscular,5224,1,267,826
1298,"Rabson-Mendenhall syndrome, 262190 (3)",INSR,147670,19p13.2,multiple,3643,1,268,403
1098,Neurofibrosarcoma (3),MXI1,600020,10q25,Cancer,4601,1,269,404
2054,"Adrenal cortical carcinoma, 202300 (3)","TP53, P53, LFS1",191170,17p13.1,Cancer,7157,1,270,20
1074,"Nasopharyngeal carcinoma, 161550 (3)","TP53, P53, LFS1",191170,17p13.1,Cancer,7157,1,271,20
5037,Multiple malignancy syndrome (3),"TP53, P53, LFS1",191170,17p13.1,Cancer,7157,1,272,20
1297,Pyruvate dehydrogenase deficiency (3),"PDHA1, PHE1A",312170,Xp22.2-p22.1,Metabolic,5160,1,273,90
1297,"Pyruvate carboxylase deficiency, 266150 (3)",PC,608786,11q13.4-q13.5,Metabolic,5091,1,273,405
1297,Pyruvate dehydrogenase E1-beta deficiency (3),PDHB,179060,3p13-q23,Metabolic,5162,1,273,406
369,"Costello syndrome, 218040 (3)",HRAS,190020,11p15.5,multiple,3265,1,274,408
1562,"Viral infections, recurrent (3)","FCGR3A, CD16, IGFR3",146740,1q23,Immunological,2214,1,275,410
1562,"Viral infection, susceptibility to (3)","OAS1, OIAS",164350,12q24.2,Immunological,4938,1,275,411
1566,"Vitelliform macular dystrophy, adult-onset, 608161 (3)",VMD2,607854,11q13,Ophthamological,7439,1,276,412
1368,"Sebastian syndrome, 605249 (3)","MYH9, MHA, FTNS, DFNA17",160775,22q11.2,Hematological,4627,1,277,414
1366,"Sea-blue histiocyte disease, 269600 (3)","APOE, AD2",107741,19q13.2,Hematological,348,1,278,415
1367,"Seasonal affective disorder, susceptibility to, 608516 (3)",HTR2A,182135,13q14-q21,Psychiatric,3356,1,279,416
1586,"Weissenbacher-Zweymuller syndrome, 277610 (3)","COL11A2, STL3, DFNA13",120290,6p21.3,Connective tissue disorder,1302,1,280,417
1585,"Weill-Marchesani syndrome, dominant, 608328 (3)","FBN1, MFS1, WMS",134797,15q21.1,Connective tissue disorder,2200,1,281,178
1585,"Weill-Marchesani syndrome, recessive, 277600 (3)","ADAMTS10, WMS",608990,19p13.3-p13.2,Connective tissue disorder,81794,1,281,418
1583,Wegener-like granulomatosis (3),"TAP2, ABCB3, PSF2, RING11",170261,6p21.3,Immunological,6891,1,282,419
1581,"Watson syndrome, 193520 (3)","NF1, VRNF, WSS, NFNS",162200,17q11.2,Cancer,4763,1,283,420
1103,"Nevo syndrome, 601451 (3)","PLOD, PLOD1",153454,1p36.3-p36.2,Connective tissue disorder,5351,1,284,72
1106,"Nicotine addiction, protection from (3)","CYP2A6, CYP2A3, CYP2A, P450C2A",122720,19q13.2,Psychiatric,1548,1,285,425
1106,"Nicotine addiction, susceptibility to, 188890 (3)","CHRNA4, ENFL1",118504,20q13.2-q13.3,Psychiatric,1137,1,285,426
1106,"Nicotine dependence, susceptibility to, 188890 (3)","GPR51, GABBR2",607340,9q22.1,Psychiatric,9568,1,285,427
1104,"Nevus, epidermal, epidermolytic hyperkeratotic type, 600648 (3)",KRT10,148080,17q21-q22,Dermatological,3858,1,286,428
644,"HDL deficiency, familial, 604091 (3)","ABCA1, ABC1, HDLDT1, TGD",600046,9q22-q31,Metabolic,19,1,287,435
644,"HDL response to hormone replacement, augmented (3)","ESR1, ESR",133430,6q25.1,Metabolic,2099,1,287,600
291,"Cerebral amyloid angiopathy, 105150 (3)","ABCA1, ABC1, HDLDT1, TGD",600046,9q22-q31,Neurological,19,1,288,435
291,"Cerebral amyloid angiopathy, 105150 (3)",CST3,604312,20p11.2,Neurological,1471,1,288,623
1473,"Tangier disease, 205400 (3)","ABCA1, ABC1, HDLDT1, TGD",600046,9q22-q31,Metabolic,19,1,289,435
1035,"Muir-Torre syndrome, 158320 (3)","MSH2, COCA1, FCC1, HNPCC1",609309,2p22-p21,Cancer,4436,1,290,13
1035,"Muir-Torre syndrome, 158320 (3)","MLH1, COCA2, HNPCC2",120436,3p21.3,Cancer,4292,1,290,104
1418,"Spastic ataxia, Charlevoix-Saguenay type, 270550 (3)","SACS, ARSACS",604490,13q12,Neurological,26278,1,291,441
1418,"Spastic paralysis, infantile onset ascending, 607225 (3)","ALS2, ALSJ, PLSJ, IAHSP",606352,2q33,Neurological,57679,1,291,735
1418,"Spastic paraplegia-2, 312920 (3)","PLP1, PMD",300401,Xq22,Neurological,5354,1,291,802
1418,"Spastic paraplegia-3A, 182600 (3)",SPG3A,606439,14q11-q21,Neurological,51062,1,291,816
1418,"Spastic paraplegia 10, 604187 (3)","KIF5A, NKHC, SPG10",602821,12q13,Neurological,3798,1,291,871
1418,"Spastic paraplegia-4, 182601 (3)","SPG4, SPAST",604277,2p22-p21,Neurological,6683,1,291,881
1418,"Spastic paraplegia-7, 607259 (3)","PGN, SPG7, CMAR, CAR",602783,16q24.3,Neurological,6687,1,291,882
1418,"Spastic paraplegia-13, 605280 (3)","HSPD1, SPG13, HSP60",118190,2q33.1,Neurological,3329,1,291,891
1418,"Spastic paraplegia-6, 600363 (3)","NIPA1, SPG6",608145,15q11.1,Neurological,123606,1,291,901
664,Hemorrhagic diathesis due to \`antithrombin\' Pittsburgh (3),"PI, AAT",107400,14q32.1,Hematological,5265,1,292,76
664,Hemorrhagic diathesis due to factor V deficiency (3),F5,227400,1q23,Hematological,2153,1,292,442
661,"Hemolytic-uremic syndrome, 235400 (3)","HF1, CFH, HUS",134370,1q32,Hematological,3075,1,293,369
660,Hemolytic anemia due to band 3 defect defect (3),"SLC4A1, AE1, EPB3",109270,17q21-q22,Hematological,6521,1,294,63
660,Hemolytic anemia due to G6PD deficiency (3),"G6PD, G6PD1",305900,Xq28,Hematological,2539,1,294,380
660,Hemolytic anemia due to hexokinase deficiency (3),HK1,142600,10q22,Hematological,3098,1,294,443
660,Hemolytic anemia due to triosephosphate isomerase deficiency (3),TPI1,190450,12p13,Hematological,7167,1,294,444
660,Hemolytic anemia due to PGK deficiency (3),"PGK1, PGKA",311800,Xq13,Hematological,5230,1,294,445
660,"Hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency, 230450 (3)","GCLC, GLCLC",606857,6p12,Hematological,2729,1,294,446
660,"Hemolytic anemia due to glutathione synthetase deficiency, 231900 (3)","GSS, GSHS",601002,20q11.2,Hematological,2937,1,294,447
660,Hemolytic anemia due to glucosephosphate isomerase deficiency (3),GPI,172400,19q13.1,Hematological,2821,1,294,448
660,Hemolytic anemia due to bisphosphoglycerate mutase deficiency (3),BPGM,222800,7q31-q34,Hematological,669,1,294,449
660,Hemolytic anemia due to adenylate kinase deficiency (3),AK1,103000,9q34.1,Hematological,203,1,294,450
1341,"Rubenstein-Taybi syndrome, 180849 (3)","CREBBP, CBP, RSTS",600140,16p13.3,multiple,1387,1,295,451
1341,"Rubinstein-Taybi syndrome, 180849 (3)",EP300,602700,22q13,multiple,2033,1,295,572
1190,"Parietal foramina 2, 168500 (3)","ALX4, PFM2, FPP",605420,11p11.2,Skeletal,60529,1,296,460
1190,"Parietal foramina 1, 168500 (3)","MSX2, CRS2, HOX8",123101,5q34-q35,Skeletal,4488,1,296,461
1190,"Parietal foramina with cleidocranial dysplasia, 168550 (3)","MSX2, CRS2, HOX8",123101,5q34-q35,Skeletal,4488,1,296,461
797,"IgE levels QTL, 147050 (3)","PHF11, NYREN34",607796,13q14.1,Immunological,51131,1,297,491
881,"Leprechaunism, 246200 (3)",INSR,147670,19p13.2,Developmental,3643,1,298,403
880,"Leopard syndrome, 151100 (3)","PTPN11, PTP2C, SHP2, NS1",176876,12q24.1,multiple,5781,1,299,334
1226,Piebaldism (3),"KIT, PBT",164920,4q12,Dermatological,3815,1,300,504
959,Mastocytosis with associated hematologic disorder (3),"KIT, PBT",164920,4q12,Immunological,3815,1,301,504
958,Mast cell leukemia (3),"KIT, PBT",164920,4q12,Cancer,3815,1,302,504
574,"Gastrointestinal stromal tumor, somatic, 606764 (3)","KIT, PBT",164920,4q12,Cancer,3815,1,303,504
574,"Gastrointestinal stromal tumor, somatic, 606764 (3)",PDGFRA,173490,4q12,Cancer,5156,1,303,602
580,Germ cell tumor (3),BCL10,603517,1p22,Cancer,8915,1,304,176
580,"Germ cell tumors, 273300 (3)","KIT, PBT",164920,4q12,Cancer,3815,1,304,504
240,"C1q deficiency, type C (3)",C1QG,120575,1p36.3-p34.1,Immunological,714,1,305,522
240,"C8 deficiency, type II (3)",C8B,120960,1p32,Immunological,732,1,305,523
240,"C1q deficiency, type B (3)",C1QB,120570,1p36.3-p34.1,Immunological,713,1,305,524
240,C3b inactivator deficiency (3),IF,217030,4q25,Immunological,3426,1,305,525
240,"C1q deficiency, type A (3)",C1QA,120550,1p36.3-p34.1,Immunological,712,1,305,526
240,C9 deficiency (3),C9,120940,5p13,Immunological,735,1,305,527
240,C9 deficiency with dermatomyositis (3),C9,120940,5p13,Immunological,735,1,305,527
240,"C1s deficiency, isolated (3)",C1S,120580,12p13,Immunological,716,1,305,528
240,C2 deficiency (3),C2,217000,6p21.3,Immunological,717,1,305,529
240,C4 deficiency (3),"C4B, C4F",120820,6p21.3,Immunological,721,1,305,530
240,C4 deficiency (3),"C4A, C4S",120810,6p21.3,Immunological,720,1,305,531
240,C7 deficiency (3),C7,217070,5p13,Immunological,730,1,305,532
240,C3 deficiency (3),C3,120700,19p13.3-p13.2,Immunological,718,1,305,533
240,C6 deficiency (3),C6,217050,5p13,Immunological,729,1,305,534
71,"Alagille syndrome, 118450 (3)","JAG1, AGS, AHD",601920,20p12,multiple,182,1,306,473
1204,"Pendred syndrome, 274600 (3)","SLC26A4, PDS, DFNB4",605646,7q31,"Ear,Nose,Throat",5172,1,307,471
205,"Birt-Hogg-Dube syndrome, 135150 (3)","FLCN, BHD",607273,17p11.2,Dermatological,201163,1,308,538
1239,"Pneumothorax, primary spontaneous, 173600 (3)","FLCN, BHD",607273,17p11.2,Respiratory,201163,1,309,538
441,"Dopamine-beta-hydroxylase activity levels, plasma (3)",DBH,609312,9q34,Metabolic,1621,1,310,539
441,"Dopamine beta-hydroxylase deficiency, 223360 (3)",DBH,609312,9q34,Metabolic,1621,1,310,539
336,"Cleft lip/palate ectodermal dysplasia syndrome, 225000 (3)","HVEC, PVRL1, PVRR1, PRR1",600644,11q23-q24,Developmental,5818,1,311,201
336,"Cleft lip/palate, nonsyndromic, 608874 (3)","MSX1, HOX7, HYD1, OFC5",142983,4p16.1,Developmental,4487,1,311,319
336,"Cleft palate with ankyloglossia, 303400 (3)","TBX22, CPX",300307,Xq12-q21,Developmental,50945,1,311,540
1345,Salivary adenoma (3),"HMGA2, HMGIC, BABL, LIPO",600698,12q14.3,Cancer,8091,1,312,543
1552,Uterine leiomyoma (3),"HMGA2, HMGIC, BABL, LIPO",600698,12q14.3,Cancer,8091,1,313,543
937,"Macular degeneration, age-related, 1, 603075 (3)","HF1, CFH, HUS",134370,1q32,Ophthamological,3075,1,314,369
937,"Macular degeneration, X-linked atrophic (3)","RPGR, RP3, CRD, RP15, COD1",312610,Xp21.1,Ophthamological,6103,1,314,678
937,"Macular degeneration, juvenile, 248200 (3)","CNGB3, ACHM3",605080,8q21-q22,Ophthamological,54714,1,314,695
937,"Macular degeneration, age-related, 3, 608895 (3)","FBLN5, ARMD3",604580,14q32.1,Ophthamological,10516,1,314,812
937,"Macular degeneration, age-related, 1, 603075 (3)","HMCN1, FBLN6, FIBL6",608548,1q24-q25,Ophthamological,83872,1,314,899
1084,"Nephropathy, chronic hypocomplementemic (3)","HF1, CFH, HUS",134370,1q32,Renal,3075,1,315,369
1347,"Sandhoff disease, infantile, juvenile, and adult forms, 268800 (3)",HEXB,606873,5q13,Metabolic,3074,1,316,544
17,"Abetalipoproteinemia, 200100 (3)",MTP,157147,4q22-q24,Metabolic,4547,1,317,546
17,Abetalipoproteinemia (3),"APOB, FLDB",107730,2p24,Metabolic,338,1,317,632
164,"Atopy, susceptibility to, 147050 (3)","PLA2G7, PAFAH",601690,6p21.2-p12,Immunological,7941,1,318,547
164,"Atopy, 147050 (3)","SPINK5, LEKTI",605010,5q32,Immunological,11005,1,318,727
164,"Atopy, susceptibility to, 147050 (3)","SELP, GRMP",173610,1q23-q25,Immunological,6403,1,318,728
164,"Atopy, resistance to, 147050 (3)","HAVCR1, HAVCR",606518,5q33.2,Immunological,26762,1,318,729
164,"Atopy, susceptibility to (3)","IL4R, IL4RA",147781,16p12.1-p11.2,Immunological,3566,1,318,730
1141,"Omenn syndrome, 603554 (3)","DCLRE1C, ARTEMIS, SCIDA",605988,10p,Immunological,64421,1,319,173
1141,"Omenn syndrome, 603554 (3)",RAG2,179616,11p13,Immunological,5897,1,319,174
1141,"Omenn syndrome, 603554 (3)",RAG1,179615,11p13,Immunological,5896,1,319,175
940,"Malaria, cerebral, susceptibility to (3)","TNF, TNFA",191160,6p21.3,Immunological,7124,1,320,315
940,"Malaria, cerebral, susceptibility to (3)",ICAM1,147840,19p13.3-p13.2,Immunological,3383,1,320,549
940,"Malaria, resistance to, 248310 (3)","GYPC, GE, GPC",110750,2q14-q21,Immunological,2995,1,320,714
940,"Malaria, resistance to, 248310 (3)","NOS2A, NOS2",163730,17cen-q11.2,Immunological,4843,1,320,858
940,"Malaria, cerebral, reduced risk of, 248310 (3)",CD36,173510,7q11.2,Immunological,948,1,320,859
940,"Malaria, cerebral, susceptibility to, 248310 (3)",CD36,173510,7q11.2,Immunological,948,1,320,859
1095,"Neurofibromatosis, familial spinal, 162210 (3)","NF1, VRNF, WSS, NFNS",162200,17q11.2,Cancer,4763,1,321,420
1096,"Neurofibromatosis-Noonan syndrome, 601321 (3)","NF1, VRNF, WSS, NFNS",162200,17q11.2,Cancer,4763,1,322,420
420,"Denys-Drash syndrome, 194080 (3)",WT1,607102,11p13,Renal,7490,1,323,305
993,"Mesangial sclerosis, isolated diffuse, 256370 (3)",WT1,607102,11p13,Renal,7490,1,324,305
552,"Frasier syndrome, 136680 (3)",WT1,607102,11p13,multiple,7490,1,325,305
1013,"Migraine without aura, susceptibility to, 157300 (3)","TNF, TNFA",191160,6p21.3,Neurological,7124,1,326,315
1013,"Migraine, familial hemiplegic, 2, 602481 (3)","ATP1A2, FHM2, MHP2",182340,1q21-q23,Neurological,477,1,326,591
1013,"Migraine, susceptibility to, 157300 (3)","ESR1, ESR",133430,6q25.1,Neurological,2099,1,326,600
1013,"Migraine, resistance to, 157300 (3)",EDNRA,131243,4q31.2,Neurological,1909,1,326,660
193,"Becker muscular dystrophy, 300376 (3)","DMD, BMD",300377,Xp21.2,Muscular,1756,1,327,275
193,"Becker muscular dystrophy modifier, 310200 (3)",MYF6,159991,12q21,Muscular,4618,1,327,559
772,"Hypoglycemia of infancy, leucine-sensitive, 240800 (3)","ABCC8, SUR, PHHI, SUR1",600509,11p15.1,Metabolic,6833,1,328,563
772,"Hypoglycemia of infancy, persistent hyperinsulinemic, 256450 (3)","ABCC8, SUR, PHHI, SUR1",600509,11p15.1,Metabolic,6833,1,328,563
737,"Hyperlipoproteinemia, type III (3)","APOE, AD2",107741,19q13.2,Metabolic,348,1,329,415
737,"Hyperlipoproteinemia, type Ib, 207750 (3)",APOC2,608083,19q13.2,Metabolic,344,1,329,565
803,"Immunodysregulation, polyendocrinopathy, and enteropathy, X-linked, 304790 (3)","FOXP3, IPEX, AIID, XPID, PIDX",300292,Xp11.23-q13.3,multiple,50943,1,330,575
1132,"Oculodentodigital dysplasia, 164200 (3)","GJA1, CX43, ODDD, SDTY3, ODOD",121014,6q21-q23.2,Skeletal,2697,1,331,576
1139,"Oligodontia, 604625 (3)",PAX9,167416,14q12-q13,Skeletal,5083,1,332,577
72,"Albinism, oculocutaneous, type IA, 203100 (3)",TYR,606933,11q14-q21,Dermatological,7299,1,333,307
72,"Albinism, oculocutaneous, type IB, 606952 (3)",TYR,606933,11q14-q21,Dermatological,7299,1,333,307
72,"Albinism, brown oculocutaneous, (3)","OCA2, P, PED, D15S12, BOCA",203200,15q11.2-q12,Dermatological,4948,1,333,580
72,"Albinism, ocular, autosomal recessive (3)","OCA2, P, PED, D15S12, BOCA",203200,15q11.2-q12,Dermatological,4948,1,333,580
72,"Albinism, oculocutaneous, type II (3)","OCA2, P, PED, D15S12, BOCA",203200,15q11.2-q12,Dermatological,4948,1,333,580
72,"Albinism, rufous, 278400 (3)","TYRP1, CAS2, GP75",115501,9p23,Dermatological,7306,1,333,689
652,"Hematopoiesis, cyclic, 162800 (3)",ELA2,130130,19p13.3,Hematological,1991,1,334,424
650,"Hemangioblastoma, cerebellar, somatic (3)",VHL,608537,3p26-p25,Cancer,7428,1,335,311
656,"Hemiplegic migraine, familial, 141500 (3)","CACNA1A, CACNL1A4, SCA6",601011,19p13,Neurological,773,1,336,583
456,"Dyserythropoietic anemia with thrombocytopenia, 300367 (3)","GATA1, GF1, ERYF1, NFE1",305371,Xp11.23,Hematological,2623,1,337,496
936,"Macrothrombocytopenia, 300367 (3)","GATA1, GF1, ERYF1, NFE1",305371,Xp11.23,Hematological,2623,1,338,496
166,"Atrial fibrillation, familial, 607554 (3)","KCNE2, MIRP1, LQT6",603796,21q22.1,Cardiovascular,9992,1,339,217
166,"Atrial fibrillation, familial, 607554 (3)","KCNQ1, KCNA9, LQT1, KVLQT1, ATFB1",607542,11p15.5,Cardiovascular,3784,1,339,218
166,Atrial septal defect 3 (3),"MYH6, ASD3, MYHCA",160710,14q12,Cardiovascular,4624,1,339,262
166,"Atrial septal defect-2, 607941 (3)",GATA4,600576,8p23.1-p22,Cardiovascular,2626,1,339,590
166,"Atrial septal defect with atrioventricular conduction defects, 108900 (3)","NKX2E, CSX",600584,5q34,Cardiovascular,1482,1,339,690
96,"Alternating hemiplegia of childhood, 104290 (3)","ATP1A2, FHM2, MHP2",182340,1q21-q23,Neurological,477,1,340,591
1046,"Myelofibrosis, idiopathic, 254450 (3)",JAK2,147796,9p24,Hematological,3717,1,341,595
1493,"Thrombocythemia, essential, 187950 (3)",JAK2,147796,9p24,Hematological,3717,1,342,595
1493,"Thrombocythemia, essential, 187950 (3)","THPO, MGDF, MPLLG, TPO",600044,3q26.3-q27,Hematological,7066,1,342,749
1242,"Polycythemia, benign familial, 263400 (3)",VHL,608537,3p26-p25,Hematological,7428,1,343,311
1242,"Polycythemia vera, 263300 (3)",JAK2,147796,9p24,Hematological,3717,1,343,595
563,G6PD deficiency (3),"G6PD, G6PD1",305900,Xq28,Metabolic,2539,1,344,380
500,"Epstein syndrome, 153650 (3)","MYH9, MHA, FTNS, DFNA17",160775,22q11.2,Hematological,4627,1,345,414
509,Estrogen resistance (3),"ESR1, ESR",133430,6q25.1,Endocrine,2099,1,346,600
726,"Hypereosinophilic syndrome, idiopathic, resistant to imatinib, 607685 (3)",PDGFRA,173490,4q12,Hematological,5156,1,347,602
583,Giant-cell fibroblastoma (3),"PDGFB, SIS",190040,22q12.3-q13.1,Cancer,5155,1,348,604
422,Dermatofibrosarcoma protuberans (3),"PDGFB, SIS",190040,22q12.3-q13.1,Cancer,5155,1,349,604
1536,"Turcot syndrome with glioblastoma, 276300 (3)","MLH1, COCA2, HNPCC2",120436,3p21.3,Cancer,4292,1,350,104
1536,"Turcot syndrome, 276300 (3)","APC, GS, FPC",175100,5q21-q22,Cancer,324,1,350,239
1536,"Turcot syndrome with glioblastoma, 276300 (3)","PMS2, PMSL2, HNPCC4",600259,7p22,Cancer,5395,1,350,605
1093,"Neuroectodermal tumors, supratentorial primitive, with cafe-au-lait spots, 608623 (3)","PMS2, PMSL2, HNPCC4",600259,7p22,multiple,5395,1,351,605
434,"Dilated cardiomyopathy with woolly hair and keratoderma, 605676 (3)","DSP, KPPS2, PPKS2",125647,6p24,multiple,1832,1,352,394
430,"Diastrophic dysplasia, 222600 (3)","SLC26A2, DTD, DTDST, D5S1708, EDM4",606718,5q32-q33.1,Skeletal,1836,1,353,606
430,"Diastrophic dysplasia, broad bone-platyspondylic variant (3)","SLC26A2, DTD, DTDST, D5S1708, EDM4",606718,5q32-q33.1,Skeletal,1836,1,353,606
439,Dissection of cervical arteries (3),COL1A1,120150,17q21.31-q22,Connective tissue disorder,1277,1,354,68
341,"Coffin-Lowry syndrome, 303600 (3)","RPS6KA3, RSK2, MRX19",300075,Xp22.2-p22.1,multiple,6197,1,355,607
345,"Coloboma, ocular, 120200 (3)","PAX6, AN2, MGDA",607108,11p13,Ophthamological,5080,1,356,120
345,"Coloboma, ocular, 120200 (3)","SHH, HPE3, HLP3, SMMCI",600725,7q36,Ophthamological,6469,1,356,237
347,"Colonic aganglionosis, total, with small bowel involvement (3)","RET, MEN2A",164761,10q11.2,Gastrointestinal,5979,1,357,229
1213,"Peters anomaly, 603807 (3)","PAX6, AN2, MGDA",607108,11p13,Developmental,5080,1,358,120
1213,"Peters anomaly, 604229 (3)","CYP1B1, GLC3A",601771,2p22-p21,Developmental,1545,1,358,811
119,"Aniridia, type II, 106210 (3)","PAX6, AN2, MGDA",607108,11p13,Ophthamological,5080,1,359,120
516,"Eye anomalies, multiplex (3)","PAX6, AN2, MGDA",607108,11p13,Ophthamological,5080,1,360,120
5144,"Optic nerve hypoplasia/aplasia, 165550 (3)","PAX6, AN2, MGDA",607108,11p13,Ophthamological,5080,1,361,120
842,"Keratitis, 148190 (3)","PAX6, AN2, MGDA",607108,11p13,Ophthamological,5080,1,362,120
548,"Foveal hypoplasia, isolated, 136520 (3)","PAX6, AN2, MGDA",607108,11p13,Ophthamological,5080,1,363,120
1323,"Rhabdomyosarcoma, 268210 (3)","SLC22A1L, BWSCR1A, IMPT1",602631,11p15.5,Cancer,5002,1,364,211
1323,"Rhabdomyosarcoma, alveolar, 268220 (3)","PAX3, WS1, HUP2, CDHS",606597,2q35,Cancer,5077,1,364,308
1323,"Rhabdomyosarcoma, alveolar, 268220 (3)",PAX7,167410,1p36.2-p36.12,Cancer,5081,1,364,616
1323,"Rhabdomyosarcoma, alveolar, 268220 (3)","FOXO1A, FKHR",136533,13q14.1,Cancer,2308,1,364,738
769,"Hypodontia, autosomal dominant, 106600 (3)","MSX1, HOX7, HYD1, OFC5",142983,4p16.1,Skeletal,4487,1,365,319
769,"Hypodontia with orofacial cleft, 106600 (3)","MSX1, HOX7, HYD1, OFC5",142983,4p16.1,Skeletal,4487,1,365,319
769,"Hypodontia, 106600 (3)",PAX9,167416,14q12-q13,Skeletal,5083,1,365,577
708,Huntington disease (3),"HD, IT15",143100,4p16.3,Neurological,3064,1,366,617
708,"Huntington disease-like 1, 603218 (3)","PRNP, PRIP",176640,20pter-p12,Neurological,5621,1,366,625
708,"Huntington disease-like-4, 607136 (3)","TBP, SCA17",600075,6q27,Neurological,6908,1,366,850
708,"Huntington disease-like 2, 606438 (3)","JPH3, JP3, HDL2",605268,16q24.3,Neurological,57338,1,366,870
1324,"Rheumatoid arthritis, progression of, 180300 (3)","IL10, CSIF",124092,1q31-q32,Connective tissue disorder,3586,1,367,230
1324,"Rheumatoid arthritis, susceptibility to, 180300 (3)","RUNX1, CBFA2, AML1",151385,21q22.3,Connective tissue disorder,861,1,367,509
1324,"Rheumatoid arthritis, systemic juvenile, susceptibility to, 604302 (3)",MIF,153620,22q11.2,Connective tissue disorder,4282,1,367,618
1324,"Rheumatoid arthritis, susceptibility to, 180300 (3)","PTPN8, PEP, PTPN22, LYP",600716,1p13,Connective tissue disorder,26191,1,367,671
1324,"Rheumatoid arthritis, susceptibility to, 180300 (3)","MHC2TA, C2TA",600005,16p13,Connective tissue disorder,4261,1,367,682
1324,"Rheumatoid arthritis, susceptibility to, 180300 (3)","PADI4, PADI5, PAD",605347,1p36,Connective tissue disorder,23569,1,367,744
1324,"Rheumatoid arthritis, susceptibility to, 180300 (3)","SLC22A4, OCTN1",604190,5q31,Connective tissue disorder,6583,1,367,745
1324,"Rheumatoid arthritis, susceptibility to, 180300 (3)",NFKBIL1,601022,6p21.3,Connective tissue disorder,4795,1,367,746
1508,"Tietz syndrome, 103500 (3)","MITF, WS2A",156845,3p14.1-p12.3,multiple,4286,1,368,310
750,Hyperproreninemia (3),REN,179820,1q32,Cardiovascular,5972,1,369,622
530,"Fechtner syndrome, 153640 (3)","MYH9, MHA, FTNS, DFNA17",160775,22q11.2,multiple,4627,1,370,414
961,"May-Hegglin anomaly, 155100 (3)","MYH9, MHA, FTNS, DFNA17",160775,22q11.2,Hematological,4627,1,371,414
1528,"Trismus-pseudocomptodactyly syndrome, 158300 (3)",MYH8,160741,17p13.1,multiple,4626,1,372,258
2287,"Central core disease, one form (3) ()","MYH7, CMH1, MPD1",160760,14q12,Muscular,4625,1,373,261
2287,"Central core disease, 117000 (3)","RYR1, MHS, CCO",180901,19q13.1,Muscular,6261,1,373,650
1263,"Prion disease with protracted course, 606688 (3)","PRNP, PRIP",176640,20pter-p12,Neurological,5621,1,374,625
581,"Gerstmann-Straussler disease, 137440 (3)","PRNP, PRIP",176640,20pter-p12,Neurological,5621,1,375,625
388,"Creutzfeldt-Jakob disease, 123400 (3)","PRNP, PRIP",176640,20pter-p12,Neurological,5621,1,376,625
388,"Creutzfeldt-Jakob disease, variant, resistance to, 123400 (3)",HLA-DQB1,604305,6p21.3,Neurological,3119,1,376,804
812,"Insomnia, fatal familial, 600072 (3)","PRNP, PRIP",176640,20pter-p12,Psychiatric,5621,1,377,625
812,Insomnia (3) (),GABRB3,137192,15q11.2-q12,Psychiatric,2562,1,377,806
129,Anxiety-related personality traits (3),"SLC6A4, HTT, OCD1",182138,17q11.1-q12,Psychiatric,6532,1,378,629
2385,"Creatine deficiency syndrome, X-linked, 300352 (3)","SLC6A8, CRTR",300036,Xq28,Neurological,6535,1,379,630
762,Hypoalphalipoproteinemia (3),APOA1,107680,11q23,Metabolic,335,1,380,594
763,Hypobetalipoproteinemia (3),"APOB, FLDB",107730,2p24,Metabolic,338,1,381,632
1099,"Neuropathy, recurrent, with pressure palsies, 162500 (3)","PMP22, CMT1A, CMT1E, DSS",601097,17p11.2,Neurological,5376,1,382,128
1099,"Neuropathy, distal hereditary motor, 608634 (3)","HSPB1, HSP27, CMT2F",602195,7q11.23,Neurological,3315,1,382,131
1099,"Neuropathy, congenital hypomyelinating, 605253 (3)","MPZ, CMT1B, CMTDI3, CHM, DSS",159440,1q22,Neurological,4359,1,382,133
1099,"Neuropathy, congenital hypomyelinating, 1, 605253 (3)","EGR2, KROX20",129010,10q21.1-q22.1,Neurological,1959,1,382,140
1099,"Neuropathy, hereditary sensory and autonomic, type 1, 162400 (3)","SPTLC1, LBC1, SPT1, HSN1, HSAN",605712,9q22.1-q22.3,Neurological,10558,1,382,633
1099,"Neuropathy, distal hereditary motor, type II, 158590 (3)","HSPB8, H11, E2IG1, DHMN2",608014,12q24-qter,Neurological,26353,1,382,893
1099,"Neuropathy, hereditary sensory and autonomic, type V, 608654 (3)","NGFB, HSAN5",162030,1p13.1,Neurological,4803,1,382,898
1099,"Neuropathy, hereditary sensory, type II, 201300 (3)",HSN2,608620,12p13.33,Neurological,378465,1,382,900
1129,"Occipital horn syndrome, 304150 (3)","ATP7A, MNK, MK, OHS",300011,Xq12-q13,multiple,538,1,383,647
942,"Malignant hyperthermia susceptibility 1, 145600 (3)","RYR1, MHS, CCO",180901,19q13.1,Neurological,6261,1,384,650
942,"Malignant hyperthermia susceptibility 5, 601887 (3)","CACNA1S, CACNL1A3, CCHL1A3",114208,1q32,Neurological,779,1,384,837
1558,"Ventricular tachycardia, stress-induced polymorphic, 604772 (3)","RYR2, VTSIP",180902,1q42.1-q43,Cardiovascular,6262,1,385,651
1558,"Ventricular tachycardia, idiopathic, 192605 (3)","GNAI2, GNAI2B, GIP",139360,3p21,Cardiovascular,2771,1,385,756
1558,"Ventricular tachycardia, stress-induced polymorphic, 604772 (3)",CASQ2,114251,1p13.3-p11,Cardiovascular,845,1,385,808
144,"Arrhythmogenic right ventricular dysplasia 8, 607450 (3)","DSP, KPPS2, PPKS2",125647,6p24,Cardiovascular,1832,1,386,394
144,"Arrhythmogenic right ventricular dysplasia 2, 600996 (3)","RYR2, VTSIP",180902,1q42.1-q43,Cardiovascular,6262,1,386,651
144,"Arrhythmogenic right ventricular dysplasia, familial, 9, 609040 (3)","PKP2, ARVD9",602861,12p11,Cardiovascular,5318,1,386,805
882,"Leprosy, susceptibility to, 607572 (3)","PRKN, PARK2, PDJ",602544,6q25.2-q27,Immunological,5071,1,387,243
1045,"Myelodysplastic syndrome, preleukemic (3)","IRF1, MAR",147575,5q31.1,Muscular,3659,1,388,331
1045,Myelodysplastic syndrome (3),"FACL6, ACS2",604443,5q31,Muscular,23305,1,388,691
1045,Myelodysplasia syndrome-1 (3),MDS1,600049,3q26,Muscular,4197,1,388,798
935,"Macrocytic anemia, refractory, of 5q- syndrome, 153550 (3)","IRF1, MAR",147575,5q31.1,Hematological,3659,1,389,331
589,"Glaucoma, normal tension, susceptibility to, 606657 (3)","OPA1, NTG, NPG",605290,3q28-q29,Ophthamological,4976,1,390,655
589,"Glaucoma 1A, primary open angle, juvenile-onset, 137750 (3)","MYOC, TIGR, GLC1A, JOAG, GPOA",601652,1q24.3-q25.2,Ophthamological,4653,1,390,784
589,"Glaucoma 1A, primary open angle, recessive (3)","MYOC, TIGR, GLC1A, JOAG, GPOA",601652,1q24.3-q25.2,Ophthamological,4653,1,390,784
589,"Glaucoma, early-onset, digenic (3)","MYOC, TIGR, GLC1A, JOAG, GPOA",601652,1q24.3-q25.2,Ophthamological,4653,1,390,784
589,"Glaucoma 3A, primary congenital, 231300 (3)","CYP1B1, GLC3A",601771,2p22-p21,Ophthamological,1545,1,390,811
589,"Glaucoma, early-onset, digenic (3)","CYP1B1, GLC3A",601771,2p22-p21,Ophthamological,1545,1,390,811
589,"Glaucoma, primary open angle, adult-onset, 137760 (3)","CYP1B1, GLC3A",601771,2p22-p21,Ophthamological,1545,1,390,811
589,"Glaucoma, primary open angle, juvenile-onset, 137750 (3)","CYP1B1, GLC3A",601771,2p22-p21,Ophthamological,1545,1,390,811
589,"Glaucoma 1E, primary open angle, adult-onset, 137760 (3)","OPTN, GLC1E, FIP2, HYPL, NRP",602432,10p15-p14,Ophthamological,10133,1,390,897
589,"Glaucoma, normal tension, susceptibility to, 606657 (3)","OPTN, GLC1E, FIP2, HYPL, NRP",602432,10p15-p14,Ophthamological,10133,1,390,897
3178,"Pancreatic agenesis, 260370 (3)",IPF1,600733,13q12.1,Gastrointestinal,3651,1,391,342
1018,"Miyoshi myopathy, 254130 (3)","DYSF, LGMD2B",603009,2p13.3-p13.1,Muscular,8291,1,392,657
83,"Allergic rhinitis, susceptibility to, 607154 (3)","IL13, ALRH",147683,5q31,Immunological,3596,1,393,661
624,"Graves disease, susceptibility to, 275000 (3)",CTLA4,123890,2q33,Endocrine,1493,1,394,353
624,"Graves disease, susceptibility to, 3, 275000 (3)","GC, DBP",139200,4q12,Endocrine,2638,1,394,663
3229,"Pigmented adrenocortical disease, primary isolated, 160980 (3)","PRKAR1A, TSE1, CNC1, CAR",188830,17q23-q24,Cancer,5573,1,395,54
1066,"Myxoma, intracardiac, 255960 (3)","PRKAR1A, TSE1, CNC1, CAR",188830,17q23-q24,Cardiovascular,5573,1,396,54
1156,"Osteogenesis imperfecta, 3 clinical forms, 166200, 166210, 259420 (3)",COL1A2,120160,7q22.1,Bone,1278,1,397,67
1156,"Osteogenesis imperfecta, type I, 166200 (3)",COL1A1,120150,17q21.31-q22,Bone,1277,1,397,68
1156,"Osteogenesis imperfecta, type II, 166210 (3)",COL1A1,120150,17q21.31-q22,Bone,1277,1,397,68
1156,"Osteogenesis imperfecta, type III, 259420 (3)",COL1A1,120150,17q21.31-q22,Bone,1277,1,397,68
1156,"Osteogenesis imperfecta, type IV, 166220 (3)",COL1A1,120150,17q21.31-q22,Bone,1277,1,397,68
950,"Marfan syndrome, atypical (3)",COL1A2,120160,7q22.1,Connective tissue disorder,1278,1,398,67
950,"Marfan syndrome, 154700 (3)","FBN1, MFS1, WMS",134797,15q21.1,Connective tissue disorder,2200,1,398,178
647,"Heart block, nonprogressive, 113900 (3)","SCN5A, LQT3, IVF, HB1, SSS1",600163,3p21,Cardiovascular,6331,1,399,51
647,"Heart block, progressive, type I, 113900 (3)","SCN5A, LQT3, IVF, HB1, SSS1",600163,3p21,Cardiovascular,6331,1,399,51
515,"Exudative vitreoretinopathy, dominant, 133780 (3)","LRP5, BMND1, LRP7, LR3, OPPG, VBCH2",603506,11q13.4,Ophthamological,4041,1,400,195
515,"Exudative vitreoretinopathy, recessive, 601813 (3)","LRP5, BMND1, LRP7, LR3, OPPG, VBCH2",603506,11q13.4,Ophthamological,4041,1,400,195
515,"Exudative vitreoretinopathy, X-linked, 305390 (3)","NDP, ND",310600,Xp11.4,Ophthamological,4693,1,400,333
515,"Exudative vitreoretinopathy, 133780 (3)","FZD4, EVR1",604579,11q14-q21,Ophthamological,8322,1,400,667
1153,"Ossification of posterior longitudinal ligament of spine, 602475 (3)","ENPP1, PDNP1, NPPS, M6S1, PCA1",173335,6q22-q23,Connective tissue disorder,5167,1,401,644
102,"Amyloid neuropathy, familial, several allelic types (3)","TTR, PALB",176300,18q11.2-q12.1,Neurological,7276,1,402,106
425,"Desmoid disease, hereditary, 135290 (3)","APC, GS, FPC",175100,5q21-q22,Cancer,324,1,403,239
359,"Convulsions, familial febrile, 4, 604352 (3)","MASS1, VLGR1, KIAA0686, FEB4, USH2C",602851,5q14,Neurological,84059,1,404,677
157,"Ataxia-telangiectasia, 208900 (3)","ATM, ATA, AT1",607585,11q22.3,Immunological,472,1,405,457
157,"Ataxia-telangiectasia-like disorder, 604391 (3)","MRE11A, MRE11, ATLD",600814,11q21,Immunological,4361,1,405,681
9038,"Multiple sclerosis, susceptibility to, 126200 (3)","PTPRC, CD45, LCA",151460,1q31-q32,Neurological,5788,1,406,170
9038,"Multiple sclerosis, susceptibility to, 126200 (3)","MHC2TA, C2TA",600005,16p13,Neurological,4261,1,406,682
1331,Rieger anomaly (3),"FOXC1, FKHL7, FREAC3",601090,6p25,multiple,2296,1,407,684
1331,"Rieger syndrome, 180500 (3)","PITX2, IDG2, RIEG1, RGS, IGDS2",601542,4q25-q26,multiple,5308,1,407,685
1333,"Rippling muscle disease, 606072 (3)","CAV3, LGMD1C",601253,3p25,Muscular,859,1,408,266
1332,"Ring dermoid of cornea, 180550 (3)","PITX2, IDG2, RIEG1, RGS, IGDS2",601542,4q25-q26,Ophthamological,5308,1,409,685
1339,"Roussy-Levy syndrome, 180800 (3)","PMP22, CMT1A, CMT1E, DSS",601097,17p11.2,multiple,5376,1,410,128
1339,"Roussy-Levy syndrome, 180800 (3)","MPZ, CMT1B, CMTDI3, CHM, DSS",159440,1q22,multiple,4359,1,410,133
1559,"Vertical talus, congenital, 192950 (3)","HOXD10, HOX4D",142984,2q31-q32,Skeletal,3236,1,411,138
2174,"Autoimmune thyroid disease, susceptibility to 3, 608175 (3)","TG, AITD3",188450,8q24.2-q24.3,Endocrine,7038,1,412,355
177,Axenfeld anomaly (3),"FOXC1, FKHL7, FREAC3",601090,6p25,Ophthamological,2296,1,413,684
126,"Anterior segment mesenchymal dysgenesis and cataract, 107250 (3)",PITX3,602669,10q25,Ophthamological,5309,1,414,116
126,Anterior segment mesenchymal dysgenesis (3),"FOXC1, FKHL7, FREAC3",601090,6p25,Ophthamological,2296,1,414,684
126,Anterior segment anomalies and cataract (3),"EYA1, BOR",601653,8q13.3,Ophthamological,2138,1,414,872
126,"Anterior segment mesenchymal dysgenesis, 107250 (3)","FOXE3, FKHL12, ASMD",601094,1p32,Ophthamological,2301,1,414,873
823,Iris hypoplasia and glaucoma (3),"FOXC1, FKHL7, FREAC3",601090,6p25,Ophthamological,2296,1,415,684
822,"Iridogoniodysgenesis, 601631 (3)","FOXC1, FKHL7, FREAC3",601090,6p25,Ophthamological,2296,1,416,684
822,"Iridogoniodysgenesis syndrome-2, 137600 (3)","PITX2, IDG2, RIEG1, RGS, IGDS2",601542,4q25-q26,Ophthamological,5308,1,416,685
1494,"Thrombocytopenia, X-linked, 313900 (3)","WAS, IMD2, THC",300392,Xp11.23-p11.22,Hematological,7454,1,417,320
1494,"Thrombocytopenia, X-linked, intermittent, 313900 (3)","WAS, IMD2, THC",300392,Xp11.23-p11.22,Hematological,7454,1,417,320
1494,Thromboembolism susceptibility due to factor V Leiden (3),F5,227400,1q23,Hematological,2153,1,417,442
1494,"Thrombocytopenia, congenital amegakaryocytic, 604498 (3)","MPL, TPOR, MPLV",159530,1p34,Hematological,4352,1,417,750
1494,"Thrombycytosis, susceptibility to, 187950 (3)","MPL, TPOR, MPLV",159530,1p34,Hematological,4352,1,417,750
1494,"Thrombocytopenia-2, 188000 (3)","FLJ14813, THC2",608221,10p12.1,Hematological,84930,1,417,751
978,"Melanoma, malignant sporadic (3)","STK11, PJS, LKB1",602216,19p13.3,Cancer,6794,1,418,25
978,"Melanoma and neural system tumor syndrome, 155755 (3)","CDKN2A, MTS1, P16, MLM, CMM2",600160,9p21,Cancer,1029,1,418,26
978,"Melanoma, cutaneous malignant, 2, 155601 (3)","CDKN2A, MTS1, P16, MLM, CMM2",600160,9p21,Cancer,1029,1,418,26
978,"Melanoma, melignant, somatic (3)",BRAF,164757,7q34,Cancer,673,1,418,244
978,"Melanoma, cutaneous malignant, susceptibility to (3)",XRCC3,600675,14q32.3,Cancer,7517,1,418,831
978,Melanoma (3),"CDK4, CMM3",123829,12q14,Cancer,1019,1,418,832
1183,Papillary serous carcinoma of the peritoneum (3),"BRCA1, PSCP",113705,17q21,Cancer,672,1,419,10
1462,"Supranuclear palsy, progressive, 601104 (3)","MAPT, MTBT1, DDPAC, MSTD",157140,17q21.1,Neurological,4137,1,420,17
1462,"Supranuclear palsy, progressive atypical, 260540 (3)","MAPT, MTBT1, DDPAC, MSTD",157140,17q21.1,Neurological,4137,1,420,17
1435,"Spondyloepiphyseal dysplasia tarda, 313400 (3)","SEDL, SEDT",300202,Xp22.2-p22.1,Skeletal,6399,1,421,693
1435,"Spondyloepiphyseal dysplasia tarda with progressive arthropathy, 208230 (3)","WISP3, PPAC, PPD",603400,6q22-q23,Skeletal,8838,1,421,796
1435,"Spondyloepiphyseal dysplasia, Omani type, 608637 (3)","CHST3, C6ST, C6ST1",603799,10q22.1,Skeletal,9469,1,421,807
1435,"Spondyloepiphyseal dysplasia, Kimberley type, 608361 (3)","AGC1, CSPG1, MSK16, SEDK",155760,15q26.1,Skeletal,176,1,421,846
1435,"Spondyloepimetaphyseal dysplasia, 608728 (3)","MATN3, EDM5, HOA",602109,2p24-p23,Skeletal,4148,1,421,847
1468,"Syndactyly, type III, 186100 (3)","GJA1, CX43, ODDD, SDTY3, ODOD",121014,6q21-q23.2,Skeletal,2697,1,422,576
29,"Achromatopsia-3, 262300 (3)","CNGB3, ACHM3",605080,8q21-q22,Ophthamological,54714,1,423,695
29,"Achromatopsia-2, 216900 (3)","CNGA3, CNG3, ACHM2",600053,2q11,Ophthamological,1261,1,423,712
29,Achromatopsia-4 (3),"GNAT2, ACHM4",139340,1p13,Ophthamological,2780,1,423,834
497,"Episodic ataxia, type 2, 108500 (3)","CACNA1A, CACNL1A4, SCA6",601011,19p13,Neurological,773,1,424,583
497,"Episodic ataxia/myokymia syndrome, 160120 (3)","KCNA1, AEMK, EA1",176260,12p13,Neurological,3736,1,424,696
1061,"Myotilinopathy, 609200 (3)","TTID, MYOT",604103,5q31,Muscular,9499,1,425,697
1062,"Myotonia congenita, dominant, 160800 (3)",CLCN1,118425,7q35,Muscular,1180,1,426,698
1062,"Myotonia congenita, recessive, 255700 (3)",CLCN1,118425,7q35,Muscular,1180,1,426,698
1062,"Myotonia levior, recessive (3)",CLCN1,118425,7q35,Muscular,1180,1,426,698
1062,"Myotonia congenita, atypical, acetazolamide-responsive, 608390 (3)","SCN4A, HYPP, NAC1A",603967,17q23.1-q25.3,Muscular,6329,1,426,699
814,"Insulin resistance, severe, digenic, 604367 (3)","PPARG, PPARG1, PPARG2",601487,3p25,Metabolic,5468,1,427,47
814,"Insulin resistance, severe, digenic, 604367 (3)","PPP1R3A, PPP1R3",600917,7q11.23-q21.11,Metabolic,5506,1,427,702
814,"Insulin resistance, susceptibility to (3)","PTPN1, PTP1B",176885,20q13.1-q13.2,Metabolic,5770,1,427,748
748,"Hyperproinsulinemia, familial (3)",INS,176730,11p15.5,Endocrine,3630,1,428,340
741,"Hyperostosis, endosteal, 144750 (3)","LRP5, BMND1, LRP7, LR3, OPPG, VBCH2",603506,11q13.4,Bone,4041,1,429,195
985,Meniere disease 156000 (3) (),"COCH, DFNA9",603196,14q12-q13,Neurological,1690,1,430,489
988,"Menkes disease, 309400 (3)","ATP7A, MNK, MK, OHS",300011,Xq12-q13,Neurological,538,1,431,647
484,"Enlarged vestibular aqueduct, 603545 (3)","SLC26A4, PDS, DFNB4",605646,7q31,"Ear,Nose,Throat",5172,1,432,471
184,"Bare lymphocyte syndrome, type I, due to TAP2 deficiency, 604571 (3)","TAP2, ABCB3, PSF2, RING11",170261,6p21.3,Immunological,6891,1,433,419
184,"Bare lymphocyte syndrome, type II, complementation group A, 209920 (3)","MHC2TA, C2TA",600005,16p13,Immunological,4261,1,433,682
184,"Bare lymphocyte syndrome, type I, 604571 (3)","TAPBP, TPSN",601962,6p21.3,Immunological,6892,1,433,717
184,"Bare lymphocyte syndrome, type II, complementation group D, 209920 (3)",RFXAP,601861,13q14,Immunological,5994,1,433,718
184,"Bare lymphocyte syndrome, type II, complementation group C, 209920 (3)",RFX5,601863,1q21.1-q21.3,Immunological,5993,1,433,719
184,"Bare lymphocyte syndrome, type II, complementation group E, 209920 (3)",RFX5,601863,1q21.1-q21.3,Immunological,5993,1,433,719
185,"Barth syndrome, 302060 (3)","TAZ, EFE2, BTHS, CMD3A, LVNCX",300394,Xq28,multiple,6901,1,434,279
160,"Atelostogenesis, type I, 108720 (3)","FLNB, SCT, AOI",603381,3p14.3,Connective tissue disorder,2317,1,435,255
160,"Atelosteogenesis II, 256050 (3)","SLC26A2, DTD, DTDST, D5S1708, EDM4",606718,5q32-q33.1,Connective tissue,1836,1,435,606
829,"Jensen syndrome, 311150 (3)","TIMM8A, DFN1, DDP, MTS, DDP1",300356,Xq22,Neurological,1678,1,436,343
168,"Atrioventricular septal defect, 600309 (3)","GJA1, CX43, ODDD, SDTY3, ODOD",121014,6q21-q23.2,Cardiovascular,2697,1,437,576
168,"Atrioventricular block, idiopathic second-degree (3)","NKX2E, CSX",600584,5q34,Cardiovascular,1482,1,437,690
168,"Atrioventricular septal defect, partial, with heterotaxy syndrome, 606217 (3)","CRELD1, AVSD2",607170,3p25.3,Cardiovascular,78987,1,437,731
168,"Atrioventricular septal defect, susceptibility to, 2, 606217 (3)","CRELD1, AVSD2",607170,3p25.3,Cardiovascular,78987,1,437,731
1051,"Myeloperoxidase deficiency, 254600 (3)",MPO,606989,17q23.1,Immunological,4353,1,438,587
1476,Tauopathy and respiratory failure (3),"MAPT, MTBT1, DDPAC, MSTD",157140,17q21.1,Neurological,4137,1,439,17
1261,"Primary lateral sclerosis, juvenile, 606353 (3)","ALS2, ALSJ, PLSJ, IAHSP",606352,2q33,Neurological,57679,1,440,735
995,Mesothelioma (3),BCL10,603517,1p22,Cancer,8915,1,441,176
1321,"Rett syndrome, atypical, 312750 (3)","CDKL5, STK9",300203,Xp22,Neurological,6792,1,442,739
1321,"Rett syndrome, 312750 (3)","MECP2, RTT, PPMX, MRX16, MRX79",300005,Xq28,Neurological,4204,1,442,740
1321,"Rett syndrome, preserved speech variant, 312750 (3)","MECP2, RTT, PPMX, MRX16, MRX79",300005,Xq28,Neurological,4204,1,442,740
1326,Rh-mod syndrome (3),"RHAG, RH50A",180297,6p21.1-p11,Hematological,6005,1,443,741
1327,Rh-negative blood type (3),RHD,111680,1p36.2-p34,Hematological,6007,1,444,742
1327,"Rh-null disease, amorph type (3)",RHCE,111700,1p36.2-p34,Hematological,6006,1,444,743
74,"Alcohol dependence, susceptibility to, 103780 (3)",HTR2A,182135,13q14-q21,Unclassified,3356,1,445,416
124,"Anorexia nervosa, susceptibility to, 606788 (3)",HTR2A,182135,13q14-q21,Nutritional,3356,1,446,416
1414,"Solitary median maxillary central incisor, 147250 (3)","SHH, HPE3, HLP3, SMMCI",600725,7q36,Skeletal,6469,1,447,237
1253,"PPM-X syndrome, 300055 (3)","MECP2, RTT, PPMX, MRX16, MRX79",300005,Xq28,Neurological,4204,1,448,740
2785,"Hypoplastic left heart syndrome, 241550 (3)","GJA1, CX43, ODDD, SDTY3, ODOD",121014,6q21-q23.2,Cardiovascular,2697,1,449,576
1088,"Netherton syndrome, 256500 (3)","SPINK5, LEKTI",605010,5q32,Dermatological,11005,1,450,727
1232,Pituitary ACTH-secreting adenoma (3),"GNAI2, GNAI2B, GIP",139360,3p21,Cancer,2771,1,451,756
1232,Pituitary ACTH secreting adenoma (3),"GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO",139320,20q13.2,Cancer,2778,1,451,759
1232,"Pituitary adenoma, nonfunctioning (3)","THRA, ERBA1, THRA1",190120,17q11.2,Cancer,7067,1,451,878
1282,"Pseudohypoparathyroidism, type Ia, 103580 (3)","GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO",139320,20q13.2,Endocrine,2778,1,452,759
1282,"Pseudohypoparathyroidism, type Ib, 603233 (3)","GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO",139320,20q13.2,Endocrine,2778,1,452,759
38,"Acromegaly, 102200 (3)","GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO",139320,20q13.2,Endocrine,2778,1,453,759
38,"Acromegaly, 102200 (3)",SSTR5,182455,16p13.3,Endocrine,6755,1,453,803
1415,Somatotrophinoma (3),"GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO",139320,20q13.2,Endocrine,2778,1,454,759
1152,"Osseous heteroplasia, progressive, 166350 (3)","GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO",139320,20q13.2,Bone,2778,1,455,759
963,"McCune-Albright syndrome, 174800 (3)","GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO",139320,20q13.2,multiple,2778,1,456,759
623,"Graft-versus-host disease, protection against (3)","IL10, CSIF",124092,1q31-q32,Immunological,3586,1,457,230
338,"Coats disease, 300216 (3)","NDP, ND",310600,Xp11.4,Ophthamological,4693,1,458,333
754,"Hyperthroidism, congenital (3)",TSHR,603372,14q31,Endocrine,7253,1,459,356
628,"Growth hormone insensitivity with immunodeficiency, 245590 (3)",STAT5B,604260,17q11.2,Endocrine,6777,1,460,517
628,Growth hormone deficient dwarfism (3),GHRHR,139191,7p15-p14,Endocrine,2692,1,460,778
571,Gardner syndrome (3),"APC, GS, FPC",175100,5q21-q22,Cancer,324,1,461,239
198,"Beta-2-adrenoreceptor agonist, reduced response to (3)",ADRB2,109690,5q32-q34,Unclassified,154,1,462,635
370,"Coumarin resistance, 122700 (3)","CYP2A6, CYP2A3, CYP2A, P450C2A",122720,19q13.2,Hematological,1548,1,463,425
377,"Craniofacial anomalies, empty sella turcica, corneal endothelial changes, and abnormal retinal and auditory bipolar cells (3)","VSX1, RINX, PPCD, PPD, KTCN",605020,20p11.2,multiple,30813,1,464,726
376,"Cramps, familial, potassium-aggravated (3)","SCN4A, HYPP, NAC1A",603967,17q23.1-q25.3,Muscular,6329,1,465,699
378,"Craniofacial-deafness-hand syndrome, 122880 (3)","PAX3, WS1, HUP2, CDHS",606597,2q35,multiple,5077,1,466,308
1317,Retinoblastoma (3),RB1,180200,13q14.1-q14.2,Cancer,5925,1,467,785
147,"Arthropathy, progressive pseudorheumatoid, of childhood, 208230 (3)","WISP3, PPAC, PPD",603400,6q22-q23,Bone,8838,1,468,796
809,Infundibular hypoplasia and hypopituitarism (3),"SOX3, MRGH",313430,Xq26.3,Endocrine,6658,1,469,776
830,"Jervell and Lange-Nielsen syndrome, 220400 (3)","KCNE1, JLNS, LQT5",176261,21q22.1-q22.2,multiple,3753,1,470,216
830,"Jervell and Lange-Nielsen syndrome, 220400 (3)","KCNQ1, KCNA9, LQT1, KVLQT1, ATFB1",607542,11p15.5,multiple,3784,1,470,218
31,"Acquired long QT syndrome, susceptibility to (3)","KCNH2, LQT2, HERG",152427,7q35-q36,Cardiovascular,3757,1,471,219
1091,"Neuroblastoma, 256700 (3)","PMX2B, NBPHOX, PHOX2B",603851,4p12,Cancer,8929,1,472,228
1091,"Neuroblastoma, 256700 (3)","NME1, NM23",156490,17q21.3,Cancer,4830,1,472,800
764,"Hypocalcemia, autosomal dominant, 146200 (3)","CASR, HHC1, PCAR1, FIH",601199,3q13.3-q21,Endocrine,846,1,473,703
764,"Hypocalcemia, autosomal dominant, with Bartter syndrome (3)","CASR, HHC1, PCAR1, FIH",601199,3q13.3-q21,Endocrine,846,1,473,703
765,"Hypocalciuric hypercalcemia, type I, 145980 (3)","CASR, HHC1, PCAR1, FIH",601199,3q13.3-q21,Endocrine,846,1,474,703
1056,Myoglobinuria/hemolysis due to PGK deficiency (3),"PGK1, PGKA",311800,Xq13,Metabolic,5230,1,475,445
1200,"Pelizaeus-Merzbacher disease, 312080 (3)","PLP1, PMD",300401,Xq22,Neurological,5354,1,476,802
385,"Creatine phosphokinase, elevated serum, 123320 (3)","CAV3, LGMD1C",601253,3p25,Metabolic,859,1,477,266
385,"Creatine phosphokinase, elevated serum, 123320 (3)","CAV3, LGMD1C",601253,3p25,Metabolic,859,1,477,266
549,"Foveomacular dystrophy, adult-onset, with choroidal neovascularization, 608161 (3)","RDS, RP7, PRPH2, PRPH, AVMD, AOFMD",179605,6p21.1-cen,Ophthamological,5961,1,478,562
239,"Butterfly dystrophy, retinal, 169150 (3)","RDS, RP7, PRPH2, PRPH, AVMD, AOFMD",179605,6p21.1-cen,Ophthamological,5961,1,479,562
1214,"Peutz-Jeghers syndrome, 175200 (3)","STK11, PJS, LKB1",602216,19p13.3,Cancer,6794,1,480,25
1278,"Pseudoachondroplasia, 177170 (3)","COMP, EDM1, MED, PSACH",600310,19p13.1,Skeletal,1311,1,481,815
1057,"Myokymia with neonatal epilepsy, 606437 (3)","KCNQ2, EBN1",602235,20q13.3,Neurological,3785,1,482,824
3212,"Persistent hyperinsulinemic hypoglycemia of infancy, 256450 (3)","KCNJ11, BIR, PHHI",600937,11p15.1,Metabolic,3767,1,483,668
27,"Achondrogenesis Ib, 600972 (3)","SLC26A2, DTD, DTDST, D5S1708, EDM4",606718,5q32-q33.1,Bone,1836,1,484,606
4350,"Combined immunodeficiency, X-linked, moderate, 312863 (3)","IL2RG, SCIDX1, SCIDX, IMD4",308380,Xq13,Immunological,3561,1,485,171
4350,Combined C6/C7 deficiency (3),C6,217050,5p13,Immunological,729,1,485,534
604,"Glutathione synthetase deficiency, 266130 (3)","GSS, GSHS",601002,20q11.2,Metabolic,2937,1,486,447
1151,"OSMED syndrome, 215150 (3)","COL11A2, STL3, DFNA13",120290,6p21.3,Bone,1302,1,487,417
953,"Marshall syndrome, 154780 (3)","COL11A1, STL2",120280,1p21,multiple,1301,1,488,797
776,"Hypokalemic periodic paralysis, 170400 (3)","SCN4A, HYPP, NAC1A",603967,17q23.1-q25.3,Renal,6329,1,489,699
776,"Hypokalemic periodic paralysis, 170400 (3)","CACNA1S, CACNL1A3, CCHL1A3",114208,1q32,Renal,779,1,489,837
776,"Hypokalemic periodic paralysis, 170400 (3)","KCNE3, HOKPP",604433,11q13-q14,Renal,10008,1,489,838
590,"Glioblastoma, somatic, 137800 (3)","ERBB2, NGL, NEU, HER2",164870,17q21.1,Cancer,2064,1,490,12
590,"Glioblastoma, early-onset, 137800 (3)","MSH2, COCA1, FCC1, HNPCC1",609309,2p22-p21,Cancer,4436,1,490,13
590,"Glioblastoma, susceptibility to, 137800 (3)","PPARG, PPARG1, PPARG2",601487,3p25,Cancer,5468,1,490,47
590,"Glioblastoma, somatic, 137800 (3)","LGI1, EPT, ETL1",604619,10q24,Cancer,9211,1,490,842
590,"Glioblastoma multiforme, somatic, 137800 (3)",DMBT1,601969,10q25.3-q26.1,Cancer,1755,1,490,902
1191,"Parkes Weber syndrome, 608355 (3)","RASA1, GAP, CMAVM, PKWS",139150,5q13.3,multiple,5921,1,491,280
1504,"Thyrotoxic periodic paralysis, susceptibility to, 188580 (3)","CACNA1S, CACNL1A3, CCHL1A3",114208,1q32,Endocrine,779,1,492,837
5233,Placental steroid sulfatase deficiency (3),"STS, ARSC1, ARSC, SSDD",308100,Xp22.32,Metabolic,412,1,493,492
957,"MASS syndrome, 604308 (3)","FBN1, MFS1, WMS",134797,15q21.1,Connective tissue disorder,2200,1,494,178
130,"Aortic aneurysm, ascending, and dissection (3)","FBN1, MFS1, WMS",134797,15q21.1,Cardiovascular,2200,1,495,178
234,"Brugada syndrome, 601144 (3)","SCN5A, LQT3, IVF, HB1, SSS1",600163,3p21,Cardiovascular,6331,1,496,51
1140,"Oligodontia-colorectal cancer syndrome, 608615 (3)",AXIN2,604025,17q24,Cancer,8313,1,497,612
1230,"Pilomatricoma, 132600 (3)",CTNNB1,116806,3p22-p21.3,Cancer,1499,1,498,9
1432,"Spondylocarpotarsal synostosis syndrome, 272460 (3)","FLNB, SCT, AOI",603381,3p14.3,Skeletal,2317,1,499,255
1554,"van Buchem disease, type 2, 607636 (3)","LRP5, BMND1, LRP7, LR3, OPPG, VBCH2",603506,11q13.4,Unclassified,4041,1,500,195
217,"Bone mineral density variability 1, 601884 (3)","LRP5, BMND1, LRP7, LR3, OPPG, VBCH2",603506,11q13.4,Bone,4041,1,501,195
1188,"Paramyotonia congenita, 168300 (3)","SCN4A, HYPP, NAC1A",603967,17q23.1-q25.3,Muscular,6329,1,502,699
113,"Angelman syndrome, 105830 (3)","MECP2, RTT, PPMX, MRX16, MRX79",300005,Xq28,Developmental,4204,1,503,740
113,"Angelman syndrome, 105830 (3)","UBE3A, ANCR",601623,15q11-q13,Developmental,7337,1,503,880
226,Branchiootic syndrome (3),"EYA1, BOR",601653,8q13.3,Neurological,2138,1,504,872
226,"Branchiootorenal syndrome, 113650 (3)","EYA1, BOR",601653,8q13.3,Neurological,2138,1,504,872
226,"Branchiootorenal syndrome with cataract, 113650 (3)","EYA1, BOR",601653,8q13.3,Neurological,2138,1,504,872
1394,"Sick sinus syndrome, 608567 (3)","SCN5A, LQT3, IVF, HB1, SSS1",600163,3p21,Cardiovascular,6331,1,505,51
483,"Enhanced S-cone syndrome, 268100 (3)","NR2E3, PNR, ESCS",604485,15q23,Ophthamological,10002,1,506,790
2365,"Coronary spasms, susceptibility to (3)",NOS3,163729,7q36,Cardiovascular,4846,1,507,584
1148,"Orolaryngeal cancer, multiple, (3)","CDKN2A, MTS1, P16, MLM, CMM2",600160,9p21,Cancer,1029,1,508,26
938,"Maculopathy, bull's-eye, 153870 (3)",VMD2,607854,11q13,Ophthamological,7439,1,509,412
733,"Hyperkalemic periodic paralysis, 170500 (3)","SCN4A, HYPP, NAC1A",603967,17q23.1-q25.3,Neurological,6329,1,510,699
451,"Duchenne muscular dystrophy, 310200 (3)","DMD, BMD",300377,Xp21.2,Muscular,1756,1,511,275
1233,Placental abruption (3),NOS3,163729,7q36,Unclassified,4846,1,512,584
930,"Lynch cancer family syndrome II, 114400 (3)","MSH2, COCA1, FCC1, HNPCC1",609309,2p22-p21,Cancer,4436,1,513,13
1396,"Silver spastic paraplegia syndrome, 270685 (3)","BSCL2, SPG17",606158,11q13,Neurological,26580,1,514,48
844,"Keratoconus, 148300 (3)","VSX1, RINX, PPCD, PPD, KTCN",605020,20p11.2,Ophthamological,30813,1,515,726
1,"17,20-lyase deficiency, isolated, 202110 (3)","CYP17A1, CYP17, P450C17",609300,10q24.3,Endocrine,1586,0,#NV,#NV
1,"17-alpha-hydroxylase/17,20-lyase deficiency, 202110 (3)","CYP17A1, CYP17, P450C17",609300,10q24.3,Endocrine,1586,0,#NV,#NV
3,"2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency, 300438 (3)","HADH2, ERAB",300256,Xp11.2,Metabolic,3028,0,#NV,#NV
4,2-methylbutyrylglycinuria (3),ACADSB,600301,10q25-q26,Metabolic,36,0,#NV,#NV
5,"3-beta-hydroxysteroid dehydrogenase, type II, deficiency (3)",HSD3B2,201810,1p13.1,Metabolic,3284,0,#NV,#NV
6,"3-hydroxyacyl-CoA dehydrogenase deficiency, 609609 (3)","HADHSC, SCHAD",601609,4q22-q26,Metabolic,3033,0,#NV,#NV
7,"3-Methylcrotonyl-CoA carboxylase 1 deficiency, 210200 (3)","MCCC1, MCCA",609010,3q25-q27,Metabolic,56922,0,#NV,#NV
7,"3-Methylcrotonyl-CoA carboxylase 2 deficiency, 210210 (3)","MCCC2, MCCB",609014,5q12-q13,Metabolic,64087,0,#NV,#NV
8,"3-methylglutaconic aciduria, type I, 250950 (3)",AUH,600529,Chr.9,Metabolic,549,0,#NV,#NV
10,"3-M syndrome, 273750 (3)",CUL7,609577,6p21.1,multiple,9820,0,#NV,#NV
12,6-mercaptopurine sensitivity (3),TPMT,187680,6p22.3,Metabolic,7172,0,#NV,#NV
14,"Abacavir hypersensitivity, susceptibility to (3)",HLA-B,142830,6p21.3,Immunological,3106,0,#NV,#NV
18,"Acampomelic campolelic dysplasia, 114290 (3)","SOX9, CMD1, SRA1",608160,17q24.3-q25.1,Skeletal,6662,0,#NV,#NV
21,Acatalasemia (3),CAT,115500,11p13,Hematological,847,0,#NV,#NV
22,"Accelerated tumor formation, susceptibility to (3)",MDM2,164785,12q14.3-q15,Cancer,4193,0,#NV,#NV
24,"Achalasia-addisonianism-alacrimia syndrome, 231550 (3)","AAAS, AAA",605378,12q13,multiple,8086,0,#NV,#NV
25,"Acheiropody, 200500 (3)","C7orf2, ACHP, LMBR1",605522,7q36,Skeletal,64327,0,#NV,#NV
30,"Acid-labile subunit, deficiency of (3)","IGFALS, ALS",601489,16p13.3,Endocrine,3483,0,#NV,#NV
32,"Acrocallosal syndrome, 200990 (3)","GLI3, PAPA, PAPB, ACLS",165240,7p13,multiple,2737,0,#NV,#NV
33,"Acrocapitofemoral dysplasia, 607778 (3)","IHH, BDA1",600726,2q33-q35,Skeletal,3549,0,#NV,#NV
34,"Acrodermatitis enteropathica, 201100 (3)","SLC39A4, ZIP4",607059,8q24.3,Dermatological,55630,0,#NV,#NV
36,"Acrokeratosis verruciformis, 101900 (3)","ATP2A2, ATP2B, DAR",108740,12q23-q24.1,Dermatological,488,0,#NV,#NV
39,"Acromesomelic dysplasia, Maroteaux type, 602875 (3)","NPR2, ANPRB, AMDM",108961,9p21-p12,Skeletal,4882,0,#NV,#NV
39,"Acromesomelic dysplasia, Hunter-Thompson type, 201250 (3)","GDF5, CDMP1",601146,20q11.2,Skeletal,8200,0,#NV,#NV
44,"Acyl-CoA dehydrogenase, long chain, deficiency of (3)","ACADL, LCAD",201460,2q34-q35,Metabolic,33,0,#NV,#NV
44,"Acyl-CoA dehydrogenase, medium chain, deficiency of, 201450 (3)","ACADM, MCAD",607008,1p31,Metabolic,34,0,#NV,#NV
44,"Acyl-CoA dehydrogenase, short-chain, deficiency of, 201470 (3)","ACADS, SCAD",606885,12q22-qter,Metabolic,35,0,#NV,#NV
50,"Adenylosuccinase deficiency, 103050 (3)",ADSL,608222,22q13.1,Metabolic,158,0,#NV,#NV
52,Adiponectin deficiency (3),"APM1, GBP28",605441,3q27,Endocrine,9370,0,#NV,#NV
53,"Adrenal hypoplasia, congenital, with hypogonadotropic hypogonadism, 300200 (3)","DAX1, AHC, AHX, NROB1",300473,Xp21.3-p21.2,Endocrine,190,0,#NV,#NV
53,"Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency (3)","CYP11B1, P450C11, FHI",202010,8q21,Endocrine,1584,0,#NV,#NV
53,"Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency (3)","CYP21A2, CYP21, CA21H",201910,6p21.3,Endocrine,1589,0,#NV,#NV
53,"Adrenal hyperplasia, congenital, due to combined P450C17 and P450C21 deficiency, 201750 (3)",POR,124015,7q11.2,Endocrine,5447,0,#NV,#NV
55,"Adrenocorticotropic hormone deficiency, 201400 (3)",TBS19,604614,1q23-q24,Endocrine,9095,0,#NV,#NV
56,"Adrenoleukodystrophy, 300100 (3)","ABCD1, ALD, AMN",300371,Xq28,Neurological,215,0,#NV,#NV
56,"Adrenoleukodystrophy, neonatal, 202370 (3)","PEX1, ZWS1",602136,7q21-q22,Neurological,5189,0,#NV,#NV
56,"Adrenoleukodystrophy, neonatal, 202370 (3)","PEX10, NALD",602859,Chr.1,Neurological,5192,0,#NV,#NV
56,"Adrenoleukodystrophy, neonatal, 202370 (3)","PEX13, ZWS, NALD",601789,2p15,Neurological,5194,0,#NV,#NV
56,"Adrenoleukodystrophy, neonatal, 202370 (3)","PXR1, PEX5, PTS1R",600414,12p13.3,Neurological,5830,0,#NV,#NV
56,"Adrenoleukodystrophy, neonatal, 202370 (3)",PEX26,608666,22q11.21,Neurological,55670,0,#NV,#NV
57,"Adrenomyeloneuropathy, 300100 (3)","ABCD1, ALD, AMN",300371,Xq28,Metabolic,215,0,#NV,#NV
59,"ADULT syndrome, 103285 (3)","TP73L, TP63, KET, EEC3, SHFM4, LMS, RHS",603273,3q27,multiple,8626,0,#NV,#NV
60,"Advanced sleep phase syndrome, familial, 604348 (3)","PER2, FASPS, KIAA0347",603426,2q37.3,Neurological,8864,0,#NV,#NV
63,"Agammaglobulinemia, type 1, X-linked (3)","BTK, AGMX1, IMD1, XLA, AT",300300,Xq21.3-q22,Hematological,695,0,#NV,#NV
63,"Agammaglobulinemia, 601495 (3)","IGHM, MU",147020,14q32.33,Hematological,3507,0,#NV,#NV
63,"Agammaglobulinemia, autosomal recessive (3)","IGLL1, IGO, IGL5, VPREB2",146770,22q11.21,Hematological,3543,0,#NV,#NV
63,"Agammaglobulinemia, non-Bruton type, 601495 (3)","LRRC8, KIAA1437",608360,9q34.13,Hematological,56262,0,#NV,#NV
64,AGAT deficiency (3),"GATM, AGAT",602360,15q15.3,Metabolic,2628,0,#NV,#NV
65,"Agenesis of the corpus callosum with peripheral neuropathy, 218000 (3)","SLC12A6, KCC3A, KCC3B, KCC3, ACCPN",604878,15q13-q14,Neurological,9990,0,#NV,#NV
69,"AICA-ribosiduria due to ATIC deficiency, 608688 (3)","ATIC, PURH, AICAR",601731,2q35,Metabolic,471,0,#NV,#NV
70,"AIDS, rapid progression to, 609423 (3)",IFNG,147570,12q14,Immunological,3458,0,#NV,#NV
70,"AIDS, delayed/rapid progression to (3)","KIR3DL1, NKAT3, NKB1, AMB11, KIR3DS1",604946,19q13.4,Immunological,3811,0,#NV,#NV
70,"AIDS, resistance to (3)","CXCL12, SDF1",600835,10q11.1,Immunological,6387,0,#NV,#NV
75,"Alcoholism, susceptibility to, 103780 (3)",GABRA2,137140,4p13-p12,Unclassified,2555,0,#NV,#NV
76,Aldolase A deficiency (3),ALDOA,103850,16q22-q24,Metabolic,226,0,#NV,#NV
77,Aldosterone to renin ratio raised (3),CYP11B2,124080,8q21,Endocrine,1585,0,#NV,#NV
78,"Aldosteronism, glucocorticoid-remediable, 103900 (3)","CYP11B1, P450C11, FHI",202010,8q21,Endocrine,1584,0,#NV,#NV
80,"Alkaptonuria, 203500 (3)","HGD, AKU",607474,3q21-q23,Metabolic,3081,0,#NV,#NV
82,"Allan-Herndon-Dudley syndrome, 300523 (3)","SLC16A2, DXS128, XPCT",300095,Xq13.2,Neurological,6567,0,#NV,#NV
85,"Alopecia universalis, 203655 (3)","HR, AU",602302,8p21.2,Dermatological,55806,0,#NV,#NV
86,"Alpers syndrome, 203700 (3)","POLG, POLG1, POLGA, PEO",174763,15q25,Neurological,5428,0,#NV,#NV
87,Alpha-1-antichymotrypsin deficiency (3),"SERPINA3, AACT, ACT",107280,14q32.1,Respiratory,12,0,#NV,#NV
88,Alpha-actinin-3 deficiency (3),ACTN3,102574,11q13-q14,Muscular,89,0,#NV,#NV
90,"Alpha-methylacetoacetic aciduria, 203750 (3)",ACAT1,607809,11q22.3-q23.1,Metabolic,38,0,#NV,#NV
91,Alpha-methylacyl-CoA racemase deficiency (3),AMACR,604489,5p13.2-q11.1,Metabolic,23600,0,#NV,#NV
92,"Alpha-thalassemia/mental retardation syndrome, 301040 (3)","ATRX, XH2, XNP, MRXS3, SHS",300032,Xq13,Hematological,546,0,#NV,#NV
92,"Alpha-thalassemia myelodysplasia syndrome, somatic, 300448 (3)","ATRX, XH2, XNP, MRXS3, SHS",300032,Xq13,Hematological,546,0,#NV,#NV
94,"Alport syndrome, autosomal recessive, 203780 (3)",COL4A3,120070,2q36-q37,Renal,1285,0,#NV,#NV
94,"Alport syndrome, autosomal recessive, 203780 (3)",COL4A4,120131,2q36-q37,Renal,1286,0,#NV,#NV
94,"Alport syndrome, 301050 (3)","COL4A5, ATS, ASLN",303630,Xq22.3,Renal,1287,0,#NV,#NV
95,"Alstrom syndrome, 203800 (3)","ALMS1, ALSS, KIAA0328",606844,2p13,Neurological,7840,0,#NV,#NV
97,"Alveolar soft-part sarcoma, 606243 (3)","ASPCR1, RCC17, ASPL, ASPS",606236,17q25,Cancer,79058,0,#NV,#NV
99,"Amelogenesis imperfecta, 301200 (3)","AMELX, AMG, AIH1, AMGX",300391,Xp22.3-p22.1,Bone,265,0,#NV,#NV
99,"Amelogenesis imperfecta, hypomaturation-hypoplastic type, with taurodontism, 104510 (3)","DLX3, TDO",600525,17q21.3-q22,Bone,1747,0,#NV,#NV
99,"Amelogenesis imperfecta, pigmented hypomaturation type, 204700 (3)","KLK4, EMSP1, PRSS17",603767,19q13.3-q13.4,Bone,9622,0,#NV,#NV
99,"Amelogenesis imperfecta 2, hypoplastic local, 104500 (3)",ENAM,606585,4q21,Bone,10117,0,#NV,#NV
99,"Amelogenesis imperfecta, hypoplastic, and openbite malocclusion, 608563 (3)",ENAM,606585,4q21,Bone,10117,0,#NV,#NV
100,"Amish infantile epilepsy syndrome, 609056 (3)","SIAT9, ST3GALV",604402,2p11.2,Neurological,8869,0,#NV,#NV
101,"AMP deaminase deficiency, erythrocytic (3)",AMPD3,102772,11pter-p13,Hematological,272,0,#NV,#NV
105,Analbuminemia (3),ALB,103600,4q11-q13,Hematological,213,0,#NV,#NV
107,"Analgesia from kappa-opioid receptor agonist, female-specific (3)",MC1R,155555,16q24.3,Unclassified,4157,0,#NV,#NV
108,"Anderson disease, 607689 (3)","SARA2, SAR1B, CMRD",607690,5q31.1,Gastrointestinal,51128,0,#NV,#NV
114,"Angioedema, hereditary, 106100 (3)","C1NH, HAE1, HAE2, SERPING1",606860,11q11-q13.1,Immunological,710,0,#NV,#NV
114,"Angioedema induced by ACE inhibitors, susceptibility to (3)",XPNPEP2,300145,Xq25,Immunological,7512,0,#NV,#NV
118,Anhaptoglobinemia (3),HP,140100,16q22.1,Hematological,3240,0,#NV,#NV
121,"Ankylosing spoldylitis, susceptibility to, 106300 (3)",HLA-B,142830,6p21.3,Connective tissue disorder,3106,0,#NV,#NV
122,"Anophthalmia 3, 206900 (3)","SOX2, ANOP3",184429,3q26.3-q27,Ophthamological,6657,0,#NV,#NV
127,Antithrombin III deficiency (3),AT3,107300,1q23-q25,Hematological,462,0,#NV,#NV
128,"Antley-Bixler syndrome, 207410 (3)",POR,124015,7q11.2,Unclassified,5447,0,#NV,#NV
132,"Aplasia of lacrimal and salivary glands, 180920 (3)",FGF10,602115,5p13-p12,Gastrointestinal,2255,0,#NV,#NV
133,"Aplastic anemia, 609135 (3)",IFNG,147570,12q14,Hematological,3458,0,#NV,#NV
133,"Aplastic anemia, 609135 (3)","TERC, TRC3, TR",602322,3q21-q28,Hematological,7012,0,#NV,#NV
133,"Aplastic anemia, susceptibility to, 609135 (3)","TERT, TCS1, EST2",187270,5p15.33,Hematological,7015,0,#NV,#NV
134,"Apnea, postanesthetic (3)","BCHE, CHE1",177400,3q26.1-q26.2,Unclassified,590,0,#NV,#NV
139,"ARC syndrome, 208085 (3)",VPS33B,608552,15q26.1,Gastrointestinal,26276,0,#NV,#NV
140,"Argininemia, 207800 (3)",ARG1,608313,6q23,Metabolic,383,0,#NV,#NV
140,"Argininosuccinic aciduria, 207900 (3)",ASL,608310,7cen-q11.2,Metabolic,435,0,#NV,#NV
142,Aromatase deficiency (3),"CYP19A1, CYP19, ARO",107910,15q21.1,Metabolic,1588,0,#NV,#NV
143,"Aromatic L-amino acid decarboxylase deficiency, 608643 (3)",DDC,107930,7p11,Metabolic,1644,0,#NV,#NV
146,"Arthrogryposis multiplex congenita, distal, type 2B, 601680 (3)","TNNI2, AMCD2B, DA2B, FSSV",191043,11p15.5,Developmental,7136,0,#NV,#NV
146,"Arthyrgryposis multiplex congenita, distal, type 2B, 601680 (3)","TNNT3, AMCD2B, DA2B, FSSV",600692,11p15.5,Developmental,7140,0,#NV,#NV
146,"Arthrogryposis multiplex congenita, distal, type 1, 108120 (3)","TPM2, TMSB, AMCD1, DA1",190990,9p13.2-p13.1,Developmental,7169,0,#NV,#NV
150,Aspartylglucosaminuria (3),AGA,208400,4q32-q33,Metabolic,175,0,#NV,#NV
162,"Athabaskan brainstem dysgenesis syndrome, 601536 (3)","HOXA1, HOX1F, BSAS",142955,7p15.3,Neurological,3198,0,#NV,#NV
165,"Atransferrinemia, 209300 (3)",TF,190000,3q21,Hematological,7018,0,#NV,#NV
167,"Atrichia with papular lesions, 209500 (3)","HR, AU",602302,8p21.2,Dermatological,55806,0,#NV,#NV
171,"Attention deficit-hyperactivity disorder, susceptibility to, 143465 (3)","DRD5, DRD1B, DRD1L2",126453,4p16.1-p15.3,Psychiatric,1816,0,#NV,#NV
175,Autonomic nervous system dysfunction (3),DRD4,126452,11p15.5,Psychiatric,1815,0,#NV,#NV
178,Azoospermia (3),"USP9Y, DFFRY",400005,Yq11.2,Endocrine,8287,0,#NV,#NV
178,"Azoospermia due to perturbations of meiosis, 270960 (3)","SYCP3, SCP3, COR1",604759,12q23,Endocrine,50511,0,#NV,#NV
180,"Bamforth-Lazarus syndrome, 241850 (3)","FOXE1, FKHL15, TITF2, TTF2",602617,9q22,Endocrine,2304,0,#NV,#NV
183,"Bardet-Biedl syndrome 1, 209900 (3)",BBS1,209901,11q13,multiple,582,0,#NV,#NV
183,"Bardet-Biedl syndrome 2, 209900 (3)",BBS2,606151,16q21,multiple,583,0,#NV,#NV
183,"Bardet-Biedl syndrome 4, 209900 (3)",BBS4,600374,15q22.3-q23,multiple,585,0,#NV,#NV
183,"Bardet-Biedl syndrome 6, 209900 (3)","MKKS, HMCS, KMS, MKS, BBS6",604896,20p12,multiple,8195,0,#NV,#NV
183,"Bardet-Biedl syndrome, 209900 (3)",BBS7,607590,4q27,multiple,55212,0,#NV,#NV
183,"Bardet-Biedl syndrome 1, modifier of, 209900 (3)","ARL6, BBS3",608845,3p12-q13,multiple,84100,0,#NV,#NV
183,"Bardet-Biedl syndrome 3, 600151 (3)","ARL6, BBS3",608845,3p12-q13,multiple,84100,0,#NV,#NV
183,"Bardet-Biedl syndrome 8, 209900 (3)","TTC8, BBS8",608132,14q32.1,multiple,123016,0,#NV,#NV
183,"Bardet-Biedl syndrome 5, 209900 (3)",BBS5,603650,2q31,multiple,129880,0,#NV,#NV
187,"Bartter syndrome, type 4, digenic, 602522 (3)",CLCNKA,602024,1p36,multiple,1187,0,#NV,#NV
187,"Bartter syndrome, type 3, 607364 (3)",CLCNKB,602023,1p36,multiple,1188,0,#NV,#NV
187,"Bartter syndrome, type 4, digenic, 602522 (3)",CLCNKB,602023,1p36,multiple,1188,0,#NV,#NV
187,"Bartter syndrome, type 2, 241200 (3)","KCNJ1, ROMK1",600359,11q24,multiple,3758,0,#NV,#NV
187,"Bartter syndrome, type 1, 601678 (3)","SLC12A1, NKCC2",600839,15q15-q21.1,multiple,6557,0,#NV,#NV
187,"Bartter syndrome, type 4, 602522 (3)",BSND,606412,1p31,multiple,7809,0,#NV,#NV
190,"B-cell non-Hodgkin lymphoma, high-grade (3)","BCL7A, BCL7",601406,12q24.1,Cancer,605,0,#NV,#NV
191,"BCG infection, generalized familial (3)",IFNGR1,107470,6q23-q24,Immunological,3459,0,#NV,#NV
194,"Beckwith-Wiedemann syndrome, 130650 (3)","CDKN1C, KIP2, BWS",600856,11p15.5,multiple,1028,0,#NV,#NV
194,"Beckwith-Wiedemann syndrome, 130650 (3)","KCNQ10T1, LIT1",604115,11p15.5,multiple,10984,0,#NV,#NV
194,"Beckwith-Wiedemann syndrome, 130650 (3)","NSD1, ARA267, STO",606681,5q35,multiple,64324,0,#NV,#NV
194,"Beckwith-Wiedemann syndrome, 130650 (3)","H19, D11S813E, ASM1, BWS",103280,11p15.5,multiple,283120,0,#NV,#NV
196,"Bernard-Soulier syndrome, 231200 (3)",GP1BA,606672,17pter-p12,Hematological,2811,0,#NV,#NV
196,"Bernard-Soulier syndrome, type B, 231200 (3)",GP1BB,138720,22q11.2,Hematological,2812,0,#NV,#NV
196,"Bernard-Soulier syndrome, type C (3)",GP9,173515,Chr.3,Hematological,2815,0,#NV,#NV
197,"Beryllium disease, chronic, susceptibility to (3)",HLA-DPB1,142858,6p21.3,Unclassified,3115,0,#NV,#NV
199,Beta-ureidopropionase deficiency (3),"UPB1, BUP1",606673,22q11.2,Metabolic,51733,0,#NV,#NV
200,"Bethlem myopathy, 158810 (3)","COL6A1, OPLL",120220,21q22.3,Muscular,1291,0,#NV,#NV
200,"Bethlem myopathy, 158810 (3)",COL6A2,120240,21q22.3,Muscular,1292,0,#NV,#NV
200,"Bethlem myopathy, 158810 (3)",COL6A3,120250,2q37,Muscular,1293,0,#NV,#NV
201,"Bietti crystalline corneoretinal dystrophy, 210370 (3)","CYP4V2, BCD",608614,4q35.1,Ophthamological,285440,0,#NV,#NV
202,"Bile acid malabsorption, primary (3)","SLC10A2, NTCP2",601295,13q33,Gastrointestinal,6555,0,#NV,#NV
203,"Biotinidase deficiency, 253260 (3)",BTD,609019,3p25,Metabolic,686,0,#NV,#NV
204,"Bipolar disorder, susceptibility to, 125480 (3)","XBP1, XBP2",194355,22q12,Psychiatric,7494,0,#NV,#NV
208,"Blau syndrome, 186580 (3)","CARD15, NOD2, IBD1, CD, ACUG, PSORAS1",605956,16q12,multiple,64127,0,#NV,#NV
209,"Bleeding due to platelet ADP receptor defect, 600515 (3)","P2RX1, P2X1",600845,17p13.3,Hematological,5023,0,#NV,#NV
209,Bleeding disorder due to defective thromboxane A2 receptor (3),TBXA2R,188070,19p13.3,Hematological,6915,0,#NV,#NV
210,"Blepharophimosis, epicanthus inversus, and ptosis, type 1, 110100 (3)","FOXL2, BPES, BPES1, PFRK, POF3",605597,3q23,multiple,668,0,#NV,#NV
210,"Blepharophimosis, epicanthus inversus, and ptosis, type 2, 110100 (3)","FOXL2, BPES, BPES1, PFRK, POF3",605597,3q23,multiple,668,0,#NV,#NV
211,"Blepharospasm, primary benign, 606798 (3)","DRD5, DRD1B, DRD1L2",126453,4p16.1-p15.3,Ophthamological,1816,0,#NV,#NV
213,"Bloom syndrome, 210900 (3)","RECQL3, RECQ2, BLM, BS",604610,15q26.1,Cancer,641,0,#NV,#NV
214,"Blue-cone monochromacy, 303700 (3)","OPN1MW, GCP, CBD, CBBM",303800,Xq28,Ophthamological,2652,0,#NV,#NV
214,"Blue-cone monochromacy, 303700 (3)","OPN1LW, RCP, CBP, CBBM",303900,Xq28,Ophthamological,5956,0,#NV,#NV
216,Bombay phenotype (3),"FUT1, H, HH",211100,19q13.3,Hematological,2523,0,#NV,#NV
216,Bombay phenotype (3),"FUT2, SE",182100,19q13.3,Hematological,2524,0,#NV,#NV
218,"Borjeson-Forssman-Lehmann syndrome, 301900 (3)","PHF6, BFLS",300414,Xq26.3,multiple,84295,0,#NV,#NV
220,"Bosley-Salih-Alorainy syndrome, 601536 (3)","HOXA1, HOX1F, BSAS",142955,7p15.3,Neurological,3198,0,#NV,#NV
224,"Brachydactyly, type A2, 112600 (3)","BMPR1B, ALK6",603248,4q23-q24,Skeletal,658,0,#NV,#NV
224,"Brachydactyly, type D, 113200 (3)","HOXD13, HOX4I, SPD",142989,2q31-q32,Skeletal,3239,0,#NV,#NV
224,"Brachydactyly, type E, 113300 (3)","HOXD13, HOX4I, SPD",142989,2q31-q32,Skeletal,3239,0,#NV,#NV
224,"Brachydactyly, type A1, 112500 (3)","IHH, BDA1",600726,2q33-q35,Skeletal,3549,0,#NV,#NV
224,"Brachydactyly, type B1, 113000 (3)","ROR2, BDB1, BDB, NTRKR2",602337,9q22,Skeletal,4920,0,#NV,#NV
224,"Brachydactyly, type C, 113100 (3)","GDF5, CDMP1",601146,20q11.2,Skeletal,8200,0,#NV,#NV
225,"Bradyopsia, 608415 (3)","RGS9, PERRS",604067,17q23-q24,Ophthamological,8787,0,#NV,#NV
225,"Bradyopsia, 608415 (3)","R9AP, RGS9, PERRS",607814,19q13.11,Ophthamological,342880,0,#NV,#NV
231,"Brody myopathy, 601003 (3)","ATP2A1, SERCA1",108730,16p12,Muscular,487,0,#NV,#NV
233,"Bruck syndrome 2, 609220 (3)",PLOD2,601865,3q23-q24,Unclassified,5352,0,#NV,#NV
235,Brunner syndrome (3),MAOA,309850,Xp11.23,Unclassified,4128,0,#NV,#NV
237,"Burkitt lymphoma, 113970 (3)",MYC,190080,8q24.12-q24.13,Cancer,4609,0,#NV,#NV
238,"Buschke-Ollendorff syndrome, 166700 (3)","LEMD3, MAN1",607844,12q14,multiple,23592,0,#NV,#NV
254,"Calcinosis, tumoral, 211900 (3)",GALNT3,601756,2q24-q31,Bone,2591,0,#NV,#NV
254,"Calcinosis, tumoral, 211900 (3)","FGF23, ADHR, HPDR2, PHPTC",605380,12p13.3,Bone,8074,0,#NV,#NV
255,"Campomelic dysplasia, 114290 (3)","SOX9, CMD1, SRA1",608160,17q24.3-q25.1,Skeletal,6662,0,#NV,#NV
255,"Campomelic dysplasia with autosomal sex reversal, 114290 (3)","SOX9, CMD1, SRA1",608160,17q24.3-q25.1,Skeletal,6662,0,#NV,#NV
256,"Camptodactyly-arthropathy-coxa vara-pericarditis syndrome, 208250 (3)","PRG4, CACP, MSF, SZP, HAPO",604283,1q24-q25,Skeletal,10216,0,#NV,#NV
257,"Camurati-Engelmann disease, 131300 (3)","TGFB1, DPD1, CED",190180,19q13.1,Skeletal,7040,0,#NV,#NV
258,"Canavan disease, 271900 (3)",ASPA,608034,17pter-p13,Metabolic,443,0,#NV,#NV
262,"Carbamoylphosphate synthetase I deficiency, 237300 (3)",CPS1,608307,2q35,Metabolic,1373,0,#NV,#NV
263,"Carbohydrate-deficient glycoprotein syndrome, type II, 212066 (3)","MGAT2, CDGS2",602616,14q21,Metabolic,4247,0,#NV,#NV
263,"Carbohydrate-deficient glycoprotein syndrome, type Ib, 602579 (3)","MPI, PMI1",154550,15q22-qter,Metabolic,4351,0,#NV,#NV
263,"Carbohydrate-deficient glycoprotein syndrome, type I, 212065 (3)","PMM2, CDG1",601785,16p13.3-p13.2,Metabolic,5373,0,#NV,#NV
264,"Carboxypeptidase N deficiency, 212070 (3)","CPN1, SCPN, CPN",603103,10q24.2,Hematological,1369,0,#NV,#NV
267,"Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency, 604377 (3)",SCO2,604272,22q13,Cardiovascular,9997,0,#NV,#NV
271,Carnitine-acylcarnitine translocase deficiency (3),"SLC25A20, CACT, CAC",212138,3p21.31,Metabolic,788,0,#NV,#NV
272,"Carnitine deficiency, systemic primary, 212140 (3)","SLC22A5, OCTN2, CDSP, SCD",603377,5q31.1,Metabolic,6584,0,#NV,#NV
276,"Cartilage-hair hypoplasia, 250250 (3)","RMRP, RMRPR, CHH",157660,9p21-p12,Skeletal,6023,0,#NV,#NV
279,"Cavernous malformations of CNS and retina, 116860 (3)","CCM1, CAM, KRIT1",604214,7q11.2-q21,Cardiovascular,889,0,#NV,#NV
283,CD59 deficiency (3),"CD59, MIC11",107271,11p13,Immunological,966,0,#NV,#NV
284,"CD8 deficiency, familial, 608957 (3)",CD8A,186910,2p12,Immunological,925,0,#NV,#NV
292,"Cerebrooculofacioskeletal syndrome, 214150 (3)","ERCC2, EM9",126340,19q13.2-q13.3,multiple,2068,0,#NV,#NV
292,"Cerebrooculofacioskeletal syndrome, 214150 (3)","ERCC5, XPG",133530,13q33,multiple,2073,0,#NV,#NV
292,Cerebrooculofacioskeletal syndrome 214150 (3),"ERCC6, CKN2, COFS, CSB",609413,10q11,multiple,2074,0,#NV,#NV
293,"Cerebrotendinous xanthomatosis, 213700 (3)","CYP27A1, CYP27, CTX",606530,2q33-qter,Metabolic,1593,0,#NV,#NV
294,"Cerebrovascular disease, occlusive (3)","SERPINA3, AACT, ACT",107280,14q32.1,Unclassified,12,0,#NV,#NV
295,"Ceroid lipofuscinosis, neuronal-1, infantile, 256730 (3)","PPT1, CLN1",600722,1p32,Neurological,5538,0,#NV,#NV
296,"Ceroid-lipofuscinosis, neuronal 2, classic late infantile, 204500 (3)",CLN2,607998,11p15.5,Neurological,1200,0,#NV,#NV
296,"Ceroid-lipofuscinosis, neuronal-3, juvenile, 204200 (3)","CLN3, BTS",607042,16p12.1,Neurological,1201,0,#NV,#NV
296,"Ceroid-lipofuscinosis, neuronal-5, variant late infantile, 256731 (3)",CLN5,608102,13q21.1-q32,Neurological,1203,0,#NV,#NV
296,"Ceroid lipofuscinosis, neuronal 8, 600143 (3)","CLN8, EPMR",607837,8pter-p22,Neurological,2055,0,#NV,#NV
296,"Ceroid lipofuscinosis, neuronal, variant juvenile type, with granular osmiophilic deposits (3)","PPT1, CLN1",600722,1p32,Neurological,5538,0,#NV,#NV
296,"Ceroid-lipofuscinosis, neuronal-6, variant late infantile, 601780 (3)",CLN6,606725,15q21-q23,Neurological,54982,0,#NV,#NV
299,"CETP deficiency, 607322 (3)",CETP,118470,16q21,Metabolic,1071,0,#NV,#NV
300,"Chanarin-Dorfman syndrome, 275630 (3)","ABHD5, CGI58, IECN2, NCIE2",604780,3p21,Metabolic,51099,0,#NV,#NV
302,"CHARGE syndrome, 214800 (3)",CHD7,608892,8q12.1,multiple,55636,0,#NV,#NV
303,"Char syndrome, 169100 (3)","TFAP2B, CHAR",601601,6p12,multiple,7021,0,#NV,#NV
304,"Chediak-Higashi syndrome, 214500 (3)","CHS1, LYST",606897,1q42.1-q42.2,multiple,1130,0,#NV,#NV
305,"Cherubism, 118400 (3)","SH3BP2, CRPM",602104,4p16.3,Unclassified,6452,0,#NV,#NV
306,"CHILD syndrome, 308050 (3)",NSDHL,300275,Xq28,Developmental,50814,0,#NV,#NV
307,Chitotriosidase deficiency (3),CHIT,600031,1q31-q32,Metabolic,1118,0,#NV,#NV
308,"Chloride diarrhea, congenital, Finnish type, 214700 (3)","SLC26A3, DRA, CLD",126650,7q22-q31.1,Gastrointestinal,1811,0,#NV,#NV
309,"Cholelithiasis, 600803 (3)","ABCB4, PGY3, MDR3",171060,7q21.1,Gastrointestinal,5244,0,#NV,#NV
310,"Cholestasis, benign recurrent intrahepatic, 243300 (3)","ATP8B1, FIC1, BRIC, PFIC1",602397,18q21,Gastrointestinal,5205,0,#NV,#NV
310,"Cholestasis, progressive familial intrahepatic 1, 211600 (3)","ATP8B1, FIC1, BRIC, PFIC1",602397,18q21,Gastrointestinal,5205,0,#NV,#NV
310,"Cholestasis, familial intrahepatic, of pregnancy, 147480 (3)","ABCB4, PGY3, MDR3",171060,7q21.1,Gastrointestinal,5244,0,#NV,#NV
310,"Cholestasis, progressive familial intrahepatic 3, 602347 (3)","ABCB4, PGY3, MDR3",171060,7q21.1,Gastrointestinal,5244,0,#NV,#NV
310,"Cholestasis, progressive familial intrahepatic 2, 601847 (3)","ABCB11, BSEP, SPGP, PFIC2",603201,2q24,Gastrointestinal,8647,0,#NV,#NV
310,"Cholestasis, progressive familial intrahepatic 4, 607765 (3)","HSD3B7, PFIC4",607764,16p12-p11.2,Gastrointestinal,80270,0,#NV,#NV
313,Cholesteryl ester storage disease (3),LIPA,278000,10q24-q25,Metabolic,3988,0,#NV,#NV
314,"Chondrocalcinosis 2, 118600 (3)","ANKH, HANK, ANK, CMDJ, CCAL2, CPPDD",605145,5p15.2-p14.1,Connective tissue disorder,56172,0,#NV,#NV
315,"Chondrodysplasia punctata, X-linked recessive, 302950 (3)","ARSE, CDPX1, CDPXR",300180,Xp22.3,Connective tissue disorder,415,0,#NV,#NV
315,"Chondrodysplasia punctata, rhizomelic, type 2, 222765 (3)","GNPAT, DHAPAT",602744,1q42,Connective tissue disorder,8443,0,#NV,#NV
315,"Chondrodysplasia punctata, X-linked dominant, 302960 (3)","EBP, CDPX2, CPXD, CPX",300205,Xp11.23-p11.22,Connective tissue disorder,10682,0,#NV,#NV
316,"Chondrosarcoma, extraskeletal myxoid (3)","EWSR1, EWS",133450,22q12,Cancer,2130,0,#NV,#NV
316,"Chondrosarcoma, 215300 (3)",EXT1,608177,8q24.11-q24.13,Cancer,2131,0,#NV,#NV
316,"Chondrosarcoma, extraskeletal myxoid (3)",CSMF,600542,9q22,Cancer,8013,0,#NV,#NV
318,"Chorea, hereditary benign, 118700 (3)","TITF1, NKX2A, TTF1",600635,14q13,Neurological,7080,0,#NV,#NV
319,"Choreoacanthocytosis, 200150 (3)","VPS13A, CHAC",605978,9q21,Neurological,23230,0,#NV,#NV
320,"Choreoathetosis, hypothyroidism, and respiratory distress (3)","TITF1, NKX2A, TTF1",600635,14q13,multiple,7080,0,#NV,#NV
323,"Choroideremia, 303100 (3)","CHM, TCD",300390,Xq21.2,Ophthamological,1121,0,#NV,#NV
326,"Chromosome 22q13.3 deletion syndrome, 606232 (3)","PSAP2, PROSAP2, KIAA1650",606230,22q13.3,multiple,85358,0,#NV,#NV
327,"Chronic granulomatous disease, autosomal, due to deficiency of CYBA, 233690 (3)",CYBA,608508,16q24,Immunological,1535,0,#NV,#NV
327,"Chronic granulomatous disease, X-linked, 306400 (3)","CYBB, CGD",300481,Xp21.1,Immunological,1536,0,#NV,#NV
327,"Chronic granulomatous disease due to deficiency of NCF-1, 233700 (3)",NCF1,608512,7q11.23,Immunological,4687,0,#NV,#NV
327,"Chronic granulomatous disease due to deficiency of NCF-2, 233710 (3)",NCF2,608515,1q25,Immunological,4688,0,#NV,#NV
328,"Chudley-Lowry syndrome, 309490 (3)","ATRX, XH2, XNP, MRXS3, SHS",300032,Xq13,multiple,546,0,#NV,#NV
329,"Chylomicronemia syndrome, familial (3)","LPL, LIPD",238600,8p22,Metabolic,4023,0,#NV,#NV
330,"Chylomicron retention disease, 246700 (3)","SARA2, SAR1B, CMRD",607690,5q31.1,Gastrointestinal,51128,0,#NV,#NV
330,"Chylomicron retention disease with Marinesco-Sjogren syndrome, 607692 (3)","SARA2, SAR1B, CMRD",607690,5q31.1,Gastrointestinal,51128,0,#NV,#NV
331,"Ciliary dyskinesia, primary, 3 608644 (3)","DNAH5, HL1, PCD, CILD3",603335,5p15-p14,Respiratory,1767,0,#NV,#NV
331,"Ciliary dyskinesia, primary, 1, 242650 (3)","DNAI1, CILD1, ICS, PCD",604366,9p21-p13,Respiratory,27019,0,#NV,#NV
332,"CINCA syndrome, 607115 (3)","CIAS1, C1orf7, FCU, FCAS",606416,1q44,multiple,114548,0,#NV,#NV
334,"Cirrhosis, cryptogenic (3)",KRT8,148060,12q13,Gastrointestinal,3856,0,#NV,#NV
334,"Cirrhosis, noncryptogenic, susceptibility to, 215600 (3)",KRT8,148060,12q13,Gastrointestinal,3856,0,#NV,#NV
334,"Cirrhosis, cryptogenic (3)",KRT18,148070,12q13,Gastrointestinal,3875,0,#NV,#NV
334,"Cirrhosis, noncryptogenic, susceptibility to, 215600 (3)",KRT18,148070,12q13,Gastrointestinal,3875,0,#NV,#NV
334,"Cirrhosis, North American Indian childhood type, 604901 (3)","CIRH1A, NAIC, TEX292, KIAA1988",607456,16q22,Gastrointestinal,84916,0,#NV,#NV
335,"Citrullinemia, 215700 (3)",ASS,603470,9q34,Metabolic,445,0,#NV,#NV
335,"Citrullinemia, adult-onset type II, 603471 (3)","SLC25A13, CTLN2",603859,7q21.3,Metabolic,10165,0,#NV,#NV
335,"Citrullinemia, type II, neonatal-onset, 605814 (3)","SLC25A13, CTLN2",603859,7q21.3,Metabolic,10165,0,#NV,#NV
337,"Cleidocranial dysplasia, 119600 (3)","RUNX2, CBFA1, PEBP2A1, AML3",600211,6p21,Skeletal,860,0,#NV,#NV
339,"Cockayne syndrome, type A, 216400 (3)","ERCC8, CKN1, CSA",609412,5q12,multiple,1161,0,#NV,#NV
339,"Cockayne syndrome, type B, 133540 (3)","ERCC6, CKN2, COFS, CSB",609413,10q11,multiple,2074,0,#NV,#NV
340,Codeine sensitivity (3),"CYP2D@, CYP2D, P450C2D",124030,22q13.1,Metabolic,1565,0,#NV,#NV
342,"Cohen syndrome, 216550 (3)",COH1,607817,8q22-q23,multiple,157680,0,#NV,#NV
343,Colchicine resistance (3),"ABCB1, PGY1, MDR1",171050,7q21.1,Unclassified,5243,0,#NV,#NV
344,"Cold-induced autoinflammatory syndrome, familial, 120100 (3)","CIAS1, C1orf7, FCU, FCAS",606416,1q44,Immunological,114548,0,#NV,#NV
348,"Colorblindness, tritan (3)","OPN1SW, BCP, CBT",190900,7q31.3-q32,Ophthamological,611,0,#NV,#NV
348,"Colorblindness, deutan (3)","OPN1MW, GCP, CBD, CBBM",303800,Xq28,Ophthamological,2652,0,#NV,#NV
348,"Colorblindness, protan (3)","OPN1LW, RCP, CBP, CBBM",303900,Xq28,Ophthamological,5956,0,#NV,#NV
350,"Combined factor V and VIII deficiency, 227300 (3)","LMAN1, ERGIC53, F5F8D, MCFD1",601567,18q21.3-q22,Hematological,3998,0,#NV,#NV
351,"Complex I, mitochondrial respiratory chain, deficiency of, 252010 (3)",NDUFS6,603848,5pter-p15.33,multiple,4726,0,#NV,#NV
351,"Complex V, mitochondrial respiratory chain, deficiency of, 604273 (3)","ATPAF2, ATP12",608918,17p11.2,multiple,91647,0,#NV,#NV
354,"Congenital disorder of glycosylation, type Ij, 608093 (3)","DPAGT2, DGPT",191350,11q23.3,Metabolic,1798,0,#NV,#NV
354,"Congenital disorder of glycosylation, type IId, 607091 (3)","B4GALT1, GGTB2, GT1, GTB",137060,9p13,Metabolic,2683,0,#NV,#NV
354,"Congenital disorder of glycosylation, type Ie, 608799 (3)","DPM1, MPDS, CDGIE",603503,20q13.13,Metabolic,8813,0,#NV,#NV
354,"Congenital disorder of glycosylation, type If, 609180 (3)","MPDU1, SL15, CDGIF",604041,17p13.1-p12,Metabolic,9526,0,#NV,#NV
354,"Congenital disorder of glycosylation, type Id, 601110 (3)","ALG3, NOT56L, CDGS4",608750,3q27,Metabolic,10195,0,#NV,#NV
354,"Congenital disorder of glycosylation, type Ic, 603147 (3)",ALG6,604566,1p22.3,Metabolic,29929,0,#NV,#NV
354,"Congenital disorder of glycosylation, type IIc, 266265 (3)","SLC35C1, FUCT1",605881,11p11.2,Metabolic,55343,0,#NV,#NV
354,"Congenital disorder of glycosylation, type Ik, 608540 (3)","ALG1, HMAT1, HMT1",605907,16p13.3,Metabolic,56052,0,#NV,#NV
354,"Congenital disorder of glycosylation, type Ih, 608104 (3)",ALG8,608103,11pter-p15.5,Metabolic,79053,0,#NV,#NV
354,"Congenital disorder of glycosylation, type Ig, 607143 (3)",ALG12,607144,Chr.22,Metabolic,79087,0,#NV,#NV
354,"Congenital disorder of glycosylation, type II, 608776 (3)","DIBD1, ALG9",606941,11q23,Metabolic,79796,0,#NV,#NV
354,"Congenital disorder of glycosylation, type Ii, 607906 (3)","ALG2, CDGII",607905,9q22,Metabolic,85365,0,#NV,#NV
354,"Congenital disorder of glycosylation, type IIe, 608779 (3)","COG7, CDG2E",606978,16p,Metabolic,91949,0,#NV,#NV
355,"Congestive heart failure, susceptibility to (3)","ADRA2C, ADRA2L2",104250,4p16.1,Cardiovascular,152,0,#NV,#NV
355,"Congestive heart failure, susceptibility to (3)","ADRB1, ADRB1R, RHR",109630,10q24-q26,Cardiovascular,153,0,#NV,#NV
356,"Conjunctivitis, ligneous, 217090 (3)",PLG,173350,6q26,Ophthamological,5340,0,#NV,#NV
357,"Conotruncal anomaly face syndrome, 217095 (3)","TBX1, DGS, CTHM, CAFS, TGA, DORV, VCFS, DGCR",602054,22q11.2,Cardiovascular,6899,0,#NV,#NV
358,"Contractural arachnodactyly, congenital (3)","FBN2, CCA",121050,5q23-q31,Connective tissue disorder,2201,0,#NV,#NV
360,"COPD, rate of decline of lung function in, 606963 (3)","MMP1, CLG",120353,11q22-q23,Respiratory,4312,0,#NV,#NV
361,Coproporphyria (3),CPO,121300,3q12,Metabolic,1371,0,#NV,#NV
364,"Cornelia de Lange syndrome, 122470 (3)","NIPBL, CDLS",608667,5p13.1,Developmental,25836,0,#NV,#NV
366,"Corpus callosum, agenesis of, with mental retardation, ocular coloboma and micrognathia, 300472 (3)",IGBP1,300139,Xq13.1-q13.3,Neurological,3476,0,#NV,#NV
367,Cortisol resistance (3),"NR3C1, GCR, GRL",138040,5q31,Endocrine,2908,0,#NV,#NV
368,"Cortisone reductase deficiency, 604931 (3)","HSD11B1, HSD11, HSD11L",600713,1q32-q41,Metabolic,3290,0,#NV,#NV
368,"Cortisone reductase deficiency, 604931 (3)",GDH,138090,1pter-p36.13,Metabolic,9563,0,#NV,#NV
380,"Craniofrontonasal dysplasia, 304110 (3)","EFNB1, EPLG2, CFNS, CFND",300035,Xq12,Skeletal,1947,0,#NV,#NV
382,"Craniometaphyseal dysplasia, 123000 (3)","ANKH, HANK, ANK, CMDJ, CCAL2, CPPDD",605145,5p15.2-p14.1,Bone,56172,0,#NV,#NV
384,"CRASH syndrome, 303350 (3)","L1CAM, CAML1, HSAS1",308840,Xq28,multiple,3897,0,#NV,#NV
389,"Crigler-Najjar syndrome, type I, 218800 (3)","UGT1A1, UGT1, GNT1",191740,2q37,multiple,54658,0,#NV,#NV
389,"Crigler-Najjar syndrome, type II, 606785 (3)","UGT1A1, UGT1, GNT1",191740,2q37,multiple,54658,0,#NV,#NV
390,"Crohn disease, susceptibility to, 266600 (3)","DLG5, PDLG, KIAA0583",604090,10q23,Gastrointestinal,9231,0,#NV,#NV
390,"Crohn disease, susceptibility to, 266600 (3)","CARD15, NOD2, IBD1, CD, ACUG, PSORAS1",605956,16q12,Gastrointestinal,64127,0,#NV,#NV
392,"Cryptorchidism, idiopathic, 219050 (3)",INSL3,146738,19p13.2,Renal,3640,0,#NV,#NV
392,"Cryptorchidism, bilateral, 219050 (3)","LGR8, GREAT",606655,13q13.1,Renal,122042,0,#NV,#NV
394,"Currarino syndrome, 176450 (3)","HLXB9, HOXHB9, SCRA1",142994,7q36,Skeletal,3110,0,#NV,#NV
397,"Cylindromatosis, familial, 132700 (3)","CYLD1, CDMT, EAC",605018,16q12-q13,Dermatological,1540,0,#NV,#NV
398,"Cystathioninuria, 219500 (3)",CTH,607657,1p31.1,Metabolic,1491,0,#NV,#NV
399,"Cystic fibrosis, 219700 (3)","CFTR, ABCC7, CF, MRP7",602421,7q31.2,Respiratory,1080,0,#NV,#NV
400,"Cystinosis, atypical nephropathic (3)",CTNS,606272,17p13,Renal,1497,0,#NV,#NV
400,"Cystinosis, late-onset juvenile or adolescent nephropathic, 219900 (3)",CTNS,606272,17p13,Renal,1497,0,#NV,#NV
400,"Cystinosis, nephropathic, 219800 (3)",CTNS,606272,17p13,Renal,1497,0,#NV,#NV
400,"Cystinosis, ocular nonnephropathic, 219750 (3)",CTNS,606272,17p13,Renal,1497,0,#NV,#NV
401,"Cystinuria, 220100 (3)","SLC3A1, ATR1, D2H, NBAT",104614,2p16.3,Renal,6519,0,#NV,#NV
401,"Cystinuria, type II (3)","SLC7A9, CSNU3",604144,19q13.1,Renal,11136,0,#NV,#NV
401,"Cystinuria, type III (3)","SLC7A9, CSNU3",604144,19q13.1,Renal,11136,0,#NV,#NV
402,"D-2-hydroxyglutaric aciduria, 600721 (3)",D2HGD,609186,2p25.3,Metabolic,257054,0,#NV,#NV
404,"Darier disease, 124200 (3)","ATP2A2, ATP2B, DAR",108740,12q23-q24.1,Dermatological,488,0,#NV,#NV
405,"D-bifunctional protein deficiency, 261515 (3)",HSD17B4,601860,5q2,Metabolic,3295,0,#NV,#NV
407,Debrisoquine sensitivity (3),"CYP2D@, CYP2D, P450C2D",124030,22q13.1,Metabolic,1565,0,#NV,#NV
411,"Delayed sleep phase syndrome, susceptibility to (3)","AANAT, SNAT",600950,17q25,Psychiatric,15,0,#NV,#NV
413,"Dengue fever, protection against (3)","CD209, CDSIGN",604672,19p13.3,Immunological,30835,0,#NV,#NV
414,"Dental anomalies, isolated (3)","RUNX2, CBFA1, PEBP2A1, AML3",600211,6p21,Skeletal,860,0,#NV,#NV
415,"Dentatorubro-pallidoluysian atrophy, 125370 (3)",DRPLA,607462,12p13.31,Neurological,1822,0,#NV,#NV
416,"Dent disease, 300009 (3)","CLCN5, CLCK2, NPHL2, DENTS",300008,Xp11.22,Renal,1184,0,#NV,#NV
416,"Dent syndrome, 300009 (3)","OCRL, LOCR, OCRL1, NPHL2",300535,Xq26.1,Renal,4952,0,#NV,#NV
424,"De Sanctis-Cacchione syndrome, 278800 (3)","ERCC6, CKN2, COFS, CSB",609413,10q11,multiple,2074,0,#NV,#NV
426,"Desmosterolosis, 602398 (3)","DHCR24, KIAA0018",606418,1p33-p31.1,Metabolic,1718,0,#NV,#NV
432,"DiGeorge syndrome, 188400 (3)","TBX1, DGS, CTHM, CAFS, TGA, DORV, VCFS, DGCR",602054,22q11.2,multiple,6899,0,#NV,#NV
433,Dihydropyrimidinuria (3),"DPYS, DHP",222748,8q22,Metabolic,1807,0,#NV,#NV
435,"Dimethylglycine dehydrogenase deficiency, 605850 (3)","DMGDH, DMGDHD",605849,5q12.2-q12.3,Metabolic,29958,0,#NV,#NV
438,"Disordered steroidogenesis, isolated (3)",POR,124015,7q11.2,Metabolic,5447,0,#NV,#NV
440,"DNA topoisomerase I, camptothecin-resistant (3)",TOP1,126420,20q12-q13.1,Metabolic,7150,0,#NV,#NV
440,"DNA topoisomerase II, resistance to inhibition of, by amsacrine (3)","TOP2A, TOP2",126430,17q21-q22,Metabolic,7153,0,#NV,#NV
443,"Dosage-sensitive sex reversal, 300018 (3)","DAX1, AHC, AHX, NROB1",300473,Xp21.3-p21.2,Endocrine,190,0,#NV,#NV
444,"Double-outlet right ventricle, 217095 (3)","CFC1, CRYPTIC, HTX2",605194,2q21.1,Cardiovascular,55997,0,#NV,#NV
445,"Down syndrome, risk of, 190685 (3)",MTR,156570,1q43,multiple,4548,0,#NV,#NV
446,"Doyne honeycomb degeneration of retina, 126600 (3)","EFEMP1, FBNL, DHRD",601548,2p16,Ophthamological,2202,0,#NV,#NV
447,"Drug addiction, susceptibility to (3)",FAAH,602935,1p35-p34,Psychiatric,2166,0,#NV,#NV
449,"Duane-radial ray syndrome, 607323 (3)","SALL4, HSAL4",607343,20q13.13-q13.2,multiple,57167,0,#NV,#NV
450,"Dubin-Johnson syndrome, 237500 (3)","ABCC2, CMOAT",601107,10q24,Metabolic,1244,0,#NV,#NV
452,"Dyggve-Melchior-Clausen disease, 223800 (3)","DYM, FLJ90130, DMC, SMC",607461,18q12-q21.1,multiple,54808,0,#NV,#NV
453,Dysalbuminemic hyperthyroxinemia (3),ALB,103600,4q11-q13,Hematological,213,0,#NV,#NV
454,"Dysautonomia, familial, 223900 (3)","IKBKAP, IKAP",603722,9q31,Neurological,8518,0,#NV,#NV
455,"Dyschromatosis symmetrica hereditaria, 127400 (3)","ADAR, DRADA, DSH, DSRAD",601059,1q21.3,Dermatological,103,0,#NV,#NV
458,"Dyskeratosis congenita-1, 305000 (3)","DKC1, DKC",300126,Xq28,Dermatological,1736,0,#NV,#NV
458,"Dyskeratosis congenita, autosomal dominant, 127550 (3)","TERC, TRC3, TR",602322,3q21-q28,Dermatological,7012,0,#NV,#NV
459,"Dyslexia, susceptibility to, 2, 600202 (3)","KIAA0319, DYX2, DYLX2, DLX2",609269,6p22.2,Psychiatric,9856,0,#NV,#NV
459,"Dyslexia, susceptibility to, 1, 127700 (3)","DYX1C1, DYXC1, DYX1",608706,15q21,Psychiatric,161582,0,#NV,#NV
460,Dysprothrombinemia (3),F2,176930,11p11-q12,Hematological,2147,0,#NV,#NV
461,"Dyssegmental dysplasia, Silverman-Handmaker type, 224410 (3)","HSPG2, PLC, SJS, SJA, SJS1",142461,1p36.1,Neurological,3339,0,#NV,#NV
462,"Dystonia-12, 128235 (3)","ATP1A3, DYT12, RDP",182350,19q12-q13.2,Neurological,478,0,#NV,#NV
462,"Dystonia, myoclonic, 159900 (3)",DRD2,126450,11q23,Neurological,1813,0,#NV,#NV
462,"Dystonia, primary cervical (3)","DRD5, DRD1B, DRD1L2",126453,4p16.1-p15.3,Neurological,1816,0,#NV,#NV
462,"Dystonia-1, torsion, 128100 (3)","DYT1, TOR1A",605204,9q34,Neurological,1861,0,#NV,#NV
462,"Dystonia, early-onset atypical, with myoclonic features (3)","DYT1, TOR1A",605204,9q34,Neurological,1861,0,#NV,#NV
462,"Dystonia, DOPA-responsive, 128230 (3)","GCH1, DYT5",600225,14q22.1-q22.2,Neurological,2643,0,#NV,#NV
462,"Dystonia, myoclonic, 159900 (3)","SGCE, DYT11",604149,7q21,Neurological,8910,0,#NV,#NV
468,"Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 (3)","TP73L, TP63, KET, EEC3, SHFM4, LMS, RHS",603273,3q27,Skeletal,8626,0,#NV,#NV
471,Elite sprint athletic performance (3),ACTN3,102574,11q13-q14,Muscular,89,0,#NV,#NV
473,"Ellis-van Creveld syndrome, 225500 (3)",EVC,604831,4p16,Skeletal,2121,0,#NV,#NV
473,"Ellis-van Creveld syndrome, 225500 (3)","LBN, EVC2",607261,4p16,Skeletal,132884,0,#NV,#NV
476,"Encephalopathy, progressive mitochondrial, with proximal renal tubulopathy due to cytochrome c oxidase deficiency (3)",COX10,602125,17p12-p11.2,Neurological,1352,0,#NV,#NV
476,"Encephalopathy, familial, with neuroserpin inclusion bodies, 604218 (3)","SERPINI1, PI12",602445,3q26,Neurological,5274,0,#NV,#NV
477,"Enchondromatosis, Ollier type, 166000 (3)","PTHR1, PTHR",168468,3p22-p21.1,Cancer,5745,0,#NV,#NV
481,Endotoxin hyporesponsiveness (3),TLR4,603030,9q32-q33,Immunological,7099,0,#NV,#NV
482,"Endplate acetylcholinesterase deficiency, 603034 (3)","COLQ, EAD",603033,3p25,Neurological,8292,0,#NV,#NV
485,Enolase-beta deficiency (3),ENO3,131370,17pter-p12,Metabolic,2027,0,#NV,#NV
487,"Enterokinase deficiency, 226200 (3)","PRSS7, ENTK",606635,21q21,Gastrointestinal,5651,0,#NV,#NV
491,"Eosinophil peroxidase deficiency, 261500 (3)",EPX,131399,17q23.1,Hematological,8288,0,#NV,#NV
492,"Epidermodysplasia verruciformis, 226400 (3)","EVER1, EV1",605828,17q25,Dermatological,11322,0,#NV,#NV
492,"Epidermodysplasia verruciformis, 226400 (3)","EVER2, EV2",605829,17q25,Dermatological,147138,0,#NV,#NV
498,"Epithelial ovarian cancer, somatic, 604370 (3)",OPCML,600632,11q25,Cancer,4978,0,#NV,#NV
502,"Erythermalgia, primary, 133020 (3)","SCN9A, NENA, PN1",603415,2q24,Neurological,6335,0,#NV,#NV
504,"Erythremias, alpha- (3)",HBA1,141800,16pter-p13.3,Hematological,3039,0,#NV,#NV
504,"Erythremias, beta- (3)",HBB,141900,11p15.5,Hematological,3043,0,#NV,#NV
505,"Erythrocytosis, familial, 133100 (3)",EPOR,133171,19p13.3-p13.2,Hematological,2057,0,#NV,#NV
505,Erythrocytosis (3),HBA2,141850,16pter-p13.3,Hematological,3040,0,#NV,#NV
510,"Ethylmalonic encephalopathy, 602473 (3)","ETHE1, HSCO, D83198",608451,19q13.32,Metabolic,23474,0,#NV,#NV
511,Ewing sarcoma (3),"EWSR1, EWS",133450,22q12,Cancer,2130,0,#NV,#NV
512,Exertional myoglobinuria due to deficiency of LDH-A (3),"LDHA, LDH1",150000,11p15.4,Metabolic,3939,0,#NV,#NV
514,"Exostoses, multiple, type 1, 133700 (3)",EXT1,608177,8q24.11-q24.13,Bone,2131,0,#NV,#NV
514,"Exostoses, multiple, type 2, 133701 (3)",EXT2,608210,11p12-p11,Bone,2132,0,#NV,#NV
517,"Ezetimibe, nonresponse to (3)",NPC1L1,608010,7p13,Unclassified,29881,0,#NV,#NV
518,Fabry disease (3),GLA,301500,Xq22,Metabolic,2717,0,#NV,#NV
519,Facioscapulohumeral muscular dystrophy-1A (3),"FSHMD1A, FSHD1A",158900,4q35,Muscular,2489,0,#NV,#NV
522,"Familial Mediterranean fever, 249100 (3)","MEFV, MEF, FMF",608107,16p13,Immunological,4210,0,#NV,#NV
526,Farber lipogranulomatosis (3),"ASAH, AC",228000,8p22-p21.3,Metabolic,427,0,#NV,#NV
527,"Fatty liver, acute, of pregnancy (3)","HADHA, MTPA",600890,2p23,Metabolic,3030,0,#NV,#NV
531,"Feingold syndrome, 164280 (3)","MYCN, NMYC, ODED, MODED",164840,2p24.1,multiple,4613,0,#NV,#NV
532,"Fertile eunuch syndrome, 228300 (3)","GNRHR, LHRHR",138850,4q21.2,Endocrine,2798,0,#NV,#NV
535,"Fibrocalculous pancreatic diabetes, susceptibility to (3)","SPINK1, PSTI, PCTT, TATI",167790,5q32,Gastrointestinal,6690,0,#NV,#NV
537,"Fibromatosis, gingival, 135300 (3)","SOS1, GINGF, GF1, HGF",182530,2p22-p21,Connective tissue disorder,6654,0,#NV,#NV
537,"Fibromatosis, juvenile hyaline, 228600 (3)","ANTXR2, CMG2, JHF, ISH",608041,4q21,Connective tissue disorder,118429,0,#NV,#NV
538,"Fibrosis of extraocular muscles, congenital, 2, 602078 (3)","PHOX2A, ARIX, CFEOM2",602753,11q13.3-q13.4,Ophthamological,401,0,#NV,#NV
538,"Fibrosis of extraocular muscles, congenital, 1, 135700 (3)","KIF21A, KIAA1708, FEOM1, CFEOM1",608283,12q12,Ophthamological,55605,0,#NV,#NV
539,"Fibular hypoplasia and complex brachydactyly, 228900 (3)","GDF5, CDMP1",601146,20q11.2,Skeletal,8200,0,#NV,#NV
540,"Fish-eye disease, 136120 (3)",LCAT,606967,16q22.1,Metabolic,3931,0,#NV,#NV
541,"Fish-odor syndrome, 602079 (3)",FMO3,136132,1q23-q25,Metabolic,2328,0,#NV,#NV
542,Fitzgerald factor deficiency (3),KNG,228960,3q27,Hematological,3827,0,#NV,#NV
544,"Fluorouracil toxicity, sensitivity to (3)","DPYD, DPD",274270,1p22,Metabolic,1806,0,#NV,#NV
545,"Focal cortical dysplasia, Taylor balloon cell type, 607341 (3)","TSC1, LAM",605284,9q34,Developmental,7248,0,#NV,#NV
546,"Follicle-stimulating hormone deficiency, isolated, 229070 (3)",FSHB,136530,11p13,Endocrine,2488,0,#NV,#NV
547,Forebrain defects (3),TDGF1,187395,3p23-p21,Neurological,6997,0,#NV,#NV
550,Fragile X syndrome (3),"FMR1, FRAXA",309550,Xq27.3,Neurological,2332,0,#NV,#NV
551,"Fraser syndrome, 219000 (3)",FRAS1,607830,4q21,multiple,80144,0,#NV,#NV
551,"Fraser syndrome, 219000 (3)",FREM2,608945,13q13.3,multiple,341640,0,#NV,#NV
553,"Friedreich ataxia, 229300 (3)","FRDA, FARR",606829,9q13,Neurological,2395,0,#NV,#NV
553,"Friedreich ataxia with retained reflexes, 229300 (3)","FRDA, FARR",606829,9q13,Neurological,2395,0,#NV,#NV
554,"Frontometaphyseal dysplasia, 304120 (3)","FLNA, FLN1, ABPX, NHBP, OPD1, OPD2, FMD, MNS",300017,Xq28,Skeletal,2316,0,#NV,#NV
555,Fructose-bisphosphatase deficiency (3),FBP1,229700,9q22.2-q22.3,Metabolic,2203,0,#NV,#NV
556,Fructose intolerance (3),ALDOB,229600,9q22.3,Metabolic,229,0,#NV,#NV
557,Fructosuria (3),KHK,229800,2p23.3-p23.2,Metabolic,3795,0,#NV,#NV
559,Fucosidosis (3),FUCA1,230000,1p34,Metabolic,2517,0,#NV,#NV
560,Fucosyltransferase-6 deficiency (3),FUT6,136836,19p13.3,Metabolic,2528,0,#NV,#NV
561,"Fumarase deficiency, 606812 (3)",FH,136850,1q42.1,Metabolic,2271,0,#NV,#NV
564,GABA-transaminase deficiency (3),"ABAT, GABAT",137150,16p13.3,Metabolic,18,0,#NV,#NV
565,"Galactokinase deficiency with cataracts, 230200 (3)",GALK1,604313,17q24,Metabolic,2584,0,#NV,#NV
566,"Galactose epimerase deficiency, 230350 (3)",GALE,606953,1p36-p35,Metabolic,2582,0,#NV,#NV
567,"Galactosemia, 230400 (3)",GALT,606999,9p13,Metabolic,2592,0,#NV,#NV
568,Galactosialidosis (3),"PPGB, GSL, NGBE, GLB2, CTSA",256540,20q13.1,Metabolic,5476,0,#NV,#NV
570,GAMT deficiency (3),GAMT,601240,19p13.3,Metabolic,2593,0,#NV,#NV
575,"Gaucher disease, 230800 (3)",GBA,606463,1q21,Metabolic,2629,0,#NV,#NV
575,"Gaucher disease with cardiovascular calcification, 231005 (3)",GBA,606463,1q21,Metabolic,2629,0,#NV,#NV
575,"Gaucher disease, variant form (3)","PSAP, SAP1",176801,10q22.1,Metabolic,5660,0,#NV,#NV
576,"Gaze palsy, horizontal, with progressive scoliosis, 607313 (3)","ROBO3, RBIG1, RIG1, HGPPS",608630,11q23-q25,Neurological,64221,0,#NV,#NV
578,"Generalized epilepsy and paroxysmal dyskinesia, 609446 (3)","KCNMA1, SLO",600150,10q22.3,Neurological,3778,0,#NV,#NV
578,"Generalized epilepsy with febrile seizures plus, 604233 (3)","SCN1B, GEFSP1",600235,19q13.1,Neurological,6324,0,#NV,#NV
582,"Giant axonal neuropathy-1, 256850 (3)","GAN, GAN1",605379,16q24.1,Neurological,8139,0,#NV,#NV
584,"Giant platelet disorder, isolated (3)",GP1BB,138720,22q11.2,Hematological,2812,0,#NV,#NV
586,"Gilbert syndrome, 143500 (3)","UGT1A1, UGT1, GNT1",191740,2q37,Metabolic,54658,0,#NV,#NV
587,"Gitelman syndrome, 263800 (3)","SLC12A3, NCCT, TSC",600968,16q13,Renal,6559,0,#NV,#NV
588,"Glanzmann thrombasthenia, type A, 273800 (3)","ITGA2B, GP2B, CD41B",607759,17q21.32,Hematological,3674,0,#NV,#NV
588,"Glanzmann thrombasthenia, type B (3)","ITGB3, GP3A",173470,17q21.32,Hematological,3690,0,#NV,#NV
596,"Glomerulosclerosis, focal segmental, 1, 603278 (3)","ACTN4, FSGS1, FSGS",604638,19q13,Renal,81,0,#NV,#NV
596,"Glomerulosclerosis, focal segmental, 2, 603965 (3)","TRPC6, TRP6, FSGS2",603652,11q21-q22,Renal,7225,0,#NV,#NV
596,"Glomerulosclerosis, focal segmental, 3, 607832 (3)","CD2AP, CMS",604241,Chr.6,Renal,23607,0,#NV,#NV
597,"Glomuvenous malformations, 138000 (3)","GLML, GVM, VMGLOM",601749,1p22-p21,Cardiovascular,11146,0,#NV,#NV
598,"Glucocorticoid deficiency, due to ACTH unresponsiveness, 202200 (3)",MC2R,607397,18p11.2,Endocrine,4158,0,#NV,#NV
598,"Glucocorticoid deficiency 2, 607398 (3)","MRAP, FALP, C21orf61",609196,21q22.1,Endocrine,56246,0,#NV,#NV
599,"Glucose/galactose malabsorption, 606824 (3)","SLC5A1, SGLT1",182380,22q13.1,Metabolic,6523,0,#NV,#NV
600,"Glucose transport defect, blood-brain barrier, 606777 (3)","SLC2A1, GLUT1",138140,1p35-p31.3,Metabolic,6513,0,#NV,#NV
601,"Glucosidase I deficiency, 606056 (3)",GCS1,601336,2p13-p12,Metabolic,7841,0,#NV,#NV
602,"Glutamate formiminotransferase deficiency, 229100 (3)",FTCD,606806,21q22.3,Metabolic,10841,0,#NV,#NV
603,"Glutaricaciduria, type IIA, 231680 (3)","ETFA, GA2, MADD",608053,15q23-q25,Metabolic,2108,0,#NV,#NV
603,"Glutaricaciduria, type IIB, 231680 (3)","ETFB, MADD",130410,19q13.3,Metabolic,2109,0,#NV,#NV
603,"Glutaricaciduria, type IIC, 231680 (3)","ETFDH, MADD",231675,4q32-qter,Metabolic,2110,0,#NV,#NV
603,"Glutaricaciduria, type I, 231670 (3)",GCDH,608801,19p13.2,Metabolic,2639,0,#NV,#NV
607,"Glycerol kinase deficiency, 307030 (3)",GK,300474,Xp21.3-p21.2,Metabolic,2710,0,#NV,#NV
608,"Glycine encephalopathy, 605899 (3)","AMT, NKH, GCE",238310,3p21.2-p21.1,Metabolic,275,0,#NV,#NV
608,"Glycine encephalopathy, 605899 (3)","GCSH, NKH",238330,16q24,Metabolic,2653,0,#NV,#NV
608,"Glycine encephalopathy, 605899 (3)","GLDC, HYGN1, GCSP, GCE, NKH",238300,9p22,Metabolic,2731,0,#NV,#NV
608,"Glycine N-methyltransferase deficiency, 606664 (3)",GNMT,606628,6p12,Metabolic,27232,0,#NV,#NV
609,"Glycogenosis, X-linked hepatic, type I (3)","PHKA2, PHK",306000,Xp22.2-p22.1,Metabolic,5256,0,#NV,#NV
609,"Glycogenosis, X-linked hepatic, type II (3)","PHKA2, PHK",306000,Xp22.2-p22.1,Metabolic,5256,0,#NV,#NV
609,"Glycogenosis, hepatic, autosomal (3)",PHKG2,172471,16p12.1-p11.2,Metabolic,5261,0,#NV,#NV
610,Glycogen storage disease IIIa (3),"AGL, GDE",232400,1p21,Metabolic,178,0,#NV,#NV
610,Glycogen storage disease IIIb (3),"AGL, GDE",232400,1p21,Metabolic,178,0,#NV,#NV
610,Glycogen storage disease I (3),"G6PC, G6PT",232200,17q21,Metabolic,2538,0,#NV,#NV
610,"Glycogen storage disease Ib, 232220 (3)",G6PT1,602671,11q23,Metabolic,2542,0,#NV,#NV
610,"Glycogen storage disease Ic, 232240 (3)",G6PT1,602671,11q23,Metabolic,2542,0,#NV,#NV
610,"Glycogen storage disease II, 232300 (3)",GAA,606800,17q25.2-q25.3,Metabolic,2548,0,#NV,#NV
610,"Glycogen storage disease IV, 232500 (3)",GBE1,607839,3p12,Metabolic,2632,0,#NV,#NV
610,"Glycogen storage disease, type 0, 240600 (3)",GYS2,138571,12p12.2,Metabolic,2998,0,#NV,#NV
610,"Glycogen storage disease IIb, 300257 (3)","LAMP2, LAMPB",309060,Xq24,Metabolic,3920,0,#NV,#NV
610,Glycogen storage disease VII (3),PFKM,232800,12q13.3,Metabolic,5213,0,#NV,#NV
610,Glycogen storage disease VI (3),PYGL,232700,14q21-q22,Metabolic,5836,0,#NV,#NV
614,GM1-gangliosidosis (3),GLB1,230500,3p21.33,Metabolic,2720,0,#NV,#NV
614,"GM2-gangliosidosis, AB variant (3)",GM2A,272750,5q31.3-q33.1,Metabolic,2760,0,#NV,#NV
614,"GM2-gangliosidosis, several forms, 272800 (3)","HEXA, TSD",606869,15q23-q24,Metabolic,3073,0,#NV,#NV
615,"Gnthodiaphyseal dysplasia, 166260 (3)","TMEM16E, GDD1",608662,11p14.3,Bone,203859,0,#NV,#NV
618,"Goldberg-Shprintzen megacolon syndrome, 609460 (3)",KIAA1279,609367,10q22.1,multiple,26128,0,#NV,#NV
619,"Gonadal dysgenesis, XY type (3)","SRY, TDF",480000,Yp11.3,Endocrine,6736,0,#NV,#NV
619,"Gonadal dysgenesis, 46XY, partial, with minifascicular neuropathy, 607080 (3)",DHH,605423,12q13.1,Endocrine,50846,0,#NV,#NV
625,"Greenberg dysplasia, 215140 (3)","LBR, PHA",600024,1q42.1,Skeletal,3930,0,#NV,#NV
626,"Greig cephalopolysyndactyly syndrome, 175700 (3)","GLI3, PAPA, PAPB, ACLS",165240,7p13,Skeletal,2737,0,#NV,#NV
627,"Griscelli syndrome, type 1, 214450 (3)","MYO5A, MYH12, GS1",160777,15q21,Dermatological,4644,0,#NV,#NV
627,"Griscelli syndrome, type 2, 607624 (3)","RAB27A, RAM, GS2",603868,15q21,Dermatological,5873,0,#NV,#NV
627,"Griscelli syndrome, type 3, 609227 (3)",MLPH,606526,2q37,Dermatological,79083,0,#NV,#NV
630,"Guttmacher syndrome, 176305 (3)","HOXA13, HOX1J",142959,7p15-p14.2,multiple,3209,0,#NV,#NV
632,"Gyrate atrophy of choroid and retina with ornithinemia, B6 responsive or unresponsive (3)",OAT,258870,10q26,Metabolic,4942,0,#NV,#NV
633,"Hailey-Hailey disease, 169600 (3)","ATP2C1, BCPM, HHD",604384,3q21-q24,Dermatological,27032,0,#NV,#NV
634,"Haim-Munk syndrome, 245010 (3)","CTSC, CPPI, PALS, PLS, HMS",602365,11q14.1-q14.3,multiple,1075,0,#NV,#NV
638,"Hand-foot-uterus syndrome, 140000 (3)","HOXA13, HOX1J",142959,7p15-p14.2,multiple,3209,0,#NV,#NV
639,Harderoporphyrinuria (3),CPO,121300,3q12,Metabolic,1371,0,#NV,#NV
640,"HARP syndrome, 607236 (3)","PANK2, NBIA1, PKAN, HARP",606157,20p13-p12.3,Metabolic,80025,0,#NV,#NV
641,"Hartnup disorder, 234500 (3)","SLC6A19, HND",608893,5p15,Metabolic,340024,0,#NV,#NV
643,"Hay-Wells syndrome, 106260 (3)","TP73L, TP63, KET, EEC3, SHFM4, LMS, RHS",603273,3q27,multiple,8626,0,#NV,#NV
646,"Hearing loss, low-frequency sensorineural, 600965 (3)","WFS1, WFRS, WFS, DFNA6",606201,4p16.1,"Ear,Nose,Throat",7466,0,#NV,#NV
648,"Heinz body anemias, alpha- (3)",HBA1,141800,16pter-p13.3,Hematological,3039,0,#NV,#NV
648,Heinz body anemia (3),HBA2,141850,16pter-p13.3,Hematological,3040,0,#NV,#NV
648,"Heinz body anemias, beta- (3)",HBB,141900,11p15.5,Hematological,3043,0,#NV,#NV
649,"HELLP syndrome, maternal, of pregnancy (3)","HADHA, MTPA",600890,2p23,Metabolic,3030,0,#NV,#NV
651,"Hemangioma, capillary infantile, somatic, 602089 (3)","FLT4, VEGFR3, PCL",136352,5q35.3,Cancer,2324,0,#NV,#NV
651,"Hemangioma, capillary infantile, somatic, 602089 (3)",KDR,191306,4q12,Cancer,3791,0,#NV,#NV
653,"Hematuria, familial benign (3)",COL4A4,120131,2q36-q37,Renal,1286,0,#NV,#NV
654,Heme oxygenase-1 deficiency (3),HMOX1,141250,22q12,Metabolic,3162,0,#NV,#NV
657,Hemochromatosis (3),"HFE, HLA-H, HFE1",235200,6p21.3,Metabolic,3077,0,#NV,#NV
657,"Hemochromatosis, type 3, 604250 (3)","TFR2, HFE3",604720,7q22,Metabolic,7036,0,#NV,#NV
657,"Hemochromatosis, type 4, 606069 (3)","SLC40A1, SLC11A3, FPN1, IREG1, HFE4",604653,2q32,Metabolic,30061,0,#NV,#NV
657,"Hemochromatosis, juvenile, 602390 (3)","HAMP, LEAP1, HEPC, HFE2",606464,19q13,Metabolic,57817,0,#NV,#NV
657,"Hemochromatosis, juvenile, digenic, 602390 (3)","HAMP, LEAP1, HEPC, HFE2",606464,19q13,Metabolic,57817,0,#NV,#NV
657,"Hemochromatosis, type 2A, 602390 (3)","HJV, HFE2A",608374,1q21,Metabolic,148738,0,#NV,#NV
659,Hemoglobin H disease (3),HBA2,141850,16pter-p13.3,Hematological,3040,0,#NV,#NV
662,"Hemophagocytic lymphohistiocytosis, familial, 2, 603553 (3)","PRF1, HPLH2",170280,10q22,Hematological,5551,0,#NV,#NV
662,"Hemophagocytic lymphohistiocytosis, familial, 3, 608898 (3)","UNC13D, MUNC13-4, HPLH3, HLH3, FHL3",608897,17q25.1,Hematological,201294,0,#NV,#NV
663,Hemophilia A (3),"F8, F8C, HEMA",306700,Xq28,Hematological,2157,0,#NV,#NV
663,Hemophilia B (3),"F9, HEMB",306900,Xq27.1-q27.2,Hematological,2158,0,#NV,#NV
666,"Hepatic failure, early onset, and neurologic disorder (3)","SCOD1, SCO1",603644,17p13-p12,Gastrointestinal,6341,0,#NV,#NV
669,"Hereditary hemorrhagic telangiectasia-2, 600376 (3)","ACVRL1, ACVRLK1, ALK1, HHT2",601284,12q11-q14,Cardiovascular,94,0,#NV,#NV
669,"Hereditary hemorrhagic telangiectasia-1, 187300 (3)","ENG, END, HHT1, ORW",131195,9q34.1,Cardiovascular,2022,0,#NV,#NV
670,"Hermansky-Pudlak syndrome, 203300 (3)",HPS1,604982,10q23.1,multiple,3257,0,#NV,#NV
670,"Hermansky-Pudlak syndrome, 608233 (3)","AP3B1, ADTB3A, HPS2",603401,5q14.1,multiple,8546,0,#NV,#NV
670,"Hermansky-pudlak syndrome, 203300 (3)","HPS5, RU2, KIAA1017",607521,11p15-p13,multiple,11234,0,#NV,#NV
670,"Hermansky-Pudlak syndrome, 203300 (3)","HPS6, RU",607522,10q24.32,multiple,79803,0,#NV,#NV
670,"Hermansky-Pudlak syndrome 7, 203300 (3)","DTNBP1, HPS7",607145,6p22.3,multiple,84062,0,#NV,#NV
670,"Hermansky-Pudlak syndrome, 203300 (3)",HPS3,606118,3q24,multiple,84343,0,#NV,#NV
670,"Hermansky-Pudlak syndrome, 203300 (3)",HPS4,606682,22q11.2-q12.2,multiple,89781,0,#NV,#NV
675,"Heterotaxy, X-linked visceral, 306955 (3)","ZIC3, HTX1, HTX",300265,Xq26.2,multiple,7547,0,#NV,#NV
675,"Heterotaxy, visceral, 605376 (3)","CFC1, CRYPTIC, HTX2",605194,2q21.1,multiple,55997,0,#NV,#NV
676,"Heterotopia, periventricular, 300049 (3)","FLNA, FLN1, ABPX, NHBP, OPD1, OPD2, FMD, MNS",300017,Xq28,Neurological,2316,0,#NV,#NV
676,"Heterotopia, periventricular, ED variant, 300537 (3)","FLNA, FLN1, ABPX, NHBP, OPD1, OPD2, FMD, MNS",300017,Xq28,Neurological,2316,0,#NV,#NV
676,"Heterotopia, periventricular nodular, with frontometaphyseal dysplasia, 300049 (3)","FLNA, FLN1, ABPX, NHBP, OPD1, OPD2, FMD, MNS",300017,Xq28,Neurological,2316,0,#NV,#NV
677,"Hex A pseudodeficiency, 272800 (3)","HEXA, TSD",606869,15q23-q24,Metabolic,3073,0,#NV,#NV
679,High-molecular-weight kininogen deficiency (3),KNG,228960,3q27,Hematological,3827,0,#NV,#NV
682,"Histidinemia, 235800 (3)","HAL, HSTD",609457,12q22-q23,Metabolic,3034,0,#NV,#NV
686,HMG-CoA lyase deficiency (3),HMGCL,246450,1pter-p33,Metabolic,3155,0,#NV,#NV
686,"HMG-CoA synthase-2 deficiency, 605911 (3)",HMGCS2,600234,1p13-p12,Metabolic,3158,0,#NV,#NV
688,"Holocarboxylase synthetase deficiency, 253270 (3)","HLCS, HCS",609018,21q22.1,Metabolic,3141,0,#NV,#NV
696,"Holt-Oram syndrome, 142900 (3)",TBX5,601620,12q24.1,Developmental,6910,0,#NV,#NV
697,"Homocysteine, total plasma, elevated (3)",CTH,607657,1p31.1,Metabolic,1491,0,#NV,#NV
699,"Homocystinuria-megaloblastic anemia, cbl E type, 236270 (3)",MTRR,602568,5p15.3-p15.2,Metabolic,4552,0,#NV,#NV
701,"Homozygous 2p16 deletion syndrome, 606407 (3)","SLC3A1, ATR1, D2H, NBAT",104614,2p16.3,multiple,6519,0,#NV,#NV
702,"Hoyeraal-Hreidarsson syndrome, 300240 (3)","DKC1, DKC",300126,Xq28,multiple,1736,0,#NV,#NV
703,"HPFH, deletion type (3)",HBB,141900,11p15.5,Hematological,3043,0,#NV,#NV
703,"HPFH, nondeletion type A (3)",HBG1,142200,11p15.5,Hematological,3047,0,#NV,#NV
703,"HPFH, nondeletion type G (3)",HBG2,142250,11p15.5,Hematological,3048,0,#NV,#NV
704,"HPRT-related gout, 300323 (3)","HPRT1, HPRT",308000,Xq26-q27.2,Metabolic,3251,0,#NV,#NV
705,"H. pylori infection, susceptibility to, 600263 (3)",IFNGR1,107470,6q23-q24,Immunological,3459,0,#NV,#NV
710,"Hyalinosis, infantile systemic, 236490 (3)","ANTXR2, CMG2, JHF, ISH",608041,4q21,multiple,118429,0,#NV,#NV
712,"Hydrocephalus due to aqueductal stenosis, 307000 (3)","L1CAM, CAML1, HSAS1",308840,Xq28,Neurological,3897,0,#NV,#NV
712,"Hydrocephalus with congenital idiopathic intestinal pseudoobstruction, 307000 (3)","L1CAM, CAML1, HSAS1",308840,Xq28,Neurological,3897,0,#NV,#NV
712,"Hydrocephalus with Hirschsprung disease and cleft palate, 142623 (3)","L1CAM, CAML1, HSAS1",308840,Xq28,Neurological,3897,0,#NV,#NV
716,"Hyperalphalipoproteinemia, 143470 (3)",CETP,118470,16q21,Metabolic,1071,0,#NV,#NV
717,"Hyperammonemia with hypoornithinemia, hypocitrullinemia, hypoargininemia, and hypoprolinemia (3)","PYCS, GSAS",138250,10q24.3,Metabolic,5832,0,#NV,#NV
718,"Hyperandrogenism, nonclassic type, due to 21-hydroxylase deficiency (3)","CYP21A2, CYP21, CA21H",201910,6p21.3,Endocrine,1589,0,#NV,#NV
719,"Hyperapobetalipoproteinemia, susceptibility to (3)","PPARA, PPAR",170998,22q12-q13.1,Metabolic,5465,0,#NV,#NV
720,"Hyperbilirubinemia, familial transcient neonatal, 237900 (3)","UGT1A1, UGT1, GNT1",191740,2q37,Gastrointestinal,54658,0,#NV,#NV
721,"Hypercalciuria, absorptive, susceptibility to, 143870 (3)","SAC, HCA2",605205,1q24,Renal,55811,0,#NV,#NV
725,Hyperekplexia and spastic paraparesis (3),"GLRA1, STHE",138491,5q32,Neurological,2741,0,#NV,#NV
725,"Hyperekplexia, autosomal recessive, 149400 (3)",GLRB,138492,4q31.3,Neurological,2743,0,#NV,#NV
727,"Hyperferritinemia-cataract syndrome, 600886 (3)",FTL,134790,19q13.3-q13.4,Ophthamological,2512,0,#NV,#NV
728,"Hyper-IgD syndrome, 260920 (3)","MVK, MVLK",251170,12q24,Immunological,4598,0,#NV,#NV
732,"Hyperinsulinism-hyperammonemia syndrome, 606762 (3)",GLUD1,138130,10q23.3,Metabolic,2746,0,#NV,#NV
734,"Hyperkeratotic cutaneous capillary-venous malformations associated with cerebral capillary malformations, 116860 (3)","CCM1, CAM, KRIT1",604214,7q11.2-q21,Neurological,889,0,#NV,#NV
736,"Hyperlipidemia, familial combined, susceptibility to, 602491 (3)","USF1, HYPLIP1",191523,1q22-q23,Metabolic,7391,0,#NV,#NV
738,"Hyperlysinemia, 238700 (3)",AASS,605113,7q31.3,Metabolic,10157,0,#NV,#NV
739,Hypermethioninemia with deficiency of S-adenosylhomocysteine hydrolase (3),"AHCY, SAHH",180960,20cen-q13.1,Metabolic,191,0,#NV,#NV
739,"Hypermethioninemia, persistent, autosomal dominant, due to methionine adenosyltransferase I/III deficiency (3)","MAT1A, MATA1, SAMS1",250850,10q22,Metabolic,4143,0,#NV,#NV
740,"Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome, 238970 (3)","SLC25A15, ORNT1, HHH",603861,13q14,Metabolic,10166,0,#NV,#NV
742,"Hyperoxaluria, primary, type 1, 259900 (3)","AGXT, SPAT",604285,2q36-q37,Metabolic,189,0,#NV,#NV
742,"Hyperoxaluria, primary, type II, 260000 (3)","GRHPR, GLXR",604296,9cen,Metabolic,9380,0,#NV,#NV
746,"Hyperphenylalaninemia, mild (3)","PAH, PKU1",261600,12q24.1,Metabolic,5053,0,#NV,#NV
746,"Hyperphenylalaninemia due to pterin-4a-carbinolamine dehydratase deficiency, 264070 (3)","PCBD, DCOH",126090,10q22,Metabolic,5092,0,#NV,#NV
751,Hyperprothrombinemia (3),F2,176930,11p11-q12,Hematological,2147,0,#NV,#NV
758,"Hypertrypsinemia, neonatal (3)","CFTR, ABCC7, CF, MRP7",602421,7q31.2,Gastrointestinal,1080,0,#NV,#NV
759,"Hyperuricemic nephropathy, familial juvenile, 162000 (3)","UMOD, HNFJ, FJHN, MCKD2, ADMCKD2",191845,16p12.3,Renal,7369,0,#NV,#NV
761,"Hypoaldosteronism, congenital, due to CMO I deficiency, 203400 (3)",CYP11B2,124080,8q21,Metabolic,1585,0,#NV,#NV
761,"Hypoaldosteronism, congenital, due to CMO II deficiency (3)",CYP11B2,124080,8q21,Metabolic,1585,0,#NV,#NV
768,Hypochromic microcytic anemia (3),HBA2,141850,16pter-p13.3,Hematological,3040,0,#NV,#NV
771,Hypoglobulinemia and absent B cells (3),"BLNK, SLP65",604515,10q23.2,Immunological,29760,0,#NV,#NV
773,"Hypogonadism, hypergonadotropic (3)",LHB,152780,19q13.32,Endocrine,3972,0,#NV,#NV
774,Hypogonadotropic hypogonadism (3),"GNRHR, LHRHR",138850,4q21.2,Endocrine,2798,0,#NV,#NV
774,Hypogonadotropic hypogonadism (3),LHCGR,152790,2p21,Endocrine,3973,0,#NV,#NV
774,"Hypogonadotropic hypogonadism, 146110 (3)",NELF,608137,9q34.3,Endocrine,26012,0,#NV,#NV
774,"Hypogonadotropic hypogonadism, 146110 (3)",GPR54,604161,19p13.3,Endocrine,84634,0,#NV,#NV
775,Hypohaptoglobinemia (3),HP,140100,16q22.1,Hematological,3240,0,#NV,#NV
777,"Hypolactasia, adult type, 223100 (3)","LCT, LAC, LPH",603202,2q21,Metabolic,3938,0,#NV,#NV
777,"Hypolactasia, adult type, 223100 (3)",MCM6,601806,2q21,Metabolic,4175,0,#NV,#NV
778,"Hypomagnesemia-2, renal, 154020 (3)","FXYD2, ATP1G1, HOMG2",601814,11q23,Renal,486,0,#NV,#NV
778,"Hypomagnesemia, primary, 248250 (3)","CLDN16, PCLN1",603959,3q27,Renal,10686,0,#NV,#NV
778,"Hypomagnesemia with secondary hypocalcemia, 602014 (3)","TRPM6, CHAK2",607009,9q22,Renal,140803,0,#NV,#NV
779,"Hypoparathyroidism, autosomal dominant(3)",PTH,168450,11p15.3-p15.1,Endocrine,5741,0,#NV,#NV
779,"Hypoparathyroidism, autosomal recessive (3)",PTH,168450,11p15.3-p15.1,Endocrine,5741,0,#NV,#NV
779,"Hypoparathyroidism, familial isolated, 146200 (3)",GCMB,603716,6p24.2,Endocrine,9247,0,#NV,#NV
780,"Hypoparathyroidism-retardation-dysmorphism syndrome, 241410 (3)","TBCE, KCS, KCS1, HRD",604934,1q42-q43,Endocrine,6905,0,#NV,#NV
781,"Hypoparathyroidism, sensorineural deafness, and renal dysplasia, 146255 (3)","GATA3, HDR",131320,10p15,Endocrine,2625,0,#NV,#NV
782,"Hypophosphatasia, childhood, 241510 (3)","ALPL, HOPS, TNSALP",171760,1p36.1-p34,Metabolic,249,0,#NV,#NV
782,"Hypophosphatasia, infantile, 241500 (3)","ALPL, HOPS, TNSALP",171760,1p36.1-p34,Metabolic,249,0,#NV,#NV
783,"Hypophosphatemia, type III (3)","CLCN5, CLCK2, NPHL2, DENTS",300008,Xp11.22,Metabolic,1184,0,#NV,#NV
783,"Hypophosphatemia, X-linked, 307800 (3)","PHEX, HYP, HPDR1",300550,Xp22.2-p22.1,Metabolic,5251,0,#NV,#NV
784,"Hypophosphatemic rickets, autosomal dominant, 193100 (3)","FGF23, ADHR, HPDR2, PHPTC",605380,12p13.3,Bone,8074,0,#NV,#NV
785,"Hypoplastic enamel pitting, localized, 608563 (3)",ENAM,606585,4q21,Connective tissue disorder,10117,0,#NV,#NV
786,Hypoprothrombinemia (3),F2,176930,11p11-q12,Hematological,2147,0,#NV,#NV
788,"Hypotrichosis, congential, with juvenile macular dystrophy, 601553 (3)","CDH3, CDHP, PCAD, HJMD",114021,16q22.1,Dermatological,1001,0,#NV,#NV
788,"Hypotrichosis simplex of scalp, 146520 (3)","CDSN, HTSS",602593,6p21.3,Dermatological,1041,0,#NV,#NV
788,"Hypotrichosis-lymphedema-telangiectasia syndrome, 607823 (3)","SOX18, HLTS",601618,20q13.33,Dermatological,54345,0,#NV,#NV
788,"Hypotrichosis, localized, autosomal recessive, 607903 (3)","DSG4, LAH",607892,18q12,Dermatological,147409,0,#NV,#NV
791,"Hypouricemia, renal, 220150 (3)","SLC22A12, OAT4L, URAT1",607096,11q13,Renal,116085,0,#NV,#NV
795,"ICOS deficiency, 607594 (3)","ICOS, AILIM",604558,2q33,Immunological,29851,0,#NV,#NV
798,"IgG2 deficiency, selective (3)",IGHG2,147110,14q32.33,Immunological,3501,0,#NV,#NV
799,"IgG receptor I, phagocytic, familial deficiency of (3)","FCGR1A, IGFR1, CD64",146760,1q21.2-q21.3,Immunological,2209,0,#NV,#NV
801,"Immunodeficiency-centromeric instability-facial anomalies syndrome, 242860 (3)","DNMT3B, ICF",602900,20q11.2,multiple,1789,0,#NV,#NV
802,Immunodeficiency due to defect in CD3-epsilon (3),CD3E,186830,11q23,Immunological,916,0,#NV,#NV
802,Immunodeficiency due to defect in CD3-gamma (3),CD3G,186740,11q23,Immunological,917,0,#NV,#NV
802,"Immunodeficiency with hyper-IgM, type 3, 606843 (3)","TNFRSF5, CD40",109535,20q12-q13.2,Immunological,958,0,#NV,#NV
802,"Immunodeficiency, X-linked, with hyper-IgM, 308230 (3)","TNFSF5, CD40LG, HIGM1, IGM",300386,Xq26,Immunological,959,0,#NV,#NV
802,"Immunodeficiency with hyper IgM, type 4, 608106 (3)","UNG, DGU, HIGM4",191525,12q23-q24.1,Immunological,7374,0,#NV,#NV
802,"Immunodeficiency with hyper-IgM, type 2, 605258 (3)","AICDA, AID, HIGM2",605257,12p13,Immunological,57379,0,#NV,#NV
804,"Immunoglobulin A deficiency, 609529 (3)","TNFRSF14B, TACI",604907,17p11.2,Immunological,23495,0,#NV,#NV
805,"Inclusion body myopathy-3, 605637 (3)",MYH2,160740,17p13.1,Muscular,4620,0,#NV,#NV
805,"Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia, 167320 (3)","VCP, IBMPFD",601023,9p13-p12,Muscular,7415,0,#NV,#NV
805,"Inclusion body myopathy, autosomal recessive, 600737 (3)","GNE, GLCNE, IBM2, DMRV, NM",603824,9p12-p11,Muscular,10020,0,#NV,#NV
810,Inosine triphosphatase deficiency (3),ITPA,147520,20p,Metabolic,3704,0,#NV,#NV
816,"Interleukin-2 receptor, alpha chain, deficiency of (3)","IL2RA, IL2R",147730,10p15-p14,Immunological,3559,0,#NV,#NV
819,Intrauterine and postnatal growth retardation (3),IGF1R,147370,15q25-q26,Developmental,3480,0,#NV,#NV
819,Intrauterine and postnatal growth retardation (3),IGF2,147470,11p15.5,Developmental,3481,0,#NV,#NV
820,"Intrinsic factor deficiency, 261000 (3)","GIF, IF",609342,11q13,Hematological,2694,0,#NV,#NV
821,"IRAK4 deficiency, 607676 (3)","IRAK4, REN64",606883,12q12,Immunological,51135,0,#NV,#NV
824,"Iron overload, autosomal dominant (3)","FTH1, FTHL6",134770,11q12-q13,Hematological,2495,0,#NV,#NV
824,"Iron deficiency anemia, susceptibility to (3)",TF,190000,3q21,Hematological,7018,0,#NV,#NV
825,"Isolated growth hormone deficiency, Illig type with absent GH and Kowarski type with bioinactive GH (3)","GH1, GHN",139250,17q22-q24,Endocrine,2688,0,#NV,#NV
826,"Isovaleric acidemia, 243500 (3)",IVD,607036,15q14-q15,Metabolic,3712,0,#NV,#NV
831,"Joubert syndrome, 213300 (3)","NPHP1, NPH1, SLSN1",607100,2q13,multiple,4867,0,#NV,#NV
831,"Joubert syndrome-3, 608629 (3)",AHI1,608894,6q23.3,multiple,54806,0,#NV,#NV
832,"Juberg-Marsidi syndrome, 309590 (3)","ATRX, XH2, XNP, MRXS3, SHS",300032,Xq13,multiple,546,0,#NV,#NV
835,"Kallikrein, decreased urinary activity of (3)","KLK1, KLKR",147910,19q13.2-q13.4,Renal,3816,0,#NV,#NV
837,"Kanzaki disease, 609242 (3)",NAGA,104170,22q11,Metabolic,4668,0,#NV,#NV
838,"Kaposi sarcoma, susceptibility to, 148000 (3)","IL6, IFNB2, BSF2",147620,7p21,Immunological,3569,0,#NV,#NV
839,Kappa light chain deficiency (3),IGKC,147200,2p12,Immunological,3514,0,#NV,#NV
840,"Kartagener syndrome, 244400 (3)","DNAH5, HL1, PCD, CILD3",603335,5p15-p14,multiple,1767,0,#NV,#NV
840,"Kartagener syndrome, 244400 (3)","DNAH11, DNAHC11",603339,Chr.7,multiple,8701,0,#NV,#NV
840,"Kartagener syndrome, 244400 (3)","DNAI1, CILD1, ICS, PCD",604366,9p21-p13,multiple,27019,0,#NV,#NV
841,"Kenny-Caffey syndrome-1, 244460 (3)","TBCE, KCS, KCS1, HRD",604934,1q42-q43,multiple,6905,0,#NV,#NV
848,Ketoacidosis due to SCOT deficiency (3),"SCOT, OXCT",245050,5p13,Metabolic,5019,0,#NV,#NV
849,"Keutel syndrome, 245150 (3)","MGP, NTI",154870,12p13.1-p12.3,multiple,4256,0,#NV,#NV
850,"Kindler syndrome, 173650 (3)","KIND1, URP1, C20orf42",607900,20p13,Dermatological,55612,0,#NV,#NV
851,Kininogen deficiency (3),KNG,228960,3q27,Hematological,3827,0,#NV,#NV
853,"Klippel-Trenaunay syndrome, 149000 (3)","VG5Q, HUS84971, FLJ10283",608464,5q13.3,multiple,55109,0,#NV,#NV
855,"Knobloch syndrome, 267750 (3)","COL18A1, KNO",120328,21q22.3,multiple,80781,0,#NV,#NV
856,"Krabbe disease, 245200 (3)",GALC,606890,14q31,Neurological,2581,0,#NV,#NV
857,"L-2-hydroxyglutaric aciduria, 236792 (3)","L2HGDH, C14orf160",609584,14q22.1,Metabolic,79944,0,#NV,#NV
858,Lactate dehydrogenase-B deficiency (3),LDHB,150100,12p12.2-p12.1,Metabolic,3945,0,#NV,#NV
859,"Lacticacidemia due to PDX1 deficiency, 245349 (3)",PDX1,608769,11p13,Metabolic,8050,0,#NV,#NV
862,"Langer mesomelic dysplasia, 249700 (3)","SHOX, GCFX, SS, PHOG",312865,Xpter-p22.32,Skeletal,6473,0,#NV,#NV
862,"Langer mesomelic dysplasia, 249700 (3)",SHOXY,400020,Ypter-p11.2,Skeletal,6473,0,#NV,#NV
863,"Laron dwarfism, 262500 (3)",GHR,600946,5p13-p12,Skeletal,2690,0,#NV,#NV
869,"Lathosterolosis, 607330 (3)","SC5DL, ERG3",602286,11q23.3,Metabolic,6309,0,#NV,#NV
870,LCHAD deficiency (3),"HADHA, MTPA",600890,2p23,Metabolic,3030,0,#NV,#NV
871,"Lead poisoning, susceptibility to (3)",ALAD,125270,9q34,Metabolic,210,0,#NV,#NV
874,Left-right axis malformations (3),ACVR2B,602730,3p22-p21.3,Developmental,93,0,#NV,#NV
874,Left-right axis malformations (3),"EBAF, TGFB4, LEFTY2, LEFTA, LEFTYA",601877,1q42.1,Developmental,7044,0,#NV,#NV
875,"Left ventricular noncompaction, familial isolated, 1, 604169 (3)","DTNA, D18S892E, DRP3, LVNC1",601239,18q12.1-q12.2,Cardiovascular,1837,0,#NV,#NV
875,"Left ventricular noncompaction with congenital heart defects, 606617 (3)","DTNA, D18S892E, DRP3, LVNC1",601239,18q12.1-q12.2,Cardiovascular,1837,0,#NV,#NV
876,"Legionaire disease, susceptibility to, 608556 (3)","TLR5, TIL3",603031,1q41-q42,Immunological,7100,0,#NV,#NV
878,"Leiomyomatosis, diffuse, with Alport syndrome, 308940 (3)",COL4A6,303631,Xq22.3,Cancer,1288,0,#NV,#NV
878,"Leiomyomatosis and renal cell cancer, 605839 (3)",FH,136850,1q42.1,Cancer,2271,0,#NV,#NV
883,"Leri-Weill dyschondrosteosis, 127300 (3)","SHOX, GCFX, SS, PHOG",312865,Xpter-p22.32,Skeletal,6473,0,#NV,#NV
883,"Leri-Weill dyschondrosteosis, 127300 (3)",SHOXY,400020,Ypter-p11.2,Skeletal,6473,0,#NV,#NV
884,"Lesch-Nyhan syndrome, 300322, (3)","HPRT1, HPRT",308000,Xq26-q27.2,Metabolic,3251,0,#NV,#NV
889,"Leukocyte adhesion deficiency, 116920 (3)","ITGB2, CD18, LCAMB, LAD",600065,21q22.3,Immunological,3689,0,#NV,#NV
891,"Leukoencephalopathy with vanishing white matter, 603896 (3)","EIF2B1, EIF2BA",606686,Chr.12,Neurological,1967,0,#NV,#NV
891,"Leukoencephaly with vanishing white matter, 603896 (3)",EIF2B4,606687,2p23.3,Neurological,8890,0,#NV,#NV
891,"Leukoencephalopathy with vanishing white matter, 603896 (3)",EIF2B3,606273,1p34.1,Neurological,8891,0,#NV,#NV
891,"Leukoencephalopathy with vanishing white matter, 603896 (3)",EIF2B2,606454,14q24,Neurological,8892,0,#NV,#NV
891,"Leukoencephalopathy with vanishing white matter, 603896 (3)","EIF2B5, LVWM, CACH, CLE",603945,3q27,Neurological,8893,0,#NV,#NV
894,"Leydig cell adenoma, with precocious puberty (3)",LHCGR,152790,2p21,Cancer,3973,0,#NV,#NV
899,"LIG4 syndrome, 606593 (3)",LIG4,601837,13q22-q34,multiple,3981,0,#NV,#NV
901,"Limb-mammary syndrome, 603543 (3)","TP73L, TP63, KET, EEC3, SHFM4, LMS, RHS",603273,3q27,multiple,8626,0,#NV,#NV
903,"Lipoid congenital adrenal hyperplasia, 201710 (3)","CYP11A, P450SCC",118485,15q23-q24,Endocrine,1583,0,#NV,#NV
903,"Lipoid adrenal hyperplasia, 201710 (3)",STAR,600617,8p11.2,Endocrine,6770,0,#NV,#NV
906,Lipoprotein lipase deficiency (3),"LPL, LIPD",238600,8p22,Metabolic,4023,0,#NV,#NV
911,"Longevity, exceptional, 152430 (3)",CETP,118470,16q21,Developmental,1071,0,#NV,#NV
911,"Longevity, reduced, 152430 (3)",AKAP10,604694,17p11.1,Developmental,11216,0,#NV,#NV
914,"Lowe syndrome, 309000 (3)","OCRL, LOCR, OCRL1, NPHL2",300535,Xq26.1,Metabolic,4952,0,#NV,#NV
915,"Low renin hypertension, susceptibility to (3)",CYP11B2,124080,8q21,Cardiovascular,1585,0,#NV,#NV
916,"LPA deficiency, congenital (3)",LPA,152200,6q27,Metabolic,4018,0,#NV,#NV
917,"Lumbar disc disease, susceptibility to, 603932 (3)",CILP,603489,15q22,Skeletal,8483,0,#NV,#NV
919,"Lupus nephritis, susceptibility to (3)","FCGR2A, IGFR2, CD32",146790,1q21-q23,Connective tissue disorder,2212,0,#NV,#NV
920,"Lymphangioleiomyomatosis, 606690 (3)","TSC1, LAM",605284,9q34,Respiratory,7248,0,#NV,#NV
920,"Lymphangioleiomyomatosis, somatic, 606690 (3)","TSC2, LAM",191092,16p13.3,Respiratory,7249,0,#NV,#NV
921,"Lymphedema and ptosis, 153000 (3)","FOXC2, FKHL14, MFH1",602402,16q24.3,Hematological,2303,0,#NV,#NV
921,"Lymphedema-distichiasis syndrome, 153400 (3)","FOXC2, FKHL14, MFH1",602402,16q24.3,Hematological,2303,0,#NV,#NV
921,Lymphedema-distichiasis syndrome with renal disease and diabetes mellitus (3),"FOXC2, FKHL14, MFH1",602402,16q24.3,Hematological,2303,0,#NV,#NV
921,"Lymphedema, hereditary II, 153200 (3)","FOXC2, FKHL14, MFH1",602402,16q24.3,Hematological,2303,0,#NV,#NV
921,"Lymphedema, hereditary I, 153100 (3)","FLT4, VEGFR3, PCL",136352,5q35.3,Hematological,2324,0,#NV,#NV
931,"Lysinuric protein intolerance, 222700 (3)","SLC7A7, LPI",603593,14q11.2,Metabolic,9056,0,#NV,#NV
933,"Machado-Joseph disease, 109150 (3)","ATXN3, MJD, SCA3",607047,14q24.3-q31,Neurological,4287,0,#NV,#NV
939,"Major depressive disorder and accelerated response to antidepressant drug treatment, 608616 (3)","FKBP5, FKBP51",602623,6p21.3-p21.2,Psychiatric,2289,0,#NV,#NV
943,"Malonyl-CoA decarboxylase deficiency, 248360 (3)","MLYCD, MCD",606761,16q24,Metabolic,23417,0,#NV,#NV
944,MALT lymphoma (3),"MALT1, MLT",604860,18q21,Cancer,10892,0,#NV,#NV
945,"Mandibuloacral dysplasia with type B lipodystrophy, 608612 (3)","ZMPSTE24, FACE1, STE24, MADB",606480,1p34,multiple,10269,0,#NV,#NV
947,"Mannosidosis, alpha-, types I and II, 248500 (3)","MAN2B1, MANB",609458,19cen-q12,Metabolic,4125,0,#NV,#NV
947,"Mannosidosis, beta, 248510 (3)","MANBA, MANB1",609489,4q22-q25,Metabolic,4126,0,#NV,#NV
952,"Maroteaux-Lamy syndrome, several forms (3)","ARSB, MPS6",253200,5q11-q13,Metabolic,411,0,#NV,#NV
955,"MASA syndrome, 303350 (3)","L1CAM, CAML1, HSAS1",308840,Xq28,multiple,3897,0,#NV,#NV
956,MASP2 deficiency (3),MASP2,605102,1p36.3-p36.2,Immunological,10747,0,#NV,#NV
960,"Mast syndrome, 248900 (3)","ACP33, MAST, SPG21",608181,15q21-q22,Neurological,51324,0,#NV,#NV
962,"McArdle disease, 232600 (3)",PYGM,608455,11q13,Metabolic,5837,0,#NV,#NV
964,"McKusick-Kaufman syndrome, 236700 (3)","MKKS, HMCS, KMS, MKS, BBS6",604896,20p12,Developmental,8195,0,#NV,#NV
965,McLeod syndrome (3),XK,314850,Xp21.2-p21.1,Hematological,7504,0,#NV,#NV
965,McLeod syndrome with neuroacanthosis (3),XK,314850,Xp21.2-p21.1,Hematological,7504,0,#NV,#NV
969,"Medullary cystic kidney disease 2, 603860 (3)","UMOD, HNFJ, FJHN, MCKD2, ADMCKD2",191845,16p12.3,Renal,7369,0,#NV,#NV
971,"Meesmann corneal dystrophy, 122100 (3)",KRT3,148043,12q13,Ophthamological,3850,0,#NV,#NV
971,"Meesmann corneal dystrophy, 122100 (3)",KRT12,601687,17q12,Ophthamological,3859,0,#NV,#NV
973,"Megakaryoblastic leukemia, acute (3)","MKL1, AMKL, MAL",606078,22q13,Cancer,57591,0,#NV,#NV
974,"Megalencephalic leukoencephalopathy with subcortical cysts, 604004 (3)","MLC1, LVM, VL",605908,22qter,Neurological,23209,0,#NV,#NV
975,"Megaloblastic anemia-1, Finnish type, 261100 (3)","CUBN, IFCR, MGA1",602997,10p12.1,Hematological,8029,0,#NV,#NV
975,"Megaloblastic anemia-1, Norwegian type, 261100 (3)",AMN,605799,14q32,Hematological,81693,0,#NV,#NV
979,"Meleda disease, 248300 (3)","SLURP1, MDM",606119,8qter,Dermatological,57152,0,#NV,#NV
981,"Melnick-Needles syndrome, 309350 (3)","FLNA, FLN1, ABPX, NHBP, OPD1, OPD2, FMD, MNS",300017,Xq28,Skeletal,2316,0,#NV,#NV
982,"Melorheostosis with osteopoikilosis, 155950 (3)","LEMD3, MAN1",607844,12q14,Developmental,23592,0,#NV,#NV
987,"Meningococcal disease, susceptibility to (3)","MBL2, MBL, MBP1",154545,10q11.2-q21,Immunological,4153,0,#NV,#NV
991,Mephenytoin poor metabolizer (3),"CYP2C, CYP2C19",124020,10q24.1-q24.3,Metabolic,1557,0,#NV,#NV
996,"Metachromatic leukodystrophy, 250100 (3)",ARSA,607574,22q13.31-qter,Neurological,410,0,#NV,#NV
996,Metachromatic leukodystrophy due to deficiency of SAP-1 (3),"PSAP, SAP1",176801,10q22.1,Neurological,5660,0,#NV,#NV
997,"Metaphyseal chondrodysplasia, Schmid type (3)",COL10A1,120110,6q21-q22.3,Connective tissue disorder,1300,0,#NV,#NV
997,"Metaphyseal chondrodysplasia, Murk Jansen type, 156400 (3)","PTHR1, PTHR",168468,3p22-p21.1,Connective tissue disorder,5745,0,#NV,#NV
997,"Metaphyseal dysplasia without hypotrichosis, 250460 (3)","RMRP, RMRPR, CHH",157660,9p21-p12,Connective tissue disorder,6023,0,#NV,#NV
999,Methemoglobinemia due to cytochrome b5 deficiency (3),CYB5,250790,18q23,Hematological,1528,0,#NV,#NV
999,"Methemoglobinemia, type I (3)",DIA1,250800,22q13.31-qter,Hematological,1727,0,#NV,#NV
999,"Methemoglobinemia, type II (3)",DIA1,250800,22q13.31-qter,Hematological,1727,0,#NV,#NV
999,"Methemoglobinemias, alpha- (3)",HBA1,141800,16pter-p13.3,Hematological,3039,0,#NV,#NV
999,"Methemoglobinemias, beta- (3)",HBB,141900,11p15.5,Hematological,3043,0,#NV,#NV
1001,"Methionine adenosyltransferase deficiency, autosomal recessive (3)","MAT1A, MATA1, SAMS1",250850,10q22,Metabolic,4143,0,#NV,#NV
1002,"Methylcobalamin deficiency, cblG type, 250940 (3)",MTR,156570,1q43,Metabolic,4548,0,#NV,#NV
1003,Methylmalonate semialdehyde dehydrogenase deficiency (3),"ALDH6A1, MMSDH",603178,14q24.3,Metabolic,4329,0,#NV,#NV
1004,"Methylmalonic aciduria, mut(0) type, 251000 (3)","MUT, MCM",609058,6p21,Metabolic,4594,0,#NV,#NV
1004,"Methylmalonic aciduria, vitamin B12-responsive, 251100 (3)",MMAA,607481,4q31.1-q31.2,Metabolic,166785,0,#NV,#NV
1004,"Methylmalonic aciduria, vitamin B12-responsive, due to defect in synthesis of adenosylcobalamin, cblB complementation type, 251110 (3)",MMAB,607568,12q24,Metabolic,326625,0,#NV,#NV
1005,Mevalonicaciduria (3),"MVK, MVLK",251170,12q24,Metabolic,4598,0,#NV,#NV
1006,"MHC class II deficiency, complementation group B, 209920 (3)",RFXANK,603200,19p12,Immunological,8625,0,#NV,#NV
1007,"Microcephaly, primary autosomal recessive, 3, 604804 (3)","CDK5RAP2, KIAA1633, MCPH3",608201,9q33.3,Neurological,55755,0,#NV,#NV
1007,"Microcephaly, primary autosomal recessive, 6, 608393 (3)","CEMPJ, CPAP, MCPH6",609279,13q12.2,Neurological,55835,0,#NV,#NV
1007,"Microcephaly, Amish type, 607196 (3)","SLC25A19, DNC, MUP1, MCPHA",606521,17q25.3,Neurological,60386,0,#NV,#NV
1007,"Microcephaly, autosomal recessive 1, 251200 (3)",MCPH1,607117,8p23,Neurological,79648,0,#NV,#NV
1007,"Microcephaly, primary autosomal recessive, 5, 608716 (3)","ASPM, MCPH5",605481,1q31,Neurological,259266,0,#NV,#NV
1009,"Microcoria-congenital nephrosis syndrome, 609049 (3)","LAMB2, LAMS",150325,3p21,Ophthamological,3913,0,#NV,#NV
1011,Micropenis (3),LHCGR,152790,2p21,Renal,3973,0,#NV,#NV
1012,"Microphthalmia, SIX6-related (3)",SIX6,606326,14q23,Ophthamological,4990,0,#NV,#NV
1012,"Microphthalmia with associated anomalies 2, 300412 (3)","BCOR, KIAA1575, MAA2, ANOP2",300485,Xp11.4,Ophthamological,54880,0,#NV,#NV
1012,"Microphthalmia, cataracts, and iris abnormalities (3)","CHX10, HOX10",142993,14q24.3,Ophthamological,338917,0,#NV,#NV
1014,"Miller-Dieker lissencephaly, 247200 (3)","YWHAE, MDCR, MDS",605066,17p13.3,multiple,7531,0,#NV,#NV
1023,"Molybdenum cofactor deficiency, type A, 252150 (3)","MOCS1, MOCOD",603707,6p21.3,Metabolic,4337,0,#NV,#NV
1023,"Molybdenum cofactor deficiency, type B, 252150 (3)","MOCS2, MPTS",603708,5q11,Metabolic,4338,0,#NV,#NV
1023,"Molybdenum cofactor deficiency, type C, 252150 (3)","GPH, KIAA1385, GEPH",603930,14q24,Metabolic,10243,0,#NV,#NV
1024,"Monilethrix, 158000 (3)","KRTHB1, HB1",602153,12q13,Dermatological,3887,0,#NV,#NV
1024,"Monilethrix, 158000 (3)","KRTHB6, HB6",601928,12q13,Dermatological,3892,0,#NV,#NV
1028,"Mowat-Wilson syndrome, 235730 (3)","ZFHX1B, SMADIP1, SIP1",605802,2q22,Developmental,9839,0,#NV,#NV
1029,Moyamoya disease 3 (3),MYMY3,608796,8q24,Neurological,493818,0,#NV,#NV
1030,"Muckle-Wells syndrome, 191900 (3)","CIAS1, C1orf7, FCU, FCAS",606416,1q44,multiple,114548,0,#NV,#NV
1031,Mucoepidermoid salivary gland carcinoma (3),"MECT1, KIAA0616",607536,19p13,Cancer,23373,0,#NV,#NV
1031,Mucoepidermoid salivary gland carcinoma (3),"MAML2, MAM3",607537,11q21,Cancer,84441,0,#NV,#NV
1032,"Mucolipidosis IV, 252650 (3)","MCOLN1, ML4",605248,19p13.3-p13.2,Metabolic,57192,0,#NV,#NV
1032,"Mucolipidosis IIIA, 252600 (3)","GNPTAB, GNPTA",607840,4q21-q23,Metabolic,79158,0,#NV,#NV
1032,"Mucolipidosis IIIC, 252605 (3)",GNPTAG,607838,16p,Metabolic,84572,0,#NV,#NV
1033,Mucopolysaccharidosis IVA (3),"GALNS, MPS4A",253000,16q24.3,Metabolic,2588,0,#NV,#NV
1033,Mucopolysaccharidosis IVB (3),GLB1,230500,3p21.33,Metabolic,2720,0,#NV,#NV
1033,"Mucopolysaccharidosis type IIID, 252940 (3)","GNS, G6S",607664,12q14,Metabolic,2799,0,#NV,#NV
1033,Mucopolysaccharidosis VII (3),"GUSB, MPS7",253220,7q21.11,Metabolic,2990,0,#NV,#NV
1033,"Mucopolysaccharidosis type IX, 601492 (3)",HYAL1,607071,3p21.3-p21.2,Metabolic,3373,0,#NV,#NV
1033,Mucopolysaccharidosis II (3),"IDS, MPS2, SIDS",309900,Xq28,Metabolic,3423,0,#NV,#NV
1033,"Mucopolysaccharidosis Ih, 607014 (3)","IDUA, IDA",252800,4p16.3,Metabolic,3425,0,#NV,#NV
1033,"Mucopolysaccharidosis Ih/s, 607015 (3)","IDUA, IDA",252800,4p16.3,Metabolic,3425,0,#NV,#NV
1033,"Mucopolysaccharidosis Is, 607016 (3)","IDUA, IDA",252800,4p16.3,Metabolic,3425,0,#NV,#NV
1036,"Mulibrey nanism, 253250 (3)","TRIM37, MUL, KIAA0898",605073,17q22-q23,multiple,4591,0,#NV,#NV
1038,"Muscle-eye-brain disease, 253280 (3)","POMGNT1, MEB",606822,1p34-p33,multiple,55624,0,#NV,#NV
1039,Muscle hypertrophy (3),"GDF8, MSTN",601788,2q32.2,Muscular,2660,0,#NV,#NV
1039,Muscle glycogenosis (3),PHKA1,311870,Xq13,Muscular,5255,0,#NV,#NV
1041,"Myasthenia, familial infantile, 1, 605809 (3)","CMS1A1, FIM1",605809,17p13,Muscular,8144,0,#NV,#NV
1043,"Mycobacterial infection, atypical, familial disseminated, 209950 (3)",IFNGR1,107470,6q23-q24,Immunological,3459,0,#NV,#NV
1043,"Mycobacterial infection, atypical, familial disseminated, 209950 (3)","IFNGR2, IFNGT1, IFGR2",147569,21q22.1-q22.2,Immunological,3460,0,#NV,#NV
1043,"Mycobacterial and salmonella infections, susceptibility to, 209950 (3)",IL12RB1,601604,19p13.1,Immunological,3594,0,#NV,#NV
1043,"Mycobacterium tuberculosis, suceptibility to infection by, 607948 (3)","NRAMP1, NRAMP",600266,2q35,Immunological,6556,0,#NV,#NV
1043,"Mycobacterial infection, atypical, familial disseminated, 209950 (3)",STAT1,600555,2q32.2-q32.3,Immunological,6772,0,#NV,#NV
1049,"Myelokathexis, isolated (3)","CXCR4, D2S201E, NPY3R, WHIM",162643,2q21,Immunological,7852,0,#NV,#NV
1050,"Myelomonocytic leukemia, chronic (3)","PDGFRB, PDGFR",173410,5q31-q32,Cancer,5159,0,#NV,#NV
1052,"Myeloproliferative disorder with eosinophilia, 131440 (3)","PDGFRB, PDGFR",173410,5q31-q32,Cancer,5159,0,#NV,#NV
1053,Myoadenylate deaminase deficiency (3),AMPD1,102770,1p21-p13,Muscular,270,0,#NV,#NV
1058,"Myoneurogastrointestinal encephalomyopathy syndrome, 603041 (3)",ECGF1,131222,22q13.32-qter,multiple,1890,0,#NV,#NV
1063,"Myotonic dystrophy, 160900 (3)","DMPK, DM, DMK",605377,19q13.2-q13.3,Muscular,1760,0,#NV,#NV
1063,"Myotonic dystrophy, type 2, 602668 (3)","ZNF9, CNBP1, DM2, PROMM",116955,3q13.3-q24,Muscular,7555,0,#NV,#NV
1064,"Myotubular myopathy, X-linked, 310400 (3)","MTM1, MTMX",300415,Xq28,Muscular,4534,0,#NV,#NV
1065,Myxoid liposarcoma (3),"DDIT3, GADD153, CHOP10",126337,12q13.1-q13.2,Cancer,1649,0,#NV,#NV
1067,"N-acetylglutamate synthase deficiency, 237310 (3)",NAGS,608300,17q21.31,Metabolic,162417,0,#NV,#NV
1070,"Nail-patella syndrome, 161200 (3)","LMX1B, NPS1",602575,9q34.1,multiple,4010,0,#NV,#NV
1070,"Nail-patella syndrome with open-angle glaucoma, 137750 (3)","LMX1B, NPS1",602575,9q34.1,multiple,4010,0,#NV,#NV
1071,"Nance-Horan syndrome, 302350 (3)",NHS,300457,Xp22.13,Ophthamological,4810,0,#NV,#NV
1073,"Narcolepsy, 161400 (3)","HCRT, OX",602358,17q21,Psychiatric,3060,0,#NV,#NV
1075,"Nasu-Hakola disease, 221770 (3)","TYROBP, PLOSL, DAP12",604142,19q13.1,Bone,7305,0,#NV,#NV
1075,"Nasu-Hakola disease, 221770 (3)",TREM2,605086,6p21.2,Bone,54209,0,#NV,#NV
1077,"Naxos disease, 601214 (3)","JUP, DP3, PDGB",173325,17q21,multiple,3728,0,#NV,#NV
1078,"Nemaline myopathy 2, autosomal recessive, 256030 (3)","NEB, NEM2",161650,2q22,Muscular,4703,0,#NV,#NV
1078,"Nemaline myopathy, Amish type, 605355 (3)","TNNT1, ANM",191041,19q13.4,Muscular,7138,0,#NV,#NV
1078,"Nemaline myopathy, 161800 (3)","TPM2, TMSB, AMCD1, DA1",190990,9p13.2-p13.1,Muscular,7169,0,#NV,#NV
1078,"Nemaline myopathy 1, autosomal dominant, 161800 (3)","TPM3, NEM1",191030,1q22-q23,Muscular,7170,0,#NV,#NV
1080,"Nephrogenic syndrome of inappropriate antidiuresis, 300539 (3)","AVPR2, DIR, DI1, ADHR",300538,Xq28,Renal,554,0,#NV,#NV
1081,"Nephrolithiasis, type I, 310468 (3)","CLCN5, CLCK2, NPHL2, DENTS",300008,Xp11.22,Renal,1184,0,#NV,#NV
1081,"Nephrolithiasis, uric acid, susceptibility to, 605990 (3)","ZNF365, UAN",607818,10q21.2,Renal,22891,0,#NV,#NV
1082,"Nephronophthisis, juvenile, 256100 (3)","NPHP1, NPH1, SLSN1",607100,2q13,Renal,4867,0,#NV,#NV
1082,"Nephronophthisis, adolescent, 604387 (3)","NPHP3, NPH3",608002,3q22,Renal,27031,0,#NV,#NV
1082,"Nephronophthisis 2, infantile, 602088 (3)","INVS, INV, NPHP2, NPH2",243305,9q31,Renal,27130,0,#NV,#NV
1082,"Nephronophthisis 4, 606966 (3)","NPHP4, SLSN4",607215,1p36,Renal,261734,0,#NV,#NV
1085,"Nephropathy with pretibial epidermolysis bullosa and deafness, 609057 (3)","CD151, PETA3, SFA1",602243,11p15.5,Renal,977,0,#NV,#NV
1087,"Nephrosis-1, congenital, Finnish type, 256300 (3)","NPHS1, NPHN",602716,19q13.1,Renal,4868,0,#NV,#NV
1087,"Nephrotic syndrome, steroid-resistant, 600995 (3)","PDCN, NPHS2, SRN1",604766,1q25-q31,Renal,7827,0,#NV,#NV
1090,"Neural tube defects, maternal risk of, 601634 (3)","MTHFD, MTHFC",172460,14q24,Developmental,4522,0,#NV,#NV
1092,"Neurodegeneration, pantothenate kinase-associated, 234200 (3)","PANK2, NBIA1, PKAN, HARP",606157,20p13-p12.3,Neurological,80025,0,#NV,#NV
1102,"Neutrophil immunodeficiency syndrome, 608203 (3)",RAC2,602049,22q12.3-q13.2,Immunological,5880,0,#NV,#NV
1107,"Niemann-Pick disease, type C1, 257220 (3)","NPC1, NPC",607623,18q11-q12,Metabolic,4864,0,#NV,#NV
1107,"Niemann-Pick disease, type D, 257220 (3)","NPC1, NPC",607623,18q11-q12,Metabolic,4864,0,#NV,#NV
1107,"Niemann-Pick disease, type A, 257200 (3)","SMPD1, NPD",607608,11p15.4-p15.1,Metabolic,6609,0,#NV,#NV
1107,"Niemann-Pick disease, type B, 607616 (3)","SMPD1, NPD",607608,11p15.4-p15.1,Metabolic,6609,0,#NV,#NV
1107,"Niemann-pick disease, type C2, 607625 (3)","NPC2, HE1",601015,14q24.3,Metabolic,10577,0,#NV,#NV
1112,"Nonaka myopathy, 605820 (3)","GNE, GLCNE, IBM2, DMRV, NM",603824,9p12-p11,Muscular,10020,0,#NV,#NV
1118,"Norum disease, 245900 (3)",LCAT,606967,16q22.1,Metabolic,3931,0,#NV,#NV
1119,"Norwalk virus infection, resistance to (3)","FUT2, SE",182100,19q13.3,Immunological,2524,0,#NV,#NV
1122,"Nucleoside phosphorylase deficiency, immunodeficiency due to (3)",NP,164050,14q13.1,Immunological,4860,0,#NV,#NV
1130,"Oculocutaneous albinism, type II, modifier of (3)",MC1R,155555,16q24.3,Ophthamological,4157,0,#NV,#NV
1130,"Ocular albinism, Nettleship-Falls type (3)",OA1,300500,Xp22.3,Ophthamological,4935,0,#NV,#NV
1130,"Oculocutaneous albinism, type IV, 606574 (3)","MATP, AIM1",606202,5p13.3,Ophthamological,51151,0,#NV,#NV
1133,"Oculofaciocardiodental syndrome, 300166 (3)","BCOR, KIAA1575, MAA2, ANOP2",300485,Xp11.4,multiple,54880,0,#NV,#NV
1135,"Oculopharyngeal muscular dystorphy, 164300 (3)","PABPN1, PABP2, PAB2",602279,14q11.2-q13,Muscular,8106,0,#NV,#NV
1135,"Oculopharyngeal muscular dystrophy, autosomal recessive, 257950 (3)","PABPN1, PABP2, PAB2",602279,14q11.2-q13,Muscular,8106,0,#NV,#NV
1136,"Odontohypophosphatasia, 146300 (3)","ALPL, HOPS, TNSALP",171760,1p36.1-p34,Bone,249,0,#NV,#NV
1137,"Oguchi disease-2, 258100 (3)","RHOK, RK, GRK1",180381,13q34,Ophthamological,6011,0,#NV,#NV
1137,"Oguchi disease-1, 258100 (3)",SAG,181031,2q37.1,Ophthamological,6295,0,#NV,#NV
1142,"Opitz G syndrome, type I, 300000 (3)","MID1, OGS1, BBBG1, FXY, OSX",300552,Xp22,multiple,4281,0,#NV,#NV
1143,Opremazole poor metabolizer (3),"CYP2C, CYP2C19",124020,10q24.1-q24.3,Metabolic,1557,0,#NV,#NV
1145,"Oral-facial-digital syndrome 1, 311200 (3)","OFD1, CXorf5",300170,Xp22.3-p22.2,Skeletal,8481,0,#NV,#NV
1146,"Ornithine transcarbamylase deficiency, 311250 (3)",OTC,300461,Xp21.1,Metabolic,5009,0,#NV,#NV
1147,"Orofacial cleft 6, 608864 (3)","IRF6, VWS, LPS, PIT, PPS, OFC6",607199,1q32-q41,Skeletal,3664,0,#NV,#NV
1149,Oroticaciduria (3),"UMPS, OPRT",258900,3q13,Metabolic,7372,0,#NV,#NV
1150,"Orthostatic intolerance, 604715 (3)","SLC6A2, NAT1, NET1",163970,16q12.2,Cardiovascular,6530,0,#NV,#NV
1157,"Osteolysis, idiopathic, Saudi type, 605156 (3)","MMP2, CLG4A, MONA",120360,16q13,Bone,4313,0,#NV,#NV
1157,"Osteolysis, familial expansile, 174810 (3)","TNFRSF11A, RANK, ODFR, OFE",603499,18q22.1,Bone,8792,0,#NV,#NV
1162,"Osteopoikilosis, 166700 (3)","LEMD3, MAN1",607844,12q14,Bone,23592,0,#NV,#NV
1165,"Osteoporosis, susceptibility to, 166710 (3)",RIL,603422,5q31.1,Bone,8572,0,#NV,#NV
1168,"Otopalatodigital syndrome, type I, 311300 (3)","FLNA, FLN1, ABPX, NHBP, OPD1, OPD2, FMD, MNS",300017,Xq28,multiple,2316,0,#NV,#NV
1168,"Otopalatodigital syndrome, type II, 304120 (3)","FLNA, FLN1, ABPX, NHBP, OPD1, OPD2, FMD, MNS",300017,Xq28,multiple,2316,0,#NV,#NV
1171,"Ovarioleukodystrophy, 603896 (3)",EIF2B4,606687,2p23.3,Neurological,8890,0,#NV,#NV
1171,"Ovarioleukodystrophy, 603896 (3)",EIF2B2,606454,14q24,Neurological,8892,0,#NV,#NV
1171,"Ovarioleukodystrophy, 603896 (3)","EIF2B5, LVWM, CACH, CLE",603945,3q27,Neurological,8893,0,#NV,#NV
1172,"Pachyonychia congenita, Jadassohn-Lewandowsky type, 167200 (3)",KRT6A,148041,12q13,Dermatological,3853,0,#NV,#NV
1172,"Pachyonychia congenita, Jackson-Lawler type, 167210 (3)","KRT6B, PC2",148042,12q13,Dermatological,3854,0,#NV,#NV
1172,"Pachyonychia congenita, Jadassohn-Lewandowsky type, 167200 (3)",KRT16,148067,17q12-q21,Dermatological,3868,0,#NV,#NV
1172,"Pachyonychia congenita, Jackson-Lawler type, 167210 (3)","KRT17, PC2, PCHC1",148069,17q12-q21,Dermatological,3872,0,#NV,#NV
1173,"Paget disease, juvenile, 239000 (3)","TNFRSF11B, OPG, OCIF",602643,8q24,Bone,4982,0,#NV,#NV
1173,"Paget disease of bone, 602080 (3)","TNFRSF11A, RANK, ODFR, OFE",603499,18q22.1,Bone,8792,0,#NV,#NV
1173,"Paget disease of bone, 602080 (3)","SQSTM1, P62, PDB3",601530,5q35,Bone,8878,0,#NV,#NV
1175,"Pallister-Hall syndrome, 146510 (3)","GLI3, PAPA, PAPB, ACLS",165240,7p13,multiple,2737,0,#NV,#NV
1176,"Palmoplantar keratoderma, nonepidermolytic, 600962 (3)",KRT16,148067,17q12-q21,Dermatological,3868,0,#NV,#NV
1176,"Palmoplantar verrucous nevus, unilateral, 144200 (3)",KRT16,148067,17q12-q21,Dermatological,3868,0,#NV,#NV
1179,"Pancreatitis, idiopathic (3)","CFTR, ABCC7, CF, MRP7",602421,7q31.2,Gastrointestinal,1080,0,#NV,#NV
1179,"Pancreatitis, hereditary, 167800 (3)","PRSS1, TRY1",276000,7q35,Gastrointestinal,5644,0,#NV,#NV
1179,"Pancreatitis, hereditary, 167800 (3)","SPINK1, PSTI, PCTT, TATI",167790,5q32,Gastrointestinal,6690,0,#NV,#NV
1184,"Papillon-Lefevre syndrome, 245000 (3)","CTSC, CPPI, PALS, PLS, HMS",602365,11q14.1-q14.3,multiple,1075,0,#NV,#NV
1195,"Paroxysmal nonkinesigenic dyskinesia, 118800 (3)","MR1, TAHCCP2, KIPP1184, BRP17, PNKD, FPD1, PDC, DYT8",609023,2q35,Neurological,25953,0,#NV,#NV
1199,"Pelger-Huet anomaly, 169400 (3)","LBR, PHA",600024,1q42.1,Hematological,3930,0,#NV,#NV
1201,"Pelizaeus-Merzbacher-like disease, autosomal recessive, 608804 (3)","GJA12, CX47, PMLDAR",608803,1q41-q42,Neurological,57165,0,#NV,#NV
1206,"Periodic fever, familial, 142680 (3)","TNFRSF1A, TNFR1, TNFAR, FPF",191190,12p13.2,Immunological,7132,0,#NV,#NV
1207,"Periodontitis, juvenile, 170650 (3)","CTSC, CPPI, PALS, PLS, HMS",602365,11q14.1-q14.3,"Ear,Nose,Throat",1075,0,#NV,#NV
1209,"Periventricular heterotopia with microcephaly, 608097 (3)","ARFGEF2, BIG2",605371,20q13.13,Neurological,10564,0,#NV,#NV
1210,"Peroxisomal biogenesis disorder, complementation group 4 (3)","PEX6, PXAAA1, PAF2",601498,6p21.1,multiple,5190,0,#NV,#NV
1210,"Peroxisomal biogenesis disorder, complementation group 6 (3)","PEX6, PXAAA1, PAF2",601498,6p21.1,multiple,5190,0,#NV,#NV
1210,Peroxisome biogenesis factor 12 (3),PEX12,601758,Chr.17,multiple,5193,0,#NV,#NV
1212,"Persistent Mullerian duct syndrome, type I, 261550 (3)","AMH, MIF",600957,19p13.3-p13.2,Developmental,268,0,#NV,#NV
1212,"Persistent Mullerian duct syndrome, type II, 261550 (3)","AMHR2, AMHR",600956,12q13,Developmental,269,0,#NV,#NV
1216,Phenylketonuria (3),"PAH, PKU1",261600,12q24.1,Metabolic,5053,0,#NV,#NV
1216,Phenylketonuria due to PTS deficiency (3),PTS,261640,11q22.3-q23.3,Metabolic,5805,0,#NV,#NV
1216,Phenylketonuria due to dihydropteridine reductase deficiency (3),"QDPR, DHPR",261630,4p15.31,Metabolic,5860,0,#NV,#NV
1217,"Phenylthiocarbamide tasting, 171200 (3)","TAS2R38, T2R61, PTC",607751,7q35-q36,"Ear,Nose,Throat",5726,0,#NV,#NV
1220,"Phosphoglycerate dehydrogenase deficiency, 601815 (3)",PHGDH,606879,1q12,Metabolic,26227,0,#NV,#NV
1221,Phosphoribosyl pyrophosphate synthetase-related gout (3),PRPS1,311850,Xq22-q24,Metabolic,5631,0,#NV,#NV
1222,"Phosphorylase kinase deficiency of liver and muscle, autosomal recessive, 261750 (3)",PHKB,172490,16q12-q13,Metabolic,5257,0,#NV,#NV
1223,Phosphoserine phosphatase deficiency (3),PSP,172480,7p15.2-p15.1,Metabolic,5723,0,#NV,#NV
1227,"Pigmentation of hair, skin, and eyes, variation in (3)","MATP, AIM1",606202,5p13.3,Dermatological,51151,0,#NV,#NV
1234,Plasmin inhibitor deficiency (3),"PLI, SERPINF2",262850,17pter-p12,Hematological,5345,0,#NV,#NV
1235,Plasminogen Tochigi disease (3),PLG,173350,6q26,Hematological,5340,0,#NV,#NV
1238,"Pneumonitis, desquamative interstitial, 263000 (3)","SFTPC, SFTP2",178620,8p21,Respiratory,6440,0,#NV,#NV
1241,"Polycystic kidney disease, adult type I, 173900 (3)",PKD1,601313,16p13.3-p13.12,Renal,5310,0,#NV,#NV
1241,"Polycystic kidney disease, adult, type II (3)","PKD2, PKD4",173910,4q21-q23,Renal,5311,0,#NV,#NV
1241,"Polycystic kidney and hepatic disease, 263200 (3)","FCYT, PKHD1, ARPKD",606702,6p21.1-p12,Renal,5314,0,#NV,#NV
1241,"Polycystic kidney disease, infantile severe, with tuberous sclerosis (3)",PKDTS,600273,16p13.3,Renal,8132,0,#NV,#NV
1243,"Polydactyly, postaxial, types A1 and B, 174200 (3)","GLI3, PAPA, PAPB, ACLS",165240,7p13,Skeletal,2737,0,#NV,#NV
1243,"Polydactyly, preaxial, type IV, 174700 (3)","GLI3, PAPA, PAPB, ACLS",165240,7p13,Skeletal,2737,0,#NV,#NV
1244,"Polymicrogyria, bilateral frontoparietal, 606854 (3)","GPR56, TM7XN1, BFPP",604110,16q13,Neurological,9289,0,#NV,#NV
1246,"Popliteal pterygium syndrome, 119500 (3)","IRF6, VWS, LPS, PIT, PPS, OFC6",607199,1q32-q41,multiple,3664,0,#NV,#NV
1247,"Porencephaly, 175780 (3)",COL4A1,120130,13q34,Neurological,1282,0,#NV,#NV
1249,"Porphyria, acute hepatic (3)",ALAD,125270,9q34,Metabolic,210,0,#NV,#NV
1249,"Porphyria variegata, 176200 (3)","HFE, HLA-H, HFE1",235200,6p21.3,Metabolic,3077,0,#NV,#NV
1249,"Porphyria, acute intermittent (3)","HMBS, PBGD, UPS",176000,11q23.3,Metabolic,3145,0,#NV,#NV
1249,"Porphyria, acute intermittent, nonerythroid variant (3)","HMBS, PBGD, UPS",176000,11q23.3,Metabolic,3145,0,#NV,#NV
1249,"Porphyria variegata, 176200 (3)",PPOX,600923,1q22,Metabolic,5498,0,#NV,#NV
1249,Porphyria cutanea tarda (3),UROD,176100,1p34,Metabolic,7389,0,#NV,#NV
1249,"Porphyria, hepatoerythropoietic (3)",UROD,176100,1p34,Metabolic,7389,0,#NV,#NV
1249,"Porphyria, congenital erythropoietic, 263700 (3)",UROS,606938,10q25.2-q26.3,Metabolic,7390,0,#NV,#NV
1254,"Prader-Willi syndrome, 176270 (3)",NDN,602117,15q11-q13,multiple,4692,0,#NV,#NV
1254,"Prader-Willi syndrome, 176270 (3)",SNRPN,182279,15q12,multiple,6638,0,#NV,#NV
1256,"Precocious puberty, male, 176410 (3)",LHCGR,152790,2p21,Developmental,3973,0,#NV,#NV
1259,Prekallikrein deficiency (3),"KLKB1, KLK3",229000,4q35,Hematological,3818,0,#NV,#NV
1260,"Premature ovarian failure 3, 608996 (3)","FOXL2, BPES, BPES1, PFRK, POF3",605597,3q23,Renal,668,0,#NV,#NV
1260,"Premature ovarian failure, 300511 (3)","DIAPH2, DIA, POF2",300108,Xq22,Renal,1730,0,#NV,#NV
1265,"Progressive external ophthalmoplegia with mitochondrial DNA deletions, 157640 (3)","SLC25A4, ANT1, T1, PEO3",103220,4q35,Ophthamological,291,0,#NV,#NV
1265,"Progressive external ophthalmoplegia with mitochondrial DNA deletions, 157640 (3)","POLG, POLG1, POLGA, PEO",174763,15q25,Ophthamological,5428,0,#NV,#NV
1265,"Progressive external ophthalmoplegia with mitochondrial DNA deletions, 157640 (3)","C10orf2, TWINKLE, PEO1, PEO",606075,10q24,Ophthamological,56652,0,#NV,#NV
1266,Proguanil poor metabolizer (3),"CYP2C, CYP2C19",124020,10q24.1-q24.3,Metabolic,1557,0,#NV,#NV
1268,Prolidase deficiency (3),PEPD,170100,19cen-q13.11,Connective tissue disorder,5184,0,#NV,#NV
1270,"Properdin deficiency, X-linked, 312060 (3)","PFC, PFD",300383,Xp11.4-p11.23,Immunological,5199,0,#NV,#NV
1271,"Propionicacidemia, 606054 (3)",PCCA,232000,13q32,Metabolic,5095,0,#NV,#NV
1271,"Propionicacidemia, 606054 (3)",PCCB,232050,3q21-q22,Metabolic,5096,0,#NV,#NV
1273,Protein S deficiency (3),PROS1,176880,3p11.1-q11.2,Hematological,5627,0,#NV,#NV
1274,"Proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis (3)","CLCN5, CLCK2, NPHL2, DENTS",300008,Xp11.22,Renal,1184,0,#NV,#NV
1276,"Protoporphyria, erythropoietic (3)","FECH, FCE",177000,18q21.3,Metabolic,2235,0,#NV,#NV
1276,"Protoporphyria, erythropoietic, recessive, with liver failure (3)","FECH, FCE",177000,18q21.3,Metabolic,2235,0,#NV,#NV
1279,"Pseudohermaphroditism, male, with gynecomastia, 264300 (3)","HSD17B3, EDH17B3",605573,9q22,Developmental,3293,0,#NV,#NV
1279,"Pseudohermaphroditism, male, with Leydig cell hypoplasia (3)",LHCGR,152790,2p21,Developmental,3973,0,#NV,#NV
1283,"Pseudovaginal perineoscrotal hypospadias, 264600 (3)",SRD5A2,607306,2p23,Unclassified,6716,0,#NV,#NV
1284,Pseudovitamin D deficiency rickets 1 (3),"CYP27B1, PDDR, VDD1",264700,12q14,Bone,1594,0,#NV,#NV
1285,"Pseudoxanthoma elasticum, autosomal dominant, 177850 (3)","ABCC6, ARA, ABC34, MLP1, PXE",603234,16p13.1,Connective tissue disorder,368,0,#NV,#NV
1285,"Pseudoxanthoma elasticum, autosomal recessive, 264800 (3)","ABCC6, ARA, ABC34, MLP1, PXE",603234,16p13.1,Connective tissue disorder,368,0,#NV,#NV
1288,"Psoriasis, susceptibility to, 177900 (3)",PSORS6,605364,19p13,Dermatological,63869,0,#NV,#NV
1288,"Psoriatic arthritis, susceptibility to, 607507 (3)","CARD15, NOD2, IBD1, CD, ACUG, PSORAS1",605956,16q12,Dermatological,64127,0,#NV,#NV
1291,"Pulmonary alveolar proteinosis, 265120 (3)",CSF2RB,138981,22q12.2-q13.1,Respiratory,1439,0,#NV,#NV
1291,"Pulmonary fibrosis, idiopathic, susceptibility to, 178500 (3)","SFTPA1, SFTP1",178630,10q22.2-q23.1,Respiratory,6435,0,#NV,#NV
1291,"Pulmonary alveolar proteinosis, congenital, 265120 (3)","SFTPB, SFTB3",178640,2p12-p11.2,Respiratory,6439,0,#NV,#NV
1291,"Pulmonary alveolar proteinosis, 265120 (3)","SFTPC, SFTP2",178620,8p21,Respiratory,6440,0,#NV,#NV
1291,"Pulmonary fibrosis, idiopathic, familial, 178500 (3)","SFTPC, SFTP2",178620,8p21,Respiratory,6440,0,#NV,#NV
1293,"Pycnodysostosis, 265800 (3)",CTSK,601105,1q21,Skeletal,1513,0,#NV,#NV
1294,"Pyloric stenosis, infantile hypertrophic, susceptibility to, 179010 (3)",NOS1,163731,12q24.2-q24.31,Developmental,4842,0,#NV,#NV
1295,"Pyogenic sterile arthritis, pyoderma gangrenosum, and acne, 604416 (3)","PSTPIP1, PSTPIP, CD2BP1, PAPAS",606347,15q24-q25.1,Dermatological,9051,0,#NV,#NV
1301,"Radioulnar synostosis with amegakaryocytic thrombocytopenia, 605432 (3)","HOXA11, HOX1I",142958,7p15-p14.2,multiple,3207,0,#NV,#NV
1303,"RAPADILINO syndrome, 266280 (3)","RECQL4, RTS, RECQ4",603780,8q24.3,multiple,9401,0,#NV,#NV
1304,Rapid progression to AIDS from HIV1 infection (3),"CX3CR1, GPR13, V28",601470,3pter-p21,Immunological,1524,0,#NV,#NV
1305,"Rapp-Hodgkin syndrome, 129400 (3)","TP73L, TP63, KET, EEC3, SHFM4, LMS, RHS",603273,3q27,multiple,8626,0,#NV,#NV
1306,Red hair/fair skin (3),MC1R,155555,16q24.3,Dermatological,4157,0,#NV,#NV
1307,"Refsum disease, infantile, 266510 (3)","PEX1, ZWS1",602136,7q21-q22,Neurological,5189,0,#NV,#NV
1307,"Refsum disease, 266500 (3)","PEX7, RCDP1",601757,6q22-q24,Neurological,5191,0,#NV,#NV
1307,"Refsum disease, 266500 (3)","PHYH, PAHX",602026,10pter-p11.2,Neurological,5264,0,#NV,#NV
1307,"Refsum disease, infantile form, 266510 (3)","PXMP3, PAF1, PMP35, PEX2",170993,8q21.1,Neurological,5828,0,#NV,#NV
1307,"Refsum disease, infantile form, 266510 (3)",PEX26,608666,22q11.21,Neurological,55670,0,#NV,#NV
1309,"Renpenning syndrome, 309500 (3)","PQBP1, NPW38, SHS, MRX55, MRXS3, RENS1, MRXS8",300463,Xp11.23,Neurological,10084,0,#NV,#NV
1311,Response to morphine-6-glucuronide (3),OPRM1,600018,6q24-q25,Neurological,4988,0,#NV,#NV
1312,"Resting heart rate, 607276 (3)","ADRB1, ADRB1R, RHR",109630,10q24-q26,Cardiovascular,153,0,#NV,#NV
1314,"Restrictive dermopathy, lethal, 275210 (3)","ZMPSTE24, FACE1, STE24, MADB",606480,1p34,Dermatological,10269,0,#NV,#NV
1318,"Retinol binding protein, deficiency of (3)",RBP4,180250,10q24,Ophthamological,5950,0,#NV,#NV
1320,Retinoschisis (3),"RS1, XLRS1",312700,Xp22.2-p22.1,Ophthamological,6247,0,#NV,#NV
1322,"Rhabdoid predisposition syndrome, familial (3)","SMARCB1, SNF5, INI1, RDT",601607,22q11,Cancer,6598,0,#NV,#NV
1322,Rhabdoid tumors (3),"SMARCB1, SNF5, INI1, RDT",601607,22q11,Cancer,6598,0,#NV,#NV
1325,"Rhizomelic chondrodysplasia punctata, type 1, 215100 (3)","PEX7, RCDP1",601757,6q22-q24,multiple,5191,0,#NV,#NV
1325,"Rhizomelic chondrodysplasia punctata, type 3, 600121 (3)","AGPS, ADHAPS",603051,2q31,multiple,8540,0,#NV,#NV
1329,"Ribose 5-phosphate isomerase deficiency, 608611 (3)","RPIA, RPI",180430,2p11.2,Metabolic,22934,0,#NV,#NV
1330,"Rickets, vitamin D-resistant, type IIA, 277440 (3)",VDR,601769,12q12-q14,Bone,7421,0,#NV,#NV
1330,"Rickets, vitamin D-resistant, type IIB, 277420 (3)",VDR,601769,12q12-q14,Bone,7421,0,#NV,#NV
1330,"Rickets due to defect in vitamin D 25-hydroxylation, 600081 (3)",CYP2R1,608713,11p15.2,Bone,120227,0,#NV,#NV
1334,"Roberts syndrome, 268300 (3)",ESCO2,609353,8p21.1,Developmental,157570,0,#NV,#NV
1335,"Robinow syndrome, autosomal recessive, 268310 (3)","ROR2, BDB1, BDB, NTRKR2",602337,9q22,multiple,4920,0,#NV,#NV
1337,"Rokitansky-Kuster-Hauser syndrome, 277000 (3)",WNT4,603490,1p35,Developmental,54361,0,#NV,#NV
1338,"Rothmund-Thomson syndrome, 268400 (3)","RECQL4, RTS, RECQ4",603780,8q24.3,multiple,9401,0,#NV,#NV
1346,"Salla disease, 604369 (3)","SLC17A5, SIASD, SLD",604322,6q14-q15,Metabolic,26503,0,#NV,#NV
1348,"Sanfilippo syndrome, type B (3)",NAGLU,252920,17q21,Metabolic,4669,0,#NV,#NV
1348,"Sanfilippo syndrome, type A, 252900 (3)","SGSH, MPS3A, SFMD",605270,17q25.3,Metabolic,6448,0,#NV,#NV
1349,"Sarcoidosis, susceptibility to, 181000 (3)",HLA-DR1B,142857,6p21.3,Immunological,3123,0,#NV,#NV
1349,"Sarcoidosis, susceptibility to, 181000 (3)",BTNL2,606000,6p21.3,Immunological,56244,0,#NV,#NV
1349,"Sarcoidosis, early-onset, 181000 (3)","CARD15, NOD2, IBD1, CD, ACUG, PSORAS1",605956,16q12,Immunological,64127,0,#NV,#NV
1350,"Sarcoma, synovial (3)","SSX1, SSRC",312820,Xp11.2,Cancer,6756,0,#NV,#NV
1350,"Sarcoma, synovial (3)",SSX2,300192,Xp11.2,Cancer,6757,0,#NV,#NV
1354,"Schimke immunoosseous dysplasia, 242900 (3)","SMARCAL1, HARP, SIOD",606622,2q34-q36,Connective tissue disorder,50485,0,#NV,#NV
1355,"Schindler disease, type I, 609241 (3)",NAGA,104170,22q11,Metabolic,4668,0,#NV,#NV
1355,"Schindler disease, type III, 609241 (3)",NAGA,104170,22q11,Metabolic,4668,0,#NV,#NV
1357,"Schizencephaly, 269160 (3)",EMX2,600035,10q26.1,Neurological,2018,0,#NV,#NV
1361,"Schwartz-Jampel syndrome, type 1, 255800 (3)","HSPG2, PLC, SJS, SJA, SJS1",142461,1p36.1,multiple,3339,0,#NV,#NV
1362,"SCID, autosomal recessive, T-negative/B-positive type (3)","JAK3, JAKL",600173,19p13.1,Immunological,3718,0,#NV,#NV
1363,"Sclerosteosis, 269500 (3)",SOST,605740,17q12-q21,Skeletal,50964,0,#NV,#NV
1365,Scurvy (3),"GULOP, GULO",240400,8p21.1,Nutritional,2989,0,#NV,#NV
1369,"Seckel syndrome 1, 210600 (3)","ATR, FRP1, SCKL",601215,3q22-q24,Developmental,545,0,#NV,#NV
1370,"Segawa syndrome, recessive (3)","TH, TYH",191290,11p15.5,Neurological,7054,0,#NV,#NV
1371,"Seizures, afebrile, 604233 (3)","SCN2A1, SCN2A",182390,2q23-q24.3,Neurological,6325,0,#NV,#NV
1371,"Seizures, benign familial neonatal-infantile, 607745 (3)","SCN2A1, SCN2A",182390,2q23-q24.3,Neurological,6325,0,#NV,#NV
1372,Selective T-cell defect (3),"ZAP70, SRK, STD",176947,2q12,Immunological,7535,0,#NV,#NV
1374,"SEMD, Pakistani type (3)","PAPSS2, ATPSK2",603005,10q22-q24,Connective tissue disorder,9060,0,#NV,#NV
1375,"Senior-Loken syndrome-1, 266900 (3)","NPHP1, NPH1, SLSN1",607100,2q13,Renal,4867,0,#NV,#NV
1375,"Senior-Loken syndrome 5, 609254 (3)","IQCB1, NPHP5, KIAA0036",609237,3q21.1,Renal,9657,0,#NV,#NV
1375,"Senior-Loken syndrome 4, 606996 (3)","NPHP4, SLSN4",607215,1p36,Renal,261734,0,#NV,#NV
1376,"Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis, 157640 (3)","POLG, POLG1, POLGA, PEO",174763,15q25,Ophthamological,5428,0,#NV,#NV
1377,Sepiapterin reductase deficiency (3),SPR,182125,2p14-p12,Metabolic,6697,0,#NV,#NV
1380,"Septooptic dysplasia, 182230 (3)","HESX1, RPX",601802,3p21.2-p21.1,multiple,8820,0,#NV,#NV
1381,"Sertoli cell-only syndrome, susceptibility to, 305700 (3)",USP26,300309,Xq26.2,Renal,83844,0,#NV,#NV
1384,"Sex reversal, XY, with adrenal failure (3)","FTZF1, FTZ1, SF1",184757,9q33,Unclassified,2516,0,#NV,#NV
1387,"Short stature, autosomal dominant, with normal serum growth hormone binding protein (3)",GHR,600946,5p13-p12,Skeletal,2690,0,#NV,#NV
1387,"Short stature, idiopathic (3)",GHR,600946,5p13-p12,Skeletal,2690,0,#NV,#NV
1387,"Short stature, idiopathic familial, 604271 (3)","SHOX, GCFX, SS, PHOG",312865,Xpter-p22.32,Skeletal,6473,0,#NV,#NV
1387,"Short stature, idiopathic familial, 604271 (3)",SHOXY,400020,Ypter-p11.2,Skeletal,6473,0,#NV,#NV
1387,"Short stature, pituitary and cerebellar defects, and small sella turcica, 606606 (3)",LHX4,602146,1q25,Skeletal,89884,0,#NV,#NV
1389,"Shwachman-Diamond syndrome, 260400 (3)","SBDS, SDS",607444,7q11,multiple,51119,0,#NV,#NV
1391,"Sialidosis, type I, 256550 (3)","NEU1, NEU, SIAL1",608272,6p21.3,Metabolic,4758,0,#NV,#NV
1391,"Sialidosis, type II, 256550 (3)","NEU1, NEU, SIAL1",608272,6p21.3,Metabolic,4758,0,#NV,#NV
1391,"Sialic acid storage disorder, infantile, 269920 (3)","SLC17A5, SIASD, SLD",604322,6q14-q15,Metabolic,26503,0,#NV,#NV
1392,"Sialuria, 269921 (3)","GNE, GLCNE, IBM2, DMRV, NM",603824,9p12-p11,Metabolic,10020,0,#NV,#NV
1393,Sickle cell anemia (3),HBB,141900,11p15.5,Hematological,3043,0,#NV,#NV
1398,"Sitosterolemia, 210250 (3)",ABCG5,605459,2p21,Metabolic,64240,0,#NV,#NV
1398,"Sitosterolemia, 210250 (3)",ABCG8,605460,2p21,Metabolic,64241,0,#NV,#NV
1399,Situs ambiguus (3),NODAL,601265,Chr.10,Developmental,4838,0,#NV,#NV
1399,"Situs inversus viscerum, 270100 (3)","DNAH11, DNAHC11",603339,Chr.7,Developmental,8701,0,#NV,#NV
1400,"Sjogren-Larsson syndrome, 270200 (3)","ALDH3A2, ALDH10, SLS, FALDH",609523,17p11.2,Metabolic,224,0,#NV,#NV
1403,Slow acetylation (3),"NAT2, AAC2",243400,8p23.1-p21.3,Metabolic,10,0,#NV,#NV
1404,"Slowed nerve conduction velocity, AD, 608236 (3)","ARHGEF10, KIAA0294",608136,8p23,Neurological,9639,0,#NV,#NV
1406,"Small patella syndrome, 147891 (3)",TBX4,601719,17q21-q22,Skeletal,9496,0,#NV,#NV
1409,"Smith-Fineman-Myers syndrome, 309580 (3)","ATRX, XH2, XNP, MRXS3, SHS",300032,Xq13,multiple,546,0,#NV,#NV
1410,"Smith-Lemli-Opitz syndrome, 270400 (3)","DHCR7, SLOS",602858,11q12-q13,multiple,1717,0,#NV,#NV
1411,"Smith-Magenis syndrome, 182290 (3)","RAI1, SMCR, SMS",607642,17p11.2,multiple,10743,0,#NV,#NV
1412,"Smith-McCort dysplasia, 607326 (3)","DYM, FLJ90130, DMC, SMC",607461,18q12-q21.1,Skeletal,54808,0,#NV,#NV
1416,"Sorsby fundus dystrophy, 136900 (3)","TIMP3, SFD",188826,22q12.1-q13.2,Ophthamological,7078,0,#NV,#NV
1417,"Sotos syndrome, 117550 (3)","NSD1, ARA267, STO",606681,5q35,Developmental,64324,0,#NV,#NV
1419,"Speech-language disorder-1, 602081 (3)","FOXP2, SPCH1, TNRC10, CAGH44",605317,7q31,Neurological,93986,0,#NV,#NV
1422,"Spermatogenic failure, susceptibility to (3)","DAZL, DAZH, SPGYLA",601486,3p24,Renal,1618,0,#NV,#NV
1425,"Spina bifida, 601634 (3)","MTHFD, MTHFC",172460,14q24,Developmental,4522,0,#NV,#NV
1425,"Spina bifida, risk of, 601634, 182940 (3)",MTR,156570,1q43,Developmental,4548,0,#NV,#NV
1425,"Spina bifida, risk of, 601634, 182940 (3)",MTRR,602568,5p15.3-p15.2,Developmental,4552,0,#NV,#NV
1430,"Split hand/foot malformation, type 3, 600095 (3)","SHFM3, DAC",608071,10q24,Skeletal,6468,0,#NV,#NV
1430,"Split-hand/foot malformation, type 4, 605289 (3)","TP73L, TP63, KET, EEC3, SHFM4, LMS, RHS",603273,3q27,Skeletal,8626,0,#NV,#NV
1433,"Spondylocostal dysostosis, autosomal recessive, 1, 277300 (3)","DLL3, SCDO1",602768,19q13,Skeletal,10683,0,#NV,#NV
1433,"Spondylocostal dysostosis, autosomal recessive 2, 608681 (3)",MESP2,605195,15q26.1,Skeletal,145873,0,#NV,#NV
1436,"Spondylometaphyseal dysplasia, Japanese type (3)",COL10A1,120110,6q21-q22.3,Skeletal,1300,0,#NV,#NV
1438,"Stapes ankylosis syndrome without symphalangism, 184460 (3)","NOG, SYM1, SYNS1",602991,17q22,multiple,9241,0,#NV,#NV
1440,"Startle disease, autosomal recessive (3)","GLRA1, STHE",138491,5q32,Neurological,2741,0,#NV,#NV
1440,"Startle disease/hyperekplexia, autosomal dominant, 149400 (3)","GLRA1, STHE",138491,5q32,Neurological,2741,0,#NV,#NV
1441,"STAT1 deficiency, complete (3)",STAT1,600555,2q32.2-q32.3,Unclassified,6772,0,#NV,#NV
1442,"Statins, attenuated cholesterol lowering by (3)",HMGCR,142910,5q13.3-q14,Metabolic,3156,0,#NV,#NV
1444,"Steatocystoma multiplex, 184500 (3)","KRT17, PC2, PCHC1",148069,17q12-q21,Dermatological,3872,0,#NV,#NV
1445,Stem-cell leukemia/lymphoma syndrome (3),"ZNF198, SCLL, RAMP, FIM",602221,13q11-q12,Cancer,7750,0,#NV,#NV
1446,"Stevens-Johnson syndrome, carbamazepine-induced, susceptibility to, 608579 (3)",HLA-B,142830,6p21.3,Dermatological,3106,0,#NV,#NV
1455,"Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome, 601559 (3)","LIFR, STWS, SWS, SJS2",151443,5p13.1,multiple,3977,0,#NV,#NV
1457,Succinic semialdehyde dehydrogenase deficiency (3),SSADH,271980,6p22,Metabolic,7915,0,#NV,#NV
1458,Sucrose intolerance (3),SI,222900,3q25-q26,Metabolic,6476,0,#NV,#NV
1459,"Sudden infant death with dysgenesis of the testes syndrome, 608800 (3)","TSPYL1, TSPYL, SIDDT",604714,6q22-q23,Unclassified,7259,0,#NV,#NV
1460,"Sulfite oxidase deficiency, 272300 (3)",SUOX,606887,Chr.12,Metabolic,6821,0,#NV,#NV
1461,"Superoxide dismutase, elevated extracellular (3)",SOD3,185490,4p15.3-p15.1,Unclassified,6649,0,#NV,#NV
1464,"Surfactant deficiency, neonatal, 267450 (3)","ABCA3, ABC3",601615,16p13.3,Respiratory,21,0,#NV,#NV
1464,Surfactant protein C deficiency (3),"SFTPC, SFTP2",178620,8p21,Respiratory,6440,0,#NV,#NV
1465,"Sutherland-Haan syndrome-like, 300465 (3)","ATRX, XH2, XNP, MRXS3, SHS",300032,Xq13,multiple,546,0,#NV,#NV
1466,Sweat chloride elevation without CF (3),"CFTR, ABCC7, CF, MRP7",602421,7q31.2,Unclassified,1080,0,#NV,#NV
1467,"Symphalangism, proximal, 185800 (3)","NOG, SYM1, SYNS1",602991,17q22,Skeletal,9241,0,#NV,#NV
1469,"Synostoses syndrome, multiple, 1, 186500 (3)","NOG, SYM1, SYNS1",602991,17q22,multiple,9241,0,#NV,#NV
1470,"Synpolydactyly, 3/3'4, associated with metacarpal and metatarsal synostoses, 608180 (3)",FBLN1,135820,22q13.3,Skeletal,2192,0,#NV,#NV
1470,"Synpolydactyly, type II, 186000 (3)","HOXD13, HOX4I, SPD",142989,2q31-q32,Skeletal,3239,0,#NV,#NV
1470,"Synpolydactyly with foot anomalies, 186000 (3)","HOXD13, HOX4I, SPD",142989,2q31-q32,Skeletal,3239,0,#NV,#NV
1472,"Tall stature, susceptibility to (3)",MCM6,601806,2q21,Skeletal,4175,0,#NV,#NV
1475,"Tarsal-carpal coalition syndrome, 186570 (3)","NOG, SYM1, SYNS1",602991,17q22,Skeletal,9241,0,#NV,#NV
1477,"Tay-Sachs disease, 272800 (3)","HEXA, TSD",606869,15q23-q24,Metabolic,3073,0,#NV,#NV
1480,"Temperature-sensitive apoptosis, cellular (3)",DAD1,600243,14q11-q12,Unclassified,1603,0,#NV,#NV
1482,"Tetra-amelia, autosomal recessive, 273395 (3)","WNT3, INT4",165330,17q21,multiple,7473,0,#NV,#NV
1486,"Thalassemias, alpha- (3)",HBA1,141800,16pter-p13.3,Hematological,3039,0,#NV,#NV
1486,"Thalassemia, alpha- (3)",HBA2,141850,16pter-p13.3,Hematological,3040,0,#NV,#NV
1486,"Thalassemia-beta, dominant inclusion-body, 603902 (3)",HBB,141900,11p15.5,Hematological,3043,0,#NV,#NV
1486,"Thalassemias, beta- (3)",HBB,141900,11p15.5,Hematological,3043,0,#NV,#NV
1486,"Thalassemia, delta- (3)",HBD,142000,11p15.5,Hematological,3045,0,#NV,#NV
1486,Thalassemia due to Hb Lepore (3),HBD,142000,11p15.5,Hematological,3045,0,#NV,#NV
1486,"Thalassemia, Hispanic gamma-delta-beta (3)",LCRB,152424,11p15.5,Hematological,387281,0,#NV,#NV
1491,"Thiamine-responsive megaloblastic anemia syndrome, 249270 (3)","SLC19A2, THTR1",603941,1q23.3,Hematological,10560,0,#NV,#NV
1502,Thymine-uraciluria (3),"DPYD, DPD",274270,1p22,Metabolic,1806,0,#NV,#NV
1505,"Thyrotropin-releasing hormone resistance, generalized (3)",TRHR,188545,8q23,Endocrine,7201,0,#NV,#NV
1506,Thyroxine-binding globulin deficiency (3),TBG,314200,Xq22.2,Hematological,6906,0,#NV,#NV
1509,"Timothy syndrome, 601005 (3)","CACNA1C, CACNL1A1, CCHL1A1, TS",114205,12p13.3,multiple,775,0,#NV,#NV
1511,Tolbutamide poor metabolizer (3),CYP2C9,601130,10q24,Unclassified,1559,0,#NV,#NV
1514,"Townes-Brocks branchiootorenal-like syndrome, 107480 (3)","SALL1, HSAL1, TBS",602218,16q12.1,multiple,6299,0,#NV,#NV
1514,"Townes-Brocks syndrome, 107480 (3)","SALL1, HSAL1, TBS",602218,16q12.1,multiple,6299,0,#NV,#NV
1515,"Transaldolase deficiency, 606003 (3)",TALDO1,602063,11p15.5-p15.4,Metabolic,6888,0,#NV,#NV
1516,Transcobalamin II deficiency (3),"TCN2, TC2",275350,22q11.2-qter,Hematological,6948,0,#NV,#NV
1519,"Transposition of the great arteries, dextro-looped, 608808 (3)","THRAP2, PROSIT240, TRAP240L, KIAA1025",608771,12q24,Developmental,23389,0,#NV,#NV
1519,"Transposition of great arteries, dextro-looped, 217095 (3)","CFC1, CRYPTIC, HTX2",605194,2q21.1,Developmental,55997,0,#NV,#NV
1520,"Treacher Collins mandibulofacial dysostosis, 154500 (3)","TCOF1, MFD1",606847,5q32-q33.1,Developmental,6949,0,#NV,#NV
1521,"Tremor, familial essential, 2, 602134 (3)","HS1BP3, FLJ14249, ETM2",609359,2p24.1,Neurological,64342,0,#NV,#NV
1522,"Trichodontoosseous syndrome, 190320 (3)","DLX3, TDO",600525,17q21.3-q22,multiple,1747,0,#NV,#NV
1524,"Trichorhinophalangeal syndrome, type I, 190350 (3)",TRPS1,604386,8q24.12,Developmental,7227,0,#NV,#NV
1524,"Trichorhinophalangeal syndrome, type III, 190351 (3)",TRPS1,604386,8q24.12,Developmental,7227,0,#NV,#NV
1525,"Trichothiodystrophy, 601675 (3)","ERCC2, EM9",126340,19q13.2-q13.3,Dermatological,2068,0,#NV,#NV
1525,Trichothiodystrophy (3),"ERCC3, XPB",133510,2q21,Dermatological,2071,0,#NV,#NV
1525,"Trichothiodystrophy, nonphotosensitive 1, 234050 (3)","TTDN1, C7orf11, ABHS",609188,7p14,Dermatological,136647,0,#NV,#NV
1525,"Trichothiodystrophy, complementation group A, 601675 (3)","TGF2H5, TTDA, TFB5, C6orf175",608780,6p25.3,Dermatological,404672,0,#NV,#NV
1526,"Trifunctional protein deficiency, type 1 (3)","HADHA, MTPA",600890,2p23,Metabolic,3030,0,#NV,#NV
1526,"Trifunctional protein deficiency, type II (3)",HADHB,143450,2p23,Metabolic,3032,0,#NV,#NV
1529,"Tropical calcific pancreatitis, 608189 (3)","SPINK1, PSTI, PCTT, TATI",167790,5q32,Gastrointestinal,6690,0,#NV,#NV
1530,"Troyer syndrome, 275900 (3)",SPG20,607111,13q12.3,Neurological,23111,0,#NV,#NV
1533,"Tuberculosis, susceptibility to, 607948 (3)",IFNG,147570,12q14,Respiratory,3458,0,#NV,#NV
1533,"Tuberculosis, susceptibility to (3)",IFNGR1,107470,6q23-q24,Respiratory,3459,0,#NV,#NV
1534,"TSC2 angiomyolipomas, renal, modifier of, 191100 (3)",IFNG,147570,12q14,multiple,3458,0,#NV,#NV
1534,"Tuberous sclerosis-1, 191100 (3)","TSC1, LAM",605284,9q34,multiple,7248,0,#NV,#NV
1534,"Tuberous sclerosis-2, 191100 (3)","TSC2, LAM",191092,16p13.3,multiple,7249,0,#NV,#NV
1538,"Twinning, dizygotic, 276400 (3)","FSHR, ODG1",136435,2p21-p16,Unclassified,2492,0,#NV,#NV
1540,"Tyrosinemia, type I (3)",FAH,276700,15q23-q25,Metabolic,2184,0,#NV,#NV
1540,"Tyrosinemia, type III (3)",HPD,276710,12q24-qter,Metabolic,3242,0,#NV,#NV
1540,"Tyrosinemia, type II (3)",TAT,276600,16q22.1-q22.3,Metabolic,6898,0,#NV,#NV
1542,"Ullrich congenital muscular dystrophy, 254090 (3)","COL6A1, OPLL",120220,21q22.3,Muscular,1291,0,#NV,#NV
1542,"Ullrich scleroatonic muscular dystrophy, 254090 (3)",COL6A2,120240,21q22.3,Muscular,1292,0,#NV,#NV
1542,"Ullrich congenital muscular dystrophy, 254090 (3)",COL6A3,120250,2q37,Muscular,1293,0,#NV,#NV
1543,"Ulnar-mammary syndrome, 181450 (3)",TBX3,601621,12q24.1,multiple,6926,0,#NV,#NV
1544,"Unipolar depression, susceptibility to, 608516 (3)","TPH2, NTPH",607478,12q21.1,Psychiatric,121278,0,#NV,#NV
1553,"UV-induced skin damage, vulnerability to (3)",MC1R,155555,16q24.3,Dermatological,4157,0,#NV,#NV
1556,"Velocardiofacial syndrome, 192430 (3)","TBX1, DGS, CTHM, CAFS, TGA, DORV, VCFS, DGCR",602054,22q11.2,multiple,6899,0,#NV,#NV
1557,"Venous malformations, multiple cutaneous and mucosal, 600195 (3)","TEK, TIE2, VMCM",600221,9p21,Cardiovascular,7010,0,#NV,#NV
1557,"Venous thrombosis, susceptibility to (3)","SERPINA10, ZPI",605271,14q32.1,Cardiovascular,51156,0,#NV,#NV
1563,"Virilization, maternal and fetal, from placental aromatase deficiency (3)","CYP19A1, CYP19, ARO",107910,15q21.1,Developmental,1588, #NV,#NV,
1565,"Vitamin K-dependent coagulation defect, 277450 (3)",GGCX,137167,2p12,Hematological,2677,0,#NV,#NV
1565,"Vitamin K-dependent clotting factors, combined deficiency of, 2, 607473 (3)","VKORC1, VKOR, VKCFD2, FLJ00289",608547,16p11.2,Hematological,79001,0,#NV,#NV
1570,"VLCAD deficiency, 201475 (3)","ACADVL, VLCAD",609575,17p13,Metabolic,37,0,#NV,#NV
1580,"Warfarin sensitivity, 122700 (3)",CYP2C9,601130,10q24,Hematological,1559,0,#NV,#NV
1580,Warfarin sensitivity (3),"F9, HEMB",306900,Xq27.1-q27.2,Hematological,2158,0,#NV,#NV
1580,"Warfarin resistance, 122700 (3)","VKORC1, VKOR, VKCFD2, FLJ00289",608547,16p11.2,Hematological,79001,0,#NV,#NV
1582,"Weaver syndrome, 277590 (3)","NSD1, ARA267, STO",606681,5q35,Developmental,64324,0,#NV,#NV
1588,"Werner syndrome, 277700 (3)","RECQL2, RECQ3, WRN",604611,8p12-p11.2,multiple,7486,0,#NV,#NV
1589,"Wernicke-Korsakoff syndrome, susceptibility to, 277730 (3)",TKT,606781,3p14.3,Metabolic,7086,0,#NV,#NV
1590,"Weyers acrodental dysostosis, 193530 (3)",EVC,604831,4p16,Skeletal,2121,0,#NV,#NV
1591,"WHIM syndrome, 193670 (3)","CXCR4, D2S201E, NPY3R, WHIM",162643,2q21,Immunological,7852,0,#NV,#NV
1592,"White sponge nevus, 193900 (3)","KRT4, CYK4",123940,12q13,Connective tissue disorder,3851,0,#NV,#NV
1592,"White sponge nevus, 193900 (3)",KRT13,148065,17q21-q22,Connective tissue disorder,3860,0,#NV,#NV
1596,"Wilson disease, 277900 (3)","ATP7B, WND",606882,13q14.3-q21.1,Metabolic,540,0,#NV,#NV
1600,"Wolcott-Rallison syndrome, 226980 (3)","EIF2AK3, PEK, PERK, WRS",604032,2p12,Bone,9451,0,#NV,#NV
1603,"Wolfram syndrome, 222300 (3)","WFS1, WFRS, WFS, DFNA6",606201,4p16.1,Metabolic,7466,0,#NV,#NV
1604,Wolman disease (3),LIPA,278000,10q24-q25,Metabolic,3988,0,#NV,#NV
1607,"Xanthinuria, type I, 278300 (3)",XDH,607633,2p23-p22,Metabolic,7498,0,#NV,#NV
1608,"Xeroderma pigmentosum, group E, DDB-negative subtype, 278740 (3)",DDB2,600811,11p12-p11,Dermatological,1643,0,#NV,#NV
1608,"Xeroderma pigmentosum, group D, 278730 (3)","ERCC2, EM9",126340,19q13.2-q13.3,Dermatological,2068,0,#NV,#NV
1608,"Xeroderma pigmentosum, group B (3)","ERCC3, XPB",133510,2q21,Dermatological,2071,0,#NV,#NV
1608,"Xeroderma pigmentosum, group F, 278760 (3)","ERCC4, XPF",133520,16p13.3-p13.13,Dermatological,2072,0,#NV,#NV
1608,"Xeroderma pigmentosum, group G, 278780 (3)","ERCC5, XPG",133530,13q33,Dermatological,2073,0,#NV,#NV
1608,"Xeroderma pigmentosum, variant type, 278750 (3)","POLH, XPV",603968,6p21.1-p12,Dermatological,5429,0,#NV,#NV
1608,"Xeroderma pigmentosum, group A (3)",XPA,278700,9q22.3,Dermatological,7507,0,#NV,#NV
1608,"Xeroderma pigmentosum, group C (3)","XPC, XPCC",278720,3p25,Dermatological,7508,0,#NV,#NV
1610,"X-inactivation, familial skewed, 300087 (3)","XIC, XCE, XIST, SXI1",314670,Xq13.2,Unclassified,7503,0,#NV,#NV
1611,"XLA and isolated growth hormone deficiency, 307200 (3)","BTK, AGMX1, IMD1, XLA, AT",300300,Xq21.3-q22,Immunological,695,0,#NV,#NV
1613,"Yellow nail syndrome, 153300 (3)","FOXC2, FKHL14, MFH1",602402,16q24.3,Immunological,2303,0,#NV,#NV
1615,"Zellweger syndrome-1, 214100 (3)","PEX1, ZWS1",602136,7q21-q22,multiple,5189,0,#NV,#NV
1615,"Zellweger syndrome, 214100 (3)","PEX10, NALD",602859,Chr.1,multiple,5192,0,#NV,#NV
1615,"Zellweger syndrome, 214100 (3)","PEX13, ZWS, NALD",601789,2p15,multiple,5194,0,#NV,#NV
1615,"Zellweger syndrome, 214100 (3)",PEX14,601791,1p36.2,multiple,5195,0,#NV,#NV
1615,"Zellweger syndrome, 214100 (3)","PXF, HK33, D1S2223E, PEX19",600279,1q22,multiple,5824,0,#NV,#NV
1615,Zellweger syndrome-2 (3),"ABCD3, PXMP1, PMP70",170995,1p22-p21,multiple,5825,0,#NV,#NV
1615,Zellweger syndrome-3 (3),"PXMP3, PAF1, PMP35, PEX2",170993,8q21.1,multiple,5828,0,#NV,#NV
1615,"Zellweger syndrome, 214100 (3)","PXR1, PEX5, PTS1R",600414,12p13.3,multiple,5830,0,#NV,#NV
1615,"Zellweger syndrome, complementation group G, 214100 (3)",PEX3,603164,6q23-q24,multiple,8504,0,#NV,#NV
1615,"Zellweger syndrome, complementation group 9 (3)",PEX16,603360,11p12-p11.2,multiple,9409,0,#NV,#NV
1615,"Zellweger syndrome, 214100 (3)",PEX26,608666,22q11.21,multiple,55670,0,#NV,#NV
2055,Adrenocortical insufficiency without ovarian defect (3),"FTZF1, FTZ1, SF1",184757,9q33,Endocrine,2516,0,#NV,#NV
2074,"Alcohol intolerance, acute (3)",ALDH2,100650,12q24.2,Metabolic,217,0,#NV,#NV
2291,"Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy, 125310 (3)","NOTCH3, CADASIL, CASIL",600276,19p13.2-p13.1,Cardiovascular,4854,0,#NV,#NV
2315,"Chondrodysplasia, Grebe type, 200700 (3)","GDF5, CDMP1",601146,20q11.2,Skeletal,8200,0,#NV,#NV
2327,"Chronic infections, due to opsonin defect (3)","MBL2, MBL, MBP1",154545,10q11.2-q21,Immunological,4153,0,#NV,#NV
2344,"Cold-induced sweating syndrome, 272430 (3)","CRLF1, CISS",604237,19p12,multiple,9244,0,#NV,#NV
2350,"Combined hyperlipemia, familial (3)","LPL, LIPD",238600,8p22,Metabolic,4023,0,#NV,#NV
2354,"Congenital bilateral absence of vas deferens, 277180 (3)","CFTR, ABCC7, CF, MRP7",602421,7q31.2,Unclassified,1080,0,#NV,#NV
2427,"Diabetes insipidus, nephrogenic, autosomal dominant, 125800 (3)",AQP2,107777,12q13,Endocrine,359,0,#NV,#NV
2427,"Diabetes insipidus, nephrogenic, autosomal recessive, 222000 (3)",AQP2,107777,12q13,Endocrine,359,0,#NV,#NV
2427,"Diabetes insipidus, neurohypophyseal, 125700 (3)","AVP, AVRP, VP",192340,20p13,Endocrine,551,0,#NV,#NV
2427,"Diabetes insipidus, nephrogenic, 304800 (3)","AVPR2, DIR, DI1, ADHR",300538,Xq28,Endocrine,554,0,#NV,#NV
2440,DNA ligase I deficiency (3),LIG1,126391,19q13.2-q13.3,multiple,3978,0,#NV,#NV
2584,"Giant cell hepatitis, neonatal, 231100 (3)",CYP7B1,603711,8q21.3,Gastrointestinal,9420,0,#NV,#NV
2628,"Growth retardation with deafness and mental retardation due to IGF1 deficiency, 608747 (3)",IGF1,147440,12q22-q24.1,Developmental,3479,0,#NV,#NV
2669,Hereditary persistence of alpha-fetoprotein (3),"AFP, HPAFP",104150,4q11-q13,Hematological,174,0,#NV,#NV
2903,"Lipoid proteinosis, 247100 (3)",ECM1,602201,1q21,Metabolic,1893,0,#NV,#NV
3016,"Mitochondrial DNA depletion myopathy, 251880 (3)",TK2,188250,16q22,Muscular,7084,0,#NV,#NV
3037,"Multiple cutaneous and uterine leiomyomata, 150800 (3)",FH,136850,1q42.1,Cancer,2271,0,#NV,#NV
3079,"Neonatal ichthyosis-sclerosing cholangitis syndrome, 607626 (3)","CLDN1, SEMP1",603718,3q28-q29,multiple,9076,0,#NV,#NV
3144,"Optic nerve coloboma with renal disease, 120330 (3)",PAX2,167409,10q24.3-q25.1,multiple,5076,0,#NV,#NV
3171,"Ovarian dysgenesis 1, 233300 (3)","FSHR, ODG1",136435,2p21-p16,Endocrine,2492,0,#NV,#NV
3171,"Ovarian dysgenesis 2, 300510 (3)","BMP15, GDF9B, ODG2",300247,Xp11.2,Endocrine,9210,0,#NV,#NV
3195,Paroxysmal nocturnal hemoglobinuria (3),PIGA,311770,Xp22.1,Hematological,5277,0,#NV,#NV
3232,Pituitary anomalies with holoprosencephaly-like features (3),GLI2,165230,2q14,multiple,2736,0,#NV,#NV
3241,"Polycystic liver disease, 174050 (3)","PRKCSH, G19P1, PCLD",177060,19p13.2-p13.1,Gastrointestinal,5589,0,#NV,#NV
3241,"Polycystic liver disease, 174050 (3)",SEC63,608648,6q21,Gastrointestinal,11231,0,#NV,#NV
3260,"Premature chromosome condensation with microcephaly and mental retardation, 606858 (3)",MCPH1,607117,8p23,Neurological,79648,0,#NV,#NV
3308,"Renal glucosuria, 233100 (3)","SLC5A2, SGLT2",182381,16p11.2,Renal,6524,0,#NV,#NV
3419,"Specific granule deficiency, 245480 (3)","CEBPE, CRP1",600749,14q11.2,Immunological,1053,0,#NV,#NV
3478,"T-cell immunodeficiency, congenital alopecia, and nail dystrophy (3)",WHN,600838,17q11-q12,Immunological,8456,0,#NV,#NV
3554,"van der Woude syndrome, 119300 (3)","IRF6, VWS, LPS, PIT, PPS, OFC6",607199,1q32-q41,Developmental,3664,0,#NV,#NV
3572,von Willebrand disease (3),"VWF, F8VWF",193400,12p13.3,Hematological,7450,0,#NV,#NV
4188,"Basal ganglia disease, adult-onset, 606159 (3)",FTL,134790,19q13.3-q13.4,Neurological,2512,0,#NV,#NV
4188,"Basal ganglia disease, biotin-responsive, 607483 (3)",SLC19A3,606152,2q36.3,Neurological,80704,0,#NV,#NV
4289,"Cerebellar hypoplasia, VLDLR-associated, 224050 (3)","VLDLR, VLDLRCH",192977,9p24,Neurological,7436,0,#NV,#NV
4291,"Cerebral cavernous malformations-1, 116860 (3)","CCM1, CAM, KRIT1",604214,7q11.2-q21,Neurological,889,0,#NV,#NV
4291,"Cerebral cavernous malformations 3, 603285 (3)","PDCD10, TFAR15, CCM3",609118,3q26.1,Neurological,11235,0,#NV,#NV
4291,"Cerebral cavernous malformations-2, 603284 (3)","C7orf22, CCM2, MGC4067",607929,7p13,Neurological,83605,0,#NV,#NV
4354,"Congenital cataracts, facial dysmorphism, and neuropathy, 604168 (3)","CTDP1, FCP1, CCFDN",604927,18q23,Ophthamological,9150,0,#NV,#NV
4666,Hepatic lipase deficiency (3),LIPC,151670,15q21-q23,Metabolic,3990,0,#NV,#NV
5016,"Mitochondrial DNA-depletion syndrome, hepatocerebral form, 251880 (3)","DGUOK, DGK",601465,2p13,multiple,1716,0,#NV,#NV
5016,"Mitochondrial DNA depletion syndrome, 251880 (3)",SUCLA2,603921,13q12.2-q13,multiple,8803,0,#NV,#NV
5170,"Ovarian hyperstimulation syndrome, gestational, 608115 (3)","FSHR, ODG1",136435,2p21-p16,Endocrine,2492,0,#NV,#NV
5232,"Pituitary hormone deficiency, combined (3)","POU1F1, PIT1",173110,3p11,Endocrine,5449,0,#NV,#NV
5232,"Pituitary hormone deficiency, combined (3)",PROP1,601538,5q,Endocrine,5626,0,#NV,#NV
5232,"Pituitary hormone deficiency, combined, with rigid cervical spine, 262600 (3)",LHX3,600577,9q34.3,Endocrine,8022,0,#NV,#NV
5232,"Pituitary hormone deficiency, combined, HESX1-related, 182230 (3)","HESX1, RPX",601802,3p21.2-p21.1,Endocrine,8820,0,#NV,#NV
5291,"Pulmonary hypertension, familial primary, 178600 (3)","BMPR2, PPH1",600799,2q33,Cardiovascular,659,0,#NV,#NV
5308,"Renal hypoplasia, isolated (3)",PAX2,167409,10q24.3-q25.1,Renal,5076,0,#NV,#NV
6291,"Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome, 609528 (3)","SNAP29, CEDNIK",604202,22q11.2,Neurological,9342,0,#NV,#NV
6350,"Combined oxidative phosphorylation deficiency, 609060 (3)","GFM1, EFG1, GFM",606639,3q25.1-q26.2,multiple,85476,0,#NV,#NV
7016,"Mitochondrial myopathy and sideroblastic anemia, 600462 (3)","PUS1, MLASA",608109,12q24.33,multiple,80324,0,#NV,#NV
7170,Ovarian sex cord tumors (3),"FSHR, ODG1",136435,2p21-p16,Cancer,2492,0,#NV,#NV
7232,"Pituitary tumor, invasive (3)","PRKCA, PKCA",176960,17q22-q23.2,Cancer,5578,0,#NV,#NV
8350,Combined SAP deficiency (3),"PSAP, SAP1",176801,10q22.1,Metabolic,5660,0,#NV,#NV
9037,Multiple myeloma (3),"IRF4, LSIRF",601900,6p25-p23,Cancer,3662,0,#NV,#NV
9037,"Multiple myeloma, resistance to, 254500 (3)",LIG4,601837,13q22-q34,Cancer,3981,0,#NV,#NV
9039,"Multiple sulfatase deficiency, 272200 (3)","SUMF1, FGE",607939,3p26,Metabolic,285362,0,#NV,#NV